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Abstract 
 
 
 
Heat shock protein 70 (HSPA/HSP70) gene expression is induced by a wide range of 
cellular stress conditions. This study investigated HSPA/HSP70 expression in human 
cell lines exposed to hypoxic conditions, in cancerous and non-cancerous brain tissue 
specimens from 18 patients (gliomas and normal conditions), and in post mortem rat 
brain samples exposed to heat shock. 
 
 
 
Three human glioma cell lines were chosen for this study, each representing various 
types of glioma: (astrocytoma, oligodendroglioma and glioblastoma), with a normal 
human astrocyte cell line used as a control.  In addition, 18 clinical brain tissue samples 
were also examined.  HSPA RNA transcripts and proteins were examined in these 
samples using qRT-PCR, immunofluorescence and flow cytometry techniques. 
 
 
 
The average HSPA mRNA copy numbers detected in glioblastoma tissue were 1.8 and 
 
8.8 fold higher respectively than in lower grade glioma and control tissues, which is 
suggestive of a grade related transcription profile. Similar patterns of grade related 
expression were also observed in corresponding cell lines.  The percentage of cells 
showing positive for HSPA protein in normal cell lines increased from 0 to 33% 
immediately after exposure to hypoxia, and gradually declined to 11% 24 h after 
treatment. However, the effects of hypoxia were marginal in glioma cells, due to the 
already elevated levels of  HSPA.   Although hypoxia induced HSPA expression in 
normal cells, it did not achieve the same level of induction in cancer cells, suggesting 
that there are other factors which contribute to the induction of HSPA.  These results 
suggest that HSPA is induced in cancer cells, not only by hypoxia, but also by other 
factors. In addition, this study indicated for the first time that HSPA expression in 
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glioma cells may possibly be grade related, and thus may have value as a prognostic 
marker. However a greater sample size is needed to validate such findings. 
 
 
 
This study showed that HSPA is expressed at low levels in normal brain tissue, but was 
more highly expressed in brain tissue subjected to mild heat shock. The levels of HSPA 
transcripts in heat shocked post mortem brain tissue showed a marked increase in HSPA 
expression. 
 
 
 
GAPDH was used as a control gene for these studies, and exhibited a consistent level of 
expression in normal and tumourous cell lines and tissue samples under normal and 
hypoxic conditions, and also in post mortem tissues exposed to heat shock. For Homo 
sapiens GAPDH, the average transcript numbers for normal and tumourous cell lines 
and brain tissue samples were approximately 145,000 copies per sample. For Rattus 
norvegicus GAPDH, levels were higher than for human samples, at an average of 
268,300 copies per sample. The consistency of these results confirms that GAPDH was 
a suitable candidate gene for the purpose of this study. 
 
 
 
Early in the post-mortem period, HSPA is expressed more highly in tissues subjected to 
single and multiple heat shocks compared to controls. However, later post-mortem 
intervals of between 3 - 24 h demonstrated inconsistent and irregular results, with no 
predictive or reproducible patterns. Therefore, although there is demonstrable de novo 
expression of HSPA in post mortem brain tissue in response to heat shock, it is difficult 
to predict the full parameters of this induction, probably as a result of other forms of 
cellular stress affecting these tissues under our experimental methodology. These initial 
studies indicate that the use of HSPA with the methodologies employed here are not 
suitable as an accurate indicator of post-mortem interval. 
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1.1     Molecular Chaperones and Heat Shock Proteins 
 
 
 
Protein synthesis is a complex molecular process which has been reviewed recently by 
Babitzke  et  al,  (2009);  Braakman  and  Bulleid,  (2011)  and  Zamecnik,  (2005). 
Translation involves interactions between three major groups of RNA molecules; 
ribosomal ribonucleic acid (rRNA), transfer ribonucleic acid (tRNA) and messenger 
ribonucleic acid (mRNA) templates, and a large number of accessory protein factors. 
Eukaryotic protein synthesis occurs in the cytoplasm at ribosomes, where the genetic 
information encoded by mRNA molecules is translated, according to the genetic code, 
into a corresponding sequence of amino acids to form a polypeptide. 
 
 
 
Amino acids are brought to the peptide site of a ribosome by charged tRNA molecules, 
and the complementary anticodon in the tRNA specifically binds to the codon in the 
mRNA.  Protein factors or initiation factors are required during the initiation phase of 
protein synthesis, interacting with the ribosome-mRNA complex, and dissociate when 
polypeptide chain synthesis is initiated.   After the initiation complex has formed, 
elongation of the polypeptide chain proceeds.  Elongation begins when the carboxyl, (– 
COOH) group of an amino acid carried by a charged aminoacyl-tRNA (aa-tRNA), binds 
to the peptidyl site of the ribosome with the amino, (NH2) group of the amino acid of 
another aa-tRNA in the aminoacyl site.   The peptidyl tRNA translocates from the 
aminoacyl site to the peptide site where the tRNA disassociates from the peptide to the 
exit site.  This process repeats until a nonsense codon is reached.  Termination of this 
process requires specific protein release factors which recognise nonsense codons, 
causing the nascent polypeptide chain to release from the peptidyl tRNA and the 
ribosome. 
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The polypeptide that emerges from the ribosome is inactive and must undergo protein 
folding, one of four post translation processes, before taking on its functional role in the 
cell. 
 
 
 
Proteins are generally considered to have four distinct levels of structural organization. 
The primary structure of a protein is formed by the linkage of amino acids via covalent 
peptide bonds to form a linear polypeptide chain. The two ends of the polypeptide 
chain are chemically distinct; the start of the polypeptide chain has a free amino group 
which is referred to as the N-terminus, and the other end of the polypeptide chain has a 
free carboxyl group, termed the C-terminus (Braakman and Bulleid, 2011). 
 
 
 
The secondary structure of proteins describes the folding and twisting of the linear 
polypeptide chain into specific conformations, such as α-helix and β-pleated sheet 
structures.    The  α-helix  structure  is  formed  by  intramolecular  hydrogen  bonding 
between the -NH groups of one amino acid and the -COOH groups of an amino acid 
that is four amino acids away within the chain.   Repeated formation of this bonding 
results in the helical coiling of the polypeptide chain.  The β-pleated sheet structure is 
formed by intermolecular hydrogen bonding between the amide hydrogen of one chain 
to the amide oxygen of a neighbouring chain resulting in a zigzag or pleated formation 
(Braakman and Bulleid, 2011). 
 
Tertiary structures are formed through the folding of secondary structure into three- 
dimensional structures determined by a variety of bonding interactions, including 
hydrogen bonding (Arunan et al, 2011), salt bridges (Kumar and Kussinov, 2002), 
disulphide bonds (Sevier and Kaiser, 2002) and non-polar hydrophobic interactions 
(Rose et al, 2006) between the ―side chains‖ on the amino acids (Braakman and Bulleid, 
2011). 
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The quaternary structure is formed by the clustering of two or more proteins linking 
together to form a multi-subunit protein, but it is worth noting that not all proteins 
exhibit quaternary structures.   Again, a variety of bonding interactions, including 
hydrogen bonding, salt bridges, and disulphide bonds, hold the protein in its final 
structural  shape,  but  also  allow  the  proteins  to  revert  back  to  their  component 
polypeptide or change their subunit composition, depending on their functional 
requirement (Braakman and Bulleid, 2011). 
 
 
 
Folding of newly synthesized proteins requires the interaction of numerous protein 
cofactors, referred to as molecular chaperones.   Molecular chaperones ensure that 
polypeptide chains are not damaged during the transport and assembly stages of protein 
production.  These proteins are not part of the final proteins with which they are 
associated.   They are a diverse family of largely unrelated proteins (Ellis and 
Hemmingsen, 1989; Ellis and van der Vies, 1991; Feder, 1999; Hartl et al, 2011). 
Molecular chaperones maintain newly synthesized polypeptides in an unfolded state for 
translocation across intracellular membranes and hence recognise and selectively bind 
to new polypeptide chains and to partially folded intermediates of proteins (Atalay et al, 
2009;  ;  Jolly  and  Morimoto  2000;  Welch  et  al,  1993).    They  also  prevent  the 
aggregation and misfolding of newly synthesized proteins, prevent non-productive 
interactions with other cell components, direct the assembly of larger proteins and 
multiprotein complexes, and cause previously folded proteins to unfold during exposure 
to stressful conditions (Atalay et al, 2009; Ellis, 1993; Jolly and Morimoto, 2000; 
Welch et al, 1993). 
 
Molecular chaperones play a crucial protective role under conditions of cellular stress 
and damage, preventing the appearance of folding intermediates that lead to either 
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misfolded or damaged protein molecules.  When their production or activity is induced 
in response to either acute or chronic stress, molecular chaperones capture folding 
intermediates and prevent their misfolding or premature aggregation.  They are also 
implicated in the control of cellular apoptosis (Ellis, 1993; Jolly and Morimoto, 2000; 
Welch et al, 1993). 
 
 
 
Molecular  chaperones  are  highly  conserved  groups  of  proteins,  which  comprise  a 
number of unrelated families, and most are classified as heat shock (stress) proteins. 
They are highly ubiquitous and are found in both prokaryotic and eukaryotic cells, 
where they can be found localized in the cytoplasm, nucleus, endoplasmic reticulum or 
the mitochondria.  The existence of these proteins, and their associated genes, was 
discovered from studies of the response to cells to heat shock, first reported by Ferrucio 
Ritossa in 1962. This was first observed in the salivary gland cells of the fruit fly 
Drosophilia busckii, which were exposed to an elevated temperature of 37oC for 30 
 
min, followed by recovery at their normal temperature of 25oC.   Ritossa described a 
unique set of chromosomal ‗puffs‘ (Figure 1.1) observed after exposure of these cells to 
heat, together with the increased production of then unknown proteins with molecular 
masses of 70 and 26 KDa (Ritossa, 1962; Ritossa, 1963; Trivedi et al, 2010).  The 
polytene chromosomes present in Drosophila salivary gland cells allowed the 
observation of ‗puffing‘ of specific regions of the chromosomes in response to heat 
shock, which resulted from high levels of transcription of heat shock genes. 
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Figure 1.1.  Representation of a light microscope image of Ritossa‘s  chromosomal 
puffs, which are characterised by localized swellings of specific regions of a polytene 
chromosome. These ‗puffs‘ result from localised synthesis of RNA, resulting from high 
levels of transcription of heat shock genes at each chromosomal location (Morimoto, 
2010). 
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Over the next decade, further studies showed that these chromosomal puffs were also 
induced by a variety of other cellular treatments, such as exposure to dinitrophenol, 
sodium salicylate (Ritossa, 1962), actinomycin D (Berendes, 1968), or anoxia 
(Ashburner, 1970); these treatments all resulted in cellular stress.   The production of 
puffing was shown to be associated with newly synthesized RNA, indicating that these 
resulted from high levels of gene expression (Leenders and Berendes, 1972; Ritossa, 
1962) and that the response was rapidly induced, as puffs were produced within a few 
minutes of treatment (Ashburner, 1970; Berendes, 1968).   The phenomenon was also 
found in other Drosophilia species such as  Drosophilia melanogaster, Drosophilia 
hydei and Drosophilia similans (Berendes, 1965; Ritossa, 1964).   Later studies by 
Guttman and Gorovsky, (1979); Kelly and Schlesinger (1982); McAlister et al, (1979); 
Miller et al, (1979) and Neidhardt et al, (1984) showed that this was a wide-spread 
phenomenon in most other organisms, indicating that heat shock response was a 
fundamental cellular function. It was discovered that heat and various other types of 
stress could induce the synthesis of similar proteins in yeast (McAlister et al, 1979; 
Miller et al, 1979); cultured avian cells (Kelly and Schlesinger, 1982); tetrahymena 
(Guttman and Gorovsky, 1979) and Escherichia coli (Neidhardt et al, 1984).  Studies 
undertaken by Ashburner and Berendes (1978); Choa and Guild, (1986) and Huet et al, 
(1993) have shown sequential activation of early and late puffs in the polytene 
chromosomes in multiple gene sets during heat shock. Early puffs are active for 
approximately 4 hours and then regress, during which time late puff sets become active 
(Ashburner, 1970; Ashburner and Berendes, 1978; Berendes, 1968; Leenders and 
Berendes, 1972).   In Drosophilia melanogaster, nine puffs induced by heat shock in 
polytene nuclei were identified on different chromosomes; the left arm of chromosome 
2 loci 33B, left arm of chromosome 3 loci  63BC, 64EF, 67B, right arm of chromosome 
 
3 loci   70A, 87A, 87C, 93D and 95D (Ashburner, 1970; Mukherjee and Lakhotia, 
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1979).  The first gene products resulting from these chromosomal puffs were identified 
some 12 years later and subsequently termed ―heat shock proteins‖ (Neuer et al, 2000; 
Tissiere et al, 1974).  In both eukaryotic and prokaryotic organisms, heat shock protein 
genes are scattered at various chromosomal locations, with some related genes clustered 
or, if unrelated, interspersed with independently regulated genes. On the right arm of 
chromosome three, five copies per haploid genome for the gene HSP70 are present, two 
at locus site 87A and three at locus site 87C, also the gene for HSP68 is present at locus 
site 95D (Holmgren et al, 1979). On the left arm of chromosome three, four of the small 
heat shock proteins are encoded at locus site 67B, in the order HSP27, HSP23, HSP26 
and HSP22 (Corces et al, 1980; Craig and McCarthy, 1980; Voellmy et al, 1981) and 
also HSP83 coding sequences are located at locus 63BC. 
 
 
 
The normal growth temperature for Drosophila cells is 25oC.   When the cells are 
subjected to heat shock with temperatures between 29 – 38oC, heat shock proteins are 
induced with a maximum response by temperatures between 36 – 37oC (Lindquist, 
1980).   Within minutes of temperature elevation, heat shock mRNAs appear in the 
cytoplasm  and  are  translated  immediately  with  high  efficiency  (Lindquist,  1980). 
Within an hour of heat shock, several thousand heat shock transcripts are found in each 
cell (Lindquist, 1980). During this time, translation of pre-existing messages (Kelly and 
Schlesinger, 1982; Lindquist, 1981) and transcription of previously active genes are 
repressed (Berendes, 1968; Findly and Pederson, 1981; Lindquist, 1986).   If the cells 
are maintained at elevated temperatures, heat shock proteins will continue to be the 
primary products of protein synthesis.  If the cells are returned to their normal growth 
temperature, normal protein synthesis will be gradually resumed, the timing of which is 
dependent on the severity of the heat shock induced (DiDomenico et al, 1982). 
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In other organisms, induction of heat shock protein genes is equally rapid. However, the 
maximum induction temperature varies depending on the physiological growth 
temperature.   For example, in humans, with a normal physiological temperature of 
37oC, the maximum response temperature is 42oC; in yeast, with a normal physiological 
 
temperature of 30 – 37oC, the maximum response temperature is 39 - 40oC (Lindquist et 
al,  1982),  in  salmon/trout,  with  a  normal  physiological  temperature  of  5  –  15oC 
(Kothary and Candido, 1982), the maximum response temperature is 28oC and in E.coli, 
with an optimal growth temperature of 37oC, the maximum response temperature is 45 
– 50oC (Neidhardt et al, 1984; Yamamori et al, 1978).  In organisms that grow over a 
broad range of temperatures, the maximum response temperature is generally 10 – 15oC 
above the optimum physiological temperature, whereas for organisms/species that grow 
over a more restricted temperature range, the maximum response temperature is 
generally 5oC above the optimum physiological temperature (Lindquist, 1986). 
 
 
 
In some organisms, heat shock response appears to be either transient or sustained.  For 
example, in E.coli heat shock response is transient when the normal growth temperature 
is raised to 42oC but is sustained when the temperature is raised to 45 - 50oC (Neidhardt 
et al, 1984; Yamamori et al, 1978).  In most organisms heat shock will be transient at 
moderate temperatures where normal growth will be resumed, and sustained at higher 
temperatures until the cells slowly begin to die (Lindquist, 1986). 
 
 
 
The majority of cells in multicellular organisms respond to heat shock.  For example, 
cells respond identically in different tissues of Drosophila such as the malpighian 
tubules, imaginal wing discs, brain, salivary glands, and tissue cultured cells (Tissiere et 
al, 1974), and in Rattus norvegicus heart, brain, liver, lung, kidney, thymus and adrenal 
gland tissues, the same phenomenon is observed (White and Currie, 1982).  However, 
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there are some exceptions. For example, in Rattus norvegicus, Hsp70 cannot be induced 
in the brain until three weeks postpartum (Tissiere et al, 1974). 
 
 
 
It is worth noting that, due to the inconsistency in nomenclature that has been used for 
heat shock genes and their products in published literature, regarding abbreviations, 
gene and protein symbols in different species, there was a need for standardization. The 
use of different names for these genes and proteins make comparison of  different 
studies very difficult. For the purposes of this thesis, nomenclature for human and non- 
human primates has been based on the Guidelines for Human Nomenclature (Show et 
al, 1987). Other species-based nomenclature, such as mouse, rat and chicken species, 
has      been      based      on      the      Rules      for      Nomenclature      of      Genes 
(http://www.informatics.jax.org/). 
 
 
 
 
For human / non-human primates and other species, nomenclature for proteins will be 
non-italicized and in lower case, and will be italicized if referring to genes. Gene 
symbols for humans and non-human primates are designated by a combination of 
italicized upper case letters and Arabic letters, e.g. HSPA.  Protein designations are the 
same as for the gene symbol but not italicized and all in upper case e.g. HSPA. 
 
 
 
For mouse, rat and chicken, nomenclature will be non-italicized and in lower case, and 
will be italicized if referring to genes.  Gene symbols are designated by a combination 
of italicized letters and Arabic letters, the first letter in upper case and the rest lower 
case: e.g. HSPA.   Protein designations are the same as for the gene symbol, but not 
italicized and all in upper case: e.g. HSPA. 
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In mammalian cells, heat shock proteins function as either molecular chaperones or 
proteases (Jolly and Morimoto, 2000) and are classified into five major families, 
according to their molecular size or function.   These are  HSP90,  HSP70,  HSP60, 
HSP40 and HSP27 (Table 1.1 Craig et al, 1994; Jolly and Morimoto, 2000; Kampinga 
et al, 2009; Lindquist and Craig, 1988; Morimoto et al, 1994; Powers et al, 2007; 
Sreedhar et al, 2004).  These families are described in more detail later in this chapter in 
section 1.3. 
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Table  1.1  Major  Heat  Shock  Proteins  (Taken  from  Craig  et  al,  1994;  Jolly  and 
 
Morimoto, 2000; Kampinga et al, 2009; Lindquist and Craig, 1988; Morimoto et al, 
 
1994; Powers et al, 2007; Sreedhar et al, 2004) 
 
 
 
Heat shock 
protein 
Families 
Co-chaperones or 
Isoforms 
Expression Localization Activity / Function 
HSP27 Various Constitutive 
/Inducible 
Cytoplasm/ 
Nucleus 
Prevent heat denaturation 
protein aggregation via ATP- 
independent formation of high 
molecular weight oligomers; 
phosphorylation of HSP27 
monomers/dimmers regulate 
microfilament polymerization. 
HSP40 Hdj1 and Hdj2 Constitutive 
/Inducible 
Cytoplasm/ 
Nucleus 
Cochaperone activity with 
HSP70 proteins. Regulates 
adenosine triphosphate (ATP) 
activity and substrate release. 
HSP60 mtHsp60/HSP10-mito 
 
TRIC/CCT 
Constitutive 
/Inducible 
Constitutive 
Mitochondria 
 
Cytoplasm 
Folds newly imported 
mitochondrial proteins. 
Folds approx. 10% of cytosolic 
polypeptide chains downstream 
  /Inducible  of the Hsp70 machinery. 
HSP70 HSC70 Constitutive 
/Inducible 
Cytoplasm 
/Nucleus 
Cognate form assists 
constitutive folding and 
transport of proteins to 
organelles. 
 HSP70.1 
 
 
HSP70.2 
Constitutive 
/Inducible 
Constitutive 
Cytoplasm 
 
 
Cytoplasm 
Induced upon heat shock and 
mediate similar functions in 
response to stress-induced 
increase in protein misfolding 
     
 HSP70.3 Constitutive Cytoplasm  and aggregation 
 mtHsp70/Grp75 Constitutive ER/Cytoplasm Protein folding and 
translocation in mitochondria 
 Bip/Grp78 Constitutive 
/Inducible 
ER/Cytoplasm Binds folding and translocation 
intermediates to prevent 
aggregation 
HSP90 HSP90-α Inducible Cytoplasm 
/Nucleus 
Growth promotion, cell cycle 
regulation, stress induced 
cytoprotection, signal 
transduction 
 HSP90-β Constitutive Cytoplasm 
/Nucleus 
Cellular transformation, signal 
transduction, cytoskeletal 
stabilization, long term cell 
adaption 
 HSP-N Constitutive 
/Inducible 
Cytoplasm 
/Nucleus 
Cellular transformation 
 HSP75 1TRAP-1 Constitutive 
/Inducible 
Mitochondria Cell cycle regulation 
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Due to the expanding number of members of the human heat shock protein families and 
the inconsistency in their nomenclature, it was suggested that a more consistent and 
standardized nomenclature should be assigned.  In recently reviewed literature names 
used for the human heat shock protein family members have been inconsistent with a 
number of different names and symbols being used for the same gene product. 
 
In 2009, the nomenclature for human heat shock protein families and the human 
chaperonin families were revised from previous designations (Kampinga et al, 2009). 
The new guidelines for the nomenclature propose HSPC (HSP90), HSPA (HSP70), 
DNAJ (HSP40), HSPB (small HSP) and HSPD/E (HSP60/HSP10) respectively.  The 
new nomenclature is mainly based on the systematic gene symbols that have been 
assigned by the HUGO Gene Nomenclature Committee that are used as primary 
identifiers in gene databases such as the National Centre of Biotechnology Information 
(NCBI), Entrez Gene and Ensembl. 
 
Throughout   this   thesis,   the   new   nomenclature   described   above   for   (example 
 
HSPA/HSP70) has been used for all the heat shock protein families reported (Table 
 
1.2). 
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Table 1.2. Revised nomenclature for the heat shock protein families used in this 
study (taken from Kampinga et al, 2009) 
 
 
Family Gene Protein Name Previous Nomenclature 
HSPB   Small heat shock proteins 
 HSPB1 HSPB1 HSP27 
DNAJ   HSP40 
 DNAJA1 DNAJA1 Hdj2, HSP40 
 DNAJB1 DNAJB1 Hdj1, HSP40 
HSPD   HSP60 
 HSPD1 HSPD1 HSP60 
HSPA   HSP70 
 HSPA1A HSPA1A HSP70-1, HSP72, HSP70.3 
 HSPA1B HSPA1B HSP70-2 
 HSPA5 HSPA5 BIP, GRP78 
 HSPA8 HSPA8 HSC70, HSP71, HSP71, 
HSP73 
 HSPA9 HSPA9 GRP75, mtHSP70 
HSPC   HSP90 
 HSPC1a HSPC1 HSP90-α 
 HSPC2a HSPC2 Hsp90-β 
 HSPC3a HSPC3 HSP-N 
 HSPC5a HSPC5 HSP75, TRAP-1 
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Each family of heat shock proteins contains members which are expressed either 
constitutively or which are induced in response to stimuli and are targeted to different 
sub-cellular compartments (Garrido et al, 2006; Powers et al, 2009).  Both constitutive 
and inducible heat shock proteins carry out numerous functions including: nascent 
protein folding; prevention of the formation of protein aggregates; assisting in the re- 
folding of denatured proteins; facilitation of degradation of irreparable proteins; 
modulation of the assembly or disassembly of protein complexes and assisting in the 
translocation of proteins across cellular membranes (Calderwood et al, 2006; Mosser 
and Morimoto, 2004; Powers et al, 2009).  In addition to the above roles, heat shock 
proteins also play a strong part  in cytoprotection and allow cells to adapt to gradual 
changes in their environment and to survive under hostile or otherwise lethal conditions 
(Calderwood et al, 2006; Mosser and Morimoto, 2004; Parcellier et al, 2003; Powers et 
al, 2009).   The expression and functions of heat shock protein genes have been 
extensively studied in a wide variety of tissues and cell types that have been exposed to 
a range of stress conditions.  Although the production of heat shock proteins results in 
the protection of cells from the effects of further stresses, they are deemed toxic if 
present in the cells for any prolonged period (Theodorakis et al, 1999). 
 
 
 
Heat shock proteins are thus a family of highly conserved ubiquitous proteins encoded 
by genes which are activated, not only in response to various physiological and 
environmental stress conditions (Figure 1.2.), but also in cells affected by various 
diseases, such as cancer, Alzheimer‘s, Parkinson‘s and Huntington‘s diseases and 
diabetes, and by fever or inflammation (Jolly and Morimoto, 2000; Lindquist, 1986; 
Morimoto, 1993). 
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Figure. 1.2. Diagram showing the conditions that induce heat shock in response to 
environmental,  physiological  and  non-stressful  conditions  (Taken  from  Morimoto, 
1998). 
54  
Heat shock proteins achieve this by recognizing nascent polypeptides, partially and 
misfolded regions of proteins and exposed hydrophobic regions of amino acids (Figure 
1.3) (Bakau and Horwich, 1998; Jolly and Morimoto, 2000; Morimoto, 1998; Nollen 
and Morimoto, 2002; Parsell and Lindquist, 1993).   Under normal growth conditions 
nearly all heat shock proteins are constitutively expressed at relatively low but constant 
levels, as their normal cellular function is to maintain protein homeostasis by regulating 
correct protein folding (Hartl and Hayer-Hartl, 2002; Nollen and Morimoto, 2002). 
However, under conditions of stress, induction of heat shock gene expression results in 
heat shock proteins being produced at much higher levels to prevent incorrect 
polypeptide aggregation and protein denaturation during physiochemical insults to 
enhance cell survival.  Constitutive heat shock proteins perform housekeeping functions 
by acting as molecular chaperones.   They assist polypeptides to achieve their proper 
conformation by binding to nascent proteins via their C-terminal domain (Mosser and 
Morimoto, 2004; Parsell and Lindquist, 1994). 
 
 
 
The response of cells to such stress conditions is dependent on the concentration of heat 
shock proteins in the cell prior to stress, and on the severity of the stress, based upon its 
intensity and duration.  The outcome of such stress events is either cell survival or 
apoptotic or  necrotic cell  death (Mosser  and  Morimoto, 2004).    Thus,  heat  shock 
proteins play a role in the cell cycle. Elevated levels of heat shock proteins are seen in 
cells recovering from induced stress, and these cells are in a cytoprotected state, 
protecting them from further exposures to stress conditions (Nollen and Morimoto, 
2002).  Cells initiating apoptosis after induced stress also elicit the production of heat 
shock proteins.  This continues until such time as heat shock protein levels in the cell 
have returned to normal (Mosser and Morimoto, 2004; Parsell and Lindquist, 1993). 
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Figure 1.3 Schematic diagram showing the stress defence mechanism mediated by heat 
shock proteins. Stress such as heat shock, hypoxia, post-mortem and cancer are 
associated with the emergence of misfolded proteins.  Initially heat shock proteins will 
assist misfolded proteins and folded intermediates to obtain a native state (pathway A), 
resulting in the activation of the heat shock transcription factor in the nucleus, which 
activates the transcription of heat shock protein genes (pathway B).  Heat shock proteins 
are also involved in the negative regulation of their own synthesis by autoregulation 
(pathway B).    In  some  tumour  cells  heat  shock  proteins  have  been  shown  to  be 
expressed at the cell surface (pathway C) (Taken from Jolly and Morimoto, 2000). 
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The  induction  of  heat  shock  gene  expression  in  response  to  stress  conditions  is 
dependent on a specific DNA sequence, termed the heat-shock element (HSE).   The 
HSE is a stress responsive operator element located in the promoter regions of heat 
shock genes (Fernandes et al, 1994; Morimoto et al, 1994; Wu et al, 1994).  It consists 
of a series of inverted pentameric units with the nucleotide sequence 5‘ nGAAn 3‘ 
(Santoro, 2000). Inducible transcription of heat shock protein genes require the de novo 
binding of the HSE by a heat shock transcription factor (HSF), which is constitutively 
produced. 
 
 
In mammalian cells, the HSF gene family consists of the four members HSF1, HSF2, 
Hsf3 and HSF4 (Table 1.3), of which three (HSF1, HSF2 and HSF4) have been 
characterized in human cells. The HSF1 protein is ubiquitously synthesised and plays a 
major role in the stress induced expression of heat shock protein genes (de Thonel et al, 
2011). The HSF2 protein is activated during specific stages of cell development and is 
associated with development of the brain and reproductive organs (de Thonel et al, 
2011). The HSF4 protein acts as an inhibitor of stress-induced gene expression (de 
Thonel et al, 2011; Jolly and Morimoto, 2000; Morimoto, 1993; Wu, 1995).  The Hsf3 
gene has only been characterized in avian species and more recently identified in mouse 
as an othologue of the chicken Hsf3 gene (de Thonel et al, 2011; Nakai, 1999; Nakai 
and Morimoto, 1993; Tanabe et al, 1998).  In mouse and avian species the HSF3 protein 
has been identified as a redundant heat shock responsive factor which is co-expressed 
with HSF1 suggesting that both HSF1 and HSF3 are involved in the activation of heat 
shock protein genes during heat shock (Tanabe et al, 1998). 
  
 
 
 
 
 
Table 1.3. Characterization of heat shock factors across species (adapted from de Thonel et al, 2011; Morimoto, 1998). 
 
 HSF1 HSF2 HSF3 HSF4(a) 
 
Species 
Homo sapiens, Mus musculus, 
 
Rattus norvegicus, Gallus gallus 
Homo sapiens, Mus musculus, Rattus 
 
Norvegicus, Gallus gallus 
 
Mus musculus, Gallus gallus 
Homo sapiens Mus musculus, Rattus 
 
Norvegicus, Gallus gallus 
Homology 
 
between species 
 
92% 
 
92% 
  
Tissue Specific 
 
Location 
 
Ubiquitous 
 
Ubiquitous 
 
Ubiquitous 
Tissue specific – heart, brain, 
 
pancreas, skeletal muscle 
In vivo conditions 37oC 42oC heat shock 37oC 42oC heat shock 37oC 42oC heat shock 37oC 
Protein size 
Native (KDa) 70 178 127 127    
Denatured (KDa) 70 85 72 72 69 69 55 
 
Localization 
Cytoplasmic / 
 
Nuclear 
 
Nuclear 
Cytoplasmic 
 
and Nuclear 
Cytoplasmic and 
 
Nuclear 
 
Cytoplasmic 
 
Nuclear 
 
Constitutively Nuclear 
Oligomeric State Monomer Trimer Dimer Dimer Dimer Trimer Trimer 
 
DNA-binding 
  
+ 
 
- 
 
- 
 
- 
 
+ 
Constitutive DNA binds but lacks 
 
transcriptional activity 
(a) DNA – binding activity is lost in vitro upon heat shock 
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Heat shock protein synthesis is regulated at the transcriptional level by heat shock 
factors (HSF) which assist, not only in the long term induction of heat shock protein 
genes, but also in the regulation of gene expression and developmental processes 
(Morimoto, 1998; Sreedhar et al, 2004).  All members of the heat shock factor protein 
family share two evolutionary conserved structural functional domains: a conserved 
DNA-binding domain (DBD) at the amino terminus and an oligomerization domain 
(Figure 1.4). The heat shock factor DBD is a member of the winged helix-turn-helix 
hepatocyte nuclear factor 3/fork (HNF-3/fork) transcription factors (de Thonel et al, 
2011; Harrison et al, 1994, Vuister et al, 1994).  The oligomerization domain comprises 
arrays of hydrophobic heptad repeats (HRs) which are divided into two subdomains: the 
amino terminal HR-A and the carboxy-terminal HR-B, both of which are essential for 
trimer formation (de Thonel et al, 2011; Peteranderl and Nelson, 1992; Shamovsky and 
Nudler, 2008; Soger and Nelson, 1989).  A third HR domain (HR-C) is also located in 
Drosophila HSF and mammalian HSF1 which maintains heat shock factors in a 
monomeric state by suppressing trimer formation through interactions with HR-A/B. 
(de Thonel et al, 2011; Green et al, 1995; Shamovsky and Nudler, 2008; Shi et al, 1995; 
Wisniewski et al, 1996; Zuo et al, 1995). 
 
 
 
Heat shock response involves the functional activation of heat shock factor 1 (HSF1), in 
response to damage to other cellular proteins which requires the action of molecular 
chaperones.  HSF1 is present in both stressed and unstressed cells.  Under normal 
conditions, HSF1 exists in the cytoplasm as an inert monomer, which is unable to bind 
to DNA and does not show any transcriptional activity (Pockley, 2003; Santoro 2000). 
HSF1 is constitutively phosphorylated and lacks the ability to bind to the cis-acting heat 
shock elements within the promoter regions of the heat shock protein genes (Wang et al, 
2003,  Wu,  1995).    In  a  stressed  state,  when  non-native  or  damaged  proteins  are 
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detected,  induction of transcriptional activity  by heat  shock  factor  1 requires  that  the 
inactive  HSF1 monomer is converted to phosphorylated trimers  which have the capacity 
to bind to DNA, and which  also translocate from the cytoplasm  to the nucleus  (Baler  et 
al, 1993; Pockley,  2003; Santoro  2000; Sarge et al, 1993;  Westwood et al, 1993). 
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Figure 1.4. Regulation of transcription of heat shock protein genes by heat shock factor. 
Heat shock factor (HSF) is present in the cytoplasm in a monomeric state that is unable 
to bind to DNA.  Under conditions of stress such as heat shock, the flux of non-native 
proteins leads to phosphorylation and trimerisation of HSFs.  The trimers translocate to 
the nucleus, bind the promoter regions of heat shock protein genes and mediate heat 
shock protein gene transcription (Adapted from Pockley, 2003). 
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Activation induced trimerization of HSF1 occurs by the intermolecular coiled-coil 
interaction of the HR-A/B and HR-C domains (Figure 1.5) (Rabindran et al, 1993), 
which is mediated by leucine zipper domains (three hydrophobic heptad repeats of HR- 
A/B) in the N-terminus, which is in turn subject to intramolecular negative regulation 
by a fourth leucine zipper (hydrophobic heptad repeat of HR-C) in the C-terminus. The 
phosphorylated HSF1 binds to the heat shock element, thereby allowing transcription of 
the target genes (Santoro, 2000). 
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Figure 1.5.  The general structural and regulatory features of HSFs. (A) A schematic 
representation of HSF1 structural motifs corresponding to the DNA-binding domain 
(DBD), hydrophobic heptad repeats (HR-A, HR-B and HR-C), the carboxyl-terminal 
transcriptional activation domain and the negative regulatory domains all of which 
influence  HSF1  activity.  (B)  A  schematic  representation  of  the  intramolecular 
negatively regulated monomer which, upon exposure to stress, becomes activated to 
form homotrimers with DNA-binding activity (adapted form de Thonel et al, 2011 and 
Santoro, 2000). 
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Various mechanisms for HSF binding and regulation of heat shock protein gene 
transcription have been proposed, and these are described here with respect to heat 
shock protein 70 gene (HSPA/HSP70) (Abravaya et al, 1992; Morimoto, 1993).  In the 
absence of stress in cells, HSF is present in both the cytoplasm and the nucleus and is 
maintained in a non-DNA binding monomeric state through transient interactions with 
HSPA/HSP70, which prevents the activation of HSF (Abravaya et al, 1992; Morimoto, 
1993).   During heat shock, denatured and misfolded proteins accumulate and prevent 
new substrates for HSPA/HSP70 which compete for HSPA/HSP70 binding with HSF 
(Abravaya et al, 1992).  This results in the release of HSF from HSPA/HSP70. The 
released  HSF  proteins  oligomerises  into  a  trimeric  state  which  binds  to  the  HSE 
sequence within the heat shock gene promoter region and becomes inducibly 
phosphorylated by active protein kinases, such as protein kinase A (PKAca) , at serine 
residues in the carboxyl-terminal domain, thus activating stress induced transcription 
(Abravaya et al, 1992; Morimoto, 1993; Zhang et al, 2011).   Activated HSF induces 
transcription of the heat shock protein genes resulting in increased levels of synthesis of 
heat shock proteins within the cell. This eventually results in the formation of a new 
HSF-HSPA/HSP70 complex (Abravaya et al, 1992), which the HSF-HSPA/HSP70 
complex dissociates from the HSE resulting in the cessation of transcription (Figure 1.6) 
(Abravaya et al, 1992; Morimoto. 1993). 
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Figure 1.6.  Heat  shock  factor regulation (adapted from Morimoto. 1993).    In  the 
absence of stress in cells, HSF is maintained in a non-DNA binding monomeric state 
(1).  Following stress, HSF oligomerises into a trimeric state (2). HSF binds to specific 
sequences, HSE, in heat shock gene promoters (3), and becomes phosphorylated (4). 
Transcriptional activation of heat shock genes increases the levels of HSPA/HSP70 
which forms a HSF-HSPA/HSP70 complex (5).   HSF dissociates from the DNA and 
reverts back to a non-DNA binding monomer (Morimoto. 1993). 
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Complexes of HSPA/HSP70 and HSF trimers have been detected in cells and are 
consistent  with   the   role  of   chaperones  during  attenuation  of   the   heat   shock 
transcriptional response (Abravaya et al, 1992; Baler et al, 1992;  Morimoto, 1998).  In 
the absence of stress, overexpression of HSPA/HSP70 or DNAJ/HSP40 prevents the 
inducible transcription of heat shock genes (Morimoto, 1998; Mosser et al, 1993; Shi et 
al,  1998).    These  molecular chaperones  bind  directly to  the  HSF1  transactivation 
domain.  However, HSPA/HSP70 chaperones and associated co-chaperones, such as 
DNAJ/HSP40, which participates in the function of HSPA/HSP70,   alone are 
insufficient to prevent the appearance of HSF1 trimers, suggesting that the acquisition 
of transcriptional activity is a separate process from that of the regulation of trimer 
formation (Figure 1.7) (Morimoto, 1998) 
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Figure 1.7. Regulation of the heat shock response and the HSF cycle.  HSF1 exists in a 
controlled state as an inert monomer in either the cytoplasm or the nucleus through 
transient interactions with a number of chaperones such as HSPA/HSP70, HSPC/HSP90 
and DNAJ/HDJ1.  In response to heat shock the transcriptional activity of HSF1 is 
suppressed  by  direct binding of  HSPA/HSP70  and  HDJ1.    The  heat  shock  factor 
binding protein 1 (HSBP1), which is a conserved protein of 76 amino acids containing 
an extended hydrophobic heptad repeat interacts and binds to the hydrophobic heptad 
repeats of both HSF1 and HSPA/HSP70.  These events lead to the appearance of HSF1 
inert monomers and the dissociation of HSF1 trimers. (Taken from Morimoto, 1998). 
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1.2     Heat shock proteins 
 
 
It is necessary to describe the main heat shock protein families found in eukaryotic 
cells. However, due to the diversity of the heat shock protein families, which cover 
approximately five hundred client proteins, this section will focus on the five heat shock 
proteins studied examples. 
 
1.2.1   Heat Shock Protein 27 (HSPB) 
 
 
 
The ubiquitous heat shock protein 27 (HSPB/HSP27) has a molecular weight of 27 KDa 
and is a member of the small heat shock protein family.  HSPB/HSP27 is highly 
conserved amongst all species and has high homology with the eye lens α-crystallin 
proteins (Ciocca et al, 1993).  α-crystallin proteins are water soluble structural proteins 
that are present in high concentrations in the cytoplasm of eye lens fibre cells (de Jong 
et al, 1989). α-crystallin proteins exhibit chaperone-like properties, which include the 
ability to prevent the acceleration of denatured proteins; an increase in cellular tolerance 
to stress and assist in the maintenance of lens transparency and prevention of cataracts 
(Augusteyn, 2004; de Jong et al, 1989). HSPB/HSP27 production is induced by stimuli 
similar to those of the larger molecular weight heat shock proteins (Garrido et al, 1997; 
Garrido et al, 2006; Parcellier et al, 2003).   It is constitutively expressed in a variety of 
tissues and this expression is up-regulated under conditions of stress, including disease 
(Kappe et al, 2003). 
 
 
 
HSPB/HSP27 contains a homologous and highly conserved amino acid sequence the α- 
crystallin domain at the C-terminus.  These sequences consist of ~ 100 residues with a 
homology between 20-60 % and which forms β sheets which are necessary for the 
formation of stable dimers. It also possesses a less conserved proline/phenylalanine rich 
region containing one or two WF/EPF motifs, tryptophan, phenylalanine / glutamic 
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acid, proline, phenylalanine, at the NH2-terminus which are essential for protection, 
maintenance of the oligomeric structure and chaperone activity of the protein (Kim et 
al, 1998; Theriault et al, 2004, von Montfort et al, 2001).   HSPB/HSP27 acts as an 
ATP-independent molecular chaperone which inhibits protein aggregation and stabilises 
partially denatured proteins, which ensures protein refolding by the HSPA/HSP70 
complex (Ehrnsperger et al, 1997; Parcellier et al, 2003).  Also, HSPB/HSP27 assists in 
cytoprotection, by protecting cells against apoptosis under stress conditions (Charette et 
al, 2000; Pandley et al, 2000; Paul et al, 2002).  Apoptosis is inhibited by interactions 
with the cellular death associated protein DAXX7, facilitating the activation of protein 
kinase B, AKT, (Rane et al, 2003) and blocking the formation of the apoptosome, a 
multisubunit protein complex involved in the activation of apoptosis, (Pandley et al, 
2000; Paul et al, 2002). HSPB/HSP27 has been shown to interact with different 
cytoskeletal elements affecting actin polymerization (Ehrnsperger et al, 1997), to 
modulate intracellular reactive oxygen species content, to prevent apoptotic cell death 
activated by various stimuli including heat, serum deprivation, tumour necrosis factor 
alpha (TNF-α) and many commonly used anti-cancer drugs such as etoposide, 
doxorubicin, vincristine and cisplatin (Garrido, 2002; Huott et al, 1991; Oesterreich et 
al, 1996; Parcellier et al, 2003). 
 
 
 
Studies have shown HSPB/HSP27 to be phosphorylated in response to a number of 
extracellular-derived signals such as TNF-α, thrombin, and also under conditions of 
stress arising from heat shock, oxidative stress and disease (Charette et al, 2000; Landry 
et al, 1992). Phosphorylation of HSPB/HSP27 occurs at three serine residues, Ser-15, 
Ser-78 and Ser-82 (Landry et al, 1992; Stokoe et al, 1992), and is activated by a number 
of protein kinases including MAPKAPK-2, MAPKAPK-3, PKACα, p7056k, PKD1, 
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AKT1 and PCK7 (Butt et al, 2001; Doppler et al, 2005; Landry et al, 1992; Rane et al, 
 
2003; Stokoe et al, 1992). 
 
 
 
 
Overexpression of HSPB/HSP27 in disease states, such as cancer, facilitates the 
adaptation of cells to stressful conditions by assisting in the suppression of apoptosis, 
leading to a more aggressive disease phenotype (Aldrian et al, 2002).   Therefore, 
overexpression of HSPB/HSP27 correlates with poor patient prognosis in a variety of 
cancers such as include: colorectal, prostate, testis, breast, and ovarian cancers (Ciocca 
et al, 2005; Garrido et al, 1998; Garrido et al, 1997; Oesterreich et al, 1993; Richards et 
al, 1996).  In vivo, HSPB/HSP27 has also been implicated in cellular thermotolerance, 
although the expression of HSPB/HSP27 alone is insufficient to induce this state and 
requires the assistance of higher molecular weight heat shock proteins (Trautinger et al, 
1997). 
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1.2.2 Heat Shock Protein 40 (DNAJ) 
 
 
 
The heat shock protein 40 (DNAJ/HSP40) family, with an average molecular weight of 
 
40 KDa, is a large protein family consisting of over 100 members.   Members of the 
DNAJ/HSP40 family have been classified into three subtypes in relation to their domain 
structures, (subfamily A, Type I; subfamily B, Type II; subfamily C, Type III) 
(Cheetham and Caplan, 1998; Ohtsuka and Hata, 2000; Uchiyama et al, 2006 ). All 
subfamiles contain a highly conserved J domain of ~ 78 residues (Fink, 1999; Laufen et 
al, 1998).  In subfamiles I and II the J-domain is located at the N-terminus, whereas in 
subfamily III, the J-domain may be located at any position within the protein sequence. 
Both subfamiles I and II have a peptide-binding fragment located at the C-terminus of 
the proteins.  The N-terminal J-domains are connected to the peptide-binding fragments 
via a Gly/Phe rich linker in subfamiles I and II.  Subfamily I members, for example the 
human member HDJ2, contain two Zinc finger motifs between the J-domain and the C- 
terminal peptide-binding fragment.   In contrast, subfamily II members, such as the 
human member HDJ1, lack this feature (Caplan et al, 1992; Cyr et al, 1994; Zhong and 
Arndt, 1993).  Subfamily III members, as mentioned above, contain the J-domain, but 
this may be located at any position within the protein and therefore lack the other 
conserved domains found in subfamily I and II members. 
The main role of DNAJ/HSP40 is that of a cochaperone, which specifies the cellular 
action of HSPA/HSP70 proteins.  DNAJ/HSP40 plays an important role in protein 
folding, unfolding, translation, translocation and degradation, primarily by stimulating 
the ATPase activity of HSPA/HSP70 proteins (Fink et al, 1999, Minami et al, 1996; 
Qiu et al, 2006). DNAJ/HSP40 in both eukaryotic and prokaryotic cells interacts with 
HSPA/HSP70 in the presence of ATP suppressing protein aggregation (Cyr, 1994; Fink 
et  al,  1999).    It  has  been  suggested  that  DNAJ/HSP40  binds  to  the  non-native 
polypeptide first and then delivers the non-native polypeptide to HSPA/HSP70 for 
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folding (Bukau and Horwich, 1998; Gething and Sambrook, 1992; Hartl, 1996). The 
main function of DNAJ/HSP40 is to regulate adenosine triphosphate (ATP) dependent 
polypeptide binding by HSPA/HSP70 protein (Fan et al, 2003; Hartl and Hayer-Hartl, 
2009; Szabo et al, 1994).  DNAJ/HSP40 strongly accelerates the hydrolysis of ATP to 
adenosine diphosphate (ADP) resulting in the closing of the α-helical lid of the peptide 
binding domain and tight binding of the peptide substrate by HSPA/HSP70. 
DNAJ/HSP40  dissociates  from  HSPA/HSP70  (Hartl  and  Hayer-Hartl,  2009). 
Interaction of the substrate with HSPA/HSP70 is mediated by the J domain, which is 
present in all DnaJ/HSP40s (Hartl and Hayer-Hartl, 2009; Mayer et al, 2000). 
DNAJ/HSP40 also directly interacts with unfolded polypeptides and can convert 
HSPA/HSP70 to protein substrates (Hartl and Hayer-Hartl, 2009; Young et al, 2003). 
Following ATP-hydrolysis, a number of nucleotide exchange factors (NEF), such as 
Bag, and HSPBP1, bind to the HSPA/HSP70 ATPase domain and catalyse ADP-ATP 
exchange, which results in the opening of the α-helical lid and release of the substrate 
(Hartl and Hayer-Hartl, 2009).  The released substrate either folds to a native state; or is 
transferred to downstream chaperones, such as HSPC/HSP90, or rebinds to 
HSPA/HSP70 (Hartl and Hayer-Hartl, 2009). 
 
 
 
The J domain, which is common to all DNAJ/HSP40 family members, is responsible for 
the regulation of HSPA/HSP70 ATPase activity.  Interactions of HSPA/HSP70 proteins 
with DNAJ/HSP40 proteins produce HSPA/HSP70-DNAJ/HSP40 heterodimers which 
assist certain processes at specific locations within a cell (Fan et al, 2003; Liu et al, 
1998).  DNAJ/HSP40 also functions as homodimers which interact with non-native 
polypeptides of at least six residues in length, through hydrophobic interactions (Cyr, 
1994; Fan et al, 2003; Fink et al, 1999; Li et al, 2009).   The peptide-binding site of 
 
DNAJ/HSP40  also  serves  as  the  binding  site  for  the  C-terminal  EEVD  motif  of 
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HSPA/HSP70 through charge-charge interactions (Freeman et al, 1995; Li et al, 2009; 
Qian et al, 2002). 
 
 
 
The overexpression of DNAJ/HSP40 and HSPA/HSP70 has been observed in colorectal 
(Kanazawa et al, 2003) and gastric tumour tissues (Isomoto et al, 2003).  However, 
immunohistochemical analysis has shown only a small proportion of samples which 
were positive for DNAJ/HSP40 in gastric cancer tissues (Isomoto et al, 2003). 
HSPA/HSP70 and DNAJ/HSP40 were shown to be down-regulated in undifferentiated 
cancers, suggesting that HSPA/HSP70-DNAJ/HSP40 chaperone systems could have a 
role in tumour differentiation (Isomoto et al, 2003; Kanazawa et al, 2003). 
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1.2.3   Heat Shock Protein 60 (HSPD) 
 
 
 
 
The heat shock protein 60 family (HSPD/HSP60) is named after the average molecular 
weight of its members of 60 KDa.  Their genes are either moderately stress inducible or 
are highly expressed constitutively (Jindal et al, 1989; Neuer et al, 2000).  Although the 
majority of HSPD/HSP60 is located in the mitochondria, ~ 15 -20% of cellular 
HSPD/HSP60 is located in extramitochondrial sites, such as the cytosol, perioxisomes, 
endoplasmic reticulum and at the cell surface (Gupta et al, 2002; Pfister et al, 2005; 
Stefano et al, 2009; Stetler et al, 2010). They are responsible for the synthesis, 
transportation and refolding of essential proteins from the cytoplasm into the 
mitochondrial domain.   Their main function is the ATP-dependant folding and/or 
refolding of approximately 15-30% of total cellular proteins and they also assist in the 
folding of linear amino acid chains into their respective tertiary structures (Ranford et 
al, 2000; Trivedi et al, 2010; Urushibara et al, 2007). 
 
 
 
HSPD/HSP60 has two main roles in relation to mitochondrial protein transport: the 
catalysis of the folding of proteins destined for the mitochondrial matrix and 
maintenance of proteins in an unfolded state for transmembrane transportation (Koll et 
al,  1992).    In  vitro  HSPD/HSP60  has  been  identified  as  a  single-stranded  DNA 
(ssDNA) binding protein that simulates DNA replication (Smiley et al, 1992). 
HSPD/HSP60 has been found to associate with ssDNA regions and to bind to ssDNA of 
active sequences with high specificity for the template of a putative origin of 
mitochondrial DNA (mtDNA) replication in a strand specific manner (Kaufman et al, 
2003; Kaufman et al, 2000). 
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Under normal physiological conditions, HSPD/HSP60 is located typically in the 
mitochondria, but can also be found in the cytoplasm (Itoh et al, 2002; Jindal et al, 
1989; Neuer et al, 2000). HSPD/HSP60 is composed of monomers that form a double 
heptameric ring structure (Cheng et al, 1990) comprised of a large central cavity 
whereby unfolded proteins bind via hydrophobic interactions (Fenton et al, 1994).  Each 
subunit of HSPD/HSP60 contains three domains: the apical domain, the equatorial 
domain, which contains the binding site for ATP, and the intermediate domain which 
links the apical and equatorial domains (Ranford et al, 2000). 
 
 
 
HSPD/HSP60 proteins play an important role in preventing apoptosis in the cytoplasm 
and are also associated with the immune response and cancer (Hansen et al, 2003; Itoh 
et al, 2002).    The cytoplasmic HSPD/HSP60  forms a complex with various other 
proteins that are responsible for apoptosis and regulates their activity (Itoh et al, 2002). 
HSPD/HSP60 has been shown to influence apoptosis in the immune response (Hansen 
et al, 2003) and in cancer cells (Itoh et al, 2002). 
 
 
 
In cancer, HSPD/HSP60 expression appears either to inhibit apoptotic and necrotic cell 
death or plays a role in the activation of apoptosis, dependent on the tumour type 
(Capello et al, 2006; Urushibara et al, 2007).   A loss of HSPD/HSP60 expression in 
bladder carcinomas, ―indicates a poor prognosis and the risk of developing tumour 
infiltration‖, (Lebret et al, 2003).  In the initial stages of ovarian cancer, HSPD/HSP60 
is over-expressed with a decrease in expression as the disease progresses, associated 
also with tumour aggressiveness (Lebret et al, 2003; Schnieder et al, 1999).  These 
changes in HSPD/HSP60 expression levels have the potential to be ―new useful 
biomarkers‖ for diagnostic and prognostic purposes (Capello et al, 2006). 
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1.2.4   Heat Shock Protein 90 (HSPC) 
 
 
 
 
The heat shock protein 90 family (HSPC/HSP90) has an average molecular weight of 
 
90 KDa and is one of the most abundant of the heat shock proteins, comprising 
approximately 1 - 2% of total cellular proteins under unstressed conditions (Csermely et 
al, 1998). HSPC/HSP90 plays an important role in the folding of newly synthesized 
proteins and the stabilization and refolding of denatured proteins after stress conditions; 
intracellular protein transport; protein degradation; facilitation of cell signalling and in 
suppressing  the  aggregation  of  numerous  client/substrate  proteins  (Buchner,  1999; 
Jakob et al, 1995; Miyata and Yahara, 1992; Wiech et al, 1992). 
 
 
 
The HSPC/HSP90 family consists of both inducible and constitutive isoforms, with the 
two major cytoplasmic isoforms being HSPC1a/HSP90α (the inducible isoform and 
HSPC2a/HSP90β (the constitutive isoform) (Chen et al, 2006; Csermely et al, 1998).  A 
further  identified  isoform  of   the  HSPC/HSP90   family  is   HSPC3a/HSP90N,  a 
constitutive protein associated with cellular transformation (Grammatikakis et al, 2002; 
Sreedhar et al, 2004).  A number of HSPC/HSP90 analogues have also been reported: 
HSPA9/Grp75, localized in the endoplasmic reticulum (ER) and 
HAPC5a/HSP75/TRAP1, localized in the mitochondrial matrix (Csermely et al, 1998; 
Sreedhar et al, 2004). 
 
 
 
All members of the HSPC/HSP90 family contain three structural domains: a highly 
conserved N-terminal nucleotide binding pocket ~ 25 KDa in length which possesses a 
high affinity ATP binding site (Chadli et al, 2000; Pearl and Prodromou, 2000; 
Prodromou et al, 1997; Prodromou and Pearl, 2003), a central domain ~ 40 KDa in 
length   which   is   involved   in   substrate   protein   folding   and   ATPase   activity 
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(Grammatikakis et al, 2002; Meyer et al, 2003) and a C-terminal domain ~ 12 KDa in 
length,  which  acts  as  a  second  ATP  binding  site  when  the  N-terminal domain is 
occupied (Garnier et al, 2002; Marcu et al, 2000;  Soti et al, 2002). 
 
 
 
HSPC/HSP90 expression can be associated with various types of cancers. HSPC/HSP90 
in cancer cells exists in a ―hyperactive state‖ in the diseased tissue compared to that of 
the normal surrounding tissue (Kamel et al, 2003). In this highly active state 
HSPC/HSP90 influences various other proteins that contribute to the pathogenesis of 
the disease. These include cell growth promotion, evasion of apoptosis and stimulation 
of angiogenesis (Kamel et al, 2003). Over-expression of HSPC1a/HSP90α has been 
associated with poor prognosis of leukaemia (Yufu et al, 1992), pancreatic carcinoma 
(Gress et al, 1994) and breast cancer (Jameel et al, 1992). 
 
 
 
A study undertaken by Ogata et al, (2000) in pancreatic carcinoma tissue showed over- 
expression of HSPC1a/HSP90α compared to pancreatitis and normal pancreas tissue. In 
contrast, HSPC2a/HSP90β was constitutively over-expressed in pancreatic carcinoma, 
pancreatitis and normal pancreatic tissues.   These results suggest that HSPC2a/HSP90β 
is correlated to structural conformation by forming complexes with tubulin and actin 
which constitute the cytoskeleton, and that HSPC1a/HSP90α is directly or indirectly 
involved with cell proliferation and carcinogenesis (Ogata et al, 2000). 
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1.2.5   Heat Shock Protein 70 (HSPA) 
 
 
 
 
The heat shock protein 70 (HSPA/HSP70) family is the most conserved group of the 
heat shock proteins (Oehler et al, 2000).   HSPA/HSP70 is an anti-apoptotic protein 
which blocks a number of steps in the stress-induced apoptotic pathway (Kang et al, 
2009; Lanneau et al, 2007).  Its functions include the folding and assembly of newly 
synthesized proteins, refolding of misfolded and aggregated proteins, regulation of 
apoptosis, membrane translocation of organellar and secretory proteins, and controlling 
the activity of regulatory proteins (Figure 1.8) (Beckman et al, 1990; Kang et al, 2009; 
Mayer and Bukau, 2005; Seidberg et al, 2003). 
 
 
 
During stress conditions, HSPA/HSP70 is induced at high levels through a combination 
of transcriptional activation, preferential translation and mRNA stabilization. It inhibits 
cell death by preventing the aggregation of cell proteins (Calderwood et al, 2005; 
Lindquist and Craig, 1988).  HSPA/HSP70 proteins are weak ATPases which cycle 
through high and low affinity substrate binding states by nucleotide hydrolysis. An ATP 
bound  HSPA  will  bind  substrates  with  low  affinity,  whereas  an  adenosine  5‘ 
diphosphate (ADP) bound HSPA will bind substrates with high affinity (Schmid et al, 
1994; Shaner and Morano, 2007). 
 
 
 
 
An extensive literature and database search undertaken by Brocchieri et al, (2008) 
identified 130 human HSPA/HSP70 proteins.  Subsequent analysis revealed 86 groups 
of non-identical sequences which were further analysed and clustered into 13 groups.  A 
representative sequence was selected from each of the 13 groups to query the human 
genome using NCBI Build 36.1 and to identify conserved and diverged sequences. This 
process yielded 47 loci, which included coding HSPA/HSP70-like sequences, of which 
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seventeen corresponded to  known  genes  recognized in the  genome  annotation (Table 
 
1.4).    Included  within  the  latter  seventeen was  HSPA 7, which  is considered to  be  a 
pseudogene. 
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Figure  1.8  Chaperone-assisted protein  folding (taken  from  Mosser  and  Morimoto, 
 
2004).   HSPA/HSP70 is required for the productive folding of newly synthesized 
proteins, translocation across intracellular membranes and import into and export of the 
nucleus. Heat shock and other protein damaging stresses cause protein misfolding and 
aggregation, which can be limited by heat shock proteins. These misfolded proteins can 
be rescued by the folding activity of HSPA/HSP70.  Proteins that cannot be refolded are 
targeted to the proteosome for degradation. 
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Table 1.4.  Expression and location of the human HSPA genes (Taken from Brocchieri 
et al, 2008) 
 
Gene  Cell Locale  Tissue Expression Location 
HSPA8 Cytosol All tissues highly 
expressed 
Constitutive. 
Moderately 
induced by 
heat shock. 
11q24.1 
HSPA12A NK  Brain/kidney/muscle Constitutive. 
Induced by 
stress. 
10q25.3 
HSPA12B NK  Skeletal/heart muscle Constitutive. 
Induced by 
stress. 
20p13 
HSPA9B Mitochondria/ 
ER/Cytosol/cystolic 
vesicles/membrane 
surface 
Many tissues Constitutive 5q31.2 
HSPA4 Cytosolic Most tissues Constitutive. 
Not induced by 
heat shock. 
5q31.1 
HSPA4L Cytosol Testis  Constitutive. 
Induced by 
heat shock. 
4q28.1 
HSPH1 Cytosol Most tissues Constitutive. 
Induced by 
heat shock. 
13q12.3 
HYOU1 ER/Cytosol Liver/pancreas Induced by ER 
stressors 
11q23.3 
HSPA14 Cytosol, associated 
ribosomes 
Many tissues Undetermined 10p13 
STCH Microsomas All tissues Constitutive 21q11.2 
HSPA2 Nucleus Testis/skeletal and heart 
muscles/oesophagus/bra 
in 
Constitutive 14q23.3 
HSPA1A Cytosol All tissue Strongly 
induced by 
heat shock 
6p21.33 
HSPA1B Cytosol All tissue Strongly 
induced by 
heat shock 
6p21.32 
HSPA1L Cytosol Spermatides Constitutive. 
Not induced by 
heat shock. 
6p21.33 
HSPA6 Cytosol/Nucleus Most tissues Induced by 
heat shock 
1q23.3 
HSPA7      1q23.3 
HSPA5 ER  All tissue Induced by ER 
stressors 
9q33.3 
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The  human  HSPA  genes  encode  proteins  which  have  been  clustered  into  seven  major 
distinct  evolutionary groups  (Figure  1.9), with  noticeable subgroups relating  to 
phylogenetic and  other  related  data,  including  pseudogenes, exon-intron and  protein 
features  (Brocchieri et al, 2008). 
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Figure 1.9.   Phylogenetic tree of 17 human HSPA proteins. This is based on the 
alignment of their protein products defined by bootstrap support values over 85 %. 
Group I refers to HSPA12B and HSPA12A, Group II, HSPA9B AND DnaK, Group III, 
HYOU1, HSPA4, HSPA4L and HSPH1, Group IV, HSPA14, Group V, STCH, Group 
VI, HSPA1B, HSPA1A, HSPA1L, HSPA2, HSPA8, HSPA7 and HSPA6 and Group 
VII, HSPA5. The distance scale of 0.2 = 20% represents the differences between 
sequences. The branch lengths are proportional to the scale, so two sequences with 
longer branches are more diverged than sequences with shorter branches (taken from 
Brocchieri et al, 2008). 
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Group I is characterised by two similar, but diverged, sequences, HSPA12A and 
HSPA12B.  Both sequences possess identical exon-intron structures and 12 exons have 
been located within their coding regions.  Group II includes the mitochondrial protein 
HSPA9B, encoded by a nuclear gene which possesses 17 exons, and the DnaK sequence 
from E. coli.   Group III proteins include three closely related 105/110 KDa proteins 
whose genes all have a common structure of 18 – 19 exons.  These Group III proteins 
include  HSPA4L,  HSPA4  and  HSPH1,  which  all  occur  as  two  isoforms.    Also 
contained within Group III is the distantly related sequence HYOU1, which encodes the 
170 KDa protein, Grp170, known to exist in three isoforms, and whose genes possess 
 
16, 24 or 25 exons respectively (Brocchieri et al, 2008). 
 
 
 
 
Group IV includes the sole sequence HSPA14, of which two isoforms exist, possessing 
 
4  and  14  exons  respectively.   Although closely associated with Group  III,  cluster 
analysis showed a bootstrap support value of 81% for HSPA14, which in below the 
bootstrap threshold value of 85% and therefore the latter protein in allocated a separate 
evolutionary group.   Group V also comprises a single sequence, STCH, which has 5 
exons within the coding region and is weakly related to Group III and Group IV, having 
a bootstrap support value of 55.6% (Brocchieri et al, 2008). 
 
 
 
Group VI contains seven sequences, each with bootstrap values of 100%, which have 
been divided into three distinct subgroups.   Subgroup one includes the intronless 
sequences for HSPA1A, HSPA1B and HSPA1L, which are positioned within the MHC- 
III region on the short arm of chromosome 6.  Subgroup two contains HSPA2 and 
HSPA8, existing as two isoforms which possess 7 – 8 exons, whilst subgroup three 
comprises HSPA6 and HSPA7.   Finally, Group VII contains one sequence HSPA5, 
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which has 8 exons within the coding region and is closely related to Group VI having a 
bootstrap support value of 78.9% (Brocchieri et al, 2008). 
 
 
 
The HSPA family share significant similarities in sequence and structure, based on 
highly conserved bipartite domain structure (Shaner and Morano, 2007).  This structure 
comprises three major functional domains, including a highly conserved N-terminal 
ATPase domain (NBD) with a molecular mass of ~ 44 KDa which controls the closing 
and opening of the peptide domain. An adjacent well-conserved substrate binding 
domain (SBD), with a molecular mass of ~ 18kD, contains a hydrophobic pocket and 
lid-like structure over the pocket and a conserved C-terminal domain, with a molecular 
mass of ~ 10 KDa, which chaperones denatured proteins and peptides (Fiege and Polla, 
1994; Hartl, 1996; Hartl and Hayer-Hartl, 2002; Mao et al, 2006; Mayer and Bukau, 
 
2005; Mosser and Morimoto, 2004; Osipiuk et al, 1999; Wisniewska et al, 2010). 
When  non-active,  HSPA/HSP70  is  usually  in  an  ATP  bound  state.    As  newly 
synthesized proteins emerge, the SBD of HSPA/HSP70 recognizes and interacts with 
sequences of hydrophobic amino acid residues, stimulating the ATPase activity of 
HSPA/HSP70 and increasing ATP hydrolysis.  As ATP is hydrolyzed to ADP, the 
hydrophobic pocket tightly closes, binding the peptides to the SBD (Hartl, 1996; Hartl 
and  Hayer-Hartl,  2002;  Mao  et  al,  2006;  Mayer  and  Bukau,  2004;  Mosser  and 
Morimoto, 2004).  In the case of partially synthesized peptide sequences, HSPA/HSP70 
will prevent aggregation, allowing them to re-fold correctly.   All three domains play 
important roles in tumour immunity, not only by enabling intracellular HSPA/HSP70 to 
prevent tumour apoptosis, but also to promote the generation of stable complexes with 
cytoplasmic tumour  antigens  stimulating anti-tumour immunity (Calderwood  et  al, 
2005; Schmitt et al, 2007). Under normal conditions, HSPA/HSP70 functions as an 
 
ATP dependent molecular chaperone and is found mainly in the cytosol.  Various stress 
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conditions   such   as   heat   shock,   hypoxia   and   cancer   increase   the   synthesis   of 
HSPA/HSP70,  and also cause it to migrate to the  nucleus and associate  with nuclear 
proteins (Santoro, 2000). 
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Heat shock proteins can be toxic if present in cells for any prolonged period of time and 
must therefore be stringently regulated.   Theodorakis et al, (1999) examined the 
expression of HSPA/HSP70 after heat shock in thermotolerant (heat resistant) and non- 
thermotolerant human hepatoblastoma cells.  During and after heat shock, HSPA/HSP70 
transcriptional activity in both thermotolerant and non-thermotolerant cells was very 
similar.    mRNA stability and expression of    HSPA/HSP70 was reduced in 
thermotolerant cells, compared to the non-thermotolerant cells after heat shock, 
suggesting that the thermotolerant cells possibly limit HSPA/HSP70 expression to avoid 
cytotoxic effects. 
 
 
 
The HSPA/HSP70 gene family is of particular interest with regard to three members 
(HSPA1A/HSP70-1, HSPA1B/HSP70-2 and HSPA1L/HSP70-Hom; Milner and 
Campbell, 1990). The nomenclature now used is specific to the allelic level of the 
genes, whose genes are located within the major histocompatibilty complex class III 
region (MHC-III)  on  the short  arm of  chromosome 6  (6p21.3),  and  are intronless 
(Figure 1.10). 
 
 
 
 
 
 
 
Figure 1.10.  Localization of the three HSPA genes (H = HSPA1L, 1 = HSPA1A, 2 = 
HSPA1B). HSPA1A and HSPA1B are 11 kb apart and HSPA1L is 4 kb telomeric to 
HSPA1A. (Taken from Singh et al, 2007) 
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Although these three genes have similar sequences, they differ in their regulation.  Both 
HSPA1A and HSPA1B have been shown to encode identical protein products of 641 
amino acids, and HSPA1L has been identified at a location 4 kb telomeric to HSPA1A 
with a 90% similarity in amino acid sequence (Sargent et al, 1989a, Sargent et al, 1989, 
Milner and Campbell, 1990).   Both HSPA1A and HSPA1B have been shown to be 
highly expressed in mammalian cells that have been subjected to heat shock at 42oC. 
 
HSPA1A is also constitutively expressed at low levels.   HSPA1L, which has no heat 
shock consensus sequence, has been shown to be expressed at low levels both 
constitutively and after heat shock at 42oC, with no comparable difference in levels 
(Milner and Campbell, 1990). 
 
 
 
1.2.5.1.          Polymorphisms in HSP70 genes 
 
 
 
 
The term polymorphism relates to the presence of multiple allelic variants of a gene and 
is a significant part of the genetic variation that exists in a population. The MHC region 
is one of the most highly polymorphic regions in the human genome.  Single nucleotide 
polymorphisms (SNPs)  are  the most  common type  of  genetic variation within the 
human genome.  They involve variation between two sequences by a single base pair, 
often due to a base-pair substitution, of which two subtypes exist: transitions, whereby a 
purine or pyrimidine base is substituted by another and transversions, whereby a purine 
is substituted by a pyrimidine or vice versa (Singh et al, 2007). 
 
 
 
Four different polymorphic locations have been described in  HSPA1A (Table 1.5). 
Three lie within the 5‘ flanking region of the gene, which is not transcribed into RNA 
and the 5‘ untranslated region (UTR).  They are located at positions -110 (A to C 
transversion), 120  (T to C transition) and  190  (G to C transversion).   The fourth 
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polymorphic location is found in the coding region of the gene at the position 438 (C to 
 
T transition) (Singh et al, 2007). 
 
 
 
 
The HSPA1B gene also has four different polymorphic locations (Table 1.5).  One lies 
within the 5‘ flanking region of the gene at the position 145 (C to T transition), and two 
lie within the coding region of the gene at positions 1267 (A to G transition) and 2074 
(C to G transversion).  The fourth polymorphism is located in the 3‘ UTR region at the 
position 2257 and is a result of a duplication of the pentameric sequence AAGTT which 
gives rise to two alleles (183bp and 188bp) differing in 5bp (Singh et al, 2007). 
 
 
 
Four different polymorphic sites have also been discovered in HSPA1L (Table 1.5). 
These lie within the coding region of the gene at positions 1097 (C to T transition), 
2180 (G to A transition), 2437 (C to G transition) and 2763 (G to A transition).  The 
polymorphisms at position 2437 and 2763 lead to amino acid substitutions at position 
493 from Methionine (Met) to Threonine (Thr) and position 602 from Glutamic acid 
 
(Glu) to Lysine (Lys) respectively (Singh et al, 2007). 
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Table 1.5.  Single nucleotide polymorphisms in three human HSPA genes (taken from 
 
Singh et al, 2007) 
 
 
SNP position Nucleotide Change  
HSPA1A 
-110 (5‘ flanking) A to C transversion  
120 (5‘ UTR) T to C transition  
190 (5‘ UTR) G to C transversion  
438 (coding) C to T transition  
HSPA1B 
145 (5‘ flanking) C to T transition  
1267 (coding) A to G transition Generates a Pst I site giving rise to 
two alleles, L allele (8.5 kb) and U 
allele (9.0 Kb) identified according 
to their length 
2074 (coding) C to G transition  
2257 (3‘UTR) Penta-duplication of the 
sequence AAGTT 
This  gives  rise  to  two  alleles  A1 
(183 bp) and A2 (188 bp) differing 
in 5 bp. 
HSPA1L 
1097 (coding) C to T transition  
2180 (coding) G to A transition  
2437 (coding) C  to  T  transition  (aa 
substitution) 
An AA change at position 493 from 
a  non-polar  hydrophobic 
Methionine (Met) to a polar neutral 
Threonine (Thr). The change of AA 
could be associated with altered 
peptide binding specificity and 
efficiency of HSP70. 
2763 (coding) G  to  A  transition  (aa 
substitution) 
An AA change at position 602 from 
Glutamic acid  (Glu)  to  Lysine 
(Lys). This change lies within the 
Nco I restriction site 
 
 
 
Due to the diversity of heat shock protein families, which cover approximately five 
hundred client proteins, the present study will only focus on HSPA/HSP70. 
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1.3 Activation of HSPA/HSP70 
 
 
 
1.3.1 Heat shock 
 
 
 
 
As stated previously, heat shock proteins are up-regulated in response to a variety of 
stressful conditions, including thermal stress (Tolson and Roberts, 2005; Welch, 1993). 
Environmental  temperatures  have  an  impact  on  the  cellular  stress  response  and 
determine how cells adapt to subsequent changes in temperature. This is referred to as 
thermotolerance, a cellular adaptation resulting from a single severe non-lethal exposure 
to heat which allows cells to better survive subsequent potentially lethal heat stress 
episodes.  The accumulation of stress-induced heat shock proteins in cells is associated 
with thermotolerance and is responsible for their ability to survive not only lethal heat 
stress, but also a variety of other stresses.  The characteristics for thermotolerance are 
dependant on survival of the cell(s) exposed to an otherwise lethal heat stress, synthesis 
of heat shock proteins and a short duration of the thermotolerant state (Moseley, 1997). 
 
 
 
As discussed previously, Theodorakis et al, (1999) compared the expression and mRNA 
degradation in thermotolerant (cells that had been subjected to an initial heat shock) and 
non-thermotolerant (cells under normal conditions that had not been subjected to an 
initial heat shock) human liver hepatocellular carcinoma (HepG2) cells after heat shock. 
The normal physiological temperature for human cells is 37oC.  Induction of heat shock 
protein genes occurs when heat shock is applied just above the normal growth 
temperature.   Cells were made thermotolerant by the application of a nonlethal heat 
shock  (43oC  for  1.5  h)  followed  by  a  recovery  period  of  24  h  at  37oC.    Both 
thermotolerant and non-thermotolerant cells were thermally stressed at 43oC for 1.5 h, 
 
followed by a 6 h recovery period at 37oC.   Results showed limited expression of 
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HSPA/HSP70 in thermotolerant cells, compared with non-thermotolerant cells after heat 
shock.   It was suggested that this was due to both a decrease in HSPA/HSP70 
transcription and an increase in HSPA/HSP70 mRNA degradation, thus increasing 
cellular levels of this protein in the recovery period, during which cells returned to non- 
heat shock conditions 37oC (Theodorakis et al, 1999).  In contrast, during the heat shock 
period, no significant differences were observed in the levels of HSPA/HSP70 
transcription in thermotolerant and non-thermotolerant cells.  HSPA/HSP70 mRNA was 
observed to be less stable in thermotolerant cells, with a half-life in non-thermotolerant 
cells of approximately 1 h and approximately half an hour in thermotolerant cells. 
However, the half-life of HSPA/HSP70 has previously been reported to be longer in 
comparison to the recovery period after stress (Theodorakis and Morimoto, 1987).  The 
explanation suggested for this is that, under normal conditions, levels of HSPA/HSP70 
mRNA are unstable, but during heat shock the mRNA becomes more stable because its 
degradation is affected by stress.    In  thermotolerant cells subjected to  heat shock, 
mRNA degradation begins immediately after returning to normal conditions, and 
therefore it is suggested that mRNA degradation is accelerated in thermotolerant cells 
resulting in a reduced HSPA/HSP70 mRNA half-life. 
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1.3.1 Glioma 
 
 
 
 
Gliomas, in the form of astrocytomas, anaplastic astrocytomas and glioblastomas, are 
the most common primary brain tumours and comprise about 2% of all newly diagnosed 
cancers every year in the UK (Chandana et al, 2008; Khalil, 2007). Gliomas are defined 
as tumours of the central nervous system (CNS), the majority of which arise from glial 
cells displaying histological, immunohistochemical and ultrastructural evidence of glial 
differentiation (Khalil, 2007). The classification of brain tumours is based upon cell 
morphology and the degree of malignant behaviour, which is in turn dependent on 
nuclear atypia, mitoses, microvascular proliferation and necrosis (Behin et al, 2003). 
The World Health Organization (WHO) classifies brain tumours into various subtypes 
such as astrocytoma, oligodendroglioma, oligoastrocytoma and ependymoma and into 
four malignancy grades; Grade I pilocytic astrocytoma, Grade II diffuse astrocytoma 
(including oligodendroglioma), Grade III anaplastic astrocytomas and Grade IV 
gliomablastoma (Table 1.6) (Khalil, 2007; Kleihues et al, 2002; Louis et al, 2007). 
 
 
Table 1.6. WHO grading and survival of gliomas (adapted in part from Christine et al, 
 
2005). 
 
WHO 
Grade 
Glioma Histological Features Survival 
I Pilocytic astrocytoma Rosenthal fibres +10  years 
II Diffuse astrocytoma/ 
oligodendroglioma/ mixed 
oligoastrocytoma 
Moderate hypercellularity 
with occasional nuclear 
atypia 
+5 years 
III Anaplastic astrocytoma / 
oligodendroglioma/ 
oligoastrocytoma 
Increased hypercellularity, 
Nuclear atypia with high 
mitotic activity, 
microvascular proliferation 
2-3 years 
IV Glioblastoma multiforme Marked nuclear atypia, 
mitotic activity, prominent 
endothelial proliferation and 
tumour necrosis 
9-12 months 
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Pilocytic astrocytomas are defined as Grade I tumours and characterised by their slow 
growth rate and regressive nature and are often considered as benign tumours.  Pilocytic 
astrocytomas generally develop in young children and young adults (Behin et al, 2003; 
Parsa and Givard, 2008).  They usually originate in the optic tracts, hypothalamus or 
basal ganglia and in the cerebellum and brainstem (posterior fossa) but they may occur 
in any area where astrocytes are present, such as the spinal cord and the cerebral 
hemespheres (Behin et al, 2003; Kleihues & Cavenee, 2000).  Imaging using MRI and 
CT scans show pilocytic astrocytomas as solid, cystic, well circumscribed and contrast- 
enhancing tumours (Figure 1.11) (Behin et al, 2003). 
 
 
 
 
 
 
Figure 1.11. Magnetic resonance imaging showing features of pilocytic astrocytomas 
 
(rad.usuhs.mil/rad/who/JPA.html). Post-contrast image reveals a large irregular, 
 
multilobulated shape, in the enhancing mass in the cerebellar hemisphere. 
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Diffuse astrocytomas, referred to as Grade II tumours, such as oligodendrogliomas, are 
well differentiated tumours that are most prevalent in young adults, commonly located 
in the frontal, temporal and insular regions within the cerebral hemispheres (Behin et al, 
2003; Huang et al, 2000).  They originate from oligodendrocytes, which are the myelin- 
forming cells of the central nervous system, and which play a crucial role in the normal 
functioning of the brain (Jiang et al, 2007).   Although slow growing, they have the 
potential for malignant progression and to develop into anaplastic astrocytomas (Grade 
III tumours) and eventually into gliomablastomas (Grade IV tumours) (Behin et al, 
2003; Huang et al, 2000).  Contrast enhancement, whereby the contrast between normal 
and cancerous tissue is enhanced, is generally absent in MRI and CT images (Figure 
1.12).      However,   presence  of   contrast  enhancement  would   suggest   malignant 
 
transformation into a higher grade of tumour (Behin et al, 2003). 
 
 
 
 
 
 
Figure 1.12. Magnetic resonance imaging showing features of a diffuse astrocytomas 
 
(rad.usuhs.mil/rad/who/JPA.html) post-contrast image reveals a large enhancing irregular, 
 
mass in the left frontal lobe. 
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Anaplastic astrocytomas, defined as Grade III tumours, may originate either ―de novo‖ 
without previous indication of a malignant lesion or as a transition from low grade 
lesions (Kleihues & Cavenee, 2000).  The latter types of tumours are less common and 
generally represent a short-term intermediate lesion during malignant transition from 
Grade II to Grade IV tumour status (Behin et al, 2003; Huang et al, 2000).  Histological 
astrocyte and anaplastic features include pleomorphism, increased tumour cellularity, 
high mitotic activity, microvascular activity, nuclear atypia and necrosis (Brat et al, 
2008).  On MRI and CT images (Figure 1.13) they present as an irregular hypodense 
 
lesion with varying degrees of contrast enhancement and oedema (Behin et al, 2003). 
 
 
 
 
 
 
Figure   1.13.   Magnetic   resonance   imaging   showing   features   of   an   anaplastic 
 
astrocytomas   (rad.usuhs.mil/rad/who/JPA.html)   post-contrast   image   reveals   a   large 
 
enhancing irregular, mass in the left temporal lobe 
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Glioblastoma multiforme (GBM) tumours are defined as Grade IV and are amongst the 
most common glioma tumours. They can arise in one of two ways, either spontaneously 
without prior indication of a malignant lesion, or as a malignant progression from a 
lower grade lesion (Kleihues & Cavenee, 2000; Tso et al, 2006).  GBMs are most 
prevalent in older adults (45-60 years), and usually arise in the frontal, temporal and 
insular regions of the cerebral hemispheres, although they occasionally may be located 
in the brainstem or  cerebellum (Behin et al, 2003; Brat et al, 2008).    GBMs  are 
normally represented in MNR images as a grossly irregular hypodense heterogeneous 
mass, with various degrees of contrast-enhancement and vascogenic oedema (Figure 
1.14).  The most common presentation is as a ring-like enhancement surrounding a 
necrotic center (Behin et al, 2003, Brat et al, 2008). 
 
 
Figure  1.14.  Magnetic  resonance  imaging  features  of  glioblastoma  multiforme 
 
(rad.usuhs.mil/rad/who/JPA.html)  (A)  post-contrast  image  revealing  a  multilobulated, 
 
enhancing mass in the right temporal lobe. (B) glioblastoma; tumour is an irregularly 
shaped, heterogeneous mass with central necrosis and ring-like contrast enhancement 
surrounded by oedema. 
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Cancerous tissues generally contain high levels of stress proteins, particularly members 
of the chaperone and heat shock protein families (Ciocca and Calderwood, 2005; Graner 
et al, 2007).  The response of cells to such stress conditions is in part dependent on the 
concentration of heat shock proteins in the cell prior to stress.   The intensity and 
duration of the stress will have an influence on the eventual outcome for the cell of 
either survival, apoptosis or necrosis (Mosser and Morimoto, 2004; Multhoff, 2007). 
During a stress response, while total protein synthesis is inhibited, the synthesis of 
specific heat shock proteins is elevated in recovering cells (cytoprotected state) 
(Lindquist and Craig, 1988).   Initiation of apoptosis induces the expression of heat 
shock proteins, which continues until protein synthesis ceases (Mosser and Morimoto, 
2004; Parsell et al, 1994). 
 
 
 
 
Protein-damaging environmental and physiological stresses induce the expression of 
heat shock proteins that are often constitutively over-expressed in various cancer cells 
and are also involved in tumour cell proliferation, cellular death, metastasis and 
differentiation, suggesting that they may be a contributing factor in tumourigenesis 
(Calderwood et al, 2006, Ciocca and Calderwood, 2005; Graner et al, 2007; Mosser and 
Morimoto, 2004; Powers et al, 2007).  It has been widely reported that elevated levels 
of HSPA/HSP70, HSPB/HSP27 and HSPC/HSP90, either as combinations or 
individually, have been observed in breast, uterine, renal, brain, endometrial and 
osteosarcoma cancers (Graner et al, 2007; Jolly and Morimoto, 2000). 
 
 
 
Numerous publications have studied heat shock protein expression and heat stress 
chraracterization in a wide range of tumour cell types (Calderwood et al, 2006; Ciocca 
and Calderwood, 2005; Li and Lee, 2006) However, studies are rare in different types of 
brain  tumours  (Fuse,  1991;  Hermisson  et  al,  2000;  Wang  et  al,  2006).    A  study 
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undertaken by Graner et al, (2007) examined changes in heat shock protein gene 
expression and localization of heat shock proteins in a number of brain tumour cell lines 
both at intracellular and cell surface/extracellular levels under normal conditions and the 
effect of heat shock on expression and localisation (Table 1.7). 
 
 
Table 1.7. Summary of inducible HSPA/HSP70 expression in select brain tumour cell 
lines (relative to unstressed cells or to non-heat shock protein expression such as actin) 
(adapted from Graner et al, 2007). 
 
 HSPA/HSP70 expression 
(Western blot) 
Cell surface 
HSPA/HSP70 expression 
(flow cytometry 
Extracellular 
HSPA/HSP70 release 
(ELISA) 
Cell Line Constitutive Heat 
Stress 
Constitutive Heat 
Stress 
Constitutive Heat 
Stress 
D54MG 
Adult malignant 
+ ++ + ++ + ++ 
D392MG 
Adult malignant 
glioma 
+/- +++ ++ +++ ++ +++ 
D341MED 
Pediatric 
medulloblastoma 
++ +/- + ++ + +++ 
SMA560 
Murine 
anaplastic 
astrocytoma 
+/- ++++ +/- ++ + ++++ 
(+/–, Detectable expression; +, moderate expression; ++     ++++, high to very high expression) 
 
 
Although a number of heat shock proteins were examined, the most significant effects 
of heat shock related to HSPA/HSP70, and a clear increase in HSPA/HSP70 expression 
following heat shock was reported by these authors.  Western blot analysis showed no 
consistent   correlation   between   the   different   cell   lines   regarding   HSPA/HSP70 
expression as a result of heat shock. D392MG (adult malignant glioma) (Ostrowski et 
al, 1991) and SMA560 (a murine anaplastic astrocytoma) (Sampson et al, 1997; Serano 
et al, 1980) cell lines showed significantly higher levels of HSPA/HSP70 gene 
expression compared to D54MG (derived from line A172, adult malignant glioma) 
(Giard, 1973) and D341MED (pediatric medulloblastoma) (Friedman et al, 1988) after 
heat shock, while the converse was observed in untreated cells. In most cell lines, 
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HSPA/HSP70 was present on the surfaces of the cells at normal temperature, and 
increased when the cells were exposed to heat shock and allowed to recover for a period 
of 24h. The fold increases ranged from ∼1.5- to ∼20-fold after heat shock. The results
 
from the spent media (media that the cells were grown in) for HSPA/HSP70 is between 
 
1.5 – 10 fold higher after heat shock, which could not be attributed to cell death as the 
number of viable cells was the same before and after heat shock (Graner et al, 2007). 
Previous work by Guzhova et al, (2001), examined the release of HSPA/HSP70 into 
culture media in human glioblastoma T98G cells and found a greater release from cells 
subjected to heat shock, compared to that from cells under normal conditions. 
 
 
 
Stress induced by heat shock produced a substantial variation in heat shock responses in 
different brain tumour cells, some of which showed a significantly higher level of 
expression after heat shock while, conversely, expression in some brain tumour cells 
was high in the absence of heat shock (Calderwood et al, 2006). 
 
 
 
The overexpression of heat shock proteins in numerous cancers, including glioma, is 
associated with tumour cell proliferation, metastasis, invasion, differentiation and death 
(Nylandsted et al, 2000).   In some cancers, the overexpression of heat shock protein 
genes is correlated with poor prognosis and a reduced positive response to therapy 
(Calderwood et al, 2006).   HSPA/HSP70 has been associated with higher cell 
proliferation, with the worst prognosis in patients suffering from breast cancer (Ciocca 
et al, 2003).  Overexpression of heat shock proteins requires the activation of heat shock 
transcription factor 1 (HSF1), which is also upregulated in cancer cells and is involved 
in invasion and metastasis (Ciocca and Calderwood, 2005). 
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1.3.2 Hypoxia 
 
 
 
 
 
Hypoxia is a condition resulting from decreased cellular oxygen levels in tissues, and is 
associated with many diseases, such as pulmonary disease, heart disease, vascular 
disease and cancer.   Research has shown that regions of acute/chronic hypoxia exist 
within the majority of  solid tumours  (Williams et  al,  2001).    In  cellular hypoxia, 
tumours require additional blood vessels, a condition which is evident in many 
neoplasms.    Hypoxia  induces  transcriptional  activation  of  many  genes  that  affect 
cellular metabolism and also promotes neoangiogenesis (the formation of new or recent 
blood vessels) (Duffy et al, 2003).   Cells are able to sense and respond to decreased 
oxygen levels through the conserved hypoxic response pathway involved in 
tumourigenesis.  Exposure to decreased oxygen levels initiates the hypoxic response 
pathway by the regulated expression of hypoxia inducible transcription factor-1 (HIF- 
1).  HIF-1 is a transcription factor which, under hypoxic conditions, specifically binds 
to the region 5‘ – RCGTG- 3‘ of the hypoxia-responsive element (HRE) in the promoter 
of various hypoxia-inducible genes such as heat shock protein gene families, 
erythropoietin (EPO); vascular endothelial growth factor (VEGF) (Simiantonaki et al, 
2008) and von hippel-lindau (VHL) (Baird et al, 2006; Gombos et al, 2011; Huang and 
Bunn, 2003). HIF-1 is a member of the basic-helix-loop-helix (bHLH)-PAS family. 
PAS is an acronym for the first three members recognised, being period homolog (Per), 
aryl hydrocarbon receptor nuclear translocator (ARNT) and single minded homolog 
(Sim) (Huang and Bunn, 2003). HIF-1 is a heterodimer composed of one of three 
subunits, HIF-1α ~120 KDa, HIF-2α ~118 KDa and ~72 KDa HIF-3α subunits and a 91 
– 94 KDa HIF-1β/ARNT subunit (Baird et al, 2006; Gombos et al, 2011; Huang and 
Bunn, 2003).  Under normal oxygen conditions (normoxia), both HIF-1α and HIF-1β 
mRNAs and proteins are constitutively expressed (Baird et al, 2006; Wang et al, 1995). 
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Many of the hypoxia-inducible genes are up-regulated during hypoxia, thus increasing 
oxygen transport to hypoxic tissues by promoting angiogenesis and also promoting cell 
proliferation and survival. However, failure to adapt to decreased oxygen levels will 
ultimately result in cell death via apoptosis (Bruick, 2003).  Angiogenesis is associated 
with metastasis, and as tumours grow, some cells become detached from the tissues 
nutrient supply limiting the delivery of oxygen and nutrients to those cells (Duffy et al, 
2003).   This results in cellular hypoxia and metabolic stress inducing changes in 
transcriptional regulation, promoting growth of highly permeable blood vessels and 
facilitating the passage of tumour cells into the circulatory system.   The response of 
cancer to hypoxia not only maintains the survival and growth of tumours, but promotes 
tissue invasion and metastasis through angiogenesis (Duffy et al, 2003). 
 
 
 
Activation of heat shock proteins plays a crucial role in adaptation by cells to hypoxic 
conditions and in tolerating the oxidative stress of reoxygenation (Baird et al, 2006; 
Semenza 1999). Heat shock proteins are regulated by heat shock factors and are linked 
to the oxygen-sensing and heat shock pathways.  The activity of the heat shock pathway 
is controlled by the trimerization and post translational modification of heat shock 
factor protein subunits (Baird et al, 2006; Orosz et al, 1996).   Transcription of heat 
shock factors is controlled by HIF-1 which is increased during hypoxia, increasing the 
cellular abundance of heat shock factors and the sensitivity of the heat shock pathway, 
thus maximising the production of protective heat shock proteins (Baird et al, 2006). 
During hypoxia, heat shock factors are up-regulated due to the direct binding by HIF-1 
to HIF-1 response elements. The up-regulation of heat shock factors are essential for the 
increase of heat shock protein transcripts during hypoxia and reoxygenation (Baird et al, 
2006). 
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1.3.3 Post-mortem conditions 
 
 
 
 
In cases of unexplained death, one of the most important investigative factors is the 
accurate and precise determination of the time interval since death occurred, which is 
usually referred to as the post-mortem interval (PMI).  There has been much debate as 
to the precise moment when death actually occurs.  Various methods involving many 
different scientific disciplines, such as forensic medicine, anthropology, physiology, 
molecular biology and entomology have been employed in determining an accurate 
post-mortem interval, and the application of these methods largely depend on whether 
the PMI is assumed to be short (hours/days), medium (weeks) or long term (years) 
(Mathur and Agrawal, 2011).  To date, the precise time of death cannot be determined 
with complete accuracy or certainty.  Broadly speaking, there are two phases of death: 
somatic death, which is the cessation of the integrated functioning of an individual at a 
physiological level, and molecular or cellular death, which is the cessation of respiration 
and the normal metabolic activity in the tissues and cells.   However, there has been 
much debate surrounding cellular death as to when this actually occurs.   Various 
methods are currently employed in determining PMI.   These include temperature 
measurements made post-mortem (Henssge and Madea, 2004), the use of biochemical 
markers such as protein fractions and enzymes (Fountoulakis et al, 2001; Sabucedo and 
Furton, 2003), potassium concentration in the vitreous humor of the eye (Madea and 
Rodig, 2006) eye temperature decrease (Kaliszan et al, 2010) and post-mortem muscle 
proteolysis (the relaxation of muscles following rigor mortis) (Madea and Henssge, 
1990). 
 
 
 
 
The most commonly used method for the determination of short term PMI by 
pathologists is based on the cooling of the body and involves the measurement of the 
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body core temperature at various time points. This requires the direct measurement of 
the intra-abdominal temperature and applying this to Newton‘s law of cooling (Besson, 
2010; Newton, 1701) which states ―the rate of cooling of a body is determined by the 
difference between the temperature of the body and that of its environment‖ (Henssge, 
1988; Henssge and Madea, 2004; Marshall and Hoare, 1962).  Various algorithm / 
nomogram models have been suggested for its use, and the current preferred model is 
the ―temperature time of death relating nomogram‖ (Figure 1.15) developed on the basis 
of physical considerations, and the two-exponential term of Marshall and Hoare (1962). 
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Figure 1.15. The temperature-time of death relating nomogram (adapted from Hessenge 
and Madea, 2004). 
Death-time (t) is expressed by: 
 
Trectum – Tambient = 1.25 exp (Bt) - .25 exp (5Bt); B= -1.2815 (kg-.625) + .0284 
37.2 - Tambient 
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The nomogram is related to the chosen standard of a naked body lying in still air. 
Cooling conditions that differ from the chosen standard may be proportionally adjusted 
by corrective factors as shown in Table 1.8 of the real body weight (Hessenge and 
Madea, 2004). 
 
 
 
Table 1.8. Empiric corrective factors of the body weight (adapted from Hessenge and 
 
Madea, 2004). 
 
Dry clothing / 
covering 
 In air Corrective 
Factor 
Wet clothing / 
covering wet 
body surfaces 
In air / water 
   3.5 Naked Flowing 
   .5 Naked Still 
   .7 Naked Moving 
   .7 1-2 thin layers Moving 
Naked Moving .75   
1-2 thin layers Moving .9 2 or more thicker Moving 
Naked Still  1.0   
1-2 thin layers Still  1.1 2 thicker layers Still 
2-3 thin layers   1.2 More than 2 
thicker layers 
still 
1-2 thicker layers Moving or still 1.2   
3-4 thin layers   1.3   
More thin/thicker 
layers 
Without 
influence 
1.45   
Thick  bedspread 
& clothing 
  1.8   
combined   2.4   
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Although this is the preferred method, there are still factors that cause much controversy 
and doubts regarding the complete accuracy of this method.  This method assumes a 
constant ambient temperature, but it has been suggested by Althaus and Henssge (1999) 
that, if there is a rapid increase or decrease in ambient temperature, the PMI based on 
this method would not be totally reliable. 
 
 
 
One area that has not been fully investigated with regards to PMI is the persistence of 
gene transcripts in post mortem tissue.  In the period immediately following death there 
are a number of cellular functions that persist, such as continued cell division, continued 
reactivity of muscle fibres to stimuli, mechanical or electrical stimulation (Jones et al, 
1995; Madea 1992; Schleyer, 1963) and continuation of enzymatic activities such as 
adenylyl cyclase which has conserved basal activity in neural tissue up to 48h after 
death (Palego et al, 1999).  During the early post mortem period, the amount of RNA in 
cells rapidly changes depending on pathophysiological changes of the 
microenvironments involved in the death process (Maeda et al, 2010). However, some 
genetic reactions continue during the early post-mortem period, such as supravital 
reactions, the reactions that occur within the body from somatic to cell death, which 
result in either an increase or decrease in mRNA transcripts, which may modify the 
biological status at time of death (; Ikematsu et al, 2008; Maeda et al, 2010). 
 
 
 
In general, the cause of death is determined by evaluating functional and morphological 
changes of the viscera (internal organs), tissues and cells following a fatal insult (Maeda 
et al, 2010).  Death due to a functional mechanism such as fatal disease, injury or 
chemical insult, may produce few morphological changes, however the status of cell 
functions may be preserved in the mRNA pattern indicated by precise up / down 
regulations of gene expression which occurs rapidly after death (Maeda et al, 2010; 
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Zhao et al, 2009).  Studies undertaken by Ikematsu et al (2008) have demonstrated a 
significant tissue-  specific increase  or  decrease  in  mRNA  levels in  the  early post 
mortem period of < 12h. The study was undertaken using mechanically asphyxiated 
mouse lung and brain after somatic death, for the detection of early response genes 
including myelocytomatosis oncogene, C-MYC, inducible-nitric oxide synthase 2, i- 
NOS, and FBJ osteosarcoma oncogene, C-FOS (Ikematsu et al, 2008).  Rapid changes 
in mRNA levels, depending on the pathophysiology of death could be useful to 
investigate acute violent deaths such as electrocution, asphyxiation or in cases of sudden 
death. 
 
 
The measurement of gene expression at the mRNA level in post-mortem tissue can 
potentially provide useful information relevant to the determination of a more accurate 
post-mortem interval and the possible circumstances, mechanisms and diagnosis 
surrounding or leading to the cause of death. 
 
 
Studies by Anderson et al, (2005); Bauer et al, (2003) and Maarti, (2004) have shown 
that RNA remains largely intact for a considerable time period (up to 24 to 48 h) after 
death under appropriate ambient conditions.  Furthermore, assessing mRNA levels by 
RT-PCR is believed to produce more accurate results than other techniques, such as 
comparison with levels of ribosomal 18S and 28S rRNAs.  Therefore, measurement of 
cellular mRNA levels could provide information about RNA quality in tissues of 
relevance to PMI determination as well for research or diagnostic purposes, such as 
wound age determination. 
 
A number of recent studies (Anderson et al, 2005; Bauer et al, 2003; Maarti, 2004) have 
shown that there is the potential to determine post-mortem interval in a forensic context 
by measuring the levels of total RNA populations and the transcripts of specific genes 
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in the early post-mortem period.  These studies were specifically undertaken in relation 
to the identification of body fluids, the age of blood and semen stains, the age of 
wounds (Anderson et al, 2005; Bauer et al, 2003) and the functional status of cells and 
organs for the purpose of forensic pathology (Maarti, 2004).   Studies have also 
demonstrated,  across  a  wide  range  of  both  human  and  rat  tissue  types,  that  the 
molecular integrity of RNA (the 28S and 18S ribosomes) and targeted gene transcripts 
can remain relatively high in post-mortem tissue for up to periods of 148 h (brain tissue; 
Inoue et al, 2002); 48 h (bone, Kuliwaba et al, 2005); 72 h (lungs, heart and muscle 
tissue, De Paepe et al, 2002; Heinrich et al, 2007; Inoue et al, 2002); and 24 h (liver, 
kidney and spleen tissue, Heinrich et al, 2007; Inoue et al, 2002).  The results were all 
obtained under ambient temperatures or at 4oC using real time quantitative reverse 
 
transcription polymerase chain reaction (RT-PCR). 
 
 
 
 
Gopee and Howard (2007) demonstrated that, over a time course of post-mortem 
intervals up to 60 min, skin excised from 10 month old hairless mice showed minimal 
variation in terms of the integrity of total RNA and also the mRNA of the genes C- 
MYC, CYR61, HIF-1α, C-CND1 and one housekeeping gene 18S ribosomal RNA. 
 
 
 
Overall these studies indicate that the cellular integrity of mRNA is unlikely to change 
significantly in the early post-mortem period, thereby allowing the opportunity to elicit 
de novo gene expressions of specific target genes in response to mild heat shock. 
 
 
 
A study undertaken by Pardue et al, (2007) compared the induction and the levels of 
HSPA/HSP70 and heat shock cognate HSPA8/HSC70 proteins and mRNAs in human 
brain (in cases of sudden or unexpected death with no known agonal stresses pre- 
mortem) with those in brains of non-stressed and heat shocked rats.   Post-mortem 
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intervals ranged from 3.5 – 22 h in human brain samples, 3 h for non-stressed rat brain 
at room temperature and 0 – 24 h for rat brains that were subjected to heat shock at 3, 5, 
8, 12 and 24 h. Results indicated that the levels of HSPA/HSP70 proteins were 43-fold 
higher in human brain than those in non-stressed rat brain and 14-fold higher than those 
subjected to heat shock. HSPA8/HSC70 results were less dramatic, showing only a 1.5- 
fold increase in that of human brain samples compared to that of non-stressed rat brain. 
Consistent with the presence of the HSPA/HSP70 protein, HSPA/HSP70 mRNA levels 
were also found to be 8.5-fold higher in human brain than in non-stressed rat brain. 
Clearly, the overall conclusion is that HSPA/HSP70 protein levels are significantly 
higher in humans who die suddenly and are not subjected to agonal stresses pre-mortem 
than in rats either non-stressed pre-mortem or subjected to heat shock post-mortem. 
 
 
 
HSPA/HSP70 has been linked with post-mortem events due to its association with 
BAG-1 (Bcl-2-associated athanogene-1) and CHIP (carboxyl terminus of the Hsc70- 
interacting protein).   BAG-1 contains a domain within HSPA/HSP70 nucleotide- 
exchange activity that is presumed to assist molecular chaperones in the removal of 
aberrant proteins from the cytosol (Curcio et al, 2006; Lanneau et al, 2007; McClellan 
et al, 2005).  BAG-1 has a capacity to inhibit apoptosis and modulates the chaperone 
activity of HSPA/HSP70 and heat shock cognate 70 (HSPA8/HSC70) by binding to 
their ATPase domains (Luders et al, 2000b; Seidberg et al, 2003; Stuart et al, 1998; 
Takayama et al, 1997;).   BAG-1 appears to alleviate cellular stress by joining 
HSPA/HSP70 and other chaperones to the ubiquitin proteasome system facilitating 
degradation of oligomeric species.  However, during the agonal state linking of BAG1 
and HSPA/HSP70 to the ubiquitin proteasome system can be affected by various pre 
and post-mortem variables (Curcio et al, 2006). 
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1.4 Aims of the Research 
 
 
 
The expression of HSPA/HSP70 is up-regulated by various cellular stress factors, 
including cancer, hypoxia and post-mortem conditions. The main research aims of this 
project were to explore and measure the effects of these factors further, using human 
and rat tissues and cell lines. Experiments were devised to characterise HSPA/HSP70 
expression in normal and glioma cell lines, and under hypoxic conditions. Expression 
was  also characterised in post mortem tissues at different stages of the early post 
mortem interval, to determine whether HSPA/HSP70 was capable of ―de novo‖ 
expression in response to cellular signals for its use as an early post-mortem marker to 
estimate PMI. In terms of the potential for clinical application, this research also 
attempted to assess the possible use of HSPA/HSP70 as a prognostic marker. 
 
 
 
To provide structure to the presentation of results in this thesis, these objectives can be 
individually summarised as follows: 
 
1. To characterize the level of HSPA expression in normal human cell lines and 
normal human brain tissue, compared to that of glioma cell lines and tumourous 
brain tissue; 
 
 
 
2.   To characterize the level of HSPA transcription in response to hypoxia in normal 
and glioma cell lines; 
 
 
 
3.   To characterize the level of HSPA transcription in post-mortem brain tissue ; 
 
 
 
 
4.   To characterize the level of HSPA transcription in response to heat shock applied 
to the brain tissue in the early post-mortem period; 
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5.   To characterize the level of HSPA transcription in response to multiple heat 
shocks applied to the brain tissue in the early post-mortem period; and 
 
 
 
6.   To determine the potential for HSPA to be used as an early post-mortem marker. 
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Chapter 2 
 
 
 
 
 
 
Materials and Methods 
113 
 
2.1     Cell Culture 
 
 
 
2.1.1   Tissue samples, cell lines and culture conditions 
 
 
 
 
Tumour and normal (control) brain tissue samples were obtained from patients admitted 
to the Royal Preston Hospital, UK.  Ethical approval from both the North Manchester 
Research Ethics Committee Ref: 06/Q1406/104 and the Ethics Committee at the 
University of Central Lancashire were obtained prior to work being carried out on tissue 
samples. Tumour tissue samples were obtained from glioma cancer patients, and normal 
(control) tissue samples were obtained from patients who required resection of normal 
brain for purposes other than primary glioma treatment. Written consent was obtained 
prior to tissue samples being used in this investigation.  For each patient, brain tissues 
samples were surgically dissected and  immediately frozen at  -80oC  and  stored for 
 
analysis  (performed  by  neurosurgeons  and  the  pathology department  at  the  Royal 
 
Preston Hospital, UK).  In total, 18 tissue samples were used in this study. 
 
 
 
 
Human brain cell lines grade I astrocytoma, 1321N1 from European Collection of Cell 
Cultures, ECACC, (UK), grade II/III oligodendroglioma GOS-3 from Deutsche 
Sammlung von Mikroorganismen und Zelkulturen GmbH, DMSZ, (Germany), grade IV 
glioblastoma, U87-MG from ECACC (UK) and normal human astrocytes, NHA from 
Lonza (UK) were used in this study.  1321N1 and GOS-3 cells were routinely cultured 
in Dulbecco‘s modified  Eagle‘s  medium (DMEM; Sigma) supplemented with 10% 
foetal bovine serum (FBS) and with 2 mM and 4 mM L-glutamide respectively, while 
U87-MG cells were cultured in Eagle‘s minimum essential medium (EMEM; Sigma) 
supplemented with 2 mM L-glutamide, 10% FBS, 1 mM sodium pyruvate and 1% (v/v) 
nonessential amino acids, NEAA,  (Sigma).   NHA  cells were  cultured in  astrocyte 
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medium (AM) supplemented with 15 ml (3%) of FBS, 0.5 ml (0.1%) ascorbic acid, 0.5 
ml recombinant human epidermal growth factor, rhEGF, 0.5 ml gentamicin 
amphotericin-B, GA-1000, 1.25 ml insulin and 5 ml L-glutamide. 
 
 
 
All cells were of human origin without infectious viruses or toxic products. Routine 
mycoplasma testing was performed at the University of Central Lancashire on all cell 
lines and strains used in the study. Cells were received as frozen ampoules in 1 ml 
plastic cryotubes containing cells suspended in appropriate freezing medium and 10 % 
(v/v) dimethyl sulphoxide (DMSO), as supplied by commercial laboratories. 
115 
 
2.1.2 Media and Reagents 
 
 
 
 
 
Complete medium for cell growth was aseptically prepared for each cell line according 
 
to the supplier‘s recommendations with the addition of specific supplements (Table 
 
2.1). 
 
 
 
 
 
Table 2.1 Media and supplements for each cell line used in this thesis. 
 
 
 
Cell Line 
 
Medium 
 
Supplements 
 
1312N1 
 
Dulbecco‘s Modified Eagle‘s 
Medium (DMEM) 
 
10% FBS 
2 mM L-glutamine 
 
GOS-3 
 
Dulbecco‘s Modified Eagle‘s 
Medium (DMEM) 
10% FBS 
4 mM L-glutamine 
 
 
 
U87-MG 
 
 
Eagle‘s  Minimum  Essential 
Medium (EMEM) 
10% FBS 
2 mM L-glutamine 
2  mM  non-essential  amino 
acids 
1 mM sodium pyruvate 
 
 
 
 
 
NHA 
 
 
 
 
 
Astrocyte Basal Medium 
(ABM) 
0.5 ml recombinant human 
epidermal growth factor 
(rhEGF) 
1.25 ml insulin 
0.5 ml ascorbic acid 
0.5 ml gentamicin 
amphotericin-B (GA-1000) 
5.0 ml L-glutamine 
3% FBS 
 
 
2.1.3   Preparation of Media 
 
 
 
The  media  for  cell  lines  were  prepared  according  to  the  individual  cell  line 
requirements,  based  on  the  ECACC  /  DMSZ  /  Lonza  recommendations  and  all 
additional supplements were added in accordance with the supplier‘s recommendations. 
Supplemented media were labeled with date of preparation and stored for up to a 
maximum of two weeks at 4oC. All reagents and chemicals used for cell culture are 
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listed in Table 2.2. Prior to inoculation of the complete media with the cell lines, the 
complete medium for each cell line was pre-incubated overnight to ensure that no 
contaminants, mycoplasma or toxic products were present. 
 
 
 
 
Table 2.2 Reagents and chemicals used in cell culture. 
 
 
 
 
Reagents 
 
Supplier 
 
Components 
 
Foetal bovine serum 
 
Gibco BRL 
 
Heat inactivated foetal bovine serum 
 
Non-essential amino acid 
 
Sigma 
 
100x non-essential amino acid 
 
Trypsin EDTA 
 
Sigma 
 
0.5 g porcine trypsin 
0.2 g EDTA 
 
L-glutamine 
 
Sigma 
 
200 mM L-glutamine 
 
Phosphate buffer saline 0.1M 
 
Sigma 
 
8 g/l sodium chloride 
0.2 g/l potassium chloride 
DMSO Sigma Dimethyl sulfoxide 99.5% 
Trypan blue (0.4% v/v) Sigma 0.81% w/v sodium chloride 
0.06% w/v potassium phosphate 
dibasic 
 
 
 
2.1.4   Resuscitation of Cells 
 
 
 
 
Complete media for cell lines were pre-warmed to 37oC before the frozen ampoules 
containing the cells were added and thawed rapidly in a 37oC water bath.  Thawed cells 
were immediately rinsed by resuspension in 4 ml of appropriate growth medium to 
remove the freezing medium and centrifuged at 150 g for 5 min.  The supernatant was 
discarded and the cells were resuspended in 3 ml of the appropriate medium and then 
aliquoted into 2 x 25 cm2  flasks together with 5 ml of the appropriate medium and 
mixed manually.  Flasks were suitably labeled with the cell line, passage number and 
then incubated at 37oC with 5% CO2 in 95% filtered air. 
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2.1.5   Subculture 
 
 
 
Following overnight incubation, the cells were observed using a phase contrast 
microscope for a monolayer growth of approximately 70–80% confluency and to 
confirm the absence of bacterial and fungal contaminants.  Depending on observations, 
cells were either trypsinised or subjected to hypoxia treatment.  However, for slow 
growing cell lines, the medium was changed every 48 h after incubation to ensure 
sufficient nutrients for cell growth. 
 
2.1.6   Hypoxia Treatment 
 
 
 
 
Cells were cultured in 75 cm2 tissue culture-treated polystyrene flasks (Sigma). Hypoxic 
conditions were induced by exposing confluent cells to nitrogen (100 %) for 30 min 
(Kay et al, 2007).  After treatment, the cells were collected at various recovery periods 
(0, 3, 6 and 24 h) for experiments concerning gene expression, immunofluorescence and 
flow cytometry assays. 
 
 
 
2.1.7   Trypsinisation 
 
 
 
 
The culture medium was removed and the cells were washed once with 5 ml of 1 x 
phosphate buffered saline (PBS) (0.1 M, pH 7.4) to remove any excess culture medium. 
Trypsin EDTA 1 x (1ml/ 25cm2 flask, 2ml/ 75cm2 flask) was added to each flask and 
cells were incubated under normal conditions for 5-10 min at 37oC (atmosphere of 95% 
 
O2, 5% CO2).  The cells were examined using a phase contrast microscope to ensure 
that all the cells had detached and were floating.  Cells were resuspended in 2ml/ 25cm2 
flasks or 4ml/ 75cm2  flasks of the appropriate medium to inactivate the trypsin.  The 
cell suspension was transferred to a 15 ml centrifuge and centrifuged (ALC PK120) at 
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1000 rpm for 5 min. The supernatant was discarded and the pellet resuspended in 1 ml 
of medium followed by gentle pipetting to aid resuspension. 
 
2.1.8   Cell Quantification 
 
 
 
 
Cell quantification involved first adding 20 µl of the cell suspension and 80 µl of trypan 
blue (Freshney, 1987) (1:5 dilutions) to a 1.5 ml microfuge tube and the suspension 
mixed by gently pipetting. Cells were observed and cell concentration calculated by the 
use of a Neubauer haemocytometer. Samples were prepared by attaching a cover slip 
using slight pressure until Newton‘s refraction rings appeared (rainbow-like rings under 
the cover-slip). Both sides of the chamber were filled (approx. 10 µl)  with cell 
suspension / trypan blue solution, ensuring no air bubbles were present, and samples 
viewed under a light microscope using x 20 magnification. The number of viable cells 
(seen as bright cells) were counted in the central square (gridded 5 x 5 squares) and the 
4 squares above and below, left and right of the central square, followed by calculation 
of the average number of cells per large square.  This number = x 104 and equalled the 
number of cells per ml within the cell suspension / trypan blue solution.  During this 
calculation, it was noted that, due to the addition of trypan blue, the number of cells had 
to be x 5 to correct for the dilution. The cell suspension was then diluted to a 
concentration of 1x105 cells/ml. The dilution factor was calculated using the following 
equation: 
 
 
 
Dilution factor = Concentration of original cell suspension         x Volume 
 
Concentration of required cell suspension 
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2.2     mRNA Isolation 
 
 
 
mRNA was isolated using mRNA Isolation Kit (Roche-applied-science, Germany Cat. 
No.  11  741  985  001).     Reagents  were  mixed  according  to  the  manufacturer‘s 
instructions using a vortex mixer and briefly centrifuged prior to commencing this 
procedure.  This kit works on the basis that the poly (A) tail of mRNA hybridises to a 
biotin-labelled oligo(dT) probe.   Streptavidin-coated magnetic particles capture the 
biotinylated hybrids and, with the aid of a magnetic separator, the magnetic particles are 
captured.  The fluid is then removed by washing the particles with washing buffer and 
finally the mRNA is eluted from the particles by incubation with redistilled water. 
 
 
 
 
 
 
Table 2.3. Reagents, composition and quantity provided mRNA isolation Kit (Roche). 
 
 
Reagent Composition Quantity 
Lysis Buffer 0.1   M   tris   buffer,   0.3   M   lithium   chloride 
(LiCl),10 mM ethylenediaminetetraacetic acid 
(EDTA), 1% lithium dodecylsulphate, 5 mM 
dithiothreitol (DTT) pH 7.5 
 
 
1 x 100 ml 
Streptavidin- 
coated magnetic 
particles 
(SMP‘s) 
10mg/ml in 50 mM hepes, 0.1%  bovine serum 
albumin, 0.1% chloracetamide, 0.01% 
methylisothiazolone, pH 7.4 
 
 
1 x 1.7 ml 
Oligo(dT)20 
probe biotin 
labelled 
100  pmol  biotin  labelled  oligo(dT)20   per  µl  of 
redistilled water 
 
 
1 x 66 µl 
Washing buffer 10 mM tris buffer, 0.2 M LiCl, 1 mM EDTA, pH 
7.5 
 
1 x 50 ml 
Double 
redistilled water, 
RNase free 
RNase-free H2O 
 
 
1 x 4 ml 
Storage buffer 10 mM tris buffer, 0.1% chloracetamide, 0.01% 
methylisothiazolone, pH 7.5 
 
1 x 7 ml 
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mRNA was isolated from 2 x 106 cells following the manufacturer‘s protocol as shown 
in the schematic diagram (Figure 2.1).  The volumes and composition of each reagent 
and  buffers  provided  within  the  kit  are  detailed  in  Table  2.3,  whilst  the  specific 
measures used during each extraction procedure are shown in Table 2.4. 
 
 
Cells were washed by suspension in 3 x 500 µl of ice cold Phosphate Buffer Saline 
(PBS, 0.1 M) to remove excess media which could potentially interfere with UV 
spectrophotometric measurements.  The suspension was centrifuged at 10,000 g for 3 
min at room temperature and the supernatant discarded.  To the cell pellet, 500 µl of 
lysing buffer (0.1 M Tris buffer, 0.3 M LiCl, 10 mM EDTA, 1% (w/v) lithium 
dodecylsulphate,  5  mM  dithiothreitol,  DTT,  pH  7.5)  was  added,  followed  by 
mechanical shearing of cells, achieved by passing samples through a 21 gauge needle 
(six times).   An aliquot of 0.5 µl biotin labelled oligo(dT)20  probe (100 pmol biotin- 
labelled oligo(dT)20 per µl of molecular biology grade H2O) was added to the cell lysate 
and allowed to hybridise with mRNA for 10 min at room temperature.  Simultaneously, 
50 µl of streptavidin magnetic particles (10 mg/ml of suspension in 50 mM Hepes, 0.1 
 
% (w/v) bovine serum albumin, 0.1 % (w/v) chlorace tamide, 0.01 % (w/v) 
methylisothiazolone, pH 7.4) was aliquoted into a 1.5 ml sterile microfuge tube and 
separated from the storage buffer by placing in a magnetic separator, after which the 
storage buffer was discarded.  The particles were cleansed by resuspension in 70 µl of 
lysing buffer (0.1 M Tris buffer, 0.3 M LiCl, 10 mM EDTA, 1% (w/v) lithium 
dodecylsulphate, 5 mM DTT, pH 7.5).  Following magnetic separation and disposal of 
the  supernatant,  the  prepared  particles  were  resuspended  in  the  dT-mRNA  hybrid 
mixture; after brief vortexing, the resultant suspension was incubated for 5 min at 37oC 
to achieve immobilisation.   Following incubation, the hybrid-linked particles were 
magnetically  separated  from  this  fluid  and  the  supernatant  was  discarded.    The 
remaining particles were then washed by resuspension in 3 × 200 µl of washing buffer 
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(10 mM Tris buffer, 0.2 M LiCl and 1 mM EDTA, pH 7.5).  Upon disposal of the final 
supernatant, mRNA was eluted from the particles by resuspension in 10 µl of redistilled 
water, mixing and incubation for 2 min at 65oC.   After magnetically separating the 
particles from the fluid, the resulting supernatant (mRNA) was stored at -20oC in an 
 
RNase free microfuge tube ready for quantification and analysis. 
 
 
 
 
 
Table  2.4.  Volumes  of  reagents  used  for  mRNA  isolation  as  per  manufacturers‘ 
 
protocol. 
 
 
 Amount of 
 
Tissue (mg) 
Number of Cells 
 200 50- 
 
100 
1 x 108 2 x 107 1 x 107 2 x 106 2 x 105 
Volume of lysis 
buffer 
3 ml 1.5 ml 15 ml 3 ml 1.5 ml 0.5 ml 0.1 ml 
Volume of 
streptavidin 
magnetic particles 
300 µl 150 µl 1.5 ml 300 µl 150 µl 50 µl 50 µl 
Volume of lysis 
buffer: 
streptavidin 
magnetic particle 
preparation 
500 µl 250 µl 2.5 ml 500 µl 250 µl 70 µl 70 µl 
Volume of 
oligo(dT)20 probe 
biotin labelled 
3 µl 1.5 µl 15 µl 3 µl 1.5 µl 0.5 µl 0.5 µl 
Volume of 
washing buffer 
3 x 
 
500 µl 
3 x 
 
250 µl 
3  x  2.5 
ml 
3 x 
 
500 µl 
3 x 250 
 
µl 
3 x 200 
 
µl 
3 x 200 µl 
Volume of 
redistilled water 
50 µl 25 µl 250 µl 50 µl 25 µl 10 µl 5 µl 
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Figure 2.1 A diagrammatic representation of the principals involved in extracting 
mRNA from culture cells and tissue using the mRNA Isolation Kit (adapted from Roche 
mRNA Isolation Kit instruction manual). 
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2.2.1   Quantification of nucleic acids by UV spectrophotometry 
 
 
 
 
Isolated mRNA was quantified by measurement of absorbance using the thermo 
spectrophotometer Helios gamma (Thermospectronics, UK) at wavelengths of 260 nm 
and 280 nm.   Samples of mRNA (2 µl) were combined with 500 µl of TAE (Tris- 
acetate-EDTA) buffer (400 mM Tris, 0.01 M EDTA; pH 8.0).   Spectrophotometric 
measurements were obtained and mRNA concentrations were calculated.  The standard 
formula was based on an absorbance of one optical density (OD) unit at 260 nm = 50 
μg/ml for dsDNA and 40 μg/ml for ssRNA.  The ratio of absorbance at 260 nm and 280 
nm was used to assess the purity of isolated nucleic acids.  A ratio of 1.8 - 2.0 indicated 
the presence of pure single-stranded (ss) RNA.   The concentrations of the isolated 
mRNA were calculated as follows 
 
Concentration mRNA (µg/ml) = A260 reading x dilution factor (250) x 40 (ssRNA) 
 
 
 
2.2.2   Analysis of Nucleic acid by agarose gel electrophoresis 
 
 
 
Isolated mRNA was visualized on 2% agarose gels to determine whether RNA was 
intact or degraded. The 2% gel was prepared using 0.6 g of agarose powder  (Geneflow, 
UK) dissolved in 30 ml TAE buffer (400mM Tris, 0.01 M EDTA; pH 8.3) and heated in 
a domestic microwave until a clear transparent solution had formed.  The solution was 
poured into a prepared electrophoresis gel tank, combs inserted and left to solidify. 
TAE buffer was used to completely submerge the gel before the samples and a 100 bp 
ladder, as a molecular weight marker, were loaded into appropriate wells. Each sample 
loaded comprised 10 µl of extracted mRNA mixed with 2 µl of loading dye (0.25% w/v 
bromophenol blue, 0.25% w/v xylene cyanol and 40% w/v sucrose),  together with 2 µl 
of 100 bp ladder  mixed with 5 µl of loading dye. The gel was electrophoresed at 100 V 
for 25 min, followed by staining in 0.4 µg/ml ethidium bromide for 45 min and then 
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destained in distilled H2O for approximately 10 min. The banding patterns were then 
visualized using a GENE GENIUS Bioimaging system and Gensnap software (Syngene, 
UK). 
 
 
2.3     Complimentary DNA Synthesis (cDNA) 
 
mRNA was reverse transcribed using First Strand cDNA Synthesis Kit, which harnesses 
enzymes isolated from Avain Myeloblastosis Virus (Roche-applied-science, Germany 
Cat. 11 483 188 001).  The composition and volumes of all reagents provided are shown 
in Table 2.5, whilst the specific quantities required by each cDNA synthesis reaction are 
shown in Table 2.6.  All reagents were kept on ice, mixed using a vortexer and briefly 
centrifuged prior to commencing this procedure. 
 
Table 2.5 Reagents, composition and quantity of each reagent provided within the First 
Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche). 
 
Reagent Composition Quantity 
10 X Reaction Buffer 100 mM tris buffer, 500 
mM KCl; pH 8.3 
1.05 ml 
MgCl2 25 mM MgCl2 3 ml 
(3 vials; 1 ml in each) 
Deoxynucleotide Mix dATP, dCTP, dTTP, 
dGTP; 10 mM each 
210 µl 
Gelatine 0.5 mg/ml (0.05% [w/v]) 
gelatine 
210 µl 
Oligo-p(dT)15 primer 0.02 A260 U/μl (0.8 μg/μl) 
oligo-p(dT)15 
primer sequence 
60 μl 
Random primer p(dN)6 0.04 A260 U/μl (2 μg/μl) 
primer sequence 
60 μl 
 RNase inhibitor 50 U/μl RNase inhibitor 30 μl 
AMV Reverse 
Transcriptase 
AMV reverse 
transcriptase 
24 μl 
Control Neo pa RNA 0.2 μg/μl RNA sample; 
1.0 kb in length with an 
additional 19-base 3'- 
poly(A) tail 
25 μl 
Molecular biology-grade 
H2O 
RNase-free H2O 2 ml 
(2 vials; 1 ml in each) 
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A master mix of 2 µl of 10 X reaction buffer (500 mM KCl; pH 8.3), 4 µl of MgCl2 (25 
mM), 2 µl of deoxynucleotide mix (dATP, dCTP, dGTP and dTTP; 10 mM each in 
sterile double distilled water, pH 8.5), 2 µl of oligo-p(dT)15 primer (0.02 A260 units/ µl 
(0.8 µg/µl)), 1 µl of RNase inhibitor (50 U/µl) and 0.8 µl of AMV reverse transcriptase 
(25 U/µl) was made, to which the appropriate amount of mRNA (100 ng) was added, 
along with the relevant volume of molecular biology-grade H2O, to make a total volume 
of 20 µl, as shown in Table 2.6.   The reaction mixture was briefly vortexed and 
centrifuged followed by an incubation period of 10 min at 25°C to allow the oligo- 
(dT)15 primer to anneal to the mRNA.  The reaction mixture was then further incubated 
for 60 min at 42oC, during which the mRNA template was reverse transcribed into 
 
single-stranded cDNA.  As a final step, AMV Reverse Transcriptase was denatured by 
further incubating the reaction mixture for 5 min at 99oC, followed by cooling on ice for 
5 min. The synthesised cDNA sample was then stored at -20oC until required. 
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Table 2.6 The quantities of reagents required for each cDNA synthesis reaction using 
 
those provided within the First Strand cDNA Synthesis Kit for RT-PCR (AMV). 
 
 
 
 
Reagent Quantity 
10 X reaction buffer 2 µl 
MgCl2 4 µl 
Deoxynucleotide (dNTP) Mix 2 µl 
Oligo-p(dT)15 primer 2 μl 
RNase inhibitor 1 μl 
AMV reverse transcriptase 0.8 µl 
mRNA sample †  
Molecular biology-grade H2O ‡  
Total reaction volume 20 µl 
 
 
† The volume of mRNA sample added to each reaction was determined by its 
concentration following extraction. Since 50–100 ng of mRNA is typically required for 
successful cDNA synthesis, 100 ng of extracted mRNA was added to each sample 
reaction. 
 
 
 
‡ Following the addition of 100 ng of extracted mRNA sample, the total reaction 
volume was made up to a final volume of 20 µl using molecular biology-grade H2O. 
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2.4 Primer Preparation 
 
 
 
HSPA and GAPDH sequence-specific primers were designed using Primer3 software 
and commercially synthesised by TIB MOLBIOL syntheselabor (Berlin, Germany). 
Primers were received in a powdered form and collected by centrifugation at 10,000 g 
for 1 min at room temperature.  Molecular biology-grade H2O (250 µl) was added to 
each primer to create 20 µM stock solutions.  Finally, 20 µl of the sense and antisense 
primer stock solutions were combined to generate a 10 µM PCR primer mix, which was 
then stored at -20oC until required.  Table 2.10 portrays the sequences of the primers 
used in this study. 
 
 
 
 
2.5 Real-time quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR) 
 
 
 
Polymerase chain reaction (PCR) is a method that allows logarithmic amplification of 
short DNA sequences (usually 100 to 600 bases) within longer double stranded DNA 
molecules.   qRT-PCR allows detection of very low copies of mRNA that would 
otherwise not show up if other analytical techniques such as northern blotting was used. 
The levels of HSPA and GAPDH (reference genes used in RT-PCR reaction, Olsvik et 
al, 2005) within all the cell lines used in this study were measured by performing real- 
time qRT-PCR (Ball et al, 2003) using the LightCycler 2.0 system (Roche Diagnostics 
Ltd,  Germany)  and  LightCycler®   FastStart  DNA  MasterPLUS   SYBR  Green  I  kit, 
 
according to the manufacturer‘s instructions.   The composition and volumes of all 
reagents provided are shown in Table 2.7, whilst the specific quantities used during the 
amplification procedure shown in Table 2.8.  All samples and reagents were kept on ice 
throughout the procedure. 
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Table  2.7  The  composition  and  quantity  of  each  reagent  provided  within  the 
 
LightCycler® FastStart DNA MasterPLUS SYBR Green I kit. 
 
 
 
 
 
 
 
 
Reagent Reagent Composition Quantity 
 
Enzyme (1a) 
 
FastStart Taq DNA Polymerase 
 
1 vial 
 
Reaction mix 
(1b) 
Reaction buffer, dNTP mix (with dUTP 
instead of dTTP), SYBR Green I dye and 
MgCl2 
 
 
3 vials 
Molecular 
biology-grade 
H2O 
 
 
RNase-free H2O 
2 ml 
(2 vials; 1 ml in 
each) 
 
 
 
Table 2.8 The quantities of reagents required for each RT-PCR reaction using those 
provided within the LightCycler® FastStart DNA MasterPLUS SYBR Green I kit. 
 
 
 
 
Reagent Quantity 
 
Molecular biology-grade H2O 
 
12 µl 
 
PCR primer mix 
 
2 µl 
 
Master Mix* 
 
4 µl 
 
Single-stranded cDNA template 
 
2 µl 
Total reaction volume 20 µl 
 
 
* The Master Mix was formed by transferring 14 µl of enzyme (Table 2.7) into the vial 
of reaction mix (Table 2.7). 
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Prior to using hot-start PCR, an enzyme reaction mix was prepared by transferring 14 µl 
of LightCycler®  FastStart Enzyme (1a) into the LightCycler®  FastStart Reaction Mix 
SYBR Green vial (1b) (Table 2.8).  Each reaction capillary contained a total reaction 
volume of 20 µl, comprising 4 µl of the ready to use hot-start reaction mix, 12 µl of 
molecular biology-grade H2O, 2 µl of 10 µM PCR primer mix (generated from section 
2.4 for each specific gene) and 2 µl of single stranded cDNA template.  A further 20 µl 
of template-free reaction mix was prepared as a negative control (in which molecular 
biology-grade H2O was substituted for cDNA). Prior to qRT-PCR being carried out, the 
definitive annealing temperature for each gene was established (Table 2.10).   The 
LightCycler protocol for use with FastStart DNA MasterPLUS SYBR Green Kit 1 utilised 
the program, shown in Table 2.9. 
 
 
Quantitative real-time PCR was used to evaluate the expression of HSPA (predicted 
amplicon size of 213 bp) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as 
a control (predicted amplicon size of 238 bp) using FastStart DNA MasterPLUS  SYBR 
Green 1 (Roche, UK).       Primers used for HSPA were 5‘ 
CGACCTGAACAAGAGCATCA 3‘ (sense) and 5‘ AAGATCTGCGTCTGCTTGGT 
3‘ (antisense) and for GAPDH primers were 5‘ GAGTCAAGCGATTTGGTCGT 3‘ 
(sense) and 5‘ TTGATTTTGGAGGGATCTCG 3‘ (antisense).   All primers were 
designed using Primer3 software and manufactured by TIB MOLBIOL.   The PCR 
protocol involved a hot start induction, with the FastStart Taq DNA polymerase enzyme 
activated by pre-incubating the reaction mixture at 95oC for 10 min.   Hot start is an 
essential step which prevents non-specific elongations and increases PCR sensitivity, 
specificity and yield (Dang and Jayasena, 1996).  The single stranded cDNA template 
was  then  subjected  to  35  amplification  cycles,  each  possessing  the  following 
parameters:  denaturation  at  95oC  for  10  s,  annealing  at  the  primer  dependant 
temperature 57oC (HSPA) and 56oC (GAPDH) for 15 s and extension at 72oC for 25 bp / 
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s (amplicon dependant, HSPA 9 s, GAPDH 10 s) (Patel et al, 2008).  At the end of each 
cycle, the fluorescence emitted was measured in a single step in channel F1 (gain1) to 
obtain data for quantification analysis (Shervington et al, 2007b, Mohammed and 
Shervington, 2007).  After the 35th cycle, the amplicons were prepared for melting curve 
analysis, heated to 95oC (denaturation) and then rapidly cooled to the previously used 
 
annealing temperature (+10oC) for 40 s.  All heating and cooling steps were performed 
with a slope of 20oC / s.   To obtain the data for the melting curve analysis, the 
temperature was subsequently raised to 95oC with a slope of 0.1oC / s and the emitted 
fluorescence was measured continuously (channel F1, gain1).  Melting curve analysis 
was used to assess the specificity of the amplified PCR product and allow for 
discrimination between primer-dimers and specific product.   At the final step, the 
generated amplicons were cooled to 40oC for 30 s and stored at -20oC until required for 
further analysis.  All PCR reactions were performed in triplicate and a negative control 
included, which contained primers but no DNA. 
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Table 2.9 LightCycler program utilising FastStart DNA MasterPLUS SYBR Green Kit 
 
 
Cycles Analysis 
 
Mode 
Target 
 
Temperature 
Hold Time  
1 None 95oC 10 min Pre-incubation 
35 None 95oC 15 s Denaturation 
35 Quantification 57oC HSPA 
 
56oC GAPDH 
15 s Annealing, 
amplification 
and  real  time 
analysis 
35 72oC 9 sec HSPA 
 
10sec GAPDH 
Extension 
 Melting Curve 
analysis 
95oC  Denaturation 
1 67oC HSPA 
 
66oC GAPDH 
40 s  
1 95oC  Melting 
1 None 40oC 30 s Cooling 
  
 
 
 
 
 
 
Table 2.10. The HSPA and GAPDH for Homo sapiens and Rattus norvegicus primers [designed using Primer3 software and commercially synthesised 
 
by TIB MOLBIOL syntheselabor (Berlin, Germany)] utilised in real-time RT-PCR. 
 
 
 
Gene 
 
 
Primer Sequences 
Annealing Temperature (oC)  Expected 
amplicon size 
(bp) 
Extension time (s) 
(amplicon dependant - 
25bp/s) 
 
 
 
 
HSPA 
 
 
 
 
Sense: 5′ - CGACCTGAACAAGAGCATCA - 3′ 
 
Primer3  TIB 
MOLBIOL 
GC / AT rule* Experimental temperature 
Homo 
sapien 
 
GAPDH 
59.98 
Antisense: 5′ - AAGATCTGCGTCTGCTTGGT - 3′ 60.02 
55.50 
56.80 
60.00 
60.00 
57 213 9 
Homo 
sapien 
 
HSPA 
Rattus 
norvegicus 
 
GAPDH 
Rattus 
norvegicus 
Sense: 5′ - GAGTCAACGGATTTGGTCGT - 3′ 
Antisense: 5′ - TTGATTTTGGAGGGATCTCG - 3′ 
 
 
Sense: 5′ - GTGTGGAGAGCCAAGAGGAG - 3′ 
Antisense: 5′ - TTTCCAAACTGGATCGAAGG - 3′ 
 
 
Sense: 5′ - AGTGCCAGCCTCGTCTCATA - 3′ 
Antisense: 5′ - GGATCTCGCTCCTGGAAGAT - 3′ 
59.97 
60.01 
 
59.99 
60.04 
 
 
60.97 
60.70 
56.20 
54.80 
 
 
56.50 
55.60 
 
 
57.10 
56.00 
60.00 
58.00 
 
 
64.00 
58.00 
 
 
62.00 
62.00 
56 238 10 
 
 
 
56 156 7 
 
 
 
57 265 11 
 
 
* GC / AT rule: A method of calculating the primer annealing temperature using the formula: T = 2o (A + T) + 4o (G + C), where A, C, G and T represent the number of adenine, cytosine, guanine and 
thymine bases respectively in the primer sequence concerned. 
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2.6 Analysis of qRT-PCR 
 
 
 
2.6.1 Agarose gel electrophoresis 
 
 
 
 
The amplicons from qRT-PCR were visualized on 2% agarose gels as described in 
section 2.2.2. 
 
2.7     Quantification analysis of qRT-PCR 
 
 
 
Genomic DNA of known concentrations was used as a standard to amplify GAPDH 
gene using the LightCycler instrument (Shervington et al, 2007b).   A standard curve 
was produced using the crossing points shown in section 3.11.1, Figure 3.35 generated 
from five concentrations of genomic DNA in duplicate: 0.005, 0.05, 0.05, 5 and 50 ng 
with known copy numbers shown in section 3.11.1, Table 3.6.  The equation generated 
(y = -1.3124Ln(x) + 32.058)) was rearranged to (=EXP ((Ct value -32.058/-1.3124)) 
and used to determine copy numbers of HSPA and GAPDH mRNA expression 
throughout this thesis. 
 
2.8     Immunofluorescence 
 
The cell culture medium was removed by gentle aspiration from the chamber slides and 
the cells were washed three times with warm PBS (0.1 M) before fixation.  The fixation 
procedure involved incubation of the cells for 10 min at room temperature with freshly 
made 4% paraformaldehyde (w/v) in PBS (0.1 M) and 0.1 M, NaOH (sodium 
hydroxide).   The excess paraformaldehyde was removed and the cells were washed 
again three times with warm PBS (0.1 M).  The cells were permeablized using 0.3 % 
(w/v) Triton X-100 in PBS and incubated for 7 min at room temperature on a shaker. 
Bovine Serum Albumin (BSA) blocking solution (1% w/v in PBS) was added to prevent 
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any non-specific binding and samples were incubated for 30 min at room temperature. 
After incubation, the blocking solution was removed by gentle aspiration.  The primary 
antibody HSPA (Anti-Hsp70 antibody [BRM-22]) diluted in blocking solution, (dilution 
factor 1:200) (Abcam, UK, Cat No. ab6535) was added to each chamber and incubated 
at 4oC overnight.  The primary antibody was removed by gentle aspiration followed by 
three consecutive washes with warm PBS (0.1 M).  The cells were incubated with light 
sensitive Anti-mouse IgG FITC (fluorescein isothiocyanate) conjugated secondary 
antibody (Goat polyclonal Secondary Antibody to Mouse IgG - H&L FITC, Abcam, 
UK, Cat. No. ab6785) diluted in blocking solution (dilution factor 1:128) for a further 
60 min at room temperature on a shaker in a dark room.  The secondary antibody was 
removed by gentle aspiration, followed by three consecutive washes with warm PBS 
(0.1 M).  The sections were mounted under a cover slip using VECTASHIELD PI (0.01 
M) (Propidium Iodide, Vector, USA) mounting medium. The cells were then visualized 
and scanned using an Axiovert 200 LSM 510 laser scanning confocal microscope (Carl 
Zeiss, USA).  Negative control cells from each sample underwent identical preparations 
for immunofluorescence staining, except that the primary antibody was omitted. 
Routinely 500 cells were analysed per sample. 
 
2.9     Flow Cytometry 
 
Cells were washed once in 0.1% BSA in PBS (500 µl), centrifuged for 5 min at 1000 
rpm, and the supernatant was removed.  Triton X-100 0.1% (100 µl) was added and 
samples incubated on ice for 15 min.   Following incubation, the suspension was 
centrifuged for 5 min at 1000 rpm, and the supernatant was removed.   Cells were 
washed once in 0.1% BSA in PBS (500 µl) and samples centrifuged for 5 min at 1000 
rpm, after which the supernatant was removed.   Goat serum (5% in PBS) and 0.1% 
BSA (50 µl) was added to each sample, which were then incubated on ice for 30 min. 
Following incubation, the suspension was centrifuged for 5 min at 1000 rpm, and the 
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supernatant was removed.  Primary antibody (HSPA) (Anti-Hsp70 antibody [BRM-22], 
Abcam,UK) in PBS, 0.1% BSA and goat serum 5% (50 µl) was added and incubated on 
ice for 30 min.  Following incubation, the suspension was centrifuged for 5 min at 1000 
rpm, before the supernatant was removed. Cells were washed once in 0.1% BSA in PBS 
(500 µl) and centrifuged for 5 min at 1000 rpm, and the supernatant was removed. 
Fluorescein isothiocyanate (FITC) conjugated secondary antibody (Goat polyclonal 
Secondary Antibody to Mouse IgG - H&L FITC, Abcam, UK,) in PBS, 0.1% BSA and 
goat serum 5% (50 µl) was added to each sample and they were then incubated on ice 
for 30 min.  Following incubation, the suspension was centrifuged for 5 min at 1000 
rpm, and the supernatant removed.  Cells were washed twice in 0.1% BSA in PBS (500 
µl) and centrifuged for 5 min at 1000 rpm, and the supernatant was again removed. 
Cells were resuspended in 0.1% BSA in PBS (300 µl) and filtered into FACS tubes. 
Becton Dickinson FACSAria flow cytometry equipment was used to count and 
distinguish between cells for the presence or absence of HSPA. 
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2.10   Rattus norvegicus Brain Tissue 
 
 
 
Studies were undertaken using post-mortem brain tissue samples from aged-matched 
male Wistar rats (obtained from the Physiology Laboratory, University of Central 
Lancashire). All procedures conformed to the ―UK Animals (Scientific Procedures) Act 
1986‖  according to the ―Principles of Laboratory Animal Care, 1985‖.  The work had 
the relevant ethical clearance from the Ethics Committee for the University of Central 
Lancashire under Home Office Licence PIL50/00824. Animals were housed in groups 
under institutional regulations at standard vivarium conditions, granted free access to 
water and commercial chow, exposed to a 12 h light / 12 h dark cycle and monitored for 
any signs of stress. Rats were humanely killed by cervical dislocation and the brain 
removed, either immediately or at the given post-mortem interval. 
 
 
 
Brain tissue samples weighing approximately 50 mg – 100 mg and no less than 0.5 cm 
in thickness, were excised using a sterile scalpel at timed intervals of 0, 3, 6, 12 and 24 
h   and   maintained  at   room  temperature.  Excised  samples   after   sacrifice  were 
immediately weighed and snap-frozen by immersion into liquid nitrogen, followed by 
grinding of the tissue to a fine powder using a pestle and mortar under liquid nitrogen. 
Samples were transferred to new sterile 1.5 ml RNase free microfuge tubes and stored at 
-80oC. 
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2.11   Treatment 
 
 
 
2.11.1            Induction of mild heat shock 
 
 
 
 
Additional brain tissue excised at 0, 3, 6, 12 and 24 h post sacrifice was subjected to 
mild heat shock.   This was performed by placing the brain tissue into sterile 1.5 
microfuge tubes and immersion in a heated water bath at 42oC for a period of 10 min, 
after which samples were stored at room temperature. Samples weighing approximately 
30 mg – 50 mg, and no greater than 0.5 cm in thickness, were excised using a sterile 
scalpel at timed intervals of 0, 3, 6, 12 and 24 h post sacrifice.  Excised samples were 
immediately weighed and snap-frozen, by immersion in liquid nitrogen followed by 
grinding of the tissue to a fine powder using a sterile pestle and mortar, again under 
liquid nitrogen, before transfer to sterile 1.5 ml RNase free microfuge tubes and storage 
at -80oC. 
 
2.11.2            Induction of multiple heat shocks 
 
 
 
Additional rat brain tissue excised at 0, 3, 6, and 24 h post sacrifice was subjected to 
mild heat shock at 0 h and again at 3, 6 and 24 h time course periods. This was 
performed by placing the brain tissue into sterile 1.5 microfuge tubes and immersion in 
a heated water bath at 42oC for a period of 10 min, after which samples were stored at 
room temperature.  Samples weighing approximately 30 mg – 50 mg, and no greater 
than 0.5 cm in thickness, were excised using a sterile scalpel at timed intervals of 0, 3, 
6, and 24 h post sacrifice. Excised samples were immediately weighed and snap-frozen, 
by immersion in liquid nitrogen followed by grinding of the tissue to a fine powder 
using a sterile pestle and mortar, again under liquid nitrogen, before transfer to sterile 
1.5 ml RNase free microfuge tubes and storage at -80oC. 
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2.12   DNA Extraction 
 
 
 
DNA was extracted from brain tissue using DNeasy®  Blood and Tissue Kit (Qiagen, 
UK.   Cat. No. 69504) and RNase A (Qiagen, UK.   Cat. No. 19101).   Prior to 
commencing this procedure, 25 ml and 30 ml ethanol (96 -100%) was added to 95 ml of 
AW1 and 66 ml of AW2 buffer concentrates respectively. 
 
 
 
 
 
Table 2.11. Reagents, components and quantity provided of each in the DNeasy® 
Blood and Tissue Kit (Qiagen). 
 
 
Reagent / Component Quantity 
DNeasy Mini Spin Columns in 2 ml Collection Tubes 50 
Collection Tubes 2 ml 100 
Buffer ATL 10 ml 
Buffer AL 12 ml 
Buffer AW1 (concentrate) 19 ml 
Buffer AW2 (concentrate) 13 ml 
Buffer AE 22 ml 
Proteinase K 1.25 ml 
RNase A (17,500 U) 2.5 ml (100mg/ml; 
7000 units/ml 
solution) 
 
 
 
 
DNA was isolated from 25 mg of ground brain tissue following the manufacturer‘s 
protocol.  The volumes of each reagent and buffers provided within the kit are detailed 
in Table 2.11, whilst the specific measures used during each extraction procedure are 
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shown in Table 2.12. Initially, 180 μl of Buffer ATL was added to 25 mg of ground 
brain  tissue  with  20  μl  of  Proteinase  K.  Samples  were  vortexed  thoroughly  and 
incubated overnight at 56oC.   Following overnight incubation, 4 μl of RNase A (100 
mg/ml) was added to each sample and mixed by vortexing before incubating for 2 min 
at room temperature.  After incubation, the lysed samples were vortexed for 15 s and 
200 μl of Buffer AL was added and mixed thoroughly by vortexing, followed by the 
addition of 200 μl of ethanol (100%) which was again mixed thoroughly by vortexing. 
The lysis solution was pipetted into a DNeasy mini-spin column placed in a 2 ml 
collection tube and centrifuged at 6000 g (8000 rpm) for 1 min.  The flow-through and 
the collection tube were discarded.  The DNeasy mini-spin column was placed in a new 
2 ml collection tube, 500 μl of Buffer AW1 was added and centrifuged at 6000 g (8000 
rpm) for 1 min.  The flow-through and the collection tube were again discarded.  The 
DNeasy mini-spin column was placed in a new 2 ml collection tube 500 μl of Buffer 
AW2 was added and centrifuged at 20000 g (14000 rpm) for 3 min, before the flow- 
through and the collection tube were discarded.   The DNeasy mini-spin column was 
placed in a new 1.5 ml micro-centrifuge tube and 200 μl of Buffer AE was added 
directly onto the DNeasy membrane, incubated at room temperature for 1 min and 
centrifuged at 6000 g (8000 rpm) for 1 min.   The resulting supernatant (DNA) was 
stored at -20oC ready for quantification and analysis. 
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Table  2.12.  Volumes  of  reagents  used  for  DNA  extraction  as  per  manufacturers‘ 
 
protocol. 
 
 
Amount of Tissue 25 mg 
Buffer ATL 180 μl 
Buffer AL 200 μl 
Buffer AW1 (concentrate) 500 μl 
Buffer AW2 (concentrate) 500 μl 
Buffer AE 200 μl 
Proteinase K 20 μl 
RNase A (17,500 U) 4 μl 
Ethanol 100% 200 μl 
 
 
 
 
 
2.12.1 Quantification of nucleic acids 
 
 
 
 
Extracted DNA was quantified by measurement of absorbance of samples using the 
 
Thermo Scientific NanoDrop™ 1000 spectrophotometer at wavelengths of 260 nm and 
 
280 nm.   A 2 µl DNA sample was pipetted onto the end of a fiber optic cable (the 
receiving fiber). A second fiber optic cable (the source fiber) was then brought into 
contact with the liquid sample, causing the liquid to bridge the gap between the fiber 
optic ends. A pulsed xenon flash lamp provide the light source and a spectrometer 
utilizing a linear CCD array was used to analyse the light passing through the sample 
(http://www.nanodrop.com/Library/nd-1000-v3.7-users-manual-8.5x11.pdf).  The ratio 
of 260 nm to 280 nm was used to determine the purity of the extracted DNA.  A ratio of 
~ 1.8 was generally accepted as indicative of pure DNA. 
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2.12.2.           Analysis of Nucleic acid by agarose gel 
 
 
 
 
Extracted DNA was visualized on 2% agarose gels to determine whether DNA was 
intact or degraded as per section 2.2.2. 
 
 
2.12.3.Quantification analysis of qRT-PCR 
 
 
 
 
Extracted Rattus norvegicus genomic DNA was used as a standard to amplify GAPDH 
gene using the LightCycler instrument.  A standard curve was produced using the 
crossing points (section 3.11.1, Figures 3.33) generated from five concentrations of 
genomic DNA in duplicate: 0.005, 0.05, 0.05, 5 and 50 ng with known copy numbers 
(section 3.11.1, Table 3.5).  The equation generated (y = -1.3124Ln(x) + 32.058)) was 
rearranged to (=EXP ((Ct value -32.058/-1.3124)) and used to determine copy numbers 
of HSPA and GAPDH mRNA expression throughout this thesis. 
 
2.14   mRNA Isolation 
 
 
mRNA was isolated using mRNA Isolation Kit (Roche-applied-science, Germany Cat. 
No.  11  741  985  001).    Reagents  were  mixed  using  a  vortex  mixer  and  briefly 
centrifuged prior to commencing this procedure. 
 
mRNA was isolated from 50 mg of ground brain tissue following the manufacturer‘s 
protocol as shown in the schematic diagram Figure 2.1.  The volumes and composition 
of each reagent and buffers provided within the kit are detailed in Table 2.3, whilst the 
specific measures used during each extraction procedure are shown in Table 2.4. 
 
Initially, 1.5 ml of lysis buffer (0.1 M Tris buffer, 0.3 M LiCl, 10 mM EDTA, 1% (w/v) 
 
lithium dodecylsulphate, 5 mM DTT (dithiothreitol) pH 7.5) was chilled to ≤ 0oC in a 
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sodium chloride-ice water bath, after which 50 mg of ground brain tissue was added 
followed by mechanical shearing of tissue achieved by passing through a 21 gauge 
needle (four).  The suspension was centrifuged at 11,000 g for 30 s between 0oC and - 
4oC.  The supernatant was captured and transferred into a 1.5 ml sterile microfuge tube 
 
and placed on ice.  An aliquot of 1.5 µl of biotin labelled oligo(dT)20 probe (100 pmol 
biotin-labelled oligo(dT)20 per µl of molecular biology grade H2O) was added to the 
tissue lysate and allowed to hybridise with mRNA for 10 min at room temperature. 
Simultaneously, 150 µl of streptavidin magnetic particles (10mg/ml of suspension in 50 
mM Hepes, 0.1 % (w/v) bovine serum albumin, 0.1 % (w/v) chlorace tamide, 0.01 % 
(w/v) methylisothiazolone, pH 7.4) was aliquoted into a 1.5 ml sterile microfuge tube 
and separated from the storage buffer by placing in a magnetic separator, after which 
the storage buffer was discarded.  The particles were cleansed by re-suspension in 250 
µl of lysing buffer (0.1 M Tris buffer, 0.3 M LiCl, 10 mM EDTA, 1% (w/v) lithium 
dodecylsulphate, 5 mM (dithiothreitol) DTT pH 7.5).  Following magnetic separation 
and disposal of the supernatant, the prepared particles were resuspended in the dT- 
mRNA hybrid mixture. After briefly vortexing, the resultant suspension was incubated 
for 5 min at 0oC to achieve immobilisation.  Following incubation, the hybrid-linked 
particles were magnetically separated from this fluid and the supernatant was discarded. 
The remaining particles were then washed by resuspension in 3 × 200 µl of washing 
buffer (10 mM Tris buffer, 0.2 M LiCl and 1 mM EDTA, pH 7.5). Upon disposal of the 
final supernatant, mRNA was eluted from the particles by resuspension in 10 µl of 
redistilled water, mixed and incubated for 2 min at 65oC.  After magnetically separating 
the particles from the fluid, the resulting supernatant (mRNA) was stored at -20oC in an 
 
RNase free microfuge tube ready for quantification and analysis. 
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2.15             Complimentary DNA Synthesis (cDNA) 
 
 
 
mRNA was reversed transcribed using First Strand cDNA Synthesis Kit harnessing 
AMV  enzymes as  per  section 2.3.    The composition and  volumes of  all  reagents 
provided are shown in Table 2.5, whilst the specific quantities required by each cDNA 
synthesis reaction are shown in Table 2.6.  Reagents were mixed using a vortex mixer 
and briefly centrifuged prior to commencing this procedure. 
 
2.16    Primer Preparation 
 
 
 
Rattus norvegicus GAPDH and HSPA sequence-specific primers were designed using 
Primer3 software and commercially synthesised by TIB MOLBIOL syntheselabor 
(Berlin, Germany). Primers were received in a powdered form and collected by micro- 
centrifugation at 10,000 g for 1 min at room temperature. Molecular biology-grade H2O 
(250 µl) was added to each primer to create 20 µM stock solutions. Finally, 20 µl of the 
sense and antisense primer stock solutions were combined to generate a 10 µM PCR 
primer mix, which was then stored at -20oC until required. Table 2.10 portrays the 
sequences of the primers corresponding to each gene. 
 
2.17 Real-time quantitative reverse transcriptase polymerase 
chain reaction (qRT-PCR) 
 
 
 
The levels of HSPA and GAPDH RNA sequences (GAPDH reference gene used in RT- 
PCR reaction, Olsvik et al, 2005) for all tissue samples were measured by performing 
real-time qRT-PCR (Ball et al, 2003) using the LightCycler 2.0 system (Roche 
Diagnostics Ltd, Germany) and LightCycler® FastStart DNA MasterPLUS SYBR Green I 
kit according to the manufacturer‘s instructions.  The composition and volumes of all 
reagents provided are shown in Table 2.7, whilst the specific quantities used during the 
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amplification procedure shown in Table 2.8.  All samples and reagents were kept on ice 
throughout the procedure. 
 
Prior to using the hot-start PCR an enzyme reaction mix was prepared by transferring 
 
14 µl of LightCycler® FastStart Enzyme (1a) into the LightCycler® FastStart Reaction 
Mix SYBR Green vial (1b) (Table 2.8).   Each reaction capillary contained a total 
reaction volume of 20 µl, comprising 4 µl of the ready to use hot-start reaction mix, 12 
µl of molecular biology-grade H2O, 2 µl of 10 µM PCR primer mix (generated from 
section 2.4 for each specific gene) and 2 µl of single stranded cDNA template.   A 
further 20 µl of template-free reaction mix was prepared as a negative control (in which 
molecular biology-grade H2O substituted for cDNA).  Prior to qRT-PCR being carried 
out, the definitive annealing temperature for each gene was established (Table 2.10). 
LightCycler protocol for use with FastStart DNA MasterPLUS SYBR Green Kit 1 utilised 
the program shown below in Table 3.13. 
 
 
Quantitative real-time PCR was used to evaluate the expression of HSPA (predicted 
amplicon size of 156 bp) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(predicted amplicon size of 207 bp) using FastStart DNA MasterPLUS  SYBR Green 1 
(Roche, UK).   Primers used for HSPA were 5‘ GTGTGGAGAGCCAAGAGGAG 3‘ 
(sense) and 5‘ TTTCCAAACTGGATCGAAGG 3‘ (antisense) and for GAPDH primers 
were 5‘ AGACAGCCGCATCTTCTTGT 3‘ (sense) and 5‘ 
CTTGCCGTGGGTAGAGTCAT 3‘ (antisense).   All primers were designed using 
Primer3 software and manufactured by TIB MOLBIOL.  The PCR protocol involved a 
hot start induction, with the FastStart Taq DNA polymerase enzyme activated by pre- 
incubating the reaction mixture at 95oC for 10 min.   Hot start includes a step which 
prevents non-specific elongations and increases PCR sensitivity, specificity and yield 
(Dang and Jayasena, 1996).  The single stranded cDNA template was then subjected to 
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35 amplification cycles, each with the following parameters: denaturation at 95oC for 10 
s, annealing at the primer dependant temperature 56oC (HSPA) and 57oC (GAPDH) for 
15 s and extension at 72oC for 25 bp / s (amplicon dependant, HSPA 7 s, GAPDH 9 s) 
(Patel et al, 2008).  At the end of each cycle, the fluorescence emitted was measured in 
a  single  step  in  channel  F1  (gain1)  to  obtain  data  for  quantification  analysis 
(Shervington et al, 2007b, Mohammed and Shervington, 2007).  After the 35th cycle, the 
amplicons were prepared for melting curve analysis, heated to 95oC (denaturation) and 
 
then rapidly cooled to the previously used annealing temperature (+10oC) for 40 s.  All 
heating and cooling steps were performed with a slope of 20oC / s.  To obtain the data 
for  the  melting  curve  analysis,  the  temperature  was  subsequently  raised  to  95oC 
(melting) with a slope of 0.1oC / s and the emitted fluorescence was measured 
continuously (channel F1,  gain1).    Melting  curve  analysis  was  used  to  assess  the 
specificity of the amplified PCR product and allow for discrimination between primer- 
dimers and specific product.  At the final step, the generated amplicons were cooled to 
40oC for 30 s and stored at -20oC until required for further analysis.  All PCR reactions 
 
were performed in triplicate with a negative control included, which contained primers 
but no DNA. 
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Table 2.13 LightCycler program utilising FastStart DNA MasterPLUS SYBR Green 
 
Kit 
 
 
Cycles Analysis 
 
Mode 
Target 
 
Temperature 
Hold Time  
1 None 95oC 10 min Pre-incubation 
35 None 95oC 15 s Denaturation 
35 Quantification 56oC HSPA 
 
57oC GAPDH 
15 s Annealing, 
amplification 
and  real  time 
analysis 
35 72oC 7 s HSPA 
 
9 s GAPDH 
Extension 
 Melting Curve 
analysis 
95oC  Denaturation 
1 66oC HSPA 
 
67oC GAPDH 
40 s  
1 95oC  Melting 
1 None 40oC 30 s Cooling 
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2.18             Quantification analysis of qRT-PCR 
 
 
 
 
Genomic DNA of known concentrations was used as a standard to amplify GAPDH 
gene using the LightCycler instrument.  A standard curve was produced using the 
crossing points as shown in section 3.11.1, Figure 3.33 generated from five 
concentrations of genomic DNA in duplicate: 0.005, 0.05, 0.05, 5 and 50 ng with 
known copy numbers shown in section 3.11.1, Table 3.6.  The equation generated (y = - 
1.3124Ln(x) + 32.058)) was rearranged to (=EXP ((Ct value -32.058/-1.3124)) and used 
to determine copy numbers of HSPA and GAPDH mRNA expression throughout this 
thesis. 
 
2.19   Cryostat 
 
 
Frozen sections of brain tissue were placed onto a chuck containing OCT (optimal 
cutting temperature) compound (10.24% polyvinyl alcohol, 4.26% polyethylene glycol, 
85.5% non-reactive ingredient) and placed in liquid nitrogen.  Once the OCT compound 
had turned solid and white, the frozen samples on the chuck were placed in the Bright‘s 
cryostat for cutting.   The samples were coarsely trimmed until a full flat face was 
visible.  Sections were then cut at 10 μ (microns) thickness and carefully placed on a 
charged slide.  A few drops of 5% acetic acid was added to the cut sections and allowed 
to   fix   for   a   few   seconds.      Slides   were   kept   at   -20oC   until   required   for 
 
immunofluorescent experiments. 
 
 
 
2.20             Immunofluorescence 
 
 
 
The tissue sections were initially fixed in freshly made 4% Paraformaldehyde (w/v) in 
PBS (0.1 M) for 15 min at room temperature, after which the excess paraformaldehyde 
was removed.  The fixed tissue sections were permeabilized using Trypsin (0.025%) in 
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aqueous calcium chloride (CaCl2) (0.1%, pH 7.8), incubated for 45 min at 37oC, and 
then washed three times in warm PBS (0.1M).   The sections were then incubated in 
blocking solution (0.1% PBS, 0.5% Tween 20, 0.1% Goat serum) for 30 min at room 
temperature, followed by overnight incubation at 4oC in the primary antibody for HSPA 
 
(Anti-Hsp70 antibody [BRM-22], Abcam,UK, dilution 1:200) to allow the antibody to 
bind, and for saturation to take place.   After overnight incubation, the sections were 
washed with PBS three times for 5 min and incubated in a solution of a light sensitive 
Anti-mouse IgG FITC (Fluorescein Isothiocyanate) conjugated secondary detection 
antibody (Goat polyclonal Secondary Antibody to Mouse IgG - H&L FITC, Abcam, 
UK, dilution 1:200) diluted in blocking solution for 1 h at room temperature.  The 
secondary antibody was removed followed by three consecutive washes with warm PBS 
(0.1 M). The sections were mounted under a cover slip using VECTASHIELD PI (0.01 
M) (Propidium Iodide, Vector, USA) mounting medium. The tissue sections were then 
examined and images recorded using an Axiovert 200 LSM 510 laser scanning confocal 
microscope (Carl Zeiss, USA).  Negative control cells from each sample encountered 
identical  preparations  for  immunofluorescence  staining,  except  that  the  primary 
antibody was omitted. 
 
 
 
 
2.21             Statistical Analysis 
 
 
For analysis of HSPA, GAPDH mRNA copy number and protein levels, all quantitative 
data was presented as the mean ± SD of three separate experiments and subjected to 
either a one-way ANOVA between groups of analysis of variance test, a two-way 
factorial mixed ANOVA analysis of variance test, a three-way factorial mixed ANOVA 
analysis of variance or an independent-samples t-test using IBM SPSS statistics 19 
software. 
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Chapter 3 
 
 
 
 
 
 
Developmental Work 
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3.1     Developmental Work 
 
 
During the course of this programme of research, initial developmental work was 
required to gain experience and establish the validity of the techniques and primer 
sequences for use in PCR experimentation. This chapter will focus on these areas of 
developmental work, to enable subsequent results chapters to focus on the results 
obtained. It will also describe the biological samples used for experimental work, and 
standard methodologies used. 
 
 
 
 
 
3.2     Tissue samples and cell lines 
 
 
 
 
Work undertaken throughout this study involved the use of the following samples: 
 
 
 
a)  Tumour and normal (control) brain tissue samples were obtained from patients 
admitted to the Royal Preston Hospital, UK (section 4.2.3, Table 4.5). Work on 
these samples was carried out with ethical approval from the North Manchester 
Research Ethics Committee (Ref: 06/Q1406/104) and the Ethics Committee at 
the University of Central Lancashire. 
 
 
b)  Human brain cell line grade I astrocytoma, 1321N1 was obtained from European 
Collection  of  Cell  Cultures,  ECACC,  (UK),  grade  II/III  oligodendroglioma 
GOS-3  from  Deutsche  Sammlung  von  Mikroorganismen  und  Zelkulturen 
GmbH,  DMSZ,  (Germany),  grade  IV  glioblastoma, U87-MG  from  ECACC 
(UK) and normal human astrocytes, NHA from Lonza (UK) (section 2.1.2, 
Table 2.1). 
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c)  Post-mortem  brain  tissue  samples  were  obtained  from  aged-matched  male 
 
Wistar rats from the Physiology Laboratory, University of Central Lancashire. 
 
 
 
Due to difficulties in obtaining post-mortem human brain tissue for all experiments, rat 
brain tissue was chosen for some experiments in this thesis. These samples were readily 
accessible from the Physiology Laboratory, University of Central Lancashire under the 
Home Office Licence PIL50/00824. Sequence homology between Homo sapiens and 
Rattus norvegicus for the target genes used indicated 73% homology for HSPA/HSP70 
nucleotide sequences, 96% homology for HSPA/HSP70 amino acid sequences, 84% 
homology for the control GAPDH nucleotide sequence and 93% homology for GAPDH 
amino acid sequence (Table 3.1). 
 
 
 
 
3.3     Introduction and history of bioinformatics 
 
 
 
Bioinformatics is an essential computational tool in molecular biology, enabling the 
storage, retrieval, analysis and distribution of biological data (Kamel 2003; Kim, 2000; 
Singh  and  Kumar,  2001).  It  is  defined  as  ―the  field  of  science  in  which  biology, 
computer science and information technology merge into a single discipline‖ (National 
Centre  for  Biotechnology  Information,  NCBI).  Broadly  speaking,  this  discipline 
consists of three main areas: 
• the  development  of  new  algorithms  and  statistics  in  order  to  determine 
relationships amongst members of large data sets, 
 
• the analysis and interpretation of various types of data, such as nucleotide and 
amino acid sequences, protein domains and structures, and 
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• the development of tools that enable the efficient access and management of 
different types of information. 
 
To date, bioinformatics encompasses a wide variety of biological data, such as protein 
structures, gene and protein functional data, metabolic pathways and genomes. Due to 
the  huge  amount  of  data  involved,  much  work  has  been  concerned  with  the 
development  of  databases  such  as  GenBank  (Genetic  Sequence  Databank,  USA), 
EMBL Nucleotide Sequence Database (Europe), DDBJ (DNA Database Japan), 
SwissProt (Switzerland), and with the associated software required for the analysis of 
the stored sequence information, primarily DNA, RNA and protein sequence data from 
the human and other genome sequencing projects (Fenstermacher, 2005). The 
management and accessibility of this data has been directly attributable to the 
development of the World Wide Web (WWW), which has facilitated access to this data 
by researchers, regardless of country or in-house research facilities. 
 
 
 
 
3.4     Candidate Genes 
 
 
 
Heat shock proteins are a family of highly conserved ubiquitous proteins encoded by 
genes which are activated not only in response to various physiological and 
environmental stress conditions, but also in cells affected by various diseases, such as 
cancer, Alzheimer‘s, Parkinson‘s and Huntington‘s diseases and diabetes, or by fever or 
inflammation (Jolly and Morimoto, 2000; Lindquist, 1986; Morimoto, 1993).  However, 
in  contrast  to  the  diversity  of  the  heat  shock  protein  families,  which  cover 
approximately five hundred client proteins, the present study will only focus on 
HSPA/HSP70. 
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The HSPA/HSP70 gene family is one of the most predominant heat shock protein gene 
families and is of particular interest due to three well-characterized members; 
HSPA1A/HSP70-1, HSPA1B/HSP70-2 and HSPA1L/HSP70-Hom; (Milner and 
Campbell, 1990). Genes for theses members are located within the major 
histocompatibilty complex class III region (MHC-III), for Homo sapiens located on the 
short arm of chromosome 6 (6p21.3), and are intronless and for Rattus norvegicus 
located on the short arm of chromosome 20 (20p12), and again are intronless. 
 
Although these three genes have similar nucleotide sequences, they differ in their 
regulation.  Both HSPA1A and HSPA1B have been shown to encode identical protein 
products of 641 amino acids, and HSPA1L has been identified at a location 4 kb 
telomeric to HSPA1A with a 90% similarity in amino acid sequence (Milner and 
Campbell, 1990; Sargent et al, 1989a; Sargent et al, 1989).  Both HSPA1A and HSPA1B 
have been shown to be highly expressed in mammalian cells that have been subjected to 
heat  shock  at  42oC  (Milner  and  Campbell, 1990).    HSPA1A is  also  constitutively 
 
expressed  at  low  levels  (Milner  and  Campbell,  1990).    HSPA1L,  which  has  no 
associated regulatory heat shock consensus sequence, has been shown to be expressed at 
low levels both constitutively and after heat shock at 42oC, with no comparable 
difference in levels (Milner and Campbell, 1990). 
 
 
 
 
GAPDH was chosen as the preferred housekeeping gene to be used throughout this 
study. GAPDH is ubiquitously expressed in cells and has been shown to remain 
relatively constant in RNA and protein levels in normal and tumourous brain tissue 
(Barber at el., 2005; Said et al, 2007). 
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3.5 Gene location 
 
 
The genomic locations of the human genes HSPA1A, HSPA1B, HSPA1L and GAPDH 
 
were (Figure 3.1) obtained from Genecards (http://www.genecards.org). 
 
 
 
A. HSPA1A 
B. HSPA1B 
C. HSPA1L 
D.  GAPDH 
Figure 3.1 Locations of human genes used in this study. A. Chromosome 6 HSPA1A, B. 
HSPA1B, C. HSPA1L D. Chromosome 12 GAPDH. Location is denoted by the red bar 
(taken from GeneCards database  http://www.genecards.org. 
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3.6     Nucleotide sequences 
 
 
Nucleotide sequences for those genes of interest in this study were located using public 
databases, such as GenBank, SwissProt and EMBL which are held by the National 
Centre for Biotechnology Information (NCBI, Unigene). The NCBI database contains a 
collection of Expression Sequence Tags (ESTs), small sub-sequences derived from 
cDNA sequences (approx. 200 – 500 bp in length) that are generated by sequencing 
either  one  or  both  ends  of  RNA  transcripts.  ESTs  are  mapped  to  corresponding 
genomes,  providing  information  regarding  putative  genes  that  have  been  located 
through analysis of biocomputational techniques. 
The mRNA sequences used for this study were accessed from NCBI at: 
 
 
 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=nucleotide&cmd=search&term 
 
 
 
The sequences obtained are shown in Appendix 9.1 (HSPA1A Homo sapiens), 9.2 
(HSPA1B Homo sapiens), 9.3 (HSPA1L Homo sapiens), 9.4 (HSPA1A Rattus 
norvegicus), 9.5 (HSPA1B Rattus norvegicus), 9.6 (HSPA1L Rattus norvegicus), 9.7 
(GAPDH Homo sapiens) and 9.8 (GAPDH Rattus norvegicus). 
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3.7     Primer Design 
 
 
 
3.7.1   Primer Specificity 
 
 
 
 
One of the most critical parameters for successful PCR is the design of amplification 
primers (Kamel et al, 2003).  The efficacy, specificity and sensitivity of PCR depend 
largely on the efficiency of these primers (Diffenbach et al, 1993; He et al, 1994).  The 
sequence of each of the designed primers in a pair determines their specificity, melting 
temperature,  G/C  content  and  product  length.  There  are  numerous  bioinformatic 
software             programs             available,             such             as             primer-Blast 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast)              and              Primer              3 
 
(http://frodo.wi.mit.edu/primer3/), which assist in the design of effective PCR primers 
 
from a template DNA sequence (Dieffenbach et al, 1993; Kamel et al, 2003). 
 
 
 
 
3.7.2   Primer Length 
 
 
 
 
For RT-PCR, the most efficient primers are between 18 and 24 nucleotides in length 
(Dieffenbach et al, 1993; He et al, 1994; Kamel et al, 2003).  In  general, primers 
between 18 and 24 nucleotides in length tend to be very specific, particularly if the 
annealing temperature is set within a few degrees of the primer melting temperature 
(Dieffenbach et al, 1993). Depending on the size of the genome for the organism being 
studied, there is a minimum optimal primer length. For each additional nucleotide, the 
primer becomes four times more specific and hence the minimum primer length used in 
most applications is 18 nucleotides (Dieffenbach et al, 1993). Primers longer than 24 
nucleotides in length may have a tendency to form secondary structures, which can 
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result in primer dimer formation and hence decrease PCR efficiency (Dieffenbach et al, 
 
1993; He et al, 1994; Kamel et al, 2003). 
 
 
 
 
3.7.3   Primer Melting (Annealing) Temperature (Tm) 
 
 
 
 
Primer  melting  temperature  (Tm)  is  important  in  determining  the  optimal  PCR 
annealing temperature, which is in turn determined by primer sequence, primer 
concentration, salt concentration and magnesium chloride (MgCl2) concentration. 
Ideally, both forward and reverse primers should have similar optimal melting 
temperatures, within the range of 52 – 62oC (Dieffenbach et al, 1993; He et al, 1994; 
Kamel et al, 2003). As a rule of thumb, most primer design programs use the following 
4 + 2 rule, based purely on primer GC content, to calculate the optimal primer melting 
temperature: 
 
 
 
Tm = 4 * (G + C) + 2 * (A + T) 
 
 
 
 
The Tm is calculated by counting the numbers of guanine or cytosine residues and 
adenine or thymine residues in both the forward and reverse primers and substituting 
this information in the above equation. Each G/C effectively represents 4oC and A/T 
represents 2oC of the calculated melting temperature. 
 
 
 
 
3.7.4    Primer GC content 
 
 
 
 
For most PCR applications, the primer G/C content should be within the range of 45 – 
 
60% of the total sequence (Dieffenbach et al, 1993; Kamel et al, 2003). If the G/C 
 
content is too low, then this could result in decreased PCR efficiency and poor primer 
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binding. Alternatively, if the G/C content is too high, this could result in mispriming 
through the formation of a stably annealed duplex with non-target templates 
(Dieffenbach et al, 1993; Kamel et al, 2003). 
 
 
 
3.7.5   Product Length (Amplicon Size) 
 
 
 
 
For accurate quantification and PCR efficiency, the product length should be within the 
range of 100 – 250 bp. Products longer than 250 bp will lead to decreased PCR 
efficiency (Dieffenbach et al, 1993; Kamel et al, 2003). The primers were designed 
using  Primer  3   software,   accessible  at   the   website  (http://frodo.wi.mit.edu/cgi- 
 
bin/primer3/primer3_www.cgi) to produce amplicons in this size range. 
 
 
 
 
3.7.6   Experimental design of Primers 
 
 
 
 
All primers were ordered and commercially synthesised by TIB MOLBIOL 
syntheselabor (Berlin, Germany). All primers were rehydrated in molecular biology 
grade H2O (250 µl) to create 20 µM stock solutions which were stored at -20oC until 
required.  Primers were designed using Primer 3 software using the following design 
 
parameters: primer length 20 ± 2 bp; G/C content between 45 – 60%; primer melting 
temperature between 52 – 62oC; and avoidance of the GC-rich 3‘ end (4 or more G‘s or 
C‘s in a row). Any potential hairpin formation, (i.e. self-complementarity of primers) 
was        checked        using        the        oligonucleotides        properties        calculator 
(http://www.basic.northwestern.edu/biotools/oligocalc.html). Section  2.7,  Table  2.10 
 
portrays the sequences of the primers used in this study. 
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Nucleotide sequences obtained from NCBI for HSPA1A, HSPA1B, HSPA1L and 
GAPDH, for both Homo sapiens and Rattus norvegicus, (appendices 9.1 – 9.8) were 
copied and pasted into a software program Primer3, which designs primers required for 
real time qRT-PCR (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi).   The 
 
program  generated a  number  of  possible  forward  and  reverse  primers,  identifying 
primer location and length, amplicon size, GC % and suggested annealing temperature. 
The primers selected for this study were chosen based on the above parameters. Product 
lengths were between 156 – 238 bp, G/C content was between 45 – 60%, melting 
temperatures was between 59 – 61oC, primers contained no GC-rich 3‘ ends and did not 
contain any hairpin formations (appendices 9.9  – 9.13).  A  Basic Local Alignment 
Search Tool (BLAST) analaysis was performed to find regions of local similarity 
between sequences. The program compares nucleotide or protein sequences to sequence 
databases and calculates the statistical significance of matches (NCBI) (Appendix xx). 
 
3.8     Sequence Homology for HSP70 between Homo sapiens and 
Rattus norvegicus 
 
 
General  purpose  multiple  sequence  alignment  programs  were  used  to  determine 
sequence homology between the human and rat genes used in this study.  This provides 
information  useful  in  identifying  conserved  sequence  regions  and  can  also  show 
multiple alignments for nucleic acid and protein sequences between species.  Alignment 
of sequences can be carried out either along the entire length (global alignment) or 
restricted  to  certain  regions  (local  alignment);  (Kulikova  et  al,  2004)  European 
Bioinformatics Institute (EBI) (http://www.ebi.ac.uk).   The best matches for selected 
 
sequences are calculated and aligned so that identities, similarities and differences may 
be observed (Chenna et al, 2003). 
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The nucleotide and amino acid sequences obtained from NCBI for HSPA1A, HSPA1B, 
HSPA1L and GAPDH for both Homo sapiens and Rattus norvegicus (appendices 9.1 to 
9.8) were copied and pasted into the software programme ClustalW2 
 
http://www.ebi.ac.uk/clustalw/. Results for gene sequence and amino acid sequence 
 
homology by species and between species are shown in appendices 9.14 -9.25 and 
 
Table 3.1. 
 
 
 
 
For Homo sapiens, results indicated 90%, 64% and 61% homology for HSPA1A v 
HSPA1B, HSPA1A v HSPA1L and HPSA1B v HSPA1L nucleotide sequences 
respectively,  and   100%,   90%   and   89%   homology  for   amino   acid   sequences 
respectively. For Rattus norvegicus, results indicated 78%, 73% and 74% homology for 
HSPA1A v HSPA1B, HSPA1A v HSPA1L and HPSA1B v HSPA1L nucleotide sequences 
respectively,  and   100%,   80%   and   80%   homology  for   amino   acid   sequences 
respectively. Sequence homology between Homo sapiens and Rattus norvegicus 
indicated 73%, 78%, 78% and 84% homology for HSPA1A, HSPA1B, HSPA1L and 
GAPDH nucleotide sequences respectively and 96%, 96%, 94% and 93% homology for 
HSPA1A, HSPA1B, HSPA1L and GAPDH amino acid sequences respectively. 
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Table 3.1. Table showing gene and amino acid sequence homology between genes and 
 
species. 
 
 
 
Species Gene Gene Sequence 
 
Homology % 
Amino Acid 
 
Sequence 
 
Homology % 
Homo sapiens    
 HSPA1A v HSPA1B 90 100 
 HSPA1A v HSPA1L 64 90 
 HSPA1B v HSPA1L 61 89 
Rattus norvegicus    
 HSPA1A v HSPA1B 78 100 
 HSPA1A v HSPA1L 73 80 
 HSPA1B v HSPA1L 74 80 
Homo sapien v 
 
Rattus norvegicus 
   
 HSPA1A 73 96 
 HSPA1B 78 96 
 HSPA1L 78 94 
 GAPDH 84 93 
 
 
Results from Clustal W2 indicated for Homo sapiens, 90%, 64% and 61% homology for 
HSPA1A v HSPA1B, HSPA1A v HSPA1L and HPSA1B v HSPA1L nucleotide sequences 
and 100%, 90% and 89% homology for amino acid sequences respectively. For Rattus 
norvegicus, results indicated 78%, 73% and 74% homology for HSPA1A v HSPA1B, 
HSPA1A v HSPA1L and HPSA1B v HSPA1L nucleotide sequences and 100%, 80% and 
80%  homology  for  amino  acid  sequences  respectively.  Results  between  species 
indicated 73%, 78%, 78% and 84% homology for HSPA1A, HSPA1B, HSPA1L and 
GAPDH nucleotide sequences and 96%, 96%, 94% and 93% homology for HSPA1A, 
HSPA1B, HSPA1L and GAPDH amino acid sequences respectively. 
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3.9     Spectrophotometry 
 
 
Spectrophotometry was conducted on the extracted mRNA samples obtained from each 
cell line and from rat brain tissue samples, to establish the purity and yield of nucleic 
acids.  The absorbance of samples was measured at wavelengths of 260 and 280 nm, 
and the concentration of mRNA present in each cell line was calculated as described in 
Section 2.2.1. Examples of typical results obtained from mRNA samples are presented 
below in Table 3.2. 
 
 
 
Table 3.2 An example of the obtained spectrophotometric readings and the subsequent 
concentrations of the mRNA isolated from all four cell lines used in this study. 
 
 
 
 
 
Cell line 
 
A260 reading 
 
A280 reading 
 
A260 / A280 ratio 
 
Concentration 
(µg/ml) 
1321N1 0.010 0.005 2.000 100 
U87- MG 0.013 0.007 1.857 130 
GOS-3 0.062 0.032 1.938 620 
NHA 0.015 0.008 1.875 150 
 
 
 
 
 
Aliquots (2ul) from mRNA samples from each of the cell lines were electrophoresed on 
a 2% agarose gel.  Visualisation of the agarose gels typically showed that intact mRNA 
was obtained from each of the cell lines.  Typically, no running streaks were observed 
on the gels, indicating that there was little or no degradation of the extracted mRNA. 
The purity of the mRNA (as assessed by the A260 / A280 ratio) is an important factor to 
be considered in these experiments because the contaminating presence of cellular 
proteins can reduce the efficiency of the first strand cDNA synthesis reaction.   The 
A260 / A280 ratios of all the mRNA samples used in this study were between 1.8 and 
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2.0, to ensure that the mRNA samples were of an appropriate quality for use in PCR 
 
experimentation. 
 
 
 
 
 
Table 3.3 An example of the obtained spectrophotometric readings and the subsequent 
concentrations of the mRNA isolated from rat brain tissue at 0, 3, 6, 12 and 24 hour post 
mortem interval used in this study. 
 
 
 
 
 
Post-mortem 
Interval 
 
A260 reading 
 
A280 reading 
 
A260 / A280 ratio 
 
Concentration 
(ng/µl) 
0 hr 2.249 1.434 1.57 89.9 
3 hr 1.563 0.872 1.79 62.5 
6 hr 2.683 1.594 1.68 107.3 
12 hr 1.086 0.662 1.64 43.4 
24 hr 0.533 0.312 1.68 21.3 
 
 
The isolated mRNA samples from each of the brain tissue samples were run on a 2% 
agarose gel.  Results indicated that intact mRNA was obtained from each of the brain 
tissue samples. The A260 / A280 ratios of all the mRNA used in this study were between 
1.57 and 1.79. Although this was lower than the cell lines, the results of downstream 
 
assays were not affected. 
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3.10   Optimization of Primer concentrations 
 
 
 
The efficiencies of sets of primers in PCR are dependent on their concentrations in each 
PCR reaction mixture (Ponchel et al, 2003). Primer concentrations that give the lowest 
threshold cycle (Ct) value should be selected since lower Ct values correspond to more 
efficient production of PCR products (Fraga et al, 2008). 
 
 
Primer concentration in an amplification reaction should be between 0.1 and 0.5 µM. 
Primer concentrations which are too high can result in mispriming, whereby subsequent 
extension of misprimed molecules results in non-specific PCR products, or may lead to 
the production of non-specific products such as primer dimers (Fraga et al, 2008).  The 
primer concentrations used in this study were based on the manufacturer‘s protocol and 
no additional optimization was required. 
 
 
Cycling  parameters  were  based  on  the  manufacturer‘s  guidelines  and  optimized 
 
empirically. No additional optimization was required. 
 
 
 
Magnesium chloride is generally used in all RT-PCR reactions, with a concentration 
ranging between 1.5 and 3.0 mM. Although the kits used in this study contained 
magnesium chloride further optimization was performed using different combinations 
of template and primers, however results indicated no difference, therefore no further 
optimization was required. 
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3.11    Real-Time Reverse Transcription Polymerase Chain Reaction 
(RT-PCR) 
 
 
 
 
Real time PCR is a highly sensitive, rapid and accurate method which can be used to 
monitor small changes in gene expression.  Quantitative measurements are taken during 
the exponential phase when the fluorescence produced is proportional to the 
accumulation of PCR product.   Absolute quantification of a target amplicon may be 
expressed as a copy number.  A positive reaction in real time PCR is detected through 
the accumulation of a fluorescent signal, referred to as the cycle threshold (Ct), which 
reflects the number of cycles required for the fluorescent signal to cross a cycle 
threshold, and hence exceeds the background level.  Fluorescence values are recorded 
during every cycle and represent the amount of amplified product. The more template 
that is present at the start of the reaction, the fewer number of cycles it will take to reach 
a point at which a fluorescent signal will be first recorded. 
 
3.11.1            Detection Chemistry used in RT-PCR 
 
 
 
 
 
The most commonly used methodologies for the detection of amplicons by RT-PCR 
involves fluorescent dyes. One of the most frequently used dyes, which was employed 
in this study, is SYBR Green I (Roche). SYBR Green I, when free in solution, displays 
relatively low fluorescence, but when bound to ds-DNA, its fluorescence increases by 
1000 fold. The more ds-DNA that is present, the more binding sites there are for the 
dye, and hence fluorescence increases in proportion to ds-DNA concentration. As the 
target sequence is  amplified, the  increase in  concentration of  the  ds-DNA  can  be 
directly measured by the corresponding increase in fluorescence signal. 
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Measurement of fluorescence at the end of the elongation step of every PCR cycle is 
performed to monitor the increasing amount of amplified DNA. Following the 
amplification reaction, PCR products are denatured and SYBR Green fluorescence 
decreases. If the PCR products consist of molecules of homogeneous length, then only a 
single thermal transition will be detected.   Correlation of fluorescence with the 
temperature curve (often referred to as a dissociation curve) can be used to differentiate 
between specific and non-specific amplicons, based on the melting temperature of the 
reaction end products. Together with a melting curve analysis performed under the same 
PCR conditions, the SYBR Green  I format provides an  excellent tool for specific 
product identification and quantification. 
 
3.11.2  Melting Curve Analysis 
 
 
 
 
Melting curve analysis is performed after the amplification stage, when it is used to 
assess the dissociation-characteristics of double-stranded DNA during heating.   For 
SYBR Green based detection of amplicons, it is important to run a dissociation curve 
following the real time PCR, because SYBR Green will detect any double stranded 
DNA, including primer-dimers, contaminating DNA, and PCR products arising from 
misannealed primers. By viewing a dissociation curve, as shown in Figure 3.2, it is 
possible to gain confidence that only the desired amplicon is being detected. Melting 
curve analysis can be used to identify different reaction products, including nonspecific 
products and primer-dimers. This is valuable because the presence of secondary 
nonspecific products and primer-dimers can severely reduce the amplification efficiency 
and accuracy of the data obtained from the experiment. Primer-dimers can also limit the 
dynamic range of the desired standard curve through competition for reaction 
components during amplification. After completion of the amplification reaction, a 
melting curve  is  generated by  increasing the  temperature in  small increments and 
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monitoring the fluorescent signal at each step. As the dsDNA in the reaction denatures, 
the fluorescence decreases rapidly and significantly. A plot of the negative first 
derivative of the change in fluorescence (–dF/dT, the rate of change of fluorescence) vs. 
temperature has distinct peaks that correspond to the melting temperature (Tm) of each 
product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 An example of a melting (dissociation) curve produced for rat GAPDH. The 
single peak indicates the presence of one PCR products, no presence of primer-dimers. 
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3.12.           Standard Curve for house keeping gene GAPDH 
 
 
 
A standard curve is a useful tool for quantifying mRNA and DNA of unknown amounts, 
and this process is referred to as absolute quantification. Absolute quantification is used 
to determine how much (number of copies, ng, etc.) of a target gene is present in a 
particular sample without reference to other samples. In absolute quantification, the 
quantity of the unknown sample is interpolated from a range of standards of known 
quantity.  To  construct  a  standard  curve,  a  template  with  known  concentration  is 
required. This template is diluted to create a range of standard concentrations. 
 
Absolute quantification is relatively simple and the mathematical calculations are easy 
to perform. It involves comparing the CT values of test samples to those of standards of 
known quantity plotted on a standard curve. Usually, the quantity is normalized to a unit 
amount of sample, such as the number of cells in the original sample material, volume, 
or the total amount of nucleic acid. The standard curve constructed from the diluted 
standard template can then be used to determine the target quantity in the unknown 
sample by interpolation, in a similar way to that by which molecular size standards are 
used to determine the molecular size of an unknown DNA band on an agarose gel. 
 
To establish a standard curve, a sample of human and rat genomic DNA was extracted 
from brain tissue. The size of the human genome was determined as 3,400,000,000 bp 
and the size of the rat genome was determined as 2,900,000,000 bp from the Database 
of Genome Sizes (DOGS):  http://www.cbs.dtu.dk/databases/DOGS/index.html. 
169 
 
For example using the calculation from Applied Biosystems protocol for mass of the rat 
haploid genome; 
(http://www6.appliedbiosystems.com/support/tutorials/pdf/quant_pcr.pdf) 
 
 
 
M = n  x 1.096 x  e-21 
 
 
 
 
 
Where: 
 
M = Mass of the haploid genome 
 
N = Genome size (bp) 
e-21 = 10-21 
 
M = 2.9e9  x 1.096 x e-21 
 
M = 3.1784e-12 g 
 
Convert from g (grams) to pg (picograms) 
 
 
3.1784e-12 g x 1e12 pg 
 
 
 
 
M = 3.1784 pg 
 
 
 
The mass  of the haploid genome was  determined as 3.1784  pg.    The target gene 
GAPDH exists as a single copy gene per haploid genome and thus two copies per cell 
(Ponchel et al, 2003), and therefore it was calculated that 3.1784 pg of rat genomic 
DNA contained 1 copy of GAPDH.  The A260 reading was 1.026, and thus the quantity 
of DNA per μl of original sample was 51,300 pg/μl.   From this, it was calculated that 
19.49 μl contained 1 million copy numbers of the GAPDH gene sequence. 
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Table 3.4 Table showing final concentration of genomic DNA required for serial 
 
dilution. 
 
 
 
 
Copy 
 
Numbers 
Mass of 
 
Haploid 
 
Genome 
Mass of gDNA 
 
Needed (pg) 
PCR 
 
Reaction 
 
Volume (µl) 
Final Conc. Of 
 
gDNA (pg/µl) 
10,000  
 
 
x 3.1784 
31784  
 
 
/ 2 
15892 
1,000 3178.4 1589.2 
100 317.84 158.92 
10 31.784 15.892 
1 3.1784 1.5892 
 
Using the data from Table 3.4, a serial dilution was carried out to give samples 
containing 1, 10, 100, 1000 and 10,000 copy numbers. The serial dilution was prepared 
using the formula: 
 
C1 x V1 = C2 x V2 
 
 
 
Where: 
 
 
C1 = Initial Concentration of gDNA (pg/µl) 
V1 = Volume of gDNA (µl) 
V2 = Final Volume (µl) 
 
 
C2 = Final Conc. of Dilution (pg/µl) 
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Table 3.5   Table showing calculation for serial dilution of known copy numbers. 
 
 
 
 
Source of 
gDNA 
Initial 
Conc. 
(pg/µl) 
Volume 
of gDNA 
(µl) 
Volume 
of 
Diluent 
(µl) 
Final 
Volume 
(µl) 
Final Conc. 
of Dilution 
(pg/µl) 
Resulting 
Copy No. 
GAPDH / 2 µl 
 C1 V1  V2 C2  
Stock 51300 31 69 100 15892 10,000 
Dilution 1 15892 10 90 100 1589.2 1,000 
Dilution 2 1589.2 10 90 100 158.92 100 
Dilution 3 158.92 10 90 100 15.892 10 
Dilution 4 15.892 10 90 100 1.5892 1 
 
 
 
 
 
A standard curve was produced using RT-PCR utilising the conditions as described in 
section      2.5 and 2.17, using the crossing points (Figures 3.3 and 3.5) generated from 
five copy number concentrations of genomic DNA, in triplicate : 1, 10, 100, 1,000 and 
10,000 copies with known concentrations (Table 3.5 and 3.6).  The equation generated 
for GAPDH for Rattus norvegicus (y = -1.192Ln(x) + 30.35)) (Figure 3.4) was 
rearranged to (=EXP ((Ct value -30.35/-1.192)) and for GAPDH Homo sapiens (y = - 
1.312Ln(x) + 32.05) (Figure 3.6) was rearranged to (=EXP ((Ct value -32.05/-1.312). 
These were then used to determine copy numbers of HSPA and GAPDH mRNA 
expression for rat brain tissue, human cell lines and brain tissue throughout this thesis. 
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Figure 3.3 Quantification Curve of known concentrations of rat DNA. Standards used 
to generate the copy numbers of HSPA. LightCycler quantification curve generated 
when known concentration of Genomic rat DNA was amplified, which shows that the 
higher the concentration the lower the Ct value i.e. earlier detection of fluorescence. 
The negative control (primer alone, NTC) showed no detection of fluorescence until 
after 30 Ct (straight line). 
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Figure 3.4  Standard curve produced from quantification curve of known concentrations 
of rat DNA. The standard curve generated from the crossing points showing the 
relationship between Ct values and copy numbers of the amplified Genomic rat DNA 
using GAPDH reference gene. 
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Table  3.6 Known  concentrations of  Genomic  human  DNA  corresponding to  the 
average Ct value and copy number. 
 
Concentration of Genomic DNA 
(ng) 
Average Ct Copy number 
0.005 30.15 1.7 
0.05 29.1 17 
0.5 26.42 170 
5 22.6 1700 
50 18.3 17000 
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Figure 3.5 Quantification Curve of known concentrations of human DNA. Standards 
used to generate the copy numbers of HSPA. LightCycler quantification curve generated 
when known concentration of Genomic human DNA was amplified, which shows that 
the higher the concentration the lower the Ct value i.e. earlier detection of fluorescence. 
The negative control (primer alone, NTC) showed no detection of fluorescence until 
after 30 Ct (straight line) (adapted from Mohammed, 2007). 
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Figure 3.6  Standard curve produced from quantification curve of known concentrations 
of human DNA. The standard curve generated from the crossing points showing the 
relationship between Ct values and copy numbers of the amplified Genomic human 
DNA using GAPDH reference gene (adapted from Mohammed, 2007). 
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3.13   Reference Genes 
 
 
Control genes, which are often referred to as housekeeping genes, are frequently used to 
normalise mRNA levels between different tissue types, such as those obtained from 
normal and diseased cells. The levels of expression of these genes may vary among 
tissues or cells and may change under certain circumstances (Barber et al, 2005; Silver 
et al, 2006). Quantitative studies are commonly used in biomedical research to compare 
RNA populations under different experimental or clinical conditions. In order to control 
experimental variations in the amount of RNA used in qRT-PCR, reference 
(housekeeping) genes are used for the normalization of target gene expression data, 
such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), β-actins, and 16S rRNA 
(Barber et al, 2005; Silver et al, 2006; Thellin et al, 1999).  It is assumed that the 
expression of these genes will remain constant in the cells or tissues under investigation. 
Although   some   exceptions   to   this   assumption   have   been   well   documented, 
housekeeping genes are of general value in fully characterized systems. The variability 
in the expression of the most commonly used housekeeping genes has shown that there 
is no ―one-size-fits-all‖ gene that can be used for normalization of gene expression data 
(Barber et al, 2005; Silver et al, 2006). A study undertaken by Barber (2005) has shown 
that, by providing copy numbers of GADPH mRNA expression, the data can be used as 
a factor for the normalization of gene expression between tissues types, where GAPDH 
is used as the housekeeping control gene. Results indicated differences in GAPDH 
mRNA expression in different tissue types however, the data provided no evidence that 
there was any effect by age or gender and in most tissues the influence of delay in 
processing surgical and post-mortem tissues was negligible (Barber et al, 2005). Due to 
the findings within this study, and given that GAPDH is one of the most commonly 
used housekeeping genes used in comparisons of gene expression data, GAPDH was 
chosen as the preferred housekeeping gene to be used throughout this study. 
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3.14 Real time PCR assay 
The  Roche  LightCycler  2.0  instrument  with  the  LightCycler®   FastStartPLUS   DNA 
Master SYBR Green I kit was used for quantitative analysis of HSPA and GAPDH 
mRNA   by   real-time   PCR.   Initial   assays   were   carried   out   according   to   the 
manufacturer‘s conditions utilising the following optimum parameters: the primer 
concentration was 1 µM, the annealing temperature for the amplification of  Homo 
sapien HSPA and GAPDH was 57oC and 56oC respectively and Rattus norvegicus 
HSPA and GAPDH 56oC and 57oC was respectively. Confirmation of PCR products 
 
was performed by incorporating a melting curve analysis step to ensure that only the 
target genes were amplified and detected. 
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4.1 Gene Expression 
 
HSPA  expression  is  up-regulated  in  cancer  cells  (Graner  et  al,  2007;  Jolly  and 
Morimoto, 2000), and thus the main research aim of work presented in this chapter was 
to measure and compare HSPA expression in normal and glioma cell lines and normal 
and cancerous brain tissue. A significant difference between these tissues might allow 
assessment of its possible use as a prognostic marker for grade related brain tumours. 
 
 
 
Tumour and normal brain tissue samples were obtained from patients admitted to the 
Royal Preston Hospital, UK.  Informed consent and ethical approval was obtained prior 
to this investigation.   Tissues were dissected and immediately frozen to -80oC and 
stored for analysis.   In total 18 tissue samples were used in this study (Table 4.5). 
Human   brain   cell   lines   GOS-3   (grade   II/III   oligodendroglioma)  from   DMSZ 
(Germany), U87-MG (grade IV glioblastoma) from ECCAC (UK) and NHA (normal 
human astrocytes) from Lonza (UK) were also used in this study.  GOS-3 cells were 
routinely cultured in Dulbecco‘s modified Eagle‘s medium (DMEM) (Sigma) 
supplemented with 10% FBS and with 4 mM L-glutamide, while U87-MG cells were 
cultured in Eagle‘s minimum essential medium (EMEM) (Sigma) supplemented with 2 
mM L-glutamide, 10% FBS and 1% (v/v) nonessential amino acids (Sigma).  The NHA 
cells were cultured in astrocyte medium (AM) supplemented with 15 ml of FBS, 0.5 ml 
Ascorbic Acid, 0.5 ml rhEGF (astrocyte growth supplement) 0.5 ml GA100 1.25 ml 
Insulin and 5 ml L-glutamide. 
 
 
 
mRNA was isolated from all four cell lines,15 human glioma brain tissues and three 
normal (control) brain tissues using mRNA Isolation Kit (Roche,UK) following the 
manufacturer‘s protocol. The concentration and purity of mRNA was determined by 
ultraviolet spectrophotometry. Isolated mRNA (100 ng) was transcribed to cDNA using 
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1st  Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche, UK) following the 
manufacturer‘s protocol, which was then used as a template for qRT-PCR.  Quantitative 
real-time PCR was used to evaluate the expression of HSPA, and GAPDH as a control 
using FastStart DNA MasterPLUS SYBR Green 1 (Roche, UK). Primers used for HSPA 
were 5‘ CGACCTGAACAAGAGCATCA 3‘ (sense) and 5‘ 
AAGATCTGCGTCTGCTTGGT 3‘ (antisense). For GAPDH, primers were 5‘ 
GAGTCAAGCGATTTGGTCGT 3‘ (sense) and 5‘ TTGATTTTGGAGGGATCTCG 3‘ 
(antisense). All primers were designed using Primer3 software and manufactured by 
TIB MOLBIOL. After an initial denaturation at 95oC for 10 min, the samples were 
subjected to 35 cycles of RT-PCR 95oC for 10 s, annealing temperature 57oC (HSPA) 
 
and 56oC (GAPDH) for 15 s, and 72oC for 15 s (Patel et al., 2008). At the end of each 
cycle, the fluorescence emitted was measured in a single step in channel F1 (gain1). 
After the 35th cycle, the specimens were heated to 95oC and rapidly cooled to 65oC for 
15 s. All heating and cooling steps were performed with a slope of 20oC / s. The 
 
temperature was subsequently raised to 95oC with a slope of 0.1oC / s and fluorescence 
was measured continuously (channel F1, gain1) to obtain data for the melting curve 
analysis.  All  PCR  reactions  were  performed  in  triplicate  and  a  negative  control 
included, which contained primers with no DNA. All PCR products were analysed 
using gel electrophoresis stained and visualised using a gel analyser (SynGene, UK). 
 
Expression of HSPA was compared between the three glioma cell lines (1321N1, GOS- 
 
3 and U87-MG) and in a normal (control) human astrocyte cell line (NHA), and also in 
 
15 glioma and 3 normal brain tissue samples. GAPDH was used as an internal standard 
throughout all RT-PCR experiments (Barber et al., 2005). 
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4.2 Constitutive Expression 
 
 
 
4.2.1 Glioma Cell lines 
 
 
 
Copy numbers of HSPA and GAPDH transcripts were determined using RT-PCR in the 
three glioma cell lines (1321N1, GOS-3 and U87-MG), and in the normal human 
astrocyte cell line (NHA). The primers and optimal temperatures used for the 
amplification of both genes are documented in Table 2.10 in section 2.5. All PCR 
experiments were carried out in triplicate for consistency and repeatability. For each 
gene analysed, a quantification graph was produced to confirm gene amplification. The 
resulting amplicons for HSPA and GAPDH were also visualized using agarose gel 
electrophoresis, each being represented by bands of 213 and 238 bp, respectively. The 
three glioma cell lines transcribed HSPA at higher levels than the normal astrocyte cell 
line NHA (Figure 4.1). GAPDH transcript levels were consistent in all glioma and 
normal cell lines, confirming comparability of HSPA results (Figure 4.1). The mRNA 
copy number for both genes was calculated for each cell line to monitor the gene 
expression level. For HSPA, mRNA copy numbers per 100 ng of extracted mRNA 
confirmed that 1321N1, produced approximately 7,500 copies, GOS-3 contained 
approximately 8,900 copies and U87-MG contained approximately 8,200 copies of this 
transcript. Glioma cell lines expressed HSPA at a higher level than normal human 
astrocyte NHA, with approximately 1,400 copies, indicating that HSPA is expressed at 
lower levels in normal cells but is highly expressed in cancer cells (Table 4). For 
GAPDH, mRNA copy numbers per 100 ng of extracted mRNA were relatively 
consistent, NHA produced approximately 146,500 copies, 1321N1 contained 
approximately 144,500 copies, GOS-3 contained approximately 147,500 copies and 
U87-MG contained approximately 147,500 copies, again confirming comparability of 
HSPA results (Table 4.1). 
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Figure 4.1 HSPA and GAPDH transcript levels in NHA, 1321N1, GOS-3 and U87-MG 
cell lines. A (HSPA) and C (GAPDH), show agarose gel electrophoresis of samples. 
Lane 1 represents the 100 bp molecular ladder, lanes 2 – 5 represents amplicons from 
NHA,  1321N1,  GOS-3  and  U87-MG  respectively.  B  and  D  histograms  represent 
mRNA copy numbers per 100 ng of extracted mRNA of HSPA (B) and GAPDH (D) in 
the same cell lines. Data values are the mean of three independent experiments, and the 
standard deviation from this mean is shown by the error bars. 
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4.2.2 Statistical Analysis 
 
 
 
 
A one-way ANOVA test between groups of analysis of variance was conducted to 
analyse results of the previous experiments of HSPA and GAPDH gene expression in 
normal (control) and glioma cell lines in three independent experiments. For this 
statistical analysis, the cell lines comprised of four groups: group 1 NHA, group 2 
1321N1, group 3 GOS-3 and group 4 U87-MG. The means and standard deviations are 
presented in Table 4.1 (HSPA) and Table 4.3 (GAPDH). 
Table 4.1 Descriptive statistics showing the mean expression levels of HSPA for each 
cell line. 
 
Cell Line N Mean HSPA 
transcript copy 
number 
Std Deviation 
NHA 3 1419.63 708.76 
1321N1 3 7491.67 2495.20 
GOS-3 3 8879.29 3210.83 
U87-MG 3 8158.12 3816.44 
 
 
There was a significant difference in HSPA transcript copy number between the four 
cell line groups [F(3,8) = 5.157, P = 0.028]. The effect size, calculated using eta squared 
indicated a large effect of 0.659. 
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Table 4.2. Statistical data from Tukey‘s HSD test showing significance of HSPA gene 
 
expression between cell lines. Any significant differences are highlighted in bold. 
 
 
(I) Cell J (Cell) Mean Difference 
between copy number 
(I – J) 
Std. Error Sig. 
NHA 1321N1 6072.04 2133.21 0.083 
NHA GOS-3 7459.67 2133.21 0.033 
NHA U87-MG 6738.49 2133.21 0.053 
1321N1 GOS-3 1387.62 2133.21 0.912 
1321N1 U87-MG 666.45 2133.21 0.989 
GOS-3 U87-MG 721.17 2133.21 0.986 
 
 
Post-hoc analyses using Tukey‘s HSD test indicated significantly lower HSPA gene 
expression in group 1, NHA than in group 3, GOS-3 (MD = 7459.67, P = 0.033). All 
other differences between groups failed to reach significance (Table 4.2). Significance ≤ 
0.05. 
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Table 4.3 Descriptive statistics showing the mean transcript levels of GAPDH in each 
 
cell line. 
 
 
Cell Line N Mean GAPDH 
transcript copy 
number 
Std Deviation 
NHA 3 146468.91 50836.00 
1321N1 3 144546.62 18955.42 
GOS-3 3 147541.72 19549.02 
U87-MG 3 147541.72 19549.02 
 
 
 
There was no significant difference in GAPDH gene expression between the four cell 
line groups [F(3,8) = 0.004, P > .05]. The effect size, calculated using eta squared 
indicated a small effect of 0.001. 
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Table 4.4. Statistical data from Tukey‘s HSD test showing significance of GAPDH 
 
gene expression between cell lines. 
 
 
 
 
(I) Cell J (Cell) Mean Difference 
between copy number 
(I – J) 
Std. Error Sig. 
NHA 1321N1 1922.29 31504.52 1.000 
NHA GOS-3 1072.82 31504.52 1.000 
NHA U87-MG 1072.82 31504.52 1.000 
1321N1 GOS-3 2995.10 31504.52 1.000 
1321N1 U87-MG 2995.10 31504.52 1.000 
GOS-3 U87-MG 0.00 31504.52 1.000 
 
 
Post-hoc  analyses  using  Tukey‘s  HSD  test  indicated  no  significant  difference  in 
 
GAPDH gene expression between any of the four groups (Table 4.4). Significance ≤ 
 
0.05. 
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4.2.3 Brain Tissue Samples 
 
 
 
 
The expression of HSPA and GAPDH were analysed in eighteen brain tissue specimens, 
of which fifteen were glioma tissues and three were normal (control) brain tissue 
samples. RNA populations were again analysed by RT-PCR, with the mRNA copy 
number for each gene being calculated for each sample, sections 2.7 and 3.11. 
 
Table 4.5 Tissues used in this study. 
 
 
 Diagnosis Grade Age Gender Survival from 
 
diagnosis to death 
G1 glioblastoma IV 16 F (Alive) 13+ months 
G2 glioblastoma IV 23 F 10 months 
G3 glioblastoma IV 38 M 8 months 
G4 glioblastoma IV 38 M 10 months 
G5 glioblastoma IV 46 F 11 months 
G6 glioblastoma IV 60 F 10 months 
G7 glioblastoma IV 62 M 11 months 
G8 glioblastoma IV 63 M 10 months 
G9 glioblastoma IV 64 M 11 months 
G10 glioblastoma IV 67 F 12 months 
G11 glioblastoma IV 68 M 8 months 
G12 glioblastoma IV 28 F 10 months 
G13 recurrent anaplastic 
 
ependymoma 
III 34 F 8 months 
G14 anaplastic 
 
oligodendroglioma 
III 56 M 11 months 
 
 
G15 
III 
 
anaplastic 
 
 
III 
 
 
62 
 
 
F 
 
 
11 months 
 
 
G16 
oligoastrocytoma III 
 
normal 
  
 
39 
 
 
F 
 
 
Alive 
G17 normal  38 F Alive 
G18 normal  66 M Alive 
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The results showed that tissue samples from 8 of the 12 glioblastoma patients showed 
high levels, (> 2000 copies), of HSPA transcripts, with approximate copy numbers per 
100 ng of extracted mRNA ranging between 2,100 and 3,300, while the remaining 
tissue samples from the 4 glioblastoma patients showed lower levels, (< 900 copy 
numbers), of HSPA transcripts, with approximate copy numbers per 100 ng of extracted 
mRNA ranging between 300 and 870 (Figure 4.2 and Table 4.6).   The tissue sample 
from the ependymoma patient showed high levels of HSPA transcripts, approximate 
copy number per sample, G13 2,000, whilst the tissue samples from the 
oligodendroglioma III patient, and from the oligoastrocytoma III patient, had low but 
detectable HSPA transcript levels, with approximate copy numbers per 100 ng of 
extracted mRNA of G14 750 and G15 350 respectively (Figure 4.2 and Table 4.6).  The 
three control samples also showed relatively low or barely detectable levels of HSPA 
transcripts, with approximate copy numbers per 100 ng of extracted mRNA ranging 
between 100 and 400 (Figure 4.2 and Table 4.6). HSPA transcription in glioma samples 
was independent of age or gender.  The mRNA copy numbers of HSPA were averaged 
for the twelve glioblastomas and compared against similar average data from the three 
low grade gliomas and three control brain tissues samples (Figure 4.4).  Significantly 
higher HSPA transcription was observed in the glioblastoma tissues compared to low 
grade tissue samples, (approximately 1.75-fold higher), and the control tissue samples, 
(approximately 9-fold higher). Significantly higher HSPA transcription was observed in 
the low grade tissue samples compared to control tissue samples, (approximately 5-fold 
higher); (Figure 4.4). 
 
 
 
As seen in the glioma cell lines, section 4.2.1, more HSPA transcripts were observed in 
the  glioma  tissues,  (approximately  6-fold  higher),  than  in  control  brain  tissue, 
confirming that HSPA expression is consistently up-regulated in some cancer cells. For 
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GAPDH,   mRNA   copy  numbers   per  100  ng  of  extracted   mRNA   were  relatively 
consistent in all brain tissue samples, with approximately 143,700 copies per 100 ng of 
extracted mRNA, giving confidence in the comparability  of HSPA experiments (Figure 
4.3 and Table 4.6). 
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Figure 4.2 HSPA mRNA copy number in 18 brain tissue samples. A. Agarose gel 
electrophoresis: Lane 1 represents the 100 bp molecular ladder; lanes 2 - 13 represent 
amplicons from glioblastoma tissues; lanes 14 - 16 represent amplicons from 
ependymoma,  oligodendroglioma  III  and  oligoastrocytoma  III  tissues  respectively; 
lanes 17 – 19  represent amplicons from normal brain tissues and lane 20 is a no 
template control. B. Histogram representing mRNA copy numbers per 100 ng of 
extracted mRNA of HSPA in tissues. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. G1 – 
G12 represents the brain tissue of individual patients with glioblastoma, G13 represents 
the brain tissue from an individual patient with ependymona, G14 represents the brain 
tissue from an individual patient with oligodendroglioma III, G15 represents the brain 
tissue from an individual patient with oligoastrocytoma III and N1 – N3 represents the 
normal (control) brain tissue from individual . 
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Figure 4.3 GAPDH mRNA in 18 brain tissue samples. A. Agarose gel electrophoresis: 
Lane 1 represents the 100 bp molecular marker; lanes 2 - 13 represent amplicons from 
glioblastoma tissues; lanes 14 - 16 represent amplicons from ependymoma, 
oligodendroglioma III and oligoastrocytoma III tissues respectively; lanes 17 – 19 
represent amplicons from normal brain tissue.  B. Histogram representing mRNA copy 
numbers per 100 ng of extracted mRNA of GAPDH in tissues. Data values are the mean 
of three independent experiments, and the standard deviation from this mean is shown 
by the error bars. G1 – G12 represents the brain tissue of individual patients with 
glioblastoma, G13 represents the brain tissue from an individual patient with 
ependymona, G14 represents the brain tissue from an individual patient with 
oligodendroglioma III, G15 represents the brain tissue from an individual patient with 
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oligoastrocytoma III and N1 – N3 represents the normal (control) brain tissue from 
individual . 
 
 
 
 
 
 
Figure 4.4 Histogram showing the mean HSPA mRNA copy numbers in brain tissues 
grouped by:  Glioblastomas (n = 12), low grade gliomas (n = 3) and normal tissues (n = 
3). mRNA copy number data from 12 glioblastoma tissues were averaged and compared 
against the three low grade gliomas and the three normal brain tissues. Data values are 
the mean of three independent experiments, and the standard deviation from this mean 
is shown by the error bars. 
 
 
 
As can be seen in Figure 4.4 HSPA transcripts are approximately 9-fold higher in the 
glioblastoma tissues compared to the control tissue samples. HSPA transcripts are also 
approximately 5-fold higher in the low grade tissue samples than in control tissue 
samples. 
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4.2.4 Statistical Analysis 
 
 
 
 
A one-way ANOVA test between groups of analysis of variance was conducted to 
analyse results of the previous experiments of HSPA and GAPDH gene expression in 
normal (control) and glioma brain tissue in three independent experiments. For this 
statistical analysis, the brain tissue samples comprised eighteen groups: groups G1 – 
G12,   glioblastomas;  group   G13,  recurrent  anaplastic  ependymona;  group   G14, 
anaplastic oligodendroglioma III; G15, anaplastic oligoastrocytoma III and groups N1 - 
N3 normal brain tissue. The means and standard deviations for HSPA and GAPDH 
results are presented in Table 4.6. 
 
There  was  significant  differences  in  HSPA  transcript  copy  numbers  between  the 
eighteen brain tissue groups [F(17,36) = 719.138, P < 0.001]. The effect size, calculated 
using eta squared indicated a large effect of 0.997. 
 
Data obtained from post-hoc analyses using Tukey‘s HSD test indicated significantly 
lower HSPA transcript copy numbers in G1 than in: G2 (MD = 1935.13, P < .05); G3 
(MD = 1893.88, P < .05); G4 (MD = 1929.31, P < .05); G5 (MD = 1729.89, P < .05); 
G8 (MD = 2132.44, P < .05); G9 (MD = 2928.44, P < .05); G10 (MD = 514.00, P < 
.05); G11 (MD = 1750.16, P < .05); G12 (MD = 1994.21, P < .05); G13 (MD = 
 
1651.22, P < .05); G14 (MD = 397.09, P < .05) and N1 (MD = 247.85, P < .05) (Table 
 
4.7). 
 
 
There was significantly lower HSPA transcript copy numbers in G2 than in: G6 (MD = 
 
1935.24, P < .05); G7 (MD = 1991.97, P< .05); G9 (MD = 993.31, P < .05); G10 (MD = 
 
1421.12, P < .05); G13 (MD = 283.90, P < .05), G14 (MD = 1538.03), G15 (MD = 
 
1937.91, P < .05); N1 (MD = 2182.97, P < .05), N2 (MD = 1883.25, P < .05) and N3 
(MD = 2180.54, P < .05) (Table 4.7). 
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There was significantly lower HSPA transcript copy numbers in G3 than in: G6 (MD = 
 
1893.99, P < .05); G7 (MD = 1950.73, P < .05); G8 (MD = 238.58, P < .05); G9 (MD = 
 
1034.55, P < .05); G10 (MD = 1379.88, P < .05); G13 (MD = 242.66, P < .05); G14 
(MD = 1496.79, P < .05); G15 (MD = 1896.67, P < .05); N1 (MD = 2141.73, P < .05); 
N2 (MD = 1842.01, P < .05) and N3 (MD = 2139.30, P < .05) (Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G4 than in: G6 (MD = 
 
1929.42, P < .05); G7 (MD = 1986.15, P < .05); G9 (MD = 999.13, P < .05); G10 (MD 
 
= 1415.31, P < .05); G13 (MD = 278.09, P < .05); G14 (MD = 1532.22, P < .05); G15 
(MD = 1932.10, P < .05); N1 (MD = 2177.16, P < .05); N2 (MD = 1877.44, P < .05) 
and N3 (MD = 2174.72, P < .05) (Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G5 than in: G6 (MD = 
 
1730.00, P < .05); G7 (MD = 1786.74, P < .05); G8 (MD = 402.55, P < .05); G9 (MD = 
 
1198.54, P < .05); G10 (MD = 1215.89, P < .05); G12 (MD = 264.32, P < .05); G14 
(MD = 1332.80, P < .05), G15 (MD = 1732.68, P < .05), N1 (MD = 1977.74, P < .05), 
N2 (MD = 1678.02, P < .05) and N3 (MD = 1975.31, P < .05) (Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G6 than in: G8 (MD = 
 
2132.55, P < .05); G9 (MD = 2928.55, P < .05); G10 (MD = 514.11, P < .05); G11 (MD 
 
= 1750.27, P < .05); G12 (MD = 1994.32, P < .05); G13 (MD = 1651.33, P < .05); G14 
(MD = 397.20, P < .05); N1 (MD = 247.74, P < .05) and N3 (MD = 245.31, P < .05) 
(Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G7 than in: G8 (MD = 
 
2189.28, P < .05); G9 (MD = 2985.28, P < .05); G10 (MD = 570.85, P < .05); G11 (MD 
 
= 1807.00, P < .05); G12 (MD = 2051.06, P < .05); G13 (MD = 1708.07, P < .05) and 
 
G14 (MD = 453.94, P < .05) (Table 4.7). 
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There was significantly lower HSPA transcript copy numbers in G8 than in: G9 (MD = 
 
796.00, P < .05); G10 (MD = 1618.44, P < .05); G11 (MD = 382.28, P < .05); G13 (MD 
 
= 481.22, P < .05); G14 (MD = 1735.35, P < .05); G15 (MD = 2135.23, P < .05); N1 
(MD = 2380.29, P < .05); N2 (MD = 2080.57, P < .05) and N3 (MD = 2377.85, P < .05) 
(Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G9 than in: G10 (MD = 
 
2414.43, P < .05); G11 (MD = 1178.28, P < .05); G12 (MD = 934.26, P < .05); G13 
(MD = 1277.21, P < .05); G14 (MD = 2531.24, P < .05); G15 (MD = 2931.22, P < .05); 
N1 (MD = 3176.28, P < .05); N2 (MD = 2876.56, P < .05) and N3 (MD = 3173.85, P < 
.05) (Table 4.7). 
 
 
There was significantly lower HSPA transcript copy numbers in G10 than in: G11 (MD 
 
= 1236.16, P < .05); G12 (MD = 1480.21, P < .05); G13 (MD = 1137.22, P < .05); G15 
(MD = 526.79, P < .05); N1 (MD = 761.85, P < .05); N2 (MD = 462.13, P < .05) and 
N3 (MD = 759.41, P < .05) (Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G11 than in: G12 (MD 
 
= 244.05, P < .05); G14 (MD = 1353.07, P < .05); G15 (MD = 1752.95, P < .05); N1 
(MD = 1998.01, P < .05); N2 (MD = 1698.29, P < .05) and N3 (MD = 1995.57, P < .05) 
(Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G12 than in: G13 (MD 
 
= 342.99, P < .05); G14 (MD = 1597.12, P < .05); G15 (MD = 1997.00, P < .05); N1 
(MD = 2242.06, P < .05); N2 (MD = 1942.34, P < .05) and N3 (MD = 2239.62, P < .05) 
(Table 4.7). 
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There was significantly lower HSPA transcript copy numbers in G13 than in: G14 (MD 
 
= 1254.13, P < .05); G15 (MD = 1654.01, P < .05); N1 (MD = 1899.07, P < .05); N2 
(MD = 1599.35, P < .05) and N3 (MD = 1896.64, P < .05) (Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G14 than in: G15 (MD 
 
= 399.88, P < .05); N1 (MD = 644.94, P < .05); N2 (MD = 345.22, P < .05) and N3 
(MD = 642.51, P < .05) (Table 4.7). 
 
There was significantly lower HSPA transcript copy numbers in G15 than in: N1 (MD = 
 
245.06, P < .05) and N3 (MD = 242.63, P < .05) (Table 4.7). 
 
 
There was significantly lower HSPA transcript copy numbers in N1 than in N2 (MD = 
 
299.72, P < .05) (Table 4.7). 
 
 
There was significantly lower HSPA transcript copy numbers in N2 than in N3 (MD = 
 
297.29, P < .05) (Table 4.7). 
 
 
All other difference between groups failed to reach significance (Table 4.7). 
 
 
There was a significant difference in GAPDH transcript copy numbers between the 
eighteen brain tissue groups [F(17,36) = 0.43, P = >.05]. The effect size, calculated 
using eta squared indicated a small effect of 0.02. 
 
Post-hoc analyses using Tukey‘s HSD test indicated no significant difference (P > .05) 
 
in GAPDH transcript copy numbers between any of the eighteen groups. 
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Table 4.6 Descriptive statistics showing the mean transcript copy numbers of HSPA and GAPDH expression in brain tissue sample. 
 
 
Tissue sample N Mean HSPA gene 
expression 
Std Deviation Mean GAPDH gene 
expression 
Std Deviation 
G1 3 352.86 13.44 141748.41 16746.50 
G2 3 2287.99 87.40 143942.85 16976.61 
G3 3 2246.74 34.24 142468.77 16727.43 
G4 3 2282.17 86.93 146885.07 20948.44 
G5 3 2082.76 79.34 141748.41 16746.50 
G6 3 352.75 8.06 142468.77 16727.43 
G7 3 296.02 4.51 146885.07 20948.44 
G8 3 2485.30 189.23 146885.07 20948.44 
G9 3 3281.30 112.51 141748.41 16746.50 
G10 3 866.86 19.81 141748.41 16746.50 
G11 3 2103.02 9.26 143942.85 16976.61 
G12 3 2347.07 98.28 142468.77 16727.43 
G13 3 2004.08 30.54 146885.07 20948.44 
G14 3 749.95 11.43 141748.41 16746.50 
G15 3 350.07 8.00 142468.77 16727.43 
N1 3 105.01 .800 146885.07 20948.44 
N2 3 404.73 15.42 141748.41 16746.50 
N3 3 107.45 1.64 143942.85 16976.61 
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Table 4.7 Statistical data from Tukey‘s HSD test showing significance of HSPA transcript copy numbers between brain tissue sample groups. Any significant differences 
 
(P ≤ 0.05) between groups are highlighted bold. 
 
 
 G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 N1 N2 N3 
G1  M1935.12 
 
Sig .000 
M1893.88 
 
Sig .000 
M1929.31 
 
Sig .000 
M1729.89 
 
Sig .000 
M.109 
 
Sig 1.0 
M56.84 
 
Sig 1.0 
M2132.44 
 
Sig .000 
M2928.44 
 
Sig .000 
M514.00 
 
Sig .000 
M1750.16 
 
Sig .000 
M1994.21 
 
Sig .000 
M1651.22 
 
Sig .000 
M397.09 
 
Sig .000 
M2.79 
 
Sig 1.0 
M247.85 
 
Sig.008 
M51.87 
 
Sig 1.0 
M245.41 
 
Sig.009 
G2 M1935.12 
 
Sig .000 
 M41.24 
 
Sig 1.0 
M5.82 
 
Sig 1.0 
M205.23 
 
Sig .056 
M1935.24 
 
Sig .000 
M1991.97 
 
Sig .000 
M197.31 
 
Sig .078 
M993.31 
 
Sig .000 
M1421.12 
 
Sig .000 
M184.97 
 
Sig .129 
M59.08 
 
Sig 1.0 
M283.90 
 
Sig .001 
M1538.03 
 
Sig .000 
M1937.91 
 
Sig .000 
M2182.97 
 
Sig .000 
M1883.25 
 
Sig .000 
M2180.54 
 
Sig .000 
G3 M1893.88 
 
Sig .000 
M41.24 
 
Sig 1.0 
 M35.43 
 
Sig 1.0 
M163.99 
 
Sig .271 
M1893.99 
 
Sig .000 
M1950.73 
 
Sig .000 
M238.56 
 
Sig .012 
M1034.55 
 
Sig .000 
M1379.88 
 
Sig .000 
M143.72 
 
Sig .483 
M100.33 
 
Sig .925 
M242.66 
 
Sig .010 
M1496.79 
 
Sig .000 
M1896.67 
 
Sig .000 
M2141.73 
 
Sig .000 
M1842.01 
 
Sig .000 
M2139.30 
 
Sig .000 
G4 M1929.31 
 
Sig .000 
M5.82 
 
Sig 1.0 
M35.43 
 
Sig 1.0 
 M199.42 
 
Sig .072 
M1929.42 
 
Sig .000 
M1986.15 
 
Sig .000 
M203.13 
 
Sig .061 
M999.13 
 
Sig .000 
M1415.31 
 
Sig .000 
M179.15 
 
Sig .160 
M64.90 
 
Sig .999 
M278.09 
 
Sig .002 
M1532.22 
 
Sig .000 
M1932.10 
 
Sig .000 
M2177.16 
 
Sig .000 
M1877.44 
 
Sig .000 
M2174.72 
 
Sig .000 
G5 M1729.89 
 
Sig .000 
M205.23 
 
Sig .056 
M163.99 
 
Sig .271 
M199.42 
 
Sig .072 
 M1730.00 
 
Sig .000 
M1786.74 
 
Sig .000 
M402.55 
 
Sig .000 
M1198.54 
 
Sig .000 
M1215.89 
 
Sig .000 
M20.26 
 
Sig 1.0 
M264.32 
 
Sig .003 
M1378.67 
 
Sig .991 
M1332.80 
 
Sig .000 
M1732.68 
 
Sig .000 
M1977.74 
 
Sig .000 
M1678.02 
 
Sig .000 
M1975.31 
 
Sig .000 
G6 M.109 
 
Sig 1.0 
M1935.24 
 
Sig .000 
M1893.99 
 
Sig .000 
M1929.42 
 
Sig .000 
M1730.00 
 
Sig .000 
 M56.74 
 
Sig 1.0 
M2132.55 
 
Sig .000 
M2928.55 
 
Sig .000 
M514.11 
 
Sig .000 
M1750.27 
 
Sig .000 
M1994.32 
 
Sig .000 
M1651.33 
 
Sig .000 
M397.20 
 
Sig .000 
M2.68 
 
Sig 1.0 
M247.74 
 
Sig .008 
M51.98 
 
Sig 1.0 
M243.30 
 
Sig .009 
G7 M56.84 
 
Sig 1.0 
M1991.97 
 
Sig .000 
M1950.73 
 
Sig .000 
M1986.15 
 
Sig .000 
M1786.74 
 
Sig .000 
M56.74 
 
Sig 1.0 
 M2189.28 
 
Sig .000 
M2985.28 
 
Sig .000 
M570.85 
 
Sig .000 
M1807.00 
 
Sig .000 
M2051.05 
 
Sig .000 
M1708.07 
 
Sig .000 
M453.94 
 
Sig .000 
M54.06 
 
Sig 1.0 
M191.00 
 
Sig .101 
M108.72 
 
Sig .868 
M188.57 
 
Sig .112 
G8 M2132.44 
 
Sig .000 
M197.31 
 
Sig .078 
M238.56 
 
Sig .012 
M203.13 
 
Sig .061 
M402.55 
 
Sig .000 
M2132.55 
 
Sig .000 
M2189.28 
 
Sig .000 
 M796 
 
Sig .000 
M1618.44 
 
Sig .000 
M382.28 
 
Sig .000 
M138.23 
 
Sig .548 
M481.22 
 
Sig .000 
M1735.35 
 
Sig .000 
M2135.23 
 
Sig .000 
M2380.29 
 
Sig .000 
M2080.57 
 
Sig .000 
M2377.85 
 
Sig .000 
G9 M2928.44 M993.31 M1034.55 M999.13 M1198.54 M2928.55 M2985.28 M796  M2414.43 M1178.28 M934.23 M1277.21 M2531.34 M2931.22 M3176.28 M2876.56 M3173.85 
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 G1 G2 G3 G4 G5 G6 G7 G8 G9 G10 G11 G12 G13 G14 G15 N1 N2 N3 
 Sig .000 Sig .000 Sig .000 Sig .000 Sig .000 Sig .000 Sig .000 Sig .000  Sig .000 Sig .000 Sig .000 Sig .000 Sig .000 Sig .000 Sig .000 Sig .000 Sig .000 
G10 M514.00 
 
Sig .000 
M1421.12 
 
Sig .000 
M1379.88 
 
Sig .000 
M1415.31 
 
Sig .000 
M1215.89 
 
Sig .000 
M514.11 
 
Sig .000 
M570.85 
 
Sig .000 
M1618.44 
 
Sig .000 
M2414.43 
 
Sig .000 
 M1236.16 
 
Sig .000 
M1480.21 
 
Sig .000 
M1137.22 
 
Sig .000 
M116.91 
 
Sig .794 
M516.79 
 
Sig .000 
M761.85 
 
Sig .000 
M462.13 
 
Sig .000 
M759.41 
 
Sig .000 
G11 M1750.16 
 
Sig .000 
M184.97 
 
Sig .129 
M143.72 
 
Sig .483 
M179.15 
 
Sig .160 
M20.26 
 
Sig 1.0 
M1750.27 
 
Sig .000 
M1807.00 
 
Sig .000 
M382.28 
 
Sig .000 
M1178.28 
 
Sig .000 
M1236.16 
 
Sig .000 
 M244.05 
 
Sig .009 
M98.93 
 
Sig .932 
M1353.07 
 
Sig .000 
M1752.94 
 
Sig .000 
M1998.01 
 
Sig .000 
M1698.29 
 
Sig .000 
M1995.57 
 
Sig .000 
G12 M1994.21 
 
Sig .000 
M59.08 
 
Sig 1.0 
M100.33 
 
Sig .925 
M64.90 
 
Sig .999 
M264.32 
 
Sig .003 
M1994.32 
 
Sig .000 
M2051.05 
 
Sig .000 
M138.23 
 
Sig .548 
M934.23 
 
Sig .000 
M1480.21 
 
Sig .000 
M244.05 
 
Sig .009 
 M342.99 
 
Sig .000 
M1597.12 
 
Sig .000 
M1997.00 
 
Sig .000 
M2242.06 
 
Sig .000 
M1942.34 
 
Sig .000 
M2239.62 
 
Sig .000 
G13 M1651.22 
 
Sig .000 
M283.90 
 
Sig .001 
M242.66 
 
Sig .010 
M278.09 
 
Sig .002 
M78.67 
 
Sig .991 
M1651.33 
 
Sig .000 
M1708.07 
 
Sig .000 
M481.22 
 
Sig .000 
M1277.21 
 
Sig .000 
M1137.22 
 
Sig .000 
M98.93 
 
Sig .932 
M342.99 
 
Sig .000 
 M1254.13 
 
Sig .000 
M1654.01 
 
Sig .000 
M1899.07 
 
Sig .000 
M1599.35 
 
Sig .000 
M1896.64 
 
Sig .000 
G14 M397.09 
 
Sig .000 
M1538.03 
 
Sig .000 
M1496.79 
 
Sig .000 
M1532.22 
 
Sig .000 
M1332.80 
 
Sig .000 
M397.20 
 
Sig .000 
M453.94 
 
Sig .000 
M1735.35 
 
Sig .000 
M2531.34 
 
Sig .000 
M116.91 
 
Sig .794 
M1353.07 
 
Sig .000 
M1597.12 
 
Sig .000 
M1254.13 
 
Sig .000 
 M399.88 
 
Sig .000 
M644.94 
 
Sig .000 
M345.22 
 
Sig .000 
M642.51 
 
Sig .000 
G15 M2.79 
 
Sig 1.0 
M1937.91 
 
Sig .000 
M1896.67 
 
Sig .000 
M1932.10 
 
Sig .000 
M1732.68 
 
Sig .000 
M2.68 
 
Sig 1.0 
M54.06 
 
Sig 1.0 
M2135.23 
 
Sig .000 
M2931.22 
 
Sig .000 
M516.79 
 
Sig .000 
M1752.94 
 
Sig .000 
M1997.00 
 
Sig .000 
M1654.01 
 
Sig .000 
M399.88 
 
Sig .000 
 M245.06 
 
Sig .009 
M54.66 
 
Sig 1.0 
M242.63 
 
Sig .010 
N1 M247.85 
 
Sig .008 
M2182.97 
 
Sig .000 
M2141.73 
 
Sig .000 
M2177.16 
 
Sig .000 
M1977.74 
 
Sig .000 
M247.74 
 
Sig .008 
M191.00 
 
Sig .101 
M2380.29 
 
Sig .000 
M3176.28 
 
Sig .000 
M761.85 
 
Sig .000 
M1998.01 
 
Sig .000 
M2242.06 
 
Sig .000 
M1899.07 
 
Sig .000 
M644.94 
 
Sig .000 
M245.06 
 
Sig .009 
 M299.72 
 
Sig .001 
M2.43 
 
Sig 1.0 
N2 M51.87 
 
Sig 1.0 
M1883.25 
 
Sig .000 
M1842.01 
 
Sig .000 
M1877.44 
 
Sig .000 
M1678.02 
 
Sig .000 
M51.98 
 
Sig 1.0 
M108.72 
 
Sig .868 
M2080.57 
 
Sig .000 
M2876.56 
 
Sig .000 
M462.13 
 
Sig .000 
M1698.29 
 
Sig .000 
M1942.34 
 
Sig .000 
M1599.35 
 
Sig .000 
M345.22 
 
Sig .000 
M54.66 
 
Sig 1.0 
M299.72 
 
Sig .001 
 M297.28 
 
Sig .001 
N3 M245.41 
 
Sig .009 
M2180.54 
 
Sig .000 
M2139.30 
 
Sig .000 
M2174.72 
 
Sig .000 
M1975.31 
 
Sig .000 
M245.30 
 
Sig .009 
M188.57 
 
Sig .112 
M2377.85 
 
Sig .000 
M3173.85 
 
Sig .000 
M759.41 
 
Sig .000 
M1995.57 
 
Sig .000 
M2239.62 
 
Sig .000 
M1896.64 
 
Sig .000 
M642.51 
 
Sig .000 
M242.63 
 
Sig .010 
M2.43 
 
Sig 1.0 
M297.28 
 
Sig .001 
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4.3     Immunofluorescence 
 
 
Under normal conditions HSPA protein in cells is localized in the cytoplasm, however 
under conditions of stress HSPA migrates to the nucleus. Immunofluorescence detection 
staining was carried out utilising a monoclonal primary HSPA antibody to identify the 
presence and localization of HSPA protein in the NHA and the three glioma cells lines, 
1321N1,  GOS-3  and  U87-MG  for  any  comparable  differences  between  normal 
 
(unstressed) and cancerous cells (stressed). 
 
 
 
 
Cells cultured on chamber slides were fixed using 4% paraformaldehyde (BDH, UK) 
for 10 min then incubated with 0.3% Triton X-100 (BDH) in PBS for 7 min after 
hypoxia treatment.  Slides were incubated in blocking solution containing 1% BSA 
(Sigma,UK) and PBS for 30 min.   HSPA1A primary antibody (1:200) (Abcam, UK) 
was diluted in the blocking solution and applied to the cells for 1 h at room temperature. 
After three washes in PBS, cells were incubated with light sensitive Anti-Mouse IgG 
FITC conjugated secondary antibody (1:200) (Sigma, UK) diluted in blocking solution 
for 1 h at room temperature.  All slides were washed three times in PBS and counter 
stained with VECTASHIELD® (1.5 µg/ml) mounting medium with Propidium iodide 
(PI; Vector, USA) for 10 min.  Cells were visualized and scanned on an Axiovert 200M 
LSM 510 laser scanning confocal microscope (Carl Zeiss Ltd, UK) as described by 
Shervington et al., (2009). 
 
 
 
 
HSPA antigens detected using an Anti-mouse IgG FITC conjugated secondary antibody 
were predominantly identified in both the nucleus and the cytoplasm in the three glioma 
cell lines; 1321N1, GOS-3 and U87-MG. HSPA protein was detected in the cytoplasm 
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in the normal astrocyte cell line, NHA, with only limited fluorescence emitted from the 
nucleus of the cells. (Figures 4.5, 4.6, 4.7 and 4.8). 
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1 2 3 
 
 
 
 
 
 
Figure 4.5 HSPA protein levels assessed using immunofluorescence in untreated NHA cells. (1) combined nuclei labelled with propidium iodide (red) 
and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) nuclei staining labelled with propidium 
iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). Objective = x 40 magnification. Scale 
bar = 20µm. 
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Figure 4.6 HSPA protein levels assessed using immunofluorescence in untreated 1321N1 cells. (1) combined nuclei labelled with propidium iodide 
(red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) nuclei staining labelled with 
propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
205  
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Figure 4.7 HSPA protein levels assessed using immunofluorescence in untreated GOS-3 cells. (1) combined nuclei labelled with propidium iodide 
(red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) nuclei staining labelled with 
propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
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Figure 4.8 HSPA protein levels assessed using immunofluorescence in untreated U87-MG cells. (1) combined nuclei labelled with propidium iodide 
(red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) nuclei staining labelled with 
propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
207  
4.4 Flow Cytometry 
 
 
To accurately quantify the presence of HSPA protein, flow cytometry analysis was 
carried out.  The data obtained from flow cytometry was used to produce fluorescence 
intensity histograms, which depict the distribution of cell surface antigen densities 
within the population under study, and provide a molecular fingerprint of protein 
distribution. Comparisons of HSPA protein production were made between the different 
cell lines. 
 
 
 
Flow cytometry involves the use of fluorescent labelled antibodies and fluorescent 
detectors to analyse large numbers of cells sequentially. Antibodies bind to their 
respective target molecule or antigen in a one-to-one ratio, such that the number of 
antibodies bound to a cell and the number of fluorescent molecules present, will in 
general be proportional to the level of production of that protein on the cell. 
 
 
 
Cultured cells were stained and subjected to flow cytometry, briefly 1x106 were washed 
once in 0.1% BSA in PBS before being re-suspended in 0.1% Triton X-100 for 15 min. 
Following incubation cells were collected and washed once with 0.1% BSA in PBS 
before being blocked in 5% goat serum in 0.1% BSA in PBS for 30 min.   HSPA 
primary antibody (1:200) diluted in blocking solution was applied for 30 min.   Cells 
were then washed with 0.1% BSA in PBS and light sensitive Anti-Mouse IgG FITC 
conjugated secondary antibody (1:200) diluted in blocking solution was added for 30 
min.  Following incubation cells were washed twice in 0.1% BSA in PBS before finally 
being re-suspended in an aliquot 0.1% BSA in PBS and filtered into FACS tubes.  All 
incubation steps were performed on ice. 
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As expected, analysis showed high relative fluorescence intensity, with approximately 
 
98% of the 1321N1 cell population showing positive, approximately 89% of GOS-3 cell 
population showing positive, and 97% of the U87-MG cell population showing positive 
compared to little or no fluorescence intensity in the NHA cell line, approximately 
0.13% showing positive for HSPA. This is taken to indicate that HSPA protein is barely 
detectable in normal cells, but is present at significantly higher levels in cancer cells; 
approximately 97-fold higher in 1321N1, 89-fold higher in GOS-3 and 97-fold higher in 
U87-MG (Figures 4.9, 4.10, 4.11, 4.12 and 4.13). 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.9 Average percentages of cells showing positive for HSPA. (A) Average percentage of normal and glioma cells positive for HSPA protein 
detected by flow cytometry, considering 10,000 events per sample. (B) Histogram showing the mean percentage of cells evaluated by flow cytometry of 
three independent experiments, and the standard deviation from this mean is shown by the error bars. No column was shown on the histogram for NHA 
as the value = 0. 
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4.4.1 Statistical Analysis 
 
 
 
 
A one-way ANOVA test between groups of analysis of variance was conducted to 
access HSPA protein production in normal and glioma cell lines in three independent 
experiments. The cell lines comprised of four groups: group 1 NHA, group 2 1321N1, 
group 3 GOS-3 and group 4 U87-MG. The means and standard deviations are presented 
in Table 4.8. 
 
 
 
 
Table 4.8 Descriptive statistics showing the mean for HSPA protein levels for each cell 
line. 
 
 
 
 
Cell Line N Mean % of HSPA 
 
protein levels 
Std Deviation 
NHA 3 0.133 0.057 
1321N1 3 96.87 0.321 
GOS-3 3 89.15 0.050 
U87-MG 3 96.85 0.050 
 
 
There was significant difference in HSPA protein levels for the four cell line groups 
[F(3,8) = 239590, P < 0.001]. The effect size, calculated using eta squared indicated a 
large effect of 0.999. 
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Table 4.9. Statistical data from Tukey‘s HSD test showing significance of HSPA 
 
protein levels between cell lines. Any significant differences P ≤ 0.05 are highlighted in 
 
bold. 
 
 
(I) Cell J (Cell) % Mean Difference (I – 
 
J) 
Std. Error Sig. 
NHA 1321N1 96.73 0.136 0.000 
NHA GOS-3 89.02 0.136 0.000 
NHA U87-MG 96.72 0.136 0.000 
1321N1 GOS-3 7.72 0.136 0.000 
1321N1 U87-MG 0.0168 0.136 0.999 
GOS-3 U87-MG 7.70 0.136 0.000 
 
 
Post-hoc analyses using Tukey‘s HSD test indicated significantly lower HSPA protein 
levels in group 1, NHA than in: group 2, 1321N1 (MD = 96.73, P < .05); group 3, GOS- 
3 (MD = 89.02, P < .05) and group 4, U87-MG (MD = 96.72, P < .05) (Table 4.9). 
 
 
There was a significantly lower HSPA protein levels in group 2, 1321N1 than in group 
 
3, GOS-3 (MD = 7.72, P < .05) (Table 4.9). 
 
 
There was a significantly lower HSPA protein levels in group 3, GOS-3 than in group 4, 
U87-MG (MD = 7.70, P < .05) (Table 4.9). 
 
All other differences between groups failed to reach significance (Table 4.9). 
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Figure 4.10 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the NHA cell lines. No fluorescence intensity was observed in the NHA cell 
line (A, negative, primary antibody omitted and B, sample) 2D scatter plot showing cell 
population of interest (P1), (C, negative, D, sample) fluorescent intensity histogram 
showing cells positive (P3) and negative (P2) for HSPA. Data values are for three 
independent experiments considering 10,000 events per sample. 
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Figure 4.11 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the 1321N1 cell lines.  Approximately 97% of 1321N1 glioma cells showed 
positive for HSPA. (A, negative, primary antibody omitted and B, sample) 2D scatter 
plot showing cell population of interest (P1), (C, negative, D, sample) fluorescent 
intensity histogram showing cells positive (P3) and negative (P2) for HSPA.  Data 
values are for three independent experiments considering 10,000 events per sample. 
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Figure 4.12 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the GOS-3 cell lines. Approximately 89% of GOS-3 glioma cells showed 
positive for HSPA. (A, negative, primary antibody omitted and B, sample) 2D scatter 
plot showing cell population of interest (P1), (C, negative, D, sample) fluorescent 
intensity histogram showing cells positive (P3) and negative (P2) for HSPA.  Data 
values are for three independent experiments considering 10,000 events per sample. 
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Figure 4.13 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the U87-MG cell lines. Approximately 97% of U87-MG glioma cells showed 
positive for HSPA. (A, negative, primary antibody omitted and B, sample) 2D scatter 
plot showing cell population of interest (P1), (C, negative, D, sample) fluorescent 
intensity histogram showing cells positive (P3) and negative (P2) for  HSPA.  Data 
values are for three independent experiments considering 10,000 events per sample. 
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Taken together, the results from these experiments show that HSPA is expressed at low 
levels in normal cells and normal brain tissue, but is more highly expressed in cancer 
cell lines and brain tumours. The average HSPA mRNA copy numbers in the three 
glioma cell lines were approximately 6 fold higher than the normal cell line, and the 
average HSPA mRNA copy numbers in glioblastoma tissue were approximately 1.8 and 
9 fold higher than the low grade glioma and normal tissue respectively, suggesting a 
grade-related transcription profile. 
 
As with HSPA mRNA, high levels of HSPA protein were detected in the three glioma 
cell lines compared to low/barely detectable levels in the NHA cell line, indicating a 
direct correlation between HSPA mRNA and HSPA protein levels in glioma cell lines. 
 
These results suggest that HSPA mRNA and HSPA protein levels in glioma may 
possibly be grade related, and therefore may be useful as a possible prognostic marker. 
 
As expected, given that cancer is a form of cellular stress, HSPA protein was detected in 
both the cytoplasm and the nucleus of the three glioma cell lines.  HSPA protein was 
detected predominantly in the cytoplasm in the normal astrocyte cell line, NHA with 
only limited fluorescence emitted from the nucleus of the cells. 
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Chapter 5 
 
 
 
 
 
 
Effects of hypoxia on HSPA gene 
expression in glioma 
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5.1 Gene Expression 
 
 
 
HSPA expression is up-regulated in cells by cancer and also in response to hypoxia, and 
the main research aim of this chapter was to measure and compare HSPA expression in 
normal and glioma cell lines under pre- and post-hypoxic conditions, with a view to 
characterising the expression of HSPA. The potential correlation between HSPA 
expression and hypoxia was investigated using three glioma cell lines (1321N1, GOS-3 
and U87-MG) and the normal human astrocyte cell line (NHA). Expression of HSPA 
was compared between the three glioma cell lines (1321N1, GOS-3 and U87-MG) and 
with a normal (control) human astrocyte cell line (NHA), under pre- and post-hypoxia 
conditions. GAPDH, was used as an internal standard throughout all RT-PCR 
experiments (Barber et al, 2005). 
 
Human   brain   cell   lines   GOS-3   (grade   II/III   oligodendroglioma)  from   DMSZ 
(Germany), U87-MG (grade IV glioblastoma) from ECCAC (UK) and NHA (normal 
human astrocytes) from  Lonza (UK)  were  used  in  this  study.    GOS-3  cells  were 
routinely cultured in Dulbecco‘s modified Eagle‘s medium (DMEM) (Sigma) 
supplemented with 10% FBS and with 4 mM L-glutamide, while U87-MG cells were 
cultured in Eagle‘s minimum essential medium (EMEM) (Sigma) supplemented with 2 
mM L-glutamide, 10% FBS and 1% (v/v) nonessential amino acids (Sigma).  The NHA 
cells were cultured in astrocyte medium (AM) supplemented with 15 ml of FBS, 0.5 ml 
Ascorbic Acid, 0.5 ml rhEGF (astrocyte growth supplement) 0.5 ml GA100 1.25 ml 
Insulin and 5 ml L-glutamide. 
 
 
 
Hypoxic conditions were induced by exposing confluent cells to nitrogen (100 %) for 
 
30 min (Kay et al, 2007).  After treatment, the cells were collected at various recovery 
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periods (0, 3, 6 and 24 h) for experiments concerning gene expression, 
immunofluorescence and flow cytometry. 
mRNA was isolated from all four cell lines, using mRNA Isolation Kit (Roche,UK) 
following the manufacturer‘s protocol. The concentration and purity of mRNA was 
determined by ultraviolet spectrophotometry. Isolated mRNA (100 ng) was transcribed 
to cDNA using 1st Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche, UK) 
following the manufacturer‘s protocol, which was then used as a template for qRT- 
PCR.   Quantitative real-time PCR was used to evaluate the expression of HSPA and 
GAPDH as a control using FastStart DNA MasterPLUS SYBR Green 1 (Roche, UK). 
 
Primers used for HSPA were 5‘ CGACCTGAACAAGAGCATCA 3‘ (sense) and 5‘ 
AAGATCTGCGTCTGCTTGGT 3‘ (antisense). For GAPDH, primers were 5‘ 
GAGTCAAGCGATTTGGTCGT 3‘ (sense) and 5‘ TTGATTTTGGAGGGATCTCG 3‘ 
(antisense). All primers were designed using Primer3 software and manufactured by 
TIB MOLBIOL. 
 
After an initial denaturation at 95oC for 10 min, the samples were subjected to 35 cycles 
of RT-PCR 95oC for 10 s, annealing temperature 57oC (HSPA) and 56oC (GAPDH) for 
15 s, and 72oC for 15 s (Patel et al., 2008). At the end of each cycle, the fluorescence 
emitted was measured in a single step in channel F1 (gain1). After the 35th  cycle, the 
specimens were heated to 95oC and rapidly cooled to 65oC for 15 s. All heating and 
cooling  steps  were  performed  with  a  slope  of  20oC  /  s.  The  temperature  was 
subsequently raised to 95oC with a slope of 0.1oC / s and fluorescence was measured 
continuously (channel F1, gain1) to obtain data for the melting curve analysis. All PCR 
reactions were performed in triplicate and a negative control included, which contained 
primers  with  no  DNA.  All  PCR  products were  analysed  using gel  electrophoresis 
stained and visualised using a gel analyser (SynGene, UK). 
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5.2 Constitutive Expression 
 
 
 
5.2.1 Glioma Cell lines 
 
 
 
Transcript copy numbers of HSPA and GAPDH were determined using RT-PCR for 
three  glioma  cell  lines;  1321N1,  GOS-3  and  U87-MG  and  in  the  normal  human 
astrocyte cell  line  NHA,  under  pre-  and  post-hypoxia  treatment. The  primers  and 
optimal temperatures used for the amplification of both genes are documented in Table 
2.10 in section 2.5. All PCR experiments were carried out in triplicate for consistency 
and repeatability. For each gene analysed, a quantification graph was produced to 
confirm gene amplification. The resulting amplicons for HSPA and GAPDH were then 
visualized using agarose gel electrophoresis, each being represented by bands of 213 
and 238 bp respectively. 
 
 
 
The mRNA copy number per 100 ng of extracted mRNA for both genes was calculated 
for each cell line. High levels of HSPA mRNA expression were observed in 1321N1, 
GOS-3 and U87-MG glioma cell lines pre-hypoxia treatment, with approximate copy 
numbers of each of 7,500, 8,900, 8,200 respectively and post-hypoxia treatment after 0 
h recovery, with approximate copy numbers of each of 8,200, 7,300, 8,100 respectively; 
after 3 h recovery, with approximate copy numbers of each of 8100, 7,500, 7,800 
respectively; after 6 h recovery, with approximate copy numbers of each of 8,100, 
7,500, 8,200 respectively and after 24 h recovery, with approximate copy numbers of 
each of 7,800, 7,800, 8,200 respectively (Figure 5.1 and Table 5.1).   In contrast, the 
normal human astrocyte cell line showed low but detectable levels of HSPA mRNA in 
pre hypoxia treatment, with an approximate copy number of 1,400 and slightly raised 
levels  of  HSPA  mRNA  in  post  hypoxia  treatment  after  0  h  recovery,  with  an 
approximate copy number of 2,500, after 3 h recovery, with an approximate copy 
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number of 1,100, after 6 h recovery, with an approximate copy number of 590 and after 
 
24 h recovery, with an approximate copy number of 350 (Figure 5.1 and Table 5.1). 
 
 
 
 
For GAPDH, mRNA copy numbers per 100 ng of extracted mRNA were relatively 
consistent for NHA, with approximate copy numbers of 148,300, for 1321N1, with 
approximate copy numbers of 147,400, for GOS-3, with approximate copy numbers of 
147,400  and  for  U87-MG,  with  approximate  copy  numbers  of  147,300,  again 
confirming comparability of HSPA results (Figure 5.2 and Table 5.1). 
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Figure 5.1 Levels of HSPA mRNA transcripts in pre- and post-hypoxia treated NHA, 
 
1321N1, GOS-3 and U87-MG cells.  (A) agarose gel electrophoresis: Lane 1 represents 
the 100 bp molecular ladder; lanes 2 - 6 represent amplicons from NHA:  pre-hypoxia, 
post-hypoxia after 0, 3, 6 and 24 h recovery, lanes 7 - 11 represent amplicons from 
1321N1: pre-hypoxia, post-hypoxia after 0, 3, 6 and 24 h recovery, lanes 12 - 16 
represent amplicons from GOS-3: pre-hypoxia, post-hypoxia after 0, 3, 6 and 24 h 
recovery and lanes 17 - 21 represent amplicons from U87-MG: pre-hypoxia, post- 
hypoxia after 0, 3, 6 and 24 h recovery.  (B) Histogram showing HSPA mRNA copy 
numbers per 100 ng of extracted mRNA for pre and post hypoxia 0, 3, 6 and 24 h, 
treated cell lines. Data values are the mean of three independent experiments, and the 
standard deviation from this mean is shown by the error bars. 
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Figure 5.2 Levels of GAPDH mRNA transcripts in pre and post hypoxia treated NHA, 
 
1321N1, GOS-3 and U87-MG cells.  (A) agarose gel electrophoresis: Lane 1 represents 
the 100 bp molecular ladder; lanes 2 - 6 represent amplicons from NHA:  pre-hypoxia, 
post-hypoxia after 0, 3, 6 and 24 h recovery, lanes 7 - 11 represent amplicons from 
1321N1: pre-hypoxia, post-hypoxia after 0, 3, 6 and 24 h recovery, lanes 12 - 16 
represent amplicons from GOS-3: pre-hypoxia, post-hypoxia after 0, 3, 6 and 24 h 
recovery and lanes 17 - 21 represent amplicons from U87-MG: pre-hypoxia, post- 
hypoxia after 0, 3, 6 and 24 h recovery.  (B) Histogram showing HSPA mRNA copy 
numbers per 100 ng of extracted mRNA for pre and post hypoxia 0, 3, 6 and 24 h, 
treated cell lines. Data values are the mean of three independent experiments, and the 
standard deviation from this mean is shown by the error bars. 
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5.2.2 Statistical Analysis 
 
 
 
A  two-way  factorial  mixed  4  (cell  line:  NHA,  1321N1,  GOS-3,  U87-MG)  x  5 
(treatment: untreated, 0, 3, 6 and 24 h recovery after hypoxia treatment) ANOVA 
analysis of variance test was performed to investigate differences of HSPA and GAPDH 
gene expression. The means and standard deviation are presented in Table 5.1. 
 
For HSPA gene expression there was a non-significant effect for: cell line [F(15,11.44) 
 
= .832, P = 0.637]; Wilks‘ Lambda = 0.131; partial eta squared = 0.493 and treatment 
[F(4,5) = 1.692; P = 0.287], Wilks‘ Lambda = 0.425, partial eta squared = 0.575. The 
interaction between treatment and cell line also failed to reach significance [F(12,13.52) 
= 1.0; P = 0.496], Wilks‘ Lambda = 0.186, partial eta squared = 0.429. 
 
 
There was a statistically significant main effect in HSPA transcript copy numbers for 
 
cell lines on the combined variables: [F(3,8) = 6.544, P = .015]; partial eta squared (ƞp2) 
 
= 0.710. 
 
 
When the results for the dependent variables were considered separately, there was a 
 
statistical significance in untreated [F(3,8) = 5.157, P = .028]; partial eta squared (ƞp2) = 
 
0.659. 
 
 
Post-hoc analyses using Tukey‘s HSD test indicated significantly lower HSPA transcript 
copy numbers in untreated NHA than in untreated, GOS-3 (MD = 7459.67, P = 0.033). 
All other differences between groups failed to reach significance (Table 5.2). 
 
There was a non statistical significance after 0 h recovery [F(3,8) = 3.187, P = .084]; 
partial eta squared (ƞp2) = 0.544. Posthoc analyses using Tukey‘s HSD indicated that all 
differences between groups failed to reach significance (Table 5.2) 
 
There was a statistical significance after 3 h recovery [F(3,8) = 5.260, P = .027]; partial 
 
eta squared (ƞp2) = 0.664. Posthoc analyses using Tukey‘s HSD indicated significantly 
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lower HSPA transcript copy numbers after 3 h recovery in NHA than in: 1321N1 (MD 
 
7042.05, P < .05) and U87-MG (MD = 6730.03, P < .05).  All other differences between 
groups failed to reach significance (Table 5.2). 
 
There was a statistical significance after 6 h recovery [F(3,8) = 5.910, P = .020]; partial 
eta squared (ƞp2) = 0.689. Posthoc analyses using Tukey‘s HSD indicated significantly 
lower HSPA transcript copy numbers after 6 h recovery in NHA than in: 1321N1 (MD 
7510.99, P < .05); GOS-3 (MD = 6901.49, P < .05) and U87-MG (MD = 7567.85, P < 
 
.05). All other differences between groups failed to reach significance (Table 5.2). 
 
 
 
There was a statistical significance after 24 h recovery [F(3,8) = 6.232, P = .017]; partial 
 
eta squared (ƞp2) = 0.700. 
 
 
 
Posthoc analyses using Tukey‘s HSD indicated significantly lower HSPA transcript 
copy numbers after 24 h recovery in NHA than in: 1321N1 (MD 7414.30, P < .05); 
GOS-3 (MD = 7414.30, P < .05) and U87-MG (MD = 7807.93, P < .05).   All other 
differences between groups failed to reach significance (Table 5.2). 
 
For GAPDH transcript copy numbers, there was a non significant effect for: cell line 
[F(15,11.44) = 0.005, P > .05]; Wilks‘ Lambda = 0.980, partial eta squared = 0.007 and 
treatment [F(4,5) = .003; P > .05], Wilks‘ Lambda = 0.998, partial eta squared = 0.002. 
The interaction between treatment and cell line also failed to reach significance 
[F(12,13.52) = .007; P > .05], Wilks‘ Lambda = .983, partial eta squared = 0.006. 
 
There was a non significant main effect in GAPDH gene expression for cell lines on the 
 
combined variables: [F(3,8) = .001, P > .05]; partial eta squared (ƞp2) = 0.000. 
 
 
 
When the results for the dependent variables were considered separately, there was a 
non statistical significance in untreated [F(3,8) = .004, P > .05]; partial eta squared (ƞp2) 
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= 0.002. Posthoc analyses using Tukey‘s HSD indicated that all differences between 
 
groups failed to reach significance. 
 
 
 
There was a non statistical significance after 0 h recovery [F(3,8) = .005, P > .05]; 
partial eta squared (ƞp2) = 0.002. Posthoc analyses using Tukey‘s HSD indicated that all 
differences between groups failed to reach significance. 
 
There was a non statistical significance after 3 h recovery [F(3,8) = .004, P > .05]; 
partial eta squared (ƞp2) = 0..002. Posthoc analyses using Tukey‘s HSD indicated that all 
differences between groups failed to reach significance. 
 
There was a non statistical significance after 6 h recovery [F(3,8) = .007, P > .05]; 
partial eta squared (ƞp2) = 0.003. Posthoc analyses using Tukey‘s HSD indicated that all 
differences between groups failed to reach significance. 
 
There was a non statistical significance after 24 h recovery [F(3,8) = .005, P > .05]; 
partial eta squared (ƞp2) = 0.002. Posthoc analyses using Tukey‘s HSD indicated that all 
differences between groups failed to reach significance. 
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Table 5.1. Descriptive statistics showing the mean mRNA copy numbers for HSPA and 
 
GAPDH gene expression for untreated and treated cell lines. 
 
 
Treatment Cell 
Line 
N Mean HSPA 
transcript 
copy number 
STD. 
Dev. 
Mean GAPDH 
Transcript copy 
number 
STD. 
Dev. 
Pre- 
hypoxia 
NHA 3 1419.63 708.76 146468.91 50836.00 
1321N1 3 7491.67 2495.20 144546.62 32831.75 
GOS-3 3 8879.29 3210.84 147541.72 33859.90 
U87- 
MG 
3 8158.12 3204.01 147541.72 33859.90 
0 h 
recovery 
after 
hypoxia 
treatment 
NHA 3 2463.77 488.26 148473.30 18197.56 
1321N1 3 8158.12 3204.01 146112.84 25188.06 
GOS-3 3 7286.28 2548.80 148927.19 46355.40 
U87- 
MG 
3 8101.26 3299.79 148439.75 24974.58 
3 h 
recovery 
after 
hypoxia 
treatment 
NHA 3 1059.21 401.35 148927.19 46355.40 
1321N1 3 8101.26 3299.79 148927.19 46355.40 
GOS-3 3 7491.67 2495.20 148473.30 18197.56 
U87- 
MG 
3 7789.23 2955.70 146112.84 25188.06 
6 h 
recovery 
after 
hypoxia 
treatment 
NHA 3 590.27 233.87 148473.30 18197.56 
1321N1 3 8101.26 3299.79 148927.19 46355.40 
GOS-3 3 7491.67 2495.20 146112.84 25188.06 
U87- 
MG 
3 8158.12 3204.01 146112.84 25188.04 
24 h 
recovery 
after 
hypoxia 
treatment 
NHA 3 350.19 167.09 148927.19 46355.40 
1321N1 3 7764.50 2930.96 148473.30 18197.56 
GOS-3 3 7764.50 2930.96 146112.84 25188.06 
U87- 
MG 
3 8158.12 3204.01 148439.75 24974.58 
 
Overall inspection of the mean scores for HSPA transcript copy numbers indicated that 
untreated and treated 1321N1; GOS-3 and U87-MG cell lines were considerably higher 
than the NHA cell line. 
 
Overall inspection of the mean scores for GAPDH transcript copy numbers indicated no 
significant differences in untreated and treated NHA, 1321N1, GOS-3 and U87-MG cell 
lines. 
  
 
 
 
 
 
 
Table 5.2. Statistical data from Tukey‘s HSD test showing significance of HSPA transcript copy numbers in treated and untreated cell lines. Any 
 
significant differences are highlighted in bold. Significance ≤ 0.05. 
 
 
  NHA 1321N1 GOS-3 U87-MG 
Treatment Cell Line Mean Diff  ± STD 
error 
SIG. Mean Diff  ± STD 
error 
SIG. Mean Diff  ± STD 
error 
SIG. Mean Diff  ± STD 
error 
SIG. 
Pre-hypoxia NHA   6072.04 ± 2311.21 .083 7459.67 ± 2133.21 .033 6738.49 ± 2133.21 .053 
1321N1 6072.04 ± 2133.21 .083   1387.62 ± 2311.21 .912 666.45 ± 2311.21 .989 
GOS-3 7459.67 ± 2133.21 .033 1387.62 ± 2311.21 .912   721.17 ± 2311.21 .986 
U87-MG 6738.49 ± 2133.21 .053 666.45 ± 2311.21 .989 721.17 ± 2311.21 .986   
0  h  recovery 
after  hypoxia 
treatment 
NHA   5694.35 ± 2155.96 .110 4822.51 ± 2155.96 .193 5637.49 ± 2155.96 .114 
1321N1 5694.35 ± 2155.96 .110   871.84 ± 2155.96 .976 56.86 ± 2155.96 1.000 
GOS-3 4822.51 ± 2155.96 .193 871.84 ± 2155.96 .976   814.98 ± 2155.96 .980 
U87-MG 5637.49 ± 2155.96 .114 56.86 ± 2155.96 1.000 814.98 ± 2155.96 .980   
3  h  recovery 
after  hypoxia 
treatment 
NHA   7042.05 ± 2082.14 .039 6432.46 ± 2082.14 .059 6730.03 ± 2082.14 .048 
1321N1 7042.05 ± 2082.14 .039   609.59 ± 2082.14 .991 312.02 ± 2082.14 .999 
GOS-3 6432.46 ± 2082.14 .059 609.59 ± 2082.14 .991   297.57 ± 2082.14 .999 
U87-MG 6730.03 ± 2082.14 .048 312.02 ± 2082.14 .999 297.57 ± 2082.14 .999   
6  h  recovery 
after  hypoxia 
treatment 
NHA   7510.99 ± 2138.34 .032 6901.40 ± 2138.34 .048 7567.85 ± 2138.34 .031 
1321N1 7510.99 ± 2138.34 .032   609.59 ± 2138.34 .991 56.86 ± 2138.34 1.000 
GOS-3 6901.40 ± 2138.34 .048 609.59 ± 2138.34 .991   666.45 ± 2138.34 .989 
U87-MG 7567.85 ± 2138.34 .031 56.86 ± 2138.34 1.000 666.45 ± 2138.34 .989   
24 h recovery 
after hypoxia 
treatment 
NHA   7414.30 ± 2139.86 .035 7414.30 ± 2139.86 .035 7807.93 ± 2139.86 .027 
1321N1 7414.30 ± 2139.86 .035   0.0  ± 2139.86 1.000 393.62 ± 2139.86 .998 
GOS-3 7414.30 ± 2139.86 .035 1.0  ± 2139.86 1.000   393.62 ± 2139.86 .998 
U87-MG 7807.93 ± 2139.86 .027 393.62 ± 2139.86 .998 393.62 ± 2139.86 .998   
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5.3     Immunofluorescence 
 
 
Under normal conditions HSPA protein in cells is localized in the cytoplasm, however 
under conditions of stress HSPA migrates to the nucleus. Immunofluorescence detection 
staining was carried out utilising a monoclonal primary HSPA antibody to identify the 
presence and localization of HSPA protein in the NHA and the three glioma cells lines, 
1321N1,  GOS-3  and  U87-MG  for  any  comparable  differences  between  normal 
 
(unstressed) and cancerous cells (stressed) under pre and post hypoxic conditions. 
 
 
 
 
Cells cultured on chamber slides were fixed using 4% paraformaldehyde (BDH, UK) 
for 10 min then incubated with 0.3% Triton X-100 (BDH) in PBS for 7 min after 
hypoxia treatment.  Slides were incubated in blocking solution containing 1% BSA 
(Sigma,UK) and PBS for 30 min.  HSPA primary antibody (1:200) (Abcam, UK) was 
diluted in the blocking solution and applied to the cells for 1 h at room temperature. 
After three washes in PBS, cells were incubated with light sensitive Anti-Mouse IgG 
FITC conjugated secondary antibody (1:200) (Sigma, UK) diluted in blocking solution 
for 1 h at room temperature.  All slides were washed three times in PBS and counter 
stained with VECTASHIELD® (1.5 µg/ml) mounting medium with Propidium iodide 
(PI; Vector, USA) for 10 min.  Cells were visualized and scanned on an Axiovert 200M 
LSM 510 laser scanning confocal microscope (Carl Zeiss Ltd, UK) as described by 
Shervington et al., (2009). 
 
 
 
 
HSPA antigens detected using an Anti-mouse IgG FITC conjugated secondary antibody 
were identified, pre- and post-hypoxic treatment, in both the nucleus and the cytoplasm 
of the three glioma cell lines; 1321N1 (Figures 5.7 – 5.14), GOS-3 (Figures 5.15 – 5.20) 
and U87-MG (Figures 5.21 – 5.26).  As with mRNA expression in the three glioma cell 
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lines, HSPA protein was detected pre-and post-hypoxia treatment in both the cytoplasm 
and the nucleus. 
 
 
 
 
HSPA protein was detected in the cytoplasm in the normal astrocyte cell line, NHA 
with only limited fluorescence emitted from the nucleus of the cells. However, post- 
hypoxia, fluorescence was observed in both the cytoplasm and the nucleus (Figures 5.3 
– 5.8). HSPA protein had migrated into the nucleus during hypoxia treatment, which 
correlates with the increased HSPA transcript levels, as shown in Figure 5.1. 
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Figure 5.3 HSPA protein levels assessed using immunofluorescence for negative control of un-treated NHA cells. (1) Negative control whereby 
primary antibody HSPA has been omitted, Anti-mouse IgG FITC conjugated secondary antibody (green), no staining, nuclei labelled with propidium 
iodide (red); (2) nuclei staining labelled with propidium iodide (red) and (3) Anti-mouse IgG FITC conjugated secondary antibody (green), no staining. 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.4 HSPA protein levels assessed using immunofluorescence in untreated NHA cells. (1) combined nuclei labelled with propidium iodide (red) 
and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) nuclei staining labelled with propidium 
iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). Objective = x 40 magnification. Scale 
bar = 20µm. 
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Figure 5.5 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated NHA cells after 0 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.6 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated NHA cells after 3 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.7 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated NHA cells after 6 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.8 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated NHA cells after 24 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.9 HSPA protein levels assessed using immunofluorescence for negative control of un-treated 1321N1 cells. (1) Negative control whereby 
primary antibody HSPA has been omitted, Anti-mouse IgG FITC conjugated secondary antibody (green), no staining, nuclei labelled with propidium 
iodide (red); (2) nuclei staining labelled with propidium iodide (red) and (3) Anti-mouse IgG FITC conjugated secondary antibody (green), no staining. 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.10 HSPA protein levels assessed using immunofluorescence in untreated 1321N1 cells. (1) combined nuclei labelled with propidium iodide 
(red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) nuclei staining labelled with 
propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
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Figure 5.11 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated 1321N1 cells after 0 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.12 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated 1321N1 cells after 3 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.13 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated 1321N1 cells after 6 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.14 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated 1321N1 cells after 24 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
243  
 
 
 
 
 
 
 
 
1 2 3 
 
 
 
 
 
Figure 5.15 HSPA protein levels assessed using immunofluorescence for negative control of un-treated GOS-3 cells. (1) Negative control whereby 
primary antibody HSPA has been omitted, Anti-mouse IgG FITC conjugated secondary antibody (green), no staining, nuclei labelled with propidium 
iodide (red); (2) nuclei staining labelled with propidium iodide (red) and (3) Anti-mouse IgG FITC conjugated secondary antibody (green), no staining. 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.16 HSPA protein levels assessed using immunofluorescence in untreated GOS-3 cells. (1) combined nuclei labelled with propidium iodide 
(red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) nuclei staining labelled with 
propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
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Figure 5.17 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated GOS-3 cells after 0 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.18 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated GOS-3 cells after 3 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.19 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated GOS-3 cells after 6 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
248  
 
 
 
 
 
 
 
 
 
1 2 3 
 
 
 
 
 
 
 
 
 
Figure 5.20 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated GOS-3 cells after 24 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.21 HSPA protein levels assessed using immunofluorescence for negative control of un-treated U87-MG cells. (1) Negative control whereby 
primary antibody HSPA has been omitted, Anti-mouse IgG FITC conjugated secondary antibody (green), no staining, nuclei labelled with propidium 
iodide (red); (2) nuclei staining labelled with propidium iodide (red) and (3) Anti-mouse IgG FITC conjugated secondary antibody (green), no staining. 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.22 HSPA protein levels assessed using immunofluorescence in untreated U87-MG cells. (1) combined nuclei labelled with propidium iodide 
(red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) nuclei staining labelled with 
propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
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Figure 5.23 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated U87-MG cells after 0 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.24 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated U87-MG cells after 3 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.25 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated U87-MG cells after 6 h recovery. (1) combined nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); (2) 
nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody (green). 
Objective = x 40 magnification. Scale bar = 20µm. 
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Figure 5.26 HSPA protein levels assessed using immunofluorescence in in post hypoxia treated U87-MG cells after 24 h recovery. (1) combined 
nuclei labelled with propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG FITC conjugated secondary antibody (green); 
(2) nuclei staining labelled with propidium iodide (red) and (3) primary antibody HSPA detected with Anti-mouse IgG FITC conjugated antibody 
(green). Objective = x 40 magnification. Scale bar = 20µm. 
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5.4 Flow Cytometry 
 
 
 
 
To accurately quantify production of the protein HSPA in cells, flow cytometry analysis 
was carried out using the same four cell lines for pre- and post-hypoxia conditions as in 
previous sections of this chapter.  Cultured cells were stained and subjected to flow 
cytometry, briefly 1x106 were washed once in 0.1% BSA in PBS before being re- 
suspended in 0.1% Triton X-100 for 15 min.  Following incubation cells were collected 
and washed once with 0.1% BSA in PBS before being blocked in 5% goat serum in 
0.1% BSA in PBS for 30 min.   HSPA primary antibody (1:200) diluted in blocking 
solution was applied for 30 min.  Cells were then washed with 0.1% BSA in PBS and 
light sensitive Anti-Mouse IgG FITC conjugated secondary antibody (1:200) diluted in 
blocking solution was added for 30 min.  Following incubation cells were washed twice 
in 0.1% BSA in PBS before finally being re-suspended in an aliquot 0.1% BSA in PBS 
and filtered into FACS tubes. All incubation steps were performed on ice. 
 
 
 
This analysis showed a higher relative fluorescence intensity in hypoxic 1321N1, GOS- 
 
3 and U87-MG cell lines (approximately 3-fold) compared to NHA, reflecting a higher 
level of production of HSPA protein (Figures 5.28 – 5.32, NHA, 5.33 – 5.37, 1321N1, 
5.38 – 5.42, GOS-3, 5.43 – 5.47, U87-MG).  In pre and post hypoxia treated 1321N1, 
GOS-3 and U87-MG glioma cells, HSPA protein levels were relatively high, with 
approximately 97%, 89% and 97% respectively showing positive for HSPA in pre 
hypoxia treatment, with approximately 99%, 73% and 84% respectively showing 
positive for HSPA in post hypoxia treatment after 0 h recovery,  with approximately 
99%, 92% and 91% respectively showing positive for HSPA in post hypoxia treatment 
after  3  h  recovery  with  approximately 99%,  92%  and  96%  respectively  showing 
positive for HSPA in post hypoxia treatment after 6 h recovery, and approximately 
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94%, 97% and 96% respectively showing positive for HSPA in post hypoxia treatment 
after 24 h recovery compared to the NHA cells showing positive for HSPA pre hypoxia 
treatment approximately 0.10% and post hypoxia treatment after 0 h recovery, 
approximately 33%; after 3 h recovery approximately 31%; after 6 h recovery 
approximately 25% and after 24 h recovery approximately 11% (Figure 5.27 and Table 
5.3). 
 
In GOS-3 and U87-MG glioma cells, hypoxic treatment resulted in a transient decrease 
in HSPA protein at 0 h recovery period from, approximate percentage level: 89 to 73 for 
GOS-3 and from 97 to 84 for U87-MG.   After a three hour recovery period, HSPA 
protein levels increased to pre-hypoxic levels and remained relatively constant up to 24 
h.   HSPA protein synthesis in the NHA cell line reached maximal levels of 
approximately 33% at the 0 h recovery period after hypoxia treatment, followed by a 
progressive decrease in HSPA protein levels up to the 24 h recovery period (Figure 
5.27).  A shift of the HSPA detection peak was observed from 1 x 102 to 1 x 104 in the 
 
NHA cell line (Figures 5.28 – 5.32), however, no such shift was observed in 1321N1, 
GOS-3 and U87-MG glioma cell lines. 
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Cell Line Pre-hypoxia Post-hypoxia (Hours) 
  0 3 6 24 
NHA 0 33.0 30.8 24.7 11.3 
1321N1 97.1 99.6 99.1 99.0 93.6 
GOS-3 89.2 73.4 91.9 92.0 96.6 
U87-MG 96.9 83.7 90.9 96.5 96.3 
 
B 
 
 
 
 
Figure 5.27 Average percentage of cells showing positive for HSPA in pre and post 
hypoxia treatment. (A) Average percentage of normal and glioma cells positive for 
HSPA pre and post hypoxia detected by flow cytometry, considering 10,000 events per 
sample. (B) Histogram showing the mean percentage of cells evaluated by flow cytometry 
of three independent experiments, and the standard deviation from this mean is shown 
by the error bars. No column was shown on the histogram for NHA as the value = 0. 
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5.4.1 Statistical Analysis 
 
A  two-way  factorial  mixed  4  (cell  line:  NHA,  1321N1,  GOS-3,  U87-MG)  x  5 
(treatment: untreated, 0, 3, 6 and 24 h recovery after hypoxia treatment) ANOVA 
analysis of variance test was performed to investigate differences of HSPA protein 
levels. The means and standard deviation are presented in Table 5.3. 
Table 5.3. Descriptive statistics showing the mean HSPA protein levels for untreated 
and treated cell lines. 
 
Treatment Cell Line N Mean HSPA protein 
level 
STD. Deviation 
Pre-hypoxia NHA 3 .13 .058 
1321N1 3 96.87 .322 
GOS-3 3 89.15 .050 
U87-MG 3 96.85 .050 
0 h recovery 
after hypoxia 
treatment 
NHA 3 32.50 .500 
1321N1 3 99.55 .050 
GOS-3 3 73.38 .076 
U87-MG 3 83.6 .100 
3 h recovery 
after hypoxia 
treatment 
NHA 3 30.83 .153 
1321N1 3 99.05 .050 
GOS-3 3 91.85 .050 
U87-MG 3 90.85 .050 
6 h recovery 
after hypoxia 
treatment 
NHA 3 24.72 .126 
1321N1 3 99.03 .061 
GOS-3 3 91.83 .764 
U87-MG 3 96.45 .050 
24 h recovery 
after hypoxia 
treatment 
NHA 3 11.30 .095 
1321N1 3 93.53 .060 
GOS-3 3 96.62 .076 
U87-MG 3 96.33 .058 
 
Overall inspection of the mean scores for HSPA protein levels indicated that untreated 
and treated 1321N1; GOS-3 and U87-MG cell lines were considerably higher than the 
NHA cell line (Table 5.3). 
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There was a significant effect for: cell line [F(15,11.44) = 32736; P < 0.001]; Wilks‘ 
 
Lambda = 0.000, partial eta squared = 1.000; a significant effect for treatment [F(4,5) = 
 
6262.1; P < 0.001], Wilks‘ Lambda = 0.000, partial eta squared = 1.000. There was a 
 
significant effect in the interaction between treatment and cell line, [F(12,13.52) = 
 
5234.5; P < 0.001], Wilks‘ Lambda = 0.000, partial eta squared = 0.999. 
 
 
 
There was a statistically significant main effect for cell lines on the combined variables: 
[F(3,8) = 406583, P < .001]; partial eta squared (ƞp2) = 1.0. 
 
 
 
When the results for the dependent variables were considered separately, there was a 
statistically high significance in untreated [F(3,8) = 239590,  P  < .000]; partial eta 
squared (ƞp2) = 1.000. Post-hoc analyses using Tukey‘s HSD test indicated significantly 
lower HSPA protein levels in untreated NHA than in: 1321N1 (MD = 96.73, P < .05); 
GOS-3 (MD = 89.02, P < .05) and U87-MG (MD = 96.72, P < .05). There was 
significantly lower HSPA protein levels in untreated 1321N1 than in GOS-3 (MD = 
 
7.72, P < .05). There was significantly lower HSPA protein levels in untreated GOS-3 
than in U87-MG (MD = 7.70, P < .05). All other differences between groups failed to 
reach significance (Table 5.4). 
 
There was a statistically high significance after 0 h recovery [F(3,8) = 36603, P < .000]; 
partial eta squared (ƞp2) = 1.000. Post-hoc analyses using Tukey‘s HSD test indicated 
significantly lower HSPA protein levels after 0 h recovery in NHA than in: 1321N1 
(MD = 67.05, P < .05);  GOS-3 (MD = 40.88, P < .05) and U87-MG (MD = 51.10, P < 
 
.05). There were significantly lower HSPA protein levels after 0 h recovery in 1321N1 
than in: GOS-3 (MD = 7.72, P < .05) and U87-MG (MD = 15.95, P < .05). There was 
significantly lower HSPA protein levels after 0 h recovery in GOS-3 than in U87-MG 
(MD = 10.22, P < .05) (Table 5.4). 
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There was a statistically high significance after 3 h recovery [F(3,8) = 392388, P < 
 
.000]; partial eta squared (ƞp2) = 1.000. Post-hoc analyses using Tukey‘s HSD test 
 
indicated significantly lower HSPA protein levels after 3 h recovery in NHA than in: 
 
1321N1 (MD = 68.22, P < .05);  GOS-3 (MD = 61.02, P < .05) and U87-MG (MD = 
 
60.02, P < .05). There were significantly lower HSPA protein levels after 3 h recovery 
in 1321N1 than in: GOS-3 (MD = 7.20, P < .05) and U87-MG (MD = 8.20, P < .05). 
There was significantly lower HSPA protein levels after 3 h recovery in GOS-3 than in 
U87-MG (MD = 1.00, P < .05) (Table 5.4). 
 
There was a statistically high significance after 6 h recovery [F(3,8) = 25196, P < .000]; 
partial eta squared (ƞp2) = 1.000.  Post-hoc analyses using Tukey‘s HSD test indicated 
significantly lower HSPA protein levels after 6 h recovery in NHA than in: 1321N1 
(MD = 74.31, P < .05);  GOS-3 (MD = 67.12, P < .05) and U87-MG (MD = 71.73, P < 
 
.05). There were significantly lower HSPA protein levels after 6 h recovery in 1321N1 
than in: GOS-3 (MD = 7.20, P < .05) and U87-MG (MD = 2.58, P < .05). There was 
significantly lower HSPA protein levels after 6 h recovery in GOS-3 than in U87-MG 
(MD = 4.62, P < .05) (Table 5.4). 
 
There was a statistically high significance after 24 h recovery [F(3,8) = 972016, P < 
 
.000]; partial eta squared (ƞp2) = 1.000. Post-hoc analyses using Tukey‘s HSD test 
 
indicated significantly lower HSPA protein levels after 24 h recovery in NHA than in: 
 
1321N1 (MD = 82.23, P < .05);  GOS-3 (MD = 85.31, P < .05) and U87-MG (MD = 
 
85.03, P < .05). There were significantly lower HSPA protein levels after 24 h recovery 
in 1321N1 than in: GOS-3 (MD = 3.09, P < .05) and U87-MG (MD = 2.80, P < .05). 
There was significantly lower HSPA protein levels after 24 h recovery in GOS-3 than in 
U87-MG (MD = .283, P < .05) (Table 5.4). 
  
 
 
 
 
 
 
Table 5.4. Statistical data from Tukey‘s HSD test showing significance of HSPA protein levels in treated and untreated cell lines. Any differences that 
 
are not significant are highlighted in bold. Significance ≤ 0.05. 
 
 
  NHA 1321N1 GOS-3 U87-MG 
Treatment Cell Line Mean Diff  ± 
STD error 
SIG. Mean Diff  ± 
STD error 
SIG. Mean Diff  ± 
STD error 
SIG. Mean Diff  ± 
STD error 
SIG. 
Untreated NHA   96.73 ± .136 .000 89.02 ± .136 .000 96.72 ±.136 .000 
 1321N1 96.73 ± .136 .000   7.72 ± .136 .000 0.017 ± .136 .999 
 GOS-3 89.02 ± .136 .000 7.72 ± .136 .000   7.70 ± .136 .000 
 U87-MG 96.72 ±.136 .000 0.017 ± .136 .999 7.70 ± .136 .000   
0h recovery NHA   67.05 ± .212 .000 40.88 ± 212 .000 51.1 ± .212 .000 
 1321N1 67.05 ± .212 .000   26.17 ± .212 .000 15.95 ± .212 .000 
 GOS-3 40.88 ± 212 .000 26.17 ± .212 .000   10.22 ± .212 .000 
 U87-MG 51.1 ± .212 .000 15.95 ± .212 .000 10.22 ± .212 .000   
3h recovery NHA   68.21 ± .072 .000 61.02 ± .072 .000 60.02 ± .072 .000 
 1321N1 68.21 ± .072 .000   7.20 ± .072 .000 8.20 ± .072 .000 
 GOS-3 61.02 ± .072 .000 7.20 ± .072 .000   1.0 .072 .000 
 U87-MG 60.02 ± .072 .000 8.20 ± .072 .000 2.0 .072 .000   
6h recovery NHA   74.31 ± .318 .000 67.12 ± .318 .000 71.73 ± .318 .000 
 1321N1 74.31 ± .318 .000   7.20 ± .318 .000 2.58 ± .318 .000 
 GOS-3 67.12 ± .318 .000 7.20 ± .318 .000   4.62 ± .318 .000 
 U87-MG 71.73 ± .318 .000 2.58 ± .318 .000 4.62 ± .318 .000   
12h recovery NHA   82.23 ± .060 .000 85.31 ± .060 .000 85.03 ± .060 .000 
 1321N1 82.23 ± .060 .000   3.09 ± .060 .000 2.80 ± .060 .000 
 GOS-3 85.31 ± .060 .000 3.09 ± .060 .000   .283 ± .060 .007 
 U87-MG 85.03 ± .060 .000 2.80 ± .060 .000 .283 ± .060 .007   
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Figure 5.28 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the NHA cell lines pre hypoxia treatment. No fluorescence intensity was 
observed in the NHA cell line (A, negative, primary antibody omitted and B, sample) 
2D scatter plot showing cell population of interest (P1), (C, negative, D, sample) 
fluorescent intensity histogram showing cells positive (P3) and negative (P2) for HSPA. 
Data  values  are  for  three  independent  experiments  considering  10,000  events  per 
sample. 
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Figure 5.29 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the NHA cell lines post hypoxia treatment after 0 h recovery. Approximately 
33% of NHA cells showed positive for HSPA. (A, negative, primary antibody omitted 
and B, sample) 2D scatter plot showing cell population of interest (P1), (C, negative, D, 
sample) fluorescent intensity histogram showing cells positive (P3) and negative (P2) 
for HSPA. Data values are for three independent experiments considering 10,000 events 
per sample. 
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Figure 5.30 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the NHA cell lines post hypoxia treatment after 3 h recovery. Approximately 
31% of NHA cells showed positive for HSPA. (A, negative, primary antibody omitted 
and B, sample) 2D scatter plot showing cell population of interest (P1), (C, negative, D, 
sample) fluorescent intensity histogram showing cells positive (P5) and negative (P2) 
for HSPA. Data values are for three independent experiments considering 10,000 events 
per sample. 
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Figure 5.31 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the NHA cell lines post hypoxia treatment after 6 h recovery. Approximately 
25% of NHA cells showed positive for HSPA. (A, negative, primary antibody omitted 
and B, sample) 2D scatter plot showing cell population of interest (P1), (C, negative, D, 
sample) fluorescent intensity histogram showing cells positive (P3) and negative (P2) 
for HSPA. Data values are for three independent experiments considering 10,000 events 
per sample. 
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Figure 5.32 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the NHA cell lines post hypoxia treatment after 24 h recovery. Approximately 
11% of NHA cells showed positive for HSPA. (A, negative, primary antibody omitted 
and B, sample) 2D scatter plot showing cell population of interest (P1), (C, negative, D, 
sample) fluorescent intensity histogram showing cells positive (P3) and negative (P2) 
for HSPA. Data values are for three independent experiments considering 10,000 events 
per sample. 
 
. 
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Figure 5.33 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the 1321N1 cell lines pre hypoxia treatment. Approximately 97% of 1321N1 
glioma cells showed positive for HSPA. (A, negative, primary antibody omitted and B, 
sample) 2D  scatter plot showing  cell population of  interest (P1),  (C,  negative, D, 
sample) fluorescent intensity histogram showing cells positive (P3) and negative (P2) 
for HSPA. Data values are for three independent experiments considering 10,000 events 
per sample. 
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Figure 5.34 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels  for  the  1321N1  cell  lines  post  hypoxia  treatment  after  0   h  recovery. 
Approximately 99% of 1321N1 glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.35 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels  for  the  1321N1  cell  lines  post  hypoxia  treatment  after  3   h  recovery. 
Approximately 99% of 1321N1 glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.36 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels  for  the  1321N1  cell  lines  post  hypoxia  treatment  after  6   h  recovery. 
Approximately 99% of 1321N1 glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.37 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the 1321N1 cell lines post hypoxia treatment after 24 h recovery. 
Approximately 94% of 1321N1 glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.38 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the GOS-3 cell lines pre hypoxia treatment. Approximately 89% of GOS-3 
glioma cells showed positive for HSPA. (A, negative, primary antibody omitted and B, 
sample) 2D  scatter plot showing  cell population of  interest (P1),  (C,  negative, D, 
sample) fluorescent intensity histogram showing cells positive (P3) and negative (P2) 
for HSPA. Data values are for three independent experiments considering 10,000 events 
per sample. 
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Figure 5.39 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels   for   the   GOS-3   cell   lines   post   hypoxia   treatment  after   0   h   recovery. 
Approximately 73% of GOS-3 glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.40 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels   for   the   GOS-3   cell   lines   post   hypoxia   treatment  after   3   h   recovery. 
Approximately 92% of GOS-3 glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.41 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels   for   the   GOS-3   cell   lines   post   hypoxia   treatment  after   6   h   recovery. 
Approximately 92% of GOS-3 glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.42 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the GOS-3 cell lines post hypoxia treatment after 24 h recovery. 
Approximately 97% of GOS-3 glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.43 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the U87-MG cell lines pre hypoxia treatment. Approximately 97% of U87- 
MG glioma cells showed positive for HSPA. (A, negative, primary antibody omitted 
and B, sample) 2D scatter plot showing cell population of interest (P1), (C, negative, D, 
sample) fluorescent intensity histogram showing cells positive (P3) and negative (P2) 
for HSPA. Data values are for three independent experiments considering 10,000 events 
per sample. 
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Figure 5.44 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the U87-MG cell lines post hypoxia treatment after 0 h recovery. 
Approximately 84% of U87-MG glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.45 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the U87-MG cell lines post hypoxia treatment after 3 h recovery. 
Approximately 91% of U87-MG glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.46 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the U87-MG cell lines post hypoxia treatment after 6 h recovery. 
Approximately 97% of U87-MG glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Figure 5.47 2D scatter plots and fluorescence intensity histograms of HSPA protein 
levels for the U87-MG cell lines post hypoxia treatment after 24 h recovery. 
Approximately 96% of U87-MG glioma cells showed positive for HSPA. (A, negative, 
primary antibody omitted and B, sample) 2D scatter plot showing cell population of 
interest (P1), (C, negative, D, sample) fluorescent intensity histogram showing cells 
positive (P3) and negative (P2) for HSPA. Data values are for three independent 
experiments considering 10,000 events per sample. 
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Results from this investigation show that HSPA is expressed at low levels in normal 
cells, but is highly expressed in cancer cell lines in pre- and post-hypoxia treatment. The 
average HSPA mRNA copy numbers in the three glioma cell lines for both pre- and 
post-hypoxia treatment were approximately 6 fold higher than the normal cell line. 
 
As with HSPA mRNA, in both pre- and post-hypoxia treatment, high levels of HSPA 
protein were detected in the three glioma cell lines compared to low/barely detectable 
levels in the NHA cell line, indicating a direct correlation between HSPA mRNA and 
HSPA protein levels in glioma cell lines. High fluorescence intensity of HSPA observed 
in 1321N1, GOS-3 and U87-MG cells exposed to hypoxia showed a 3-fold increase 
compared to NHA cell line. 
Again these results suggest that HSPA mRNA and HSPA protein levels in glioma may 
possibly be grade related, and therefore may be useful as a possible prognostic marker. 
 
As expected, given that cancer is a form of cellular stress, HSPA protein was detected in 
both the cytoplasm and the nucleus of the three glioma cell lines under pre and post 
hypoxic conditions. Although HSPA protein was detected mainly in the cytoplasm in 
the normal (NHA) cell line pre-hypoxia, after hypoxia treatment migration of HSPA 
protein to the nucleus was observed. 
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Chapter 6 
 
 
 
 
 
 
Effects of heat shock treatment on 
 
 
 
 
HSPA gene expression in rat 
brain tissue 
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6.1 Gene Expression 
 
 
 
 
HSPA expression is up-regulated in cells in response to heat shock and post-mortem 
conditions. The main research aims of this chapter was to measure and compare HSPA 
expression in normal and heat shocked post-mortem rat brain tissue and to characterise 
the possible “de-novo” expression of HSPA in response to severe heat shock. 
 
Studies were undertaken using post-mortem brain tissue samples from aged-matched 
male Wistar rats (obtained from the Physiology Laboratory, University of Central 
Lancashire). All procedures conformed to the ―UK Animals (Scientific Procedures) Act 
1986‖conforming to the ―Principles of Laboratory Animal Care, 1985‖. 
 
 
Rat brain tissue excised at 0, 3, 6, 12 and 24 h post sacrifice was subjected to mild heat 
shock  at  0  h  time  course  interval.  For  thermotolerance  studies,  brain  tissue  was 
subjected to mild heat shock at 0 h and again at 3, 6 and 24 h time course periods.  Mild 
heat shock was conducted by immersion of the brain tissue, held in sterile 1.5 microfuge 
tubes, into a heated water bath at 42oC for a period of 10 min, after which brain tissue 
samples were stored at room temperature.   Samples weighing approximately 50 mg 
were excised at timed intervals of 0, 3, 6, 12 and 24 h post sacrifice.  Excised samples 
were immediately weighed and snap-frozen by immersion in liquid nitrogen, followed 
by grinding of the tissue to a fine powder using a sterile pestle and mortar, again under 
liquid nitrogen. 
 
 
 
 
 
 
 
mRNA was isolated from post-mortem rat brain tissue, using mRNA Isolation Kit 
(Roche,UK) following the manufacturer‘s protocol. The concentration and purity of 
mRNA was determined by ultraviolet spectrophotometry. Isolated mRNA (100 ng) was 
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transcribed to cDNA using 1st Strand cDNA Synthesis Kit for RT-PCR (AMV) (Roche, 
UK) following the manufacturer‘s protocol, which was then used as a template for qRT- 
PCR.   Quantitative real-time PCR was used to evaluate the expression of HSPA and 
GAPDH as a control using FastStart DNA MasterPLUS SYBR Green 1 (Roche, UK). 
 
Primers used for HSPA were 5‘ GTGTGGAGAGCCAAGAGGAG 3‘ (sense) and 5‘ 
TTTCCAAACTGGATCGAAGG 3‘ (antisense). For GAPDH, primers were 5‘ 
AGACAGCCGCATCTTCTTGT 3‘ (sense) and 5‘ CTTGCCGTGGGTAGAGTCAT 3‘ 
(antisense). All primers were designed using Primer3 software and manufactured by 
TIB MOLBIOL. 
 
After an initial denaturation at 95oC for 10 min, the samples were subjected to 35 cycles 
of RT-PCR 95oC for 10 s, annealing temperature 56oC (HSPA) and 57oC (GAPDH) for 
15 s, and 72oC for 15 s (Patel et al., 2008). At the end of each cycle, the fluorescence 
emitted was measured in a single step in channel F1 (gain1). After the 35th  cycle, the 
specimens were heated to 95oC and rapidly cooled to 65oC for 15 s. All heating and 
cooling  steps  were  performed  with  a  slope  of  20oC  /  s.  The  temperature  was 
subsequently raised to 95oC with a slope of 0.1oC / s and fluorescence was measured 
continuously (channel F1, gain1) to obtain data for the melting curve analysis. All PCR 
reactions were performed in triplicate and a negative control included, which contained 
primers  with  no  DNA.  All  PCR  products were  analysed  using gel  electrophoresis 
stained and visualised using a gel analyser (SynGene, UK). 
 
Expression of HSPA was measured in rat post-mortem brain tissue at post-mortem 
intervals 0, 3, 6, 12 and 24 h and at time course intervals of 0, 3, 6, 12 and 24 h within 
each post-mortem interval. Post sacrifice, the brain was sectioned in two. Half was used 
for control (non-heat shock) and half was subjected to mild heat shock at 0 h time 
course for 10 min at 42oC. 
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The expression of HSPA was also measured in rat post-mortem brain tissue at post- 
mortem intervals 0, 3, 6 and 24 h and at time course intervals of 0, 3, 6 and 24 h within 
each post-mortem interval to access the effect of thermotolerance. Post sacrifice, the 
brain was sectioned in two, and half was used as a control (non-heat shock) and half 
was subjected to mild heat shock at 0 h time course for 10 min at 42oC, and then again 
at 3, 12 and 24 h time course intervals. The brain tissue both control and after heat 
shock at the various post-mortem intervals and time course was used for experiments 
concerning gene expression and immunofluorescence. GAPDH was used as an internal 
standard throughout all RT-PCR experiments (Barber et al., 2005). 
 
 
 
6.2 Constitutive Expression 
 
 
 
6.2.1 Rat Brain tissue 
 
 
 
Transcript copy numbers of HSPA and GAPDH were evaluated using RT-PCR in rat 
post-mortem brain tissue at post-mortem intervals 0, 3, 6, 12 and 24 h and at time 
course intervals of 0, 3, 6, 12 and 24 h within each post-mortem interval, for both 
control (non-heat shock) and mild heat shock treatment samples. The primers and 
optimal temperatures used for the amplification of both genes are documented in Table 
2.10 in section 2.5. All PCR experiments were carried out in triplicate for consistency 
and repeatability. For each gene analysed, a quantification graph was produced to 
confirm gene amplification. The resulting amplicons for HSPA and GAPDH were then 
visualized using agarose gel electrophoresis, when they were represented by bands of 
156 and 265 bp respectively. 
 
 
 
At 0 h and 3 h post-mortem interval at 0, 3, 6, 12 and 24 h time course, heat shocked 
brain tissue contained HSPA transcripts at a higher level compared to that of the non- 
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heat shocked brain tissue (Figure 6.1 and 6.2). At 6 h post-mortem interval HSPA 
transcribed higher in heat shocked brain tissue at time course 0, 3, 12 and 24 h, but 
lower at the 6 h time course than non-heat shocked brain tissue (Figure 6.3). At 12 h 
post-mortem interval HSPA transcribed higher in heat shocked brain tissue at time 
course 0 and 12 h, but lower at the 3, 6 and 24 h time course than non-heat shocked 
brain tissue (Figure 6.4). At 24 h post-mortem interval HSPA transcribed higher in heat 
shocked brain tissue at time course intervals; 0, 3 and 24 h, but lower at the 6 h and 12 h 
time course intervals than non-heat shocked brain tissue (Figure 6.5). 
 
 
 
GAPDH expression level remained relatively consistent throughout each set of 
experiments confirming it as an ideal reference gene (Figures 6.6 – 6.10). 
 
 
 
The mRNA copy number per 100 ng of extracted mRNA for both genes was calculated 
for each time course 0, 3, 6, 12 and 24 h within each post-mortem interval 0, 3, 6, 12 
and 24 h for both non-heat shock and heat shock to monitor the gene expression level. 
mRNA copy numbers confirmed that at: 0 h post-mortem interval, HSPA was expressed 
at a higher level in heat shocked brain tissue at different time course intervals, with 
approximately 21 copies after 0 h recovery, with approximately 52 copies after 3 h 
recovery, with approximately 83  copies after 6 h recovery, with approximately 55 
copies after 12 h recovery and approximately 31 copies after 24 h recovery  compared 
to non-heat shocked brain tissue at different time course intervals, with approximately 
19 copies after 0 h recovery, with approximately 38 copies after 3 h recovery, with 
approximately 55 copies after 6 h recovery, with approximately 36 copies after 12 h 
recovery and approximately 17 copies after 24 h recovery (Figure 6.1 and Table 6.1). 
At 3 h post-mortem interval, HSPA was expressed at a higher level in heat shocked 
brain tissue at different time course intervals, with approximately 58 copies after 0 h 
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recovery, with approximately 53  copies after 3 h recovery, with approximately 15 
copies after 6 h recovery, with approximately 45 copies after 12 h recovery and 
approximately 42 copies after 24 h recovery compared with non-heat shocked brain 
tissue  at  different  time  course  intervals,  with  approximately  17  copies  after  0  h 
recovery, with approximately 37 copies after 3 h recovery, with approximately 9 copies 
after 6 h recovery, with approximately 35 copies after 12 h recovery and approximately 
36 copies after 24 h recovery (Figure 6.2 and Table 6.1). 
 
 
 
 
At 6 h post-mortem interval, HSPA was expressed at a higher level in heat shocked 
brain tissue at different time course intervals, with approximately 19 copies after 0 h 
recovery, with approximately 34  copies after 3 h recovery, with approximately 21 
copies after 12 h recovery and approximately 37 copies after 24 h recovery compared to 
non-heat shocked brain tissue at different time course intervals, with approximately 10 
copies after 0 h recovery, with approximately 12 copies after 3 h recovery, with 
approximately 3 copies after 12 h recovery and approximately 17 copies after 24 h 
recovery. Expression was lower in heat shocked brain tissue after 6 h recovery, 
approximately 9 copies compared to non-heat shocked brain tissue after 6 h recovery, 
approximately 20 copies (Figure 6.3 and Table 6.1). 
 
 
 
At 12 h post-mortem interval, HSPA was expressed at a higher level in heat shocked 
brain tissue at different time course intervals, with approximately 25 copies after 0 h 
recovery  and  approximately  67  copies  after  12  h  recovery  compared  to  non-heat 
shocked brain tissue at different time course intervals, with approximately 18 copies 
after 0 h recovery and approximately 17 copies after 12 h recovery. Expression was 
lower in heat shocked brain tissue at different time course intervals, with approximately 
38 copies after 3 h recovery, with approximately 23 copies after 6 h recovery and 
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approximately 30 copies after 24 h recovery compare to non-heat shocked brain tissue 
at different time course intervals, with approximately 57 copies after 3 h recovery, with 
approximately 65 copies after 6 h recovery and approximately 40 copies after 24 h 
recovery (Figure 6.4 and Table 6.1). 
 
 
 
At 24 h post-mortem interval, HSPA was expressed at a higher level in heat shocked 
brain tissue at different time course intervals, with approximately 25 copies after 0 h 
recovery, with approximately 27  copies after 3 h recovery, with approximately 20 
copies after 6 h recovery and approximately 23 copies after 24 h recovery compare to 
non-heat shocked brain tissue at different time course intervals, with approximately 12 
copies after 0 h recovery, with approximately 2 copies after 3 h recovery, with 
approximately 13 copies after 6 h recovery and approximately 9 copies after 24 h 
recovery. Expression was lower in heat shocked brain tissue after 12 h recovery, 
approximately 4 copies compared to non-heat shocked brain tissue after 12 h recovery, 
approximately 4 copies (Figure 6.5, Table 6.1). 
 
 
 
For GAPDH, mRNA copy numbers per 100 ng of extracted mRNA were relatively 
consistent throughout each PMI, time course in both non-heat shock and heat shocked 
brain tissue, with approximately 268,500 copies for non-heat shock and approximately 
267,300 copies for heat shock, again confirming comparability of HSPA results (Figures 
 
6.6 – 6.10 and Table 6.2). 
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Figure 6.1 Transcription levels of HSPA mRNA in non-heat shock and heat shocked rat 
brain tissue at 0 h PMI. (A) agarose gel electrophoresis: Lane 1 represents the 100 bp 
molecular ladder; lanes 2, 4, 6, 8 and 10 represent amplicons from non-heat shocked rat 
brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively. Lanes 3, 5, 7, 9 
and 11 represent amplicons from heat shocked rat brain tissue at time course intervals of 
0, 3, 6, 12 and 24 h respectively.  (B) Histogram showing HSPA mRNA copy numbers 
for non-heat shock and heat shocked brain tissue at 0, 3, 6, 12 and 24 h time course 
intervals. Data values are the mean of three independent experiments, and the standard 
deviation from this mean is shown by the error bars. 
Control samples show post-mortem effect, as HSPA transcripts increase over time. 
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Figure 6.2 Transcription levels of HSPA mRNA in non-heat shock and heat shocked rat 
brain tissue at 3 h PMI. (A) agarose gel electrophoresis: Lane 1 represents the 100 bp 
molecular ladder; lanes 2, 4, 6, 8 and 10 represent amplicons from non-heat shocked rat 
brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively. Lanes 3, 5, 7, 9 
and 11 represent amplicons from heat shocked rat brain tissue at time course intervals of 
0, 3, 6, 12 and 24 h respectively.  (B) Histogram showing HSPA mRNA copy numbers 
for non-heat shock and heat shocked brain tissue at 0, 3, 6, 12 and 24 h time course 
intervals. Data values are the mean of three independent experiments, and the standard 
deviation from this mean is shown by the error bars. For both non-heat shock and heat 
shocked samples at time course intervals 0, 3 and 6 h no error bars are present as a 0 
value standard deviation was calculated. 
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Figure 6.3 Transcription levels of HSPA mRNA in non-heat shock and heat shocked rat 
brain tissue at 6 h PMI. (A) Agarose gel electrophoresis: Lane 1 represents the 100 bp 
molecular ladder; lanes 2, 4, 6, 8 and 10 represent amplicons from non-heat shocked rat 
brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively. Lanes 3, 5, 7, 9 
and 11 represent amplicons from heat shocked rat brain tissue at time course intervals of 
0, 3, 6, 12 and 24 h respectively.  (B) Histogram showing HSPA mRNA copy numbers 
for non-heat shock and heat shocked brain tissue at 0, 3, 6, 12 and 24 h time course 
intervals. Data values are the mean of three independent experiments, and the standard 
deviation from this mean is shown by the error bars. 
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Figure 6.4 Transcription levels of HSPA mRNA in non-heat shock and heat shocked rat 
brain tissue at 12 h PMI. (A) Agarose gel electrophoresis: Lane 1 represents the 100 bp 
molecular ladder; lanes 2, 4, 6, 8 and 10 represent amplicons from non-heat shocked rat 
brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively. Lanes 3, 5, 7, 9 
and 11 represent amplicons from heat shocked rat brain tissue at time course intervals of 
0, 3, 6, 12 and 24 h respectively.  (B) Histogram showing HSPA mRNA copy numbers 
for non-heat shock and heat shocked brain tissue at 0, 3, 6, 12 and 24 h time course 
intervals. Data values are the mean of three independent experiments, and the standard 
deviation from this mean is shown by the error bars. At 3 h heat shock and 12 h non- 
heat shock no error bars are present as a 0 value standard deviation was calculated. 
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Figure 6.5 Transcription levels of HSPA mRNA in non-heat shock and heat shocked rat 
brain tissue at 24 h PMI. (A) Agarose gel electrophoresis: Lane 1 represents the 100 bp 
molecular ladder; lanes 2, 4, 6, 8 and 10 represent amplicons from non-heat shocked rat 
brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively. Lanes 3, 5, 7, 9 
and 11 represent amplicons from heat shocked rat brain tissue at time course intervals of 
0, 3, 6, 12 and 24 h respectively.  (B) Histogram showing HSPA mRNA copy numbers 
for non-heat shock and heat shocked brain tissue at 0, 3, 6, 12 and 24 h time course 
intervals. Data values are the mean of three independent experiments, and the standard 
deviation from this mean is shown by the error bars. At 3 h non-heat shock and 6 h heat 
shock no error bars are present as a 0 value standard deviation was calculated. 
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Figure 6.6 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 0 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5, 7 and 9 
represent amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 
3, 6, 12 and 24 h respectively. Lanes 2, 4, 6, 8 and 10 represent amplicons from heat 
shocked rat brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively.  (B) 
Histogram showing GAPDH mRNA copy numbers for non-heat shock and heat shocked 
brain tissue at 0, 3, 6, 12 and 24 h time course intervals. Data values are the mean of 
three independent experiments, and the standard deviation from this mean is shown by 
the error bars. 
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Figure 6.7 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 3 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5, 7 and 9 
represent amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 
3, 6, 12 and 24 h respectively. Lanes 2, 4, 6, 8 and 10 represent amplicons from heat 
shocked rat brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively.  (B) 
Histogram showing GAPDH mRNA copy numbers for non-heat shock and heat shocked 
brain tissue at 0, 3, 6, 12 and 24 h time course intervals. Data values are the mean of 
three independent experiments, and the standard deviation from this mean is shown by 
the error bars. 
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Figure 6.8 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 6 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5, 7 and 9 
represent amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 
3, 6, 12 and 24 h respectively. Lanes 2, 4, 6, 8 and 10 represent amplicons from heat 
shocked rat brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively.  (B) 
Histogram showing GAPDH mRNA copy numbers for non-heat shock and heat shocked 
brain tissue at 0, 3, 6, 12 and 24 h time course intervals. Data values are the mean of 
three independent experiments, and the standard deviation from this mean is shown by 
the error bars. 
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Figure 6.9 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 12 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5, 7 and 9 
represent amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 
3, 6, 12 and 24 h respectively. Lanes 2, 4, 6, 8 and 10 represent amplicons from heat 
shocked rat brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively.  (B) 
Histogram showing GAPDH mRNA copy numbers for non-heat shock and heat shocked 
brain tissue at 0, 3, 6, 12 and 24 h time course intervals. Data values are the mean of 
three independent experiments, and the standard deviation from this mean is shown by 
the error bars. 
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Figure 6.10 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 24 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5, 7 and 9 
represent amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 
3, 6, 12 and 24 h respectively. Lanes 2, 4, 6, 8 and 10 represent amplicons from heat 
shocked rat brain tissue at time course intervals of 0, 3, 6, 12 and 24 h respectively.  (B) 
Histogram showing GAPDH mRNA copy numbers for non-heat shock and heat shocked 
brain tissue at 0, 3, 6, 12 and 24 h time course intervals. Data values are the mean of 
three independent experiments, and the standard deviation from this mean is shown by 
the error bars. 
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6.2.2 Statistical Analysis 
 
 
 
A three-way factorial mixed 5 (PMI: 0 h, 3 h, 6 h, 12 h, 24 h) x 2 (treatment: non-heat 
shock, heat shock) x 5 (time course: 0 h, 3 h, 6 h, 12 h, 24 h) ANOVA analysis of 
variance was performed to investigate differences of HSPA and GAPDH transcript copy 
numbers in rat brain tissue. The means and standard deviation are presented in Table 6.1 
(HSPA) and Table 6.2 (GAPDH). 
 
HSPA transcript copy numbers had a significant effect for time course [F(4,17)  = 
 
443.06, P < .05]; Wilks‘ Lambda = 0.010; partial eta squared = 0.990. HSPA transcript 
copy numbers had a significant effect between the interaction of: time course and PMI 
[F(16,52.57) = 77.93; P < .05], Wilks‘ Lambda = 0.000, partial eta squared = 0.914; 
time course and treatment [F(4,17) = 47.30; P < .05], Wilks‘ Lambda = 0.082, partial 
eta squared = 0.918; time course and PMI and treatment [F(16,52.57) = 69.17; P < .05], 
Wilks‘ Lambda = 0.000, partial eta squared = 0.906. 
 
There was a statistically significant main effect in HSPA transcript copy numbers on the 
combined variables for PMI [F(4,20) = 473.82, P < .05]; partial eta squared (ƞp2) = 
0.990; treatment [F(1,20) = 431.83, P < .05]; partial eta squared 0.956 and PMI and 
 
treatment [F(4,20) = 45.76, P < .05]; partial eta squared = 0.901. 
 
 
 
When the results for the dependent variables were considered separately, there was a 
statistical significance in PMI at time course: 0 h [F(4,20) = 208.28, P < .05]; partial eta 
squared = .977; 3 h [F(4,20) = 175.74, P < .05]; partial eta squared = .972; 6 h [F(4,20) 
= 271.82, P < .05]; partial eta squared = .982; 12 h [F(4,20) = 244.31, P < .05]; partial 
eta squared = .980 and 24 h [F(4,20) = 476.20, P < .05]; partial eta squared = .855. 
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There was a statistical significance in treatment at time course: 0 h [F(1,20) = 744.96, P 
 
< .05]; partial eta squared = .973; 3 h [F(1,20) = 124.37, P < .05]; partial eta squared = 
 
.861; 12 h [F(1,20) = 313.15, P < .05]; partial eta squared = .940 and 24 h [F(1,20) = 
 
37.54, P < .05]; partial eta squared = .652. There was a non-significant difference in 
treatment at time course 6 h [F(1,20) = 2.70, P < .05]; partial eta squared = .119. 
 
There was a statistical significance in PMI and treatment at time course: 0 h [F(4,20) = 
 
166.73, P < .05]; partial eta squared = .971; 3 h [F(4,20) = 58.54, P < .05]; partial eta 
squared = .921; 6 h [F(4,20) = 75.95, P < .05]; partial eta squared = .938; 12 h [F(4,20) 
= 59.82, P < .05]; partial eta squared = .923 and 24 h [F(3,20) = 12.33, P < .05]; partial 
eta squared = .712. 
 
An  independent-samples  t-test  was  conducted  to  compare  HSPA  transcript  copy 
numbers estimated marginal mean scores for non-heat shock and heat shock over time 
course by PMI (Figures 6.11 – 6.15). 
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Figure 6.11 Estimated marginal means of HSPA transcript copy numbers at 0 h 
PMI.There was a non-significant difference in HSPA transcript copy numbers at 0 h 
PMI, 0 h time course between non-heat shock (MD = 19.21, SD = .922) and heat shock 
[MD 21.34, SD = 1.41; t(4) = 2.181, P > .05]. There was significantly lower HSPA 
transcript copy numbers at 0 h PMI, 3 h time course in non-heat shock (MD = 37.73, 
SD = .3.32) than heat shock [MD 51.57, SD = .986; t(4) = 6.915, P = .002]. There was 
significantly lower HSPA transcript copy numbers at 0 h PMI, 6 h time course in non- 
heat shock (MD = 54.94, SD = 4.47) than heat shock [MD 83.47, SD = 9.03; t(4) = 
4.903, P = .008]. There was significantly lower HSPA transcript copy numbers at 0 h 
 
PMI, 12 h time course in non-heat shock (MD = 36.23, SD = .572) than heat shock [MD 
 
55.10,  SD  =  1.58;  t(4)  =  19.494,  P  <  .05].  There  was  significantly lower  HSPA 
transcript copy numbers at 0 h PMI, 24 h time course in non-heat shock (MD = 17.40, 
SD = 2.79) than heat shock [MD 31.03, SD = 3.90; t(4) = 4.921, P = .008] (Table 6.1). 
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Figure 6.12 Estimated marginal means of HSPA transcript copy numbers at 3 h PMI. 
There was significantly lower HSPA transcript copy numbers at 3 h PMI, 0 h time 
course in non-heat shock (MD = 16.49, SD = .000) than heat shock [MD 57.96, SD = 
.000]. There was significantly lower HSPA transcript copy numbers at 3 h PMI, 3 h time 
course in non-heat shock (MD = 37.26, SD = .000) than heat shock [MD 52.89, SD = 
.000]. There was a non-significant difference in HSPA transcript copy numbers at 3 h 
PMI, 6 h time course between non-heat shock (MD = 8.83, SD = .000) and heat shock 
[MD 14.93, SD = .000]. There was a non-significant difference in HSPA transcript copy 
numbers at 3 h PMI, 12 h time course between non-heat shock (MD = 34.64, SD = 6.25) 
and heat shock [MD 44.80, SD = 5.08; t(4) = 2.184, P > .05]. There was a non- 
significant difference in HSPA transcript copy numbers at 3 h PMI, 24 h time course 
between non-heat shock (MD = 35.55, SD = 2.29) and heat shock [MD 41.59, SD = 
7.51; t(4) = 1.334, P > .05] (Table 6.1). 
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Figure 6.13 Estimated marginal means of HSPA transcript copy numbers at 6 h PMI. 
There was significantly lower HSPA transcript copy numbers at 6 h PMI, 0 h time 
course in non-heat shock (MD = 10.01, SD = 1.58) than heat shock [MD 19.13, SD = 
2.07; t(4) = 6.058, P = .004]. There was significantly lower HSPA transcript copy 
numbers at 6 h PMI, 3 h time course in non-heat shock (MD = 11.91, SD = .943) than 
heat shock [MD 33.89, SD = 7.37; t(4) = 5.124, P = .034]. There was significantly 
higher HSPA transcript copy numbers at 6 h PMI, 6 h time course in non-heat shock 
(MD = 19.98, SD = 2.25) than heat shock [MD 9.22, SD = 2.95; t(4) = 5.025, P = .007]. 
There was significantly lower HSPA transcript copy numbers at 6 h PMI, 12 h time 
course in non-heat shock (MD = 2.86, SD = .496) than heat shock [MD 20.66, SD = 
.092; t(4) = 81.08,  P  < .05].  There was  significantly lower  HSPA transcript copy 
numbers at 6 h PMI, 24 h time course in non-heat shock (MD = 16.51, SD = 4.91) than 
heat shock [MD 36.96, SD = 6.14; t(4) = 4.503, P = .011]. (Table 6.1) 
numbers at 12 h PMI, 24 h time course in non-heat shock (MD = 39.92, SD = 1.52) than 
heat shock [MD 30.41, SD = 2.77; t(4) = 5.203, P = .007] (Table 6.1). 
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Figure 6.14 Estimated marginal means of HSPA transcript copy numbers at 12 h PMI. 
There was significantly lower HSPA transcript copy numbers at 12 h PMI, 0 h time 
course in non-heat shock (MD = 17.99, SD = .842) than heat shock [MD 24.71, SD = 
1.24; t(4) = 7.775, P = .001]. There was significantly higher HSPA transcript copy 
numbers at 12 h PMI, 3 h time course in non-heat shock (MD = 57.23, SD = 1.01) than 
heat shock [MD 438.31, SD = .167; t(4) = 31.998, P = .001]. There was significantly 
higher HSPA transcript copy numbers at 12 h PMI, 6 h time course in non-heat shock 
(MD = 64.65, SD = .571) than heat shock [MD 22.54, SD = .782; t(4) = 75.276, P < 
.05]. There was significantly lower HSPA transcript copy numbers at 12 h PMI, 12 h 
time course in non-heat shock (MD = 16.49, SD = .000) than heat shock [MD 66.82, SD 
= .295; t(4) = 296.06, P < .05]. There was significantly higher HSPA transcript copy 
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Figure 6.15 Estimated marginal means of HSPA transcript copy numbers at 24 h PMI. 
There was significantly lower HSPA transcript copy numbers at 24 h PMI, 0 h time 
course in non-heat shock (MD = 11.70, SD = 1.02) than heat shock [MD 24.93, SD = 
2.98; t(4) = 7.26,  P  = .002].  There was  significantly lower  HSPA transcript copy 
numbers at 24 h PMI, 3 h time course in non-heat shock (MD = 2.24, SD = .000) than 
heat shock [MD 26.84, SD = 3.23; t(4) = 13.183, P < .05]. There was significantly 
lower HSPA transcript copy numbers at 24 h PMI, 6 h time course in non-heat shock 
(MD = 12.48, SD = 4.51) than heat shock [MD 19.64, SD = .010; t(4) = 2.751, P < .05]. 
There was a non-significant difference in HSPA transcript copy numbers at 24 h PMI, 
12 h time course between non-heat shock (MD = 4.37, SD = 3.69) and heat shock [MD 
4.05, SD = 2.86; t(4) = .118, P > .05]. There was significantly lower HSPA transcript 
copy numbers at 24 h PMI, 24 h time course in non-heat shock (MD = 9.02, SD = 1.95) 
than heat shock [MD 23.43, SD = 1.34; t(4) = 10.56, P < .05] (Table 6.1). 
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For GAPDH transcript copy numbers, had a non-significant effect for time course 
[F(4,17)  =  .270,  P  =  .893];  Wilks‘  Lambda  =  0.940;  partial  eta  squared  =  0.060. 
GAPDH transcript copy numbers had a non-significant effect between the interaction 
of: time course and PMI [F(16,52.57) = .280; P = .996], Wilks‘ Lambda = .779, partial 
eta squared = 0.061; time course and treatment [F(4,17) = 1.235; P = .333], Wilks‘ 
Lambda = 0.775, partial eta squared = 0.225; time course and PMI and treatment 
[F(16,52.57) = .763; P = .717], Wilks‘ Lambda = 0.528, partial eta squared = 0.147. 
 
There was a non-significant effect in GAPDH transcript copy numbers on the combined 
variables for PMI [F(4,20) = .031, P = .998]; partial eta squared (ƞp2) = 0.006; treatment 
[F(1,20) = 1.044, P = .319]; partial eta squared 0..050 and PMI and treatment [F(4,20) = 
.055, P = .994]; partial eta squared = 0.011. 
 
 
 
Post-hoc analyses using Tukey‘s HSD test indicated that all differences failed to reach 
 
significance. 
 
 
 
When the results for the dependent variables were considered separately, there was a 
statistical non-significance in PMI at time course: 0 h [F(4,20) = .250, P = .906]; partial 
eta squared = .048; 3 h [F(4,20) = .293, P = .897]; partial eta squared = .055; 6 h 
[F(4,20) = .200, P = .935]; partial eta squared = .039; 12 h [F(4,20) = .365, P = .831]; 
partial eta squared = .068 and 24 h [F(4,20) = 0.000, P > .05]; partial eta squared = .000. 
 
There was a statistical non-significance in treatment at time course: 0 h [F(1,20) = .783, 
P = .387]; partial eta squared = .038; 3 h [F(1,20) = .150, P = .703]; partial eta squared = 
.007; 6 h [F(1,20) = .769, P = .391]; partial eta squared = .037; 12 h [F(1,20) = .326, P = 
 
.574]; partial eta squared = .016 and 24 h [F(1,20) = 3.71, P = .068]; partial eta squared 
 
= .156. 
308  
There was a statistical non-significance in PMI and treatment at time course: 0 h 
[F(1,20) = .006, P > .05]; partial eta squared = .001; 3 h [F(1,20) = .293, P = .879]; 
partial eta squared = .055; 6 h [F(1,20) = .392, P = .812]; partial eta squared = .073; 12 
h [F(1,20) = .456, P = .767]; partial eta squared = .083 and 24 h [F(1,20) = .942, P = 
.460]; partial eta squared = .159. 
 
 
 
Overall inspection of the mean scores for GAPDH transcript copy numbers indicated no 
significant differences in PMI, time course and treatment (Table 6.2) 
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Table 6.1. Descriptive statistics showing the mean HSPA transcript copy numbers for untreated and treated brain tissue. 
 
 
PMI Treatment N Time Course 
   0 Hour 3 Hour 6 Hour 12 Hour 24 Hour 
   Mean STD 
Dev. 
Mean STD 
Dev. 
Mean STD 
Dev. 
Mean STD 
Dev. 
Mean STD 
Dev. 
0 Hour Non 3 19.21 .923 37.73 3.32 54.94 4.47 36.23 .572 17.40 2.79 
Heat 3 21.34 1.41 51.57 .986 83.47 9.03 55.10 1.58 31.03 3.91 
3 Hour Non 3 16.49 .00 37.26 .00 8.83 .00 34.64 6.25 35.55 2.29 
Heat 3 57.96 .00 52.89 .00 14.93 .00 44.80 5.08 41.59 7.51 
6 Hour Non 3 10.01 1.58 11.91 .943 19.98 2.25 2.86 .497 16.51 4.91 
Heat 3 19.13 2.07 33.90 7.37 9.22 2.95 20.67 .092 36.96 6.14 
12 
 
Hour 
Non 3 17.99 .84 57.23 1.01 64.65 .572 16.49 .00 39.92 1.52 
Heat 3 24.71 1.24 38.31 .167 22.54 .782 66.82 .295 30.41 2.78 
24 
 
Hour 
Non 3 11.70 1.03 2.24 .00 12.48 4.51 4.37 3.69 9.02 1.95 
Heat 3 24.93 2.98 26.84 3.23 19.64 .010 4.05 2.86 23.43 1.34 
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Table 6.2. Descriptive statistics showing the mean GAPDH transcript copy numbers for untreated and treated brain tissue. 
 
 
PMI Treatment N Time Course 
 
0 Hour 3 Hour 6 Hour 12 Hour 24 Hour 
 
Mean STD Dev. Mean STD 
 
Dev. 
Mean STD 
 
Dev. 
Mean STD 
 
Dev. 
Mean STD 
 
Dev. 
 
0 
 
Hour 
 
3 
 
Hour 
 
6 
 
Hour 
 
12 
 
Hour 
 
24 
 
Hour 
Non 3 267595.53 2348.43 264904.33 4036.84 267652.60 7175.04 269709.77 7719.68 270333.27 3140.67 
 
Heat 3 269034.67 8198.82 266945.90 5354.84 268281.23 3116.86 266945.90 5354.84 266239.67 2348.43 
 
Non 3 264904.33 4036.84 269709.77 7719.68 270333.27 3140.67 270333.27 3140.67 266949.90 5354.84 
 
Heat 3 266945.00 5353.81 266945.90 5354.84 269709.77 7719.68 266239.67 2348.43 269709.77 7719.68 
 
Non 3 267595.53 2348.43 269709.77 7719.68 270333.27 3140.67 264904.33 4036.84 270333.27 3140.67 
 
Heat 3 269709.772 7719.68 266945.90 5354.84 266239.67 2348.43 266945.90 5354.84 266239.67 2348.43 
 
Non 3 267595.43 2348.34 264904.33 4036.84 267652.60 7175.04 269709.77 7719.68 270333.27 3140.67 
 
Heat 3 269034.67 8198.82 266945.90 5354.84 268281.23 3116.86 266945.90 5354.84 266239.67 2348.43 
 
Non 3 267595.53 2348.43 269709.77 7719.68 270333.27 3140.67 264904.33 4036.84 270333.27 3140.67 
 
Heat 3 269709.77 7719.68 266945.90 5354.84 266239.67 2348.43 266945.90 5354.84 266239.67 2348.43 
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Table 6.3. Statistical data from Tukey‘s HSD test showing significance of HSPA 
 
transcript copy numbers between PMI. Any significant differences P ≤ 0.05 are 
 
highlighted in bold. 
 
 
(I) PMI J (PMI) Mean Difference (I – J) Std. Error Sig. 
0 3 6.31 .793 .000 
6 22.69 .793 .000 
12 2.90 .793 .012 
24 26.93 .793 .000 
3 6 16.38 .793 .000 
12 3.41 .793 .003 
24 20.62 .793 .000 
6 12 19.79 .793 .000 
24 4.24 .793 .000 
12 24 24.04 .793 .000 
 
 
 
 
 
Post-hoc analyses using Tukey‘s HSD test indicated significantly lower HSPA transcript 
copy numbers in 0 h PMI than in: 3 h PMI (MD = 6.31, P < .05); 6 h PMI (MD = 22.69, 
P < .05); 12 h PMI (MD = 0.012, P < .05) and 24 h PMI (MD = 26.93, P < .05). There 
was significantly lower HSPA transcript copy numbers in 3 h PMI than in: 6 h PMI 
(MD = 16.38, P < .05); 12 h PMI (MD = 3.41, P = .003) and 24 h PMI (MD = 20.62, P 
< .05). There was significantly lower HSPA transcript copy numbers in 6 h PMI than in: 
 
12 h PMI (MD = 19.79, P < .05) and 24 h PMI (MD = 4.24, P < .05). There was 
significantly lower HSPA transcript copy numbers in 3 h PMI than in: 6 h PMI (MD = 
16.38, P < .05); 12 h PMI (MD = 3.41, P = .003) and 24 h PMI (MD = 20.62, P < .05). 
There was significantly lower HSPA transcript copy numbers in 12 h PMI than in 24 h 
PMI (MD = 24.04, P < .05) (Table 6.3). 
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6.2.3 Rat Brain tissue - thermotolerance 
 
 
 
Expression of HSPA and GAPDH in thermotolerant tissue was evaluated using RT-PCR 
in rat post-mortem brain tissue, at post-mortem intervals of 0, 3, 6 and 24 h and at time 
course intervals of 0, 3, 6 and 24 h within each post-mortem interval for both control 
(non-heat shock) and mild heat shock treated samples. The primers and optimal 
temperatures used for the amplification of both genes are documented in Table 2.10 in 
section 2.5. All PCR experiments were carried out in triplicate for consistency and 
repeatability. For each gene analysed, a quantification graph was produced to confirm 
gene amplification. The resulting amplicons for HSPA and GAPDH were then analysed 
using agarose gel electrophoresis, represented by bands of 156 and 265 bp respectively. 
 
 
 
At 3 h, 6 and 24 h post-mortem interval at 0, 3, 6 and 24 h time course, heat shocked 
brain tissue transcribed HSPA at a higher level compared to that of the non-heat shocked 
brain tissue (Figure 6.17, 6.18 and 6.19). At 0 h post-mortem interval HSPA transcribed 
higher in heat shocked brain tissue at time course 0, 3 and 6 h, but lower at the 24 h 
time course than non-heat shocked brain tissue (Figure 6.17). 
 
 
 
GAPDH expression level remained relatively consistent throughout each PMI, time 
course and non-heat shock and heat shocked brain tissue confirming it as an ideal 
reference gene (Figures 6.20 – 6.23). 
 
The mRNA copy number per 100 ng of extracted mRNA for both genes was calculated 
for each time course 0, 3, 6 and 24 h within each post-mortem interval 0, 3, 6 and 24 h 
for both non-heat shock and heat shock to monitor the gene expression level.  mRNA 
copy numbers confirmed that at: 0 h post-mortem interval, HSPA was expressed at a 
higher  level  in  heat  shocked  brain  tissue  at  different  time  course  intervals;  with 
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approximately 13 copies after 0 h recovery, with approximately 19 copies after 3 h 
recovery and approximately 4 copies after 6 h recovery compare to non-heat shocked 
brain tissue at different time course intervals; with approximately 2 copies after 0 h 
recovery, approximately 2 copies after 3 h recovery and approximately 16 copies after 6 
h recovery. Expression was lower in heat shocked brain tissue after 24 h recovery, 
approximately 19 copies compare to non-heat shocked brain tissue after 24 h recovery, 
approximately 19 copies (Figure 6.16). 
 
 
 
At 3 h post-mortem interval, HSPA was expressed at a higher level in heat shocked 
brain tissue at different time course intervals; with approximately 37 copies after 0 h 
recovery, with approximately 20  copies after 3 h recovery, with approximately 59 
copies after 6 h recovery and approximately 20 copies after 24 h recovery compared to 
non-heat shocked brain tissue at different time course intervals; with approximately 2 
copies after 0 h recovery, with approximately 10 copies after 3 h recovery, with 
approximately 19 copies after 6 h recovery and approximately 19 copies after 24 h 
recovery (Figure 6.17). 
 
 
 
At 6 h post-mortem interval, HSPA was expressed at a higher level in heat shocked 
brain tissue at different time course intervals; with approximately 130 copies after 0 h 
recovery, with approximately 167 copies after 3 h recovery, with approximately 66 
copies after 6 h recovery and approximately 63 copies after 24 h recovery compare to 
non-heat shocked brain tissue at different time course intervals; with approximately 30 
copies after 0 h recovery, with approximately 47 copies after 3 h recovery, with 
approximately 50 copies after 6 h recovery and approximately 46 copies after 24 h 
recovery (Figure 6.18). 
314 
 
At 24 h post-mortem interval, HSPA was expressed at a higher level in heat shocked 
brain tissue at different time course intervals; with approximately 51 copies after 0 h 
recovery, with approximately 59  copies after 3 h recovery, with approximately 66 
copies after 6 h recovery and approximately 121 copies after 24 h recovery compared to 
non-heat shocked brain tissue at different time course intervals; with approximately 44 
copies after 0 h recovery, with approximately 31 copies after 3 h recovery, with 
approximately 43 copies after 6 h recovery and approximate 59 copies after 24 h 
recovery (Figure 6.19). 
 
 
 
GAPDH expression level remained relatively consistent throughout each PMI, time 
course in both non-heat shock and heat shocked brain tissue again confirming 
comparability of HSPA results (Figures 6.20 – 6.23). 
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Figure 6.16 Transcription levels of HSPA mRNA in non-heat shock and heat shocked 
rat brain tissue at 0 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5 and 7 represent 
amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 3, 6 and 
24 h respectively. Lanes 2, 4, 6 and 8 represent amplicons from heat shocked rat brain 
tissue at time course intervals of 0, 3, 6 and 24 h respectively.  (B) Histogram showing 
HSPA mRNA copy numbers for non-heat shock and heat shocked brain tissue at 0, 3, 6 
and 24 h time course intervals. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. At 0, 
3 and 6 h non-heat shock no error bars are present as a 0 value standard deviation was 
calculated. 
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Figure 6.17 Transcription levels of HSPA mRNA in non-heat shock and heat shocked 
rat brain tissue at 3 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5 and 7 represent 
amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 3, 6 and 
24 h respectively. Lanes 2, 4, 6 and 8 represent amplicons from heat shocked rat brain 
tissue at time course intervals of 0, 3, 6 and 24 h respectively.  (B) Histogram showing 
HSPA mRNA copy numbers for non-heat shock and heat shocked brain tissue at 0, 3, 6 
and 24 h time course intervals. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. At 0 
h  non-heat  shock  no  error  bars  are  present  as  a  0  value  standard  deviation  was 
calculated. 
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Figure 6.18 Transcription levels of HSPA mRNA in non-heat shock and heat shocked 
rat brain tissue at 6 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5 and 7 represent 
amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 3, 6 and 
24 h respectively. Lanes 2, 4, 6 and 8 represent amplicons from heat shocked rat brain 
tissue at time course intervals of 0, 3, 6 and 24 h respectively.  (B) Histogram showing 
HSPA mRNA copy numbers for non-heat shock and heat shocked brain tissue at 0, 3, 6 
and 24 h time course intervals. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. 
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Figure 6.19 Transcription levels of HSPA mRNA in non-heat shock and heat shocked 
rat brain tissue at 24 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5 and 7 
represent amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 
3, 6 and 24 h respectively. Lanes 2, 4, 6 and 8 represent amplicons from heat shocked 
rat brain tissue at time course intervals of 0, 3, 6 and 24 h respectively.  (B) Histogram 
showing HSPA mRNA copy numbers for non-heat shock and heat shocked brain tissue 
at 0, 3, 6 and 24 h time course intervals. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. 
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Figure 6.20 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 0 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5 and 7 represent 
amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 3, 6 and 
24 h respectively. Lanes 2, 4, 6 and 8 represent amplicons from heat shocked rat brain 
tissue at time course intervals of 0, 3, 6 and 24 h respectively.  (B) Histogram showing 
HSPA mRNA copy numbers for non-heat shock and heat shocked brain tissue at 0, 3, 6 
and 24 h time course intervals. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. 
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Figure 6.21 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 3 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5 and 7 represent 
amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 3, 6 and 
24 h respectively. Lanes 2, 4, 6 and 8 represent amplicons from heat shocked rat brain 
tissue at time course intervals of 0, 3, 6 and 24 h respectively.  (B) Histogram showing 
HSPA mRNA copy numbers for non-heat shock and heat shocked brain tissue at 0, 3, 6 
and 24 h time course intervals. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. 
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Figure 6.22 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 6 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5 and 7 represent 
amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 3, 6 and 
24 h respectively. Lanes 2, 4, 6 and 8 represent amplicons from heat shocked rat brain 
tissue at time course intervals of 0, 3, 6 and 24 h respectively.  (B) Histogram showing 
HSPA mRNA copy numbers for non-heat shock and heat shocked brain tissue at 0, 3, 6 
and 24 h time course intervals. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. 
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Figure 6.23 Transcription levels of GAPDH mRNA in non-heat shock and heat shocked 
rat brain tissue at 24 h PMI. (A) Agarose gel electrophoresis: Lane 1, 3, 5 and 7 
represent amplicons from non-heat shocked rat brain tissue at time course intervals of 0, 
3, 6 and 24 h respectively. Lanes 2, 4, 6 and 8 represent amplicons from heat shocked 
rat brain tissue at time course intervals of 0, 3, 6 and 24 h respectively.  (B) Histogram 
showing HSPA mRNA copy numbers for non-heat shock and heat shocked brain tissue 
at 0, 3, 6 and 24 h time course intervals. Data values are the mean of three independent 
experiments, and the standard deviation from this mean is shown by the error bars. 
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6.2.4 Statistical Analysis 
 
 
 
A three-way factorial mixed 4 (PMI: 0 h, 3 h, 6 h, 24 h) x 2 (treatment: non-heat shock, 
heat shock) x 4 (time course: 0 h, 3 h, 6 h, 24 h) ANOVA analysis of variance was 
performed to investigate differences of HSPA and GAPDH transcript copy numbers in 
rat brain tissue. The means and standard deviation are presented in Table 6.4 (HSPA) 
and Table 6.5 (GAPDH). 
 
HSPA transcript copy numbers had a significant effect for time course [F(3,14)  = 
 
108.67, P < .05]; Wilks‘ Lambda = 0.041; partial eta squared = 0.959. HSPA transcript 
copy numbers had a significant effect between the interaction of: time course and PMI 
[F(9,34.22) = 146.62; P < .05], Wilks‘ Lambda = 0.000, partial eta squared = 0.949; 
time course and treatment [F(3,14) = 50.74; P < .05], Wilks‘ Lambda = 0.084, partial 
eta squared = 0.916; time course and PMI and treatment [F(9,34.22) = 167.44; P < .05], 
Wilks‘ Lambda = 0.000, partial eta squared = 0.954. 
 
There was a statistically significant main effect in HSPA transcript copy numbers on the 
 
combined variables for PMI [F(3,16) = 1809.72, P < .05]; partial eta squared (ƞp2) = 
 
0.997; treatment [F(1,16) = 1982.83, P < .05]; partial eta squared 0.992 and PMI and 
treatment [F(3,16) = 265.01, P < .05]; partial eta squared = 0.980. 
 
When the results for the dependent variables were considered separately, there was a 
statistical significance in PMI at time course: 0 h [F(3,16) = 680.86, P < .05]; partial eta 
squared = .992; 3 h [F(3,16) = 726.52, P < .05]; partial eta squared = .993; 6 h [F(3,16) 
= 759.73, P < .05]; partial eta squared = .993 and 24 h [F(3,16) = 2291.07, P < .05]; 
 
partial eta squared = .998. 
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There was a statistical significance in treatment at time course: 0 h [F(1,16) = 942.42, P 
 
< .05]; partial eta squared = .983; 3 h [F(1,16) = 695.39, P < .05]; partial eta squared = 
 
.978; 6 h [F(1,16) = 817.26, P < .05]; partial eta squared = .981 and 24 h [F(1,16) = 
 
789.92, P < .05]; partial eta squared = .980. 
 
 
 
There was a statistical significance in PMI and treatment at time course: 0 h [F(3,16) = 
 
299.93, P < .05]; partial eta squared = .983; 3 h [F(3,16) = 241.46, P < .05]; partial eta 
squared = .978; 6 h [F(3,16) = 55.22, P < .05]; partial eta squared = .912 and 24 h 
[F(3,16) = 424.45, P < .05]; partial eta squared = .988. 
 
An  independent-samples  t-test  was  conducted  to  compare  HSPA  transcript  copy 
numbers estimated marginal mean scores for non-heat shock and heat shock over time 
course by PMI (Figures 6.24 – 6.27). 
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Figure 6.24 Estimated marginal means of HSPA transcript copy numbers at 0 h PMI. 
There was significantly lower in HSPA transcript copy numbers at 0 h PMI, 0 h time 
course in non-heat shock (MD = 2.24, SD = .00) than heat shock [MD 12.80, SD = 
1.98; t(4) = 9.258, P = .001]. There was significantly lower HSPA transcript copy 
numbers at 0 h PMI, 3 h time course in non-heat shock (MD = 2.24, SD = .00) than heat 
shock [MD 19.20, SD = 0.526; t(4) = 55.90, P < .05]. There was significantly lower 
HSPA transcript copy numbers at 0 h PMI, 6 h time course in non-heat shock (MD = 
2.24, SD = .00) than heat shock [MD 15.75, SD = 3.67; t(4) = 6.38, P = .024]. There 
was a non-significant difference in HSPA transcript copy numbers at 0 h PMI, 24 h time 
course between non-heat shock (MD = 19.31, SD = 0.84) and heat shock [MD 18.99, 
SD = 1.23; t(4) = 0.372, P = .729] (Table 6.4). 
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Figure 6.25 Estimated marginal means of HSPA transcript copy numbers at 3 h PMI. 
There was significantly lower HSPA transcript copy numbers at 3 h PMI, 0 h time 
course in non-heat shock (MD = 2.24, SD = .00) than heat shock [MD 36.51, SD = 
.647; t(4) = 91.80,  P  < .05].  There was  significantly lower  HSPA transcript copy 
numbers at 3 h PMI, 3 h time course in non-heat shock (MD = 10.21, SD = 1.03) than 
heat shock [MD 19.97, SD = 1.07; t(4) = 11.40, P < .05]. There was significantly lower 
HSPA transcript copy numbers at 3 h PMI, 6 h time course in non-heat shock (MD = 
19.01, SD = .811) than heat shock [MD 59.30, SD = .785; t(4) = 61.80, P < .05]. There 
was a non-significant difference in HSPA transcript copy numbers at 3 h PMI, 24 h time 
course between non-heat shock (MD = 18.82, SD = .438) and heat shock [MD 19.90, 
SD = 1.70; t(4) = 1.06, P = .388] (Table 6.4). 
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Figure 6.26 Estimated marginal means of HSPA transcript copy numbers at 6 h PMI. 
There was significantly lower HSPA transcript copy numbers at 6 h PMI, 0 h time 
course in non-heat shock (MD = 30.08, SD = 2.30) than heat shock [MD 129.81, SD = 
7.59;  t(4)  =  21.79,  P  <.05].  There  was  significantly lower  HSPA  transcript  copy 
numbers at 6 h PMI, 3 h time course in non-heat shock (MD = 47.45, SD = 2.07) than 
heat shock [MD 167.39, SD = 10.83; t(4) = 18.84, P = .002]. There was significantly 
lower HSPA transcript copy numbers at 6 h PMI, 6 h time course in non-heat shock 
(MD = 50.44, SD = 2.19) than heat shock [MD 66.48, SD = .878; t(4) = 11.79, P < .05]. 
There was significantly lower HSPA transcript copy numbers at 6 h PMI, 24 h time 
course in non-heat shock (MD = 45.89, SD = 1.01) than heat shock [MD 62.57, SD = 
1.91; t(4) = 13.41, P = .001] (Table 6.4). 
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Figure 6.27 Estimated marginal means of HSPA transcript copy numbers at 24 h PMI. 
There was significantly lower HSPA transcript copy numbers at 24 h PMI, 0 h time 
course in non-heat shock (MD = 44.06, SD = 0.583) than heat shock [MD 51.47, SD = 
2.45; t(4) = 5.093, P = .029]. There was significantly lower HSPA transcript copy 
numbers at 24 h PMI, 3 h time course in non-heat shock (MD = 30.86, SD = 2.49) than 
heat shock [MD 58.71, SD = 1.03; t(4) = 17.88, P < .05]. There was significantly lower 
HSPA transcript copy numbers at 24 h PMI, 6 h time course in non-heat shock (MD = 
42.65, SD = 1.85) than heat shock [MD 65.68, SD = 2.82; t(4) = 11.82, P = .001]. There 
was significantly lower HSPA transcript copy numbers at 24 h PMI, 24 h time course in 
non-heat shock (MD = 58.90, SD = 3.06) than heat shock [MD 120.73, SD = 2.14; t(4) 
= 28.71, P < .05] (Table 6.4). 
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For GAPDH transcript copy numbers had a non-significant effect for time course 
[F(3,14)  =  .163,  P  =  .920];  Wilks‘  Lambda  =  0.966;  partial  eta  squared  =  0.034. 
GAPDH gene expression had a non-significant effect between the interaction of: time 
course and PMI [F(9,34.22) = .367; P = .943], Wilks‘ Lambda = .799, partial eta 
squared = 0.072; time course and treatment [F(3,14) = 1.020; P = .413], Wilks‘ Lambda 
= 0.821, partial eta squared = 0.179; time course and PMI and treatment [F(9,34.22) = 
 
.766; P = .717], Wilks‘ Lambda = 0.648, partial eta squared = 0.138. 
 
 
 
There was a non-significant effect in GAPDH transcript copy numbers on the combined 
variables for PMI [F(3,16) = .085, P = .967]; partial eta squared (ƞp2) = 0.016; treatment 
[F(1,16) = 0.672, P = .424]; partial eta squared 0.040 and PMI and treatment [F(3,16) = 
.313, P = .815]; partial eta squared = 0.056. 
 
 
 
Post-hoc analyses using Tukey‘s HSD test indicated that all differences failed to reach 
 
significance. 
 
 
 
When the results for the dependent variables were considered separately, there was a 
statistical non-significance in PMI at time course: 0 h [F(3,16) = .336, P = .800]; partial 
eta squared = .059; 3 h [F(3,16) = .224, P = .879]; partial eta squared = .040; 6 h 
[F(3,16) = .259, P = .854]; partial eta squared = .046 and 24 h [F(3,16) = 0.00, P > .05]; 
partial eta squared = .000. 
 
There was a statistical non-significance in treatment at time course: 0 h [F(1,16) = .719, 
P = .409]; partial eta squared = .043; 3 h [F(1,16) = .378, P = .547]; partial eta squared = 
.023; 6 h [F(1,16) = 1.244, P = .281]; partial eta squared = .072 and 24 h [F(1,16) = 
 
2.022, P = .174]; partial eta squared = .112. 
 
 
 
There was a statistical non-significance in PMI and treatment at time course: 0 h 
 
[F(3,16) = .005, P = > .999]; partial eta squared = .001; 3 h [F(3,16) = .224, P = .879]; 
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partial eta squared.040; 6 h [F(3,16).435,  P.731]; partial eta squared.075 and 
 
24 h [F(3,16)1.050, P.398]; partial eta squared.164. 
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Table 6.4. Descriptive statistics showing the mean HSPA transcript copy numbers for untreated and treated brain tissue. 
 
 
PMI Treatment N Time Course 
   0 Hour 3 Hour 6 Hour 24 Hour 
   Mean STD 
Dev. 
Mean STD 
Dev. 
Mean STD 
Dev. 
Mean STD 
Dev. 
0 Hour Non 3 2.24 .00 2.24 .00 2.24 .00 19.31 .837 
Heat 3 12.80 1.98 19.20 .526 15.75 3.67 18.99 1.24 
3 Hour Non 3 2.24 .00 10.21 1.03 19.02 .811 18.82 .437 
Heat 3 36.51 .647 19.97 1.07 59.30 .785 19.90 1.70 
6 Hour Non 3 30.08 2.30 47.45 2.07 50.44 2.19 45.89 1.01 
Heat 3 129.81 7.59 167.39 10.83 66.48 .878 62.57 1.91 
24 
 
Hour 
Non 3 44.06 .583 30.86 2.49 42.65 1.85 58.90 3.06 
Heat 3 51.47 2.45 58.71 1.03 65.68 2.82 120.76 2.14 
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Table 6.5. Descriptive statistics showing the mean GAPDH transcript copy numbers for untreated and treated brain tissue. 
 
 
PMI Treatment N Time Course 
 
0 Hour 3 Hour 6 Hour 24 Hour 
 
Mean STD 
 
Dev. 
Mean STD 
 
Dev. 
Mean STD 
 
Dev. 
Mean STD 
 
Dev. 
 
0 Hour Non 3 267595.53 2348.43 264904.33 4036.84 267652.60 7175.04 270333.27 3140.67 
 
Heat 3 269034.67 8198.82 266945.90 5354.84 268281.23 3116.86 266239.67 2348.43 
 
3 Hour Non 3 264904.33 4036.84 269709.77 7719.68 270333.27 3140.67 266945.90 5354.84 
 
Heat 3 266945.00 5353.81 266945.90 5354.84 269709.77 7719.68 269709.77 7719.68 
 
6 Hour Non 3 267595.53 2348.43 269709.77 7719.68 270333.27 3140.67 270333.27 3140.67 
 
Heat 3 269709.77 7719.68 266945.90 5354.84 266239.67 2348.43 266239.67 2348.43 
 
24 
 
Hour 
Non 3 267595.53 2348.43 269709.77 7719.68 270333.27 3140.67 270333.27 3140.67 
 
Heat 3 269709.77 7719.68 266945.90 5354.84 266239.67 2348.43 266239.67 2348.43 
 
 
 
 
Overall inspection of the mean scores for GAPDH transcript copy numbers indicated no significant differences in PMI, time course and treatment 
 
(Table 6.5) 
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Table 6.6. Statistical data from Tukey‘s HSD test showing significance of HSPA 
 
transcript copy numbers between PMI. Any significant differences  P ≤ 0.05 are 
 
highlighted in bold. 
 
 
(I) PMI J (PMI) Mean Difference (I – J) Std. Error Sig. 
0 3 11.65 .990 .000 
6 63.42 .990 .000 
24 47.54 .990 .000 
3 6 51.77 .990 .000 
24 35.89 .990 .000 
6 24 35.89 .990 .000 
 
 
Post-hoc analyses using Tukey‘s HSD test indicated significantly lower HSPA transcript 
copy numbers in 0 h PMI than in: 3 h PMI (MD = 11.65, P < .05); 6 h PMI (MD = 
63.42, P < .05) and 24 h PMI (MD = 47.54, P < .05). There was significantly lower 
 
HSPA transcript copy numbers in 3 h PMI than in: 6 h PMI (MD = 51.77, P < .05) and 
 
24 h PMI (MD = 35.90, P < .05). There was significantly lower HSPA transcript copy 
numbers in 6 h PMI than in: 24 h PMI (MD = 15.88, P < .05) (Table 6.6). 
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6.3     Immunofluorescence 
 
 
Under normal conditions HSPA protein in cells is localized in the cytoplasm, however 
under conditions of stress HSPA migrates to the nucleus. Immunofluorescence detection 
staining was carried out utilising a monoclonal primary HSPA antibody to identify the 
presence and localization of HSPA protein in post-mortem rat brain tissue for any 
comparable differences between control (unstressed) and under heat shock (stressed) 
conditions. 
 
The tissue sections were initially fixed in freshly made 4% Paraformaldehyde (w/v) in 
PBS (0.1 M) for 15 min at room temperature, following which the excess 
paraformaldehyde was removed.   The fixed tissue sections were permeabilized using 
Trypsin (0.025%) in aqueous calcium chloride (CaCl2) (0.1%, pH 7.8) and incubated for 
45 min at 37oC, then washed three times in warm PBS (0.1M).  The sections were then 
 
incubated in blocking solution (0.1% PBS, 0.5% Tween 20, 0.1% Goat serum) for 30 
min at room temperature, followed by overnight incubation at 4oC in the primary 
antibody for HSPA (Anti-Hsp70 antibody [BRM-22], Abcam,UK, dilution 1:200) to 
allow the antibody to bind and for permitted saturation to take place.  After overnight 
incubation, the sections were washed with PBS three times for 5 min and incubated in a 
light sensitive Anti-mouse IgG FITC (Fluorescein Isothiocyanate) conjugated secondary 
detection antibody (Goat polyclonal Secondary Antibody to Mouse IgG - H&L FITC, 
Abcam, UK, dilution 1:200) diluted in blocking solution for 1 h at room temperature. 
The secondary antibody was removed followed by three consecutive washes with warm 
PBS (0.1 M). The sections were mounted under a cover slip using VECTASHIELD PI 
(0.01 M) (Propidium Iodide, Vector, USA) mounting medium. The tissue sections were 
then examined and images recorded using an Axiovert 200 LSM 510 laser scanning 
confocal microscope (Carl Zeiss, USA).    Negative control cells from each sample 
335  
encountered identical preparations for immunofluorescence staining, except that the 
primary antibody was omitted. 
 
 
 
 
 
 
 
HSPA antigens detected using an Anti-mouse IgG FITC conjugated secondary antibody 
were identified in the non-heat shock brain tissue, at 0 h post-mortem interval: in the 
cytoplasm at 0, 3 and 24 h time course, predominantly in the cytoplasm with a little 
fluorescence emitted from the nucleus at 6 h time course and in both cytoplasm and 
nucleus at 12 h time course (Figure 6.28). At 3 h post-mortem interval fluorescence was 
emitted: in the cytoplasm at 0 h time course and predominantly in the cytoplasm with a 
little fluorescence emitted from the nucleus at 3, 6, 12 and 24 h time course (Figure 
6.29). At 6 h post-mortem interval fluorescence was emitted: in both the cytoplasm and 
nucleus at 0, 3 and 6 h time course and predominantly in the cytoplasm with a little 
fluorescence emitted from the nucleus at 12 and 24 h time course (Figure 6.30). At 12 h 
post-mortem interval fluorescence was emitted: in both the cytoplasm and nucleus at 0 h 
time course and predominantly in the cytoplasm with a little fluorescence emitted from 
the nucleus at 3, 6, 12 and 24 h time course (Figure 6.31). At 24 h post-mortem interval 
fluorescence was emitted predominantly in the cytoplasm with a little fluorescence 
emitted from the nucleus at 0, 3, 6, 12 and 24 h time course (Figure 6.32). 
In heat shocked brain tissue HSPA protein was detected in both the cytoplasm and the 
nucleus for each time course 0, 3, 6, 12 and 24 h for each post-mortem interval 0, 3, 6, 
12 and 24 h (Figures 6.33 – 6.37). 
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Figure 6.28 HSPA protein levels assessed using immunofluorescence in non-heat 
shocked rat brain tissue, PMI 0 h. (1) 0 h time course (2) 3 h time course (3) 6 h time 
course (4) 12 h time course (5) 24 h time course showing combined staining of nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti- 
mouse   IgG   FITC   conjugated   secondary   antibody   (green)   Objective   =   x   40 
magnification. Scale bar = 20µm. 
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Figure 6.29 HSPA protein levels assessed using immunofluorescence in non-heat 
shocked rat brain tissue, PMI 3 h. (1) 0 h time course (2) 3 h time course (3) 6 h time 
course (4) 12 h time course (5) 24 h time course showing combined staining of nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti- 
mouse IgG FITC conjugated secondary antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
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Figure 6.30 HSPA protein levels assessed using immunofluorescence in non-heat 
shocked rat brain tissue, PMI 6 h. (1) 0 h time course (2) 3 h time course (3) 6 h time 
course (4) 12 h time course (5) 24 h time course showing combined staining of nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti- 
mouse IgG FITC conjugated secondary antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
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Figure 6.31 HSPA protein levels assessed using immunofluorescence in non-heat 
shocked rat brain tissue, PMI 12 h. (1) 0 h time course (2) 3 h time course (3) 6 h time 
course (4) 12 h time course (5) 24 h time course showing combined staining of nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti- 
mouse IgG FITC conjugated secondary antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
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Figure 6.32 HSPA protein levels assessed using immunofluorescence in non-heat 
shocked rat brain tissue, PMI 24 h. (1) 0 h time course (2) 3 h time course (3) 6 h time 
course (4) 12 h time course (5) 24 h time course showing combined staining of nuclei 
labelled with propidium iodide (red) and primary antibody HSPA detected with Anti- 
mouse IgG FITC conjugated secondary antibody (green). Objective = x 40 
magnification. Scale bar = 20µm. 
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Figure 6.33 HSPA protein levels assessed using immunofluorescence in heat shocked 
rat brain tissue, PMI 0 h. (1) 0 h time course (2) 3 h time course (3) 6 h time course (4) 
12 h time course (5) 24 h time course showing combined staining of nuclei labelled with 
propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG 
FITC conjugated secondary antibody (green). Objective = x 40 magnification. Scale bar 
= 20µm. 
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Figure 6.34 HSPA protein levels assessed using immunofluorescence in heat shocked 
rat brain tissue, PMI 3 h. (1) 0 h time course (2) 3 h time course (3) 6 h time course (4) 
12 h time course (5) 24 h time course showing combined staining of nuclei labelled with 
propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG 
FITC conjugated secondary antibody (green). Objective = x 40 magnification. Scale bar 
= 20µm. 
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Figure 6.35 HSPA protein levels assessed using immunofluorescence in heat shocked 
rat brain tissue, PMI 6 h. (1) 0 h time course (2) 3 h time course (3) 6 h time course (4) 
12 h time course (5) 24 h time course showing combined staining of nuclei labelled with 
propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG 
FITC conjugated secondary antibody (green). Objective = x 40 magnification. Scale bar 
= 20µm. 
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Figure 6.36 HSPA protein levels assessed using immunofluorescence in heat shocked 
rat brain tissue, PMI 12 h. (1) 0 h time course (2) 3 h time course (3) 6 h time course (4) 
12 h time course (5) 24 h time course showing combined staining of nuclei labelled with 
propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG 
FITC conjugated secondary antibody (green). Objective = x 40 magnification. Scale bar 
= 20µm. 
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Figure 6.37 HSPA protein levels assessed using immunofluorescence in heat shocked 
rat brain tissue, PMI 24 h. (1) 0 h time course (2) 3 h time course (3) 6 h time course (4) 
12 h time course (5) 24 h time course showing combined staining of nuclei labelled with 
propidium iodide (red) and primary antibody HSPA detected with Anti-mouse IgG 
FITC conjugated secondary antibody (green). Objective = x 40 magnification. Scale bar 
= 20µm. 
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Results from this investigation show that HSPA is expressed at low levels in normal 
brain tissue, but is highly expressed in brain tissue subjected to mild heat shock. In the 
non–heat shocked brain tissue, low level expression of HSPA was observed in the 0 h post- 
mortem interval at 0 h time course, followed by a gradual increase up to the 6 h time course 
interval,  returning back to near basal levels at the 24 h time course interval . HSPA expression 
gradually decreased at 3 and 6 h post-mortem intervals however, HSPA transcripts 
substantially increased at the 12  h  post-mortem interval.  At  the 24  h post-mortem 
interval HSPA transcripts were only present at low levels, below the initial basal levels 
observed at 0 h post-mortem 0 h time course interval. A higher level of HSPA expression 
was observed in samples taken at 0 h post-mortem that had been subjected to heat shock, 
compared to non-heat shock at each time course interval. HSPA transcripts were observed in 
the 0 h post-mortem interval at 0 h time course, followed by a gradual increase up to the 
6 h time course interval, returning back to near basal levels at the 24 h time course 
interval. At 3 post-mortem, HSPA transcripts expressed high at 0 h time course with a 
gradual decline up to the 24 h time course. HSPA expression gradually decreased at 6 h 
post-mortem,  however,  as  with  non-heat  shock,  HSPA  transcripts  substantially 
increased at 12 h post-mortem. Again as with non-heat shock, HSPA transcripts were 
only present at low levels at the 24 h post-mortem interval, below or near to the initial 
basal levels observed at 0 h post-mortem 0 h time course interval. 
 
The levels of HSPA transcripts in brain tissue that had been subjected to a mild heat 
shock, the first at 0 h time course followed by subsequent heat shocks at 3, 6 and 24 h 
time course intervals, showed a marked increase in HSPA expression in heat shocked 
brain tissue compared to non-heat shock within each post-mortem interval. 
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As expected,  given that post-mortem  and mild heat shock is a form of cellular stress, 
HSPA protein was detected in both the cytoplasm and the nucleus in all tissue samples 
at each post-mortem interval for both non-heat shock and heat shocked samples. 
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Discussion 
349  
7.1. Discussion 
 
 
 
7.1.1   Chapter 3 results 
 
 
 
 
The target genes chosen for this study, Homo sapiens and Rattus norvegicus HSPA, 
both members of the heat shock protein family, are induced in response to various 
physiological and environmental stress conditions, or in response to certain diseases, 
such as cancer (Garrido et al., 2006; Jolly and Morimoto, 2000; Lindquist, 1986; 
Morimoto, 1993; Powers et al, 2009). 
 
 
 
As discussed in chapter 3, section 3.3, the HSPA gene family contains three well 
characterized members: HSPA1A, HSPA1B and HSPA1L, which are located within the 
major histocompatibilty complex class III region (MHC-III). In the human genome, 
they are located on the short arm of chromosome 6 (6p21.3), while in the rat genome, 
they are located on the short arm of chromosome 20 (20p12) (Milner and Campbell, 
1990;  Sargent  et  al,  1989a;  Sargent  et  al,  1989).  Although  they  contain  similar 
nucleotide sequences, these three genes differ in their regulation. HSPA1L has no 
associated regulatory heat shock consensus sequence and is constitutively expressed at 
low levels, and is also induced by heat shock (Milner and Campbell, 1990). Therefore, 
this gene was excluded for the purposes of this study. Both HSPA1A and HSPA1B have 
been shown to encode identical protein products with 100% homology, and the genes 
also show 90% homology between their nucleotide sequences. Both have been shown to 
be expressed at high levels after heat shock, but only HSPA1A has been shown to be 
constitutively expressed at low levels (Milner and Campbell, 1990). After running a 
BLAST  analysis  for  HSPA1A  and  HSPA1B  and  for  the  designed  primers,  results 
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indicated that both genes will be amplified at the same position and of the same product 
length for the designed primers (Appendix 9.26 and 9.27). 
 
 
 
Studies have shown that, across a wide range of both human and rat tissues, the 
molecular integrity of 28S and 18S ribosomal RNAs and of some specific gene 
transcripts, such a s interleukin-1β (IL-1β), can persist under post-mortem conditions for 
up to periods of 148 h in brain tissue (Inoue et al, 2002), making brain a suitable tissue 
for the purposes of this study. The molecular integrity of RNA is thus shown to be 
unlikely to change significantly in the early post-mortem period, up to 148 h in human 
and rat brain tissue, allowing the opportunity to elicit de novo gene expression of the 
HSPA gene in response to mild heat shock. Due to difficulties in obtaining post-mortem 
human brain tissue, rat brain tissue was chosen as an alternative source of tissue, and 
this was readily accessible from the Physiology Laboratory of this University. Sequence 
homology  comparison  between  human  and  rat  genes  for  HSPA  indicated  73% 
homology between these two species for HSPA gene sequences and 96% homology for 
HSPA amino acid sequences, which also indicates that the rat is a comparable species to 
humans for the purposes of this study. 
 
 
 
Primers for both Homo sapiens and Rattus norvegicus HSPA genes were designed using 
Primer 3 software. Melting curve analysis produced during RT-PCR showed only one 
defined peak indicating specific binding of primers to HSPA. This was confirmed by 
visualizing the resultant amplicons by agarose gel electrophoresis. Visualization of the 
amplicons showed  the presence of a single band of the required product size. No 
primer-dimers or degradation were observed. 
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The choice of an appropriate internal standard is critical for quantitative protein and 
RNA analyses. Housekeeping genes are normally expressed in all cells and their 
expression levels should remain relatively constant under different experimental 
conditions. There is no single housekeeping gene that possesses stable expression levels 
under all experimental conditions. Therefore, it was necessary to characterize the 
suitability of any housekeeping gene chosen as an internal RNA control under particular 
experimental  conditions  where  transcription  effects  are  being  tested.  The  chosen 
internal standard for this study was Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), a housekeeping gene which encodes a glycolytic enzyme that possesses 
diverse functions that are independent of its role in glycolysis (Said et al, 2009, 2007; 
Sirover, 1999). GAPDH is a multifunctional enzyme reportedly over-expressed in many 
tumours and malignant cells (Said et al, 2009, 2007). 
 
 
Literature has shown that GAPDH expression is regulated by a variety of different 
factors such as insulin (Nasrin et al, 1990); calcium (Chao et al, 1990) and hypoxia 
(Graven et al, 1994).  The transcription factor hypoxia-inducible factor-1 alpha (HIF-1 
α), which regulates the expression of genes involved in glucose supply, growth, 
metabolism, redox reactions and blood supply, is undetectable under normoxic 
conditions because it undergoes rapid ubiquitination and proteosomal degradation 
(Rapisarda et al, 2002).  Hypoxia, which is the inadequate delivery of oxygen to tissue 
causes an imbalance between oxygen demand and energy supply, results in the 
transcription of HIF-1  regulated hypoxia induced genes (Cangul, 2004; Said et al, 
2007). A number of the proteins encoded by these genes are involved in adaptive 
responses to hypoxia, such as angiogenesis, erythropoiesis, cell proliferation and cell 
survival (Said et al, 2007; Schmid et al, 1998). It has been suggested that GAPDH 
expression is regulated as a consequence of the hypoxic development of the cellular 
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environment in vitro and that GAPDH mRNA expression was regulated during hypoxic 
events (Graven et al, 1994; Graven and Farber, 1998; Said et al, 2005; Zhong and 
Simons, 1999). 
 
 
There are two types of hypoxia: transient and chronic hypoxia. Transient hypoxia is a 
temporary reduction in oxygen availability. The inadequate vascular geometry relative 
to the volume of oxygen-consuming tumour cells creates diffusion-limited oxygen 
delivery, resulting in chronic hypoxia (Greco et al, 2003). The synthesis of HIF-1 is up- 
regulated in response to hypoxia. In general, tumours often contain hypoxic regions, 
since tumour vasculature is dysfunctional and unable to meet the metabolic needs of 
rapidly proliferating cancer cells (Hanahan and Folkman, 1996). The extent of hypoxic 
regions in a tumour tissue depends on the arrangement, blood flow rate and blood 
oxygen content of microvessels, and on the tissue's oxygen consumption rate (Said et al, 
2007). 
 
 
 
 
Studies undertaken by Said et al, (2007, 2009) compared the expression of GAPDH 
with 18S RNA in relation to HIF-1α under different oxygen concentrations of severe 
hypoxia, normoxia and re-oxygenation in human glioblastoma, low-grade astrocytoma 
and normal brain tissue samples, together with human glioblastoma cell lines. These 
results did not indicate any correlation between hypoxia induced HIF-1α protein over- 
expression and GAPDH regulation on mRNA and protein level in vitro in human 
glioblastoma cell lines. GAPDH was not significantly regulated under hypoxic 
conditions in a panel of human tumour cell lines in vitro, and the expression of the HIF- 
1 gene was not altered after substitution of the GAPDH by the 18S RNA band (Said et 
al, 2005). Extended studies by Said et al, (2009) indicated significant mRNA over- 
expression of known hypoxia-regulated genes in glioblastoma, compared to low-grade 
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astrocytoma (Said et al, 2007). It can be suggested that from these studies that the 
regulation of GAPDH mRNA synthesis as a response to the hypoxic development in the 
tumour cell environment in vitro and in vivo occurs as a cell-specific post- 
transcriptionally regulated event and that there is no hypoxia-dependent regulation of 
GAPDH in astrocytic tumours in vivo. It can therefore be concluded that GAPDH is a 
suitable reference gene for studies in normal and tumour brain tissue and cell lines 
under hypoxic conditions. 
 
 
 
Results described in chapter 4 for GAPDH showed that mRNA copy numbers were 
relatively consistent in NHA (approximately 146,500 copies per sample) 1321N1, 
(approximately 144,500 copies per sample), GOS-3, (approximately 147,500 copies per 
sample) and U87-MG, (approximately 147,500 copies per sample), confirming the 
routine comparability of HSPA results (Table 4.1). For GAPDH, mRNA copy numbers 
were relatively consistent in all brain tissue samples, at approximately 143,700 copies 
per sample), again confirming the relative comparability of HSPA results (Figure 4.3 
and Table 4.6). 
 
 
 
Results described in chapter 5 for GAPDH showed that mRNA copy numbers were 
relatively consistent in NHA-, (approximately 148,300 copies per sample), 1321N1, 
(approximately 147,400 copies per sample), GOS-3, (approximately 147,400 copies per 
sample) and U87-MG, (approximately 147,300 copies per sample), again confirming 
the relative comparability of HSPA results (Figure 5.2 and Table 5.1). 
One of the most important technical considerations in this study was the quality of the 
isolated mRNA. Cellular mRNA is less stable than DNA due to the ubiquitous nature 
and stability of RNases compared with DNases, and so RNA is more susceptible to 
spontaneous degradation. In addition to the intrinsic RNases already present in cells and 
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tissues, samples may become contaminated by RNases from other sources, such as 
bench surfaces and laboratory equipment, and therefore rigorous laboratory procedures 
for aseptic technique were required. During this study, contaminating RNase activity 
was precluded by careful preparation of reagents, aseptic handling of samples and use of 
equipment. During this study only RNase free pipette tips, microfuge tubes and RNase 
free water was used and all equipment was pre-treated with RNase-Zap, a commercial 
surface decontamination solution that destroys RNases on contact (Sigma, UK), prior to 
use. 
 
 
 
mRNA isolated from NHA, 1321N1, GOS-3 and U87-MG cell lines and rat brain tissue 
samples showed little or no degradation or contamination. The overall A260 / A280 value 
for isolated mRNA ranged between 1.8 – 2.0 in the cell lines and 1.6 – 1.8 in the brain 
tissue samples, which was deemed acceptable for the purpose of this study. 
 
 
 
The  primary  and  secondary  antibodies  used  for  flow  cytometry  and 
immunofluorescence were obtained from Abcam, UK. The primary antibody 
Monoclonal Anti-Heat Shock Protein 70 (HSP70) reacts specifically with HSP70 and 
recognizes brain HSP70 in both human and rat. Immunofluorescent staining using this 
antibody has demonstrated a rapid and reversible accumulation of the HSP70 protein 
within the nucleus of heat-stressed (42°C, 1 hr.) human fibroblasts (Morimoto, 1998). 
 
 
 
The secondary antibody Goat polyclonal Secondary Antibody to Mouse IgG - H&L 
FITC, was recommended by Abcam. No dilution factor was recommended for either 
antibody, and following a number of pilot trials with different dilutions, 1:200 (1 µl of 
antibody in 200 µl of blocking solution was the most efficient and gave the best results. 
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This study had six main objectives: 
 
1.   To characterize the level of HSPA expression in normal human cell lines and 
normal human brain tissue compared to glioma cell lines and tumourous brain 
tissue. 
2.   To characterize the level of HSPA transcription in response to hypoxia in normal 
and glioma cell lines. 
3.   To characterize the level of HSPA transcription in post-mortem brain tissue. 
 
4.   To characterize the level of HSPA transcription in response to heat shock applied 
to the brain tissue in the early post-mortem period. 
5.   To characterize the level of HSPA transcription in response to multiple heat 
shocks applied to the brain tissue in the early post-mortem period. 
6.   Validate if HSPA can be used as an early post-mortem marker. 
 
 
 
 
7.1.2   Chapter 4 and 5 results 
 
 
 
 
HSPA is expressed at low levels in normal cells and tissues, but its expression is highly 
induced by cancer.  The results from this study show that HSPA is expressed at high 
levels in pre and post hypoxia treated glioma cells.  The average HSPA mRNA copy 
numbers in the three glioma cell lines were approximately 6 fold higher than the normal 
cell line and the average HSPA mRNA copy numbers in glioblastoma tissue were 
approximately 1.8 and 9 fold higher than in the low grade glioma and normal tissues, 
respectively. In cancer, HSPA expression is induced to assist the stabilization of native 
proteins (Rohde et al, 2005).  On the other hand, HSPA mRNA levels in the untreated 
NHA cells were relatively low in comparison to hypoxia treated cells. This is in 
agreement with previous reports such as Rohde et al, (2005), where significantly higher 
expression was reported in cancer tissue in comparison to normal tissue, supporting the 
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notion that the increased expression of HSPA is associated with cellular stress (Rohde et 
al, 2005). 
 
 
 
Although prolonged exposure to extreme stress conditions can result in cell and tissue 
death, induction of heat shock protein synthesis can afford cytoprotection and stress 
tolerance against stress-induced molecular damage.  Heat shock protein synthesis is 
induced by numerous stress stimuli resulting in the accumulation of non-native proteins. 
 
 
 
The heat shock response in mammalian cells involves the activation of heat shock factor 
 
1 (HSF1) in response to the presence of non-native proteins which require the action of 
molecular chaperones.   HSF1 is present in both stressed and unstressed cells. In 
unstressed cells HSF1 is found in the cytoplasm as an inert monomer bound to HSPA 
and therefore does not show any transcriptional activity.  In a stressed state when non- 
native proteins are detected, HSF1 translocates to the nucleus and oligomerises into a 
trimer that becomes inducibly phosphorylated and binds to the heat shock element 
upstream of the HSPA gene, resulting in stress-induced transcription (Santoro, 2000). 
 
 
 
Given that cancer is a form of cellular stress, it is to be expected that HSPA protein 
should be observed in both the cytoplasm and the nucleus of glioma and normal cell 
lines under pre and post hypoxic conditions.  Although HSPA protein was detected 
mainly in the cytoplasm in the normal cell line, after hypoxia treatment, migration of 
HSPA to the nucleus was observed.   Increased synthesis of heat shock proteins to a 
level proportional to that of non-native proteins results in  HSPA  relocating to the 
nucleus  and  binding  to  the  HSF1  transcriptional  transactivation  domain,  thereby 
blocking transcription of heat shock genes (Santoro, 2000). 
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As mentioned previously, HSPA is expressed at low levels in normal cells and tissues, 
but its expression is highly induced by cancer. Results from this study showed that 
HSPA is highly expressed at mRNA levels in pre and post hypoxia treated glioma cells. 
The average HSPA mRNA copy numbers in the three glioma cell lines were 
approximately 6 fold higher than the normal cell line in both pre- and post-hypoxia 
treatment. In glioma cancerous cells, HSPA is induced to assist the stabilization of 
native proteins in an effort to maintain its functionality (Rhode et al, 2005).   On the 
other hand, HSPA mRNA levels in the untreated NHA cells were relatively low in 
comparison to hypoxic cells.   A previous citation, Rohde et al, (2005), reported a 
significantly higher expression in breast cancer tissue in comparison to normal, 
supporting the notion that the increased expression of HSPA is associated with stress 
(Rhode et al, 2005) 
 
 
 
High fluorescence intensity of HSPA observed in 1321N1, GOS-3 and U87-MG cells 
exposed to hypoxia showed a 3-fold increase compared to NHA cells, which suggests 
that hypoxia can activate HSF1 in many cell types, resulting in an increased expression 
of HSPA.  Production of heat shock proteins in response to hypoxia depends on the cell 
type.   In some endothelial cells, such as human microvascular (HMEC1), HSPA 
expression in response to hypoxia is down-regulated (Oehler et al, 2000).  In contrast, 
HSPA expression is up-regulated in human hepatoma (HEP G2) (Patel et al, 1995) and 
human proximal tubular epithelial cells (Turman et al, 1997). 
 
 
 
In neoplasms, HSPA expression has been associated in the regulation of apoptosis as a 
modulator of p53 function in the immune response against tumours and multidrug 
resistance (Ciocca et al, 1993; Soussi and Lozano, 2005).  Increased HSPA expression 
enhances the resistance of cells to apoptosis which elevates immunity due to their 
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highly immunogenic properties.   Thus, during carcinogenesis, the expression of heat 
shock proteins will be altered in many tumour types (Schmitt et al, 2007).   High 
expression  levels  of  HSPA  protein  were  detected  in  the  cytoplasm  of  bladder 
carcinomas,  but  no  correlation  was  found  between  the  expression  level,  grade  of 
tumour, disease phase and patient outcome (Lebret et al, 2003). 
 
 
 
Glioblastoma patient  survival  rate  is  considerably short,  as  indicated in  Table  4.5 
section 4.2.3.  The survival period of patients from diagnosis to death ranged between 8 
to 12 months with only one patient exceeding this period.  The sample size used in this 
study indicating survival period across the patient sample data range is too small to 
make any significant conclusion.  Future studies need to be undertaken using a larger 
sample base to include a larger variance of survival rate together with a wider ranger of 
cancer grade.  However, from this initial study, the notion that expression of HSPA 
appears to be grade related is consistent with the results obtained in Figure 4.5. 
 
 
 
Results from this part of the study showed that HSPA was similarly expressed at high 
levels in all three glioma cells lines in vitro, (Figure 4.1) however in the human brain 
tissue samples HSPA was predominantly expressed in malignant astrocytomas in vivo 
especially in gliomablastomas (Figure 4.2), the most aggressive and phenotypically 
transformed of the gliomas. Although the resulys indicated an apparent grade related 
expression in the human brain tissue samples, this was not replicated in the three glioma 
cells lines. A possible explantation for this is that in vitro (cell lines) experiments, in 
cellular biology, are conducted outside of the organisms which do not correspond to the 
same conditions inside the organism (in vivo) which may lead to results that do not 
correspond to the same situation that arises in a living organism. For example, in vivo, 
tumour cells can release a variety of degradative enzymes, and enhanced proteolytic 
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activity which has been associated with tumour growth, angiogenesis and invasiveness 
 
(Yamamoto et al, 1996). 
 
 
 
 
Significant differences were shown in HSPA mRNA expression levels between normal 
and the three glioma cells (Table 4.2), however no differences were observed at the 
protein level (Table 4.9), indicating that the level of HSPA protein did not directly 
correlate with the level of HSPA mRNA, suggesting HSPA expression in the glioma cell 
lines might be regulated either at the transcriptional level by a mechanism governing 
message stability or at the posttranscriptional level. 
 
 
 
Although heat shock protein levels are not informative as diagnostic markers, they are 
useful biomarkers for carcinogenesis in some tissues (Ciocca and Calderwood, 2005). 
The high levels of HSPA expression detected in the majority of glioblastoma tissues, 
compared to low grade gliomas and normal tissues, may be taken as an indicator of its 
potential use as a biomarker for carcinogenesis in glioma.   Elevated levels of HSPA 
have  been  related  to  malignancy,  metastasis,  poor  prognosis  and  resistance  to 
therapeutic strategies, including chemotherapy or radiation in glioblastoma, breast, 
bladder, endometrial and cervical carcinomas (Piura et al, 2002; Syrigos et al, 2003; 
Thanner et al, 2003).  In contrast, a high level of HSPA expression has been associated 
with good prognosis in melanoma, pancreatic and renal carcinomas (Ricaniadis et al, 
2001; Sagol et al, 2002; Santarosa et al, 1997), suggesting possible tissue specificity. 
 
 
 
 
Previous studies have shown that silencing of HSPA isoforms produces variable effects 
on cell viability, depending on the cell line used.  Furthermore, silencing of one isoform 
heat shock cognate 70 (HSPA8/HSC70) leads to concurrent induction of the other 
isoform heat shock protein 72 (HSPA/HSP72) in glioblastoma, colon and ovarian cancer 
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cell lines (Powers et al, 2008). By silencing the HSPA isoforms, heat shock protein 90 
(HSPC1a/HSP90) function was modulated and also induced apoptosis in cancer cells. 
HSPC1a/HSP90 inhibition has been a promising target for cancer inhibition over the last 
decade.  Thus, it can be postulated that a multi-target approach should be adopted 
modulating HSPA and HSPC1a/HSP90 function, for the future (Powers et al, 2009). 
 
 
 
BAG1 and HSPA protein synthesis is up-regulated during the early post-mortem period 
(up to 4 hours) (Curcio et al, 2006; Torres et al, 2004).  In cases of unexplained deaths 
one of the most important factors is accurate and precise determination of time since 
death, referred to as the post-mortem interval (PMI).   Various methods are currently 
employed to determine PMI: temperature measurements post-mortem, biochemical 
markers and post-mortem muscle proteolysis (relaxation of muscles following rigor 
mortis).  In many types of cancers, HSPA expression becomes dysregulated, resulting in 
elevated levels under stress conditions; furthermore, HSPA protects cancer cells from 
apoptosis (Calderwood, 2005).  As HSPA1A protein is up-regulated in diseases such as 
cancer, Alzheimer‘s and Parkinson‘s disease (Petrucelli et al, 2004), in order to use 
HSPA as an early post-mortem marker, the possible disease of the tissue also needs to 
be considered as a potential parameter. 
 
 
 
7.1.3   Chapter 6 results 
 
 
 
 
This part of the study had three main phases.  Firstly, RNA was extracted from post- 
mortem rat brain tissue following post-mortem intervals of 0, 3, 6, 12 and 24 h at 
subsequent time course intervals of 0, 3, 6, 12 and 24 h, to determine when expression 
of HSPA was induced to characterise the persistence of HSPA transcripts in cells and as 
an indicator of de novo expression in these post mortem samples.  The second part of 
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the study characterised the level of transcription in response to post-mortem cellular 
changes, and in response to heat shock applied to the rat brain tissue at 0 h time course 
interval within each post-mortem interval. The third part of this study characterised the 
levels of transcription in response to post-mortem cellular changes, and as a result of 
heat shock applied to the rat brain tissue at 0 h, and then again at 3, 6 and 24 h time 
course intervals within each post-mortem interval. 
 
 
In the initial part of the study, it was determined that HSPA gene transcripts were 
present at each post-mortem interval (0, 3, 6, 12 and 24 h), which supported findings 
from previous literature (Blake et al, 1989; Inoue et al, 2002; Pardue et al, 2007). Low 
level expression of HSPA was observed in the 0 h post-mortem interval at 0 h time 
course (copy number 19.21 ± .923), followed by a gradual increase up to the 6 h time 
course interval (copy number 54.94 ± 4.47) and then returning to near basal levels at the 
24 h time course interval (copy number 17.40 ± 2.79). No HSPA expression was 
expected at the 0 h time course interval, as HSPA is only induced by stress conditions, 
but, the low levels of HSPA transcripts may have resulted from induced stress during 
the initial sacrifice procedure of the rat and during the subsequent excision of the brain. 
As expected, HSPA expression gradually decreased at 3 and 6 h post-mortem intervals. 
However, HSPA transcripts substantially increased at the 12 h post-mortem interval by 
approximately 2 fold at 0 h time course, 6 fold at 3 h time course, 3 fold at 6 h time 
course, 3 fold at 12 h time course and 2.5 fold at 24 h time course.  At the 24 h post- 
mortem interval HSPA transcripts were only present at low levels, below the initial 
basal levels observed at 0 h post-mortem 0 h time course interval. 
 
 
 
In the second stage of this study, the levels of HSPA transcripts in brain tissue that had 
been subjected to a mild heat shock at the 0 h time course interval within each post- 
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mortem interval were compared to HSPA transcript levels in the non-heat shocked brain 
tissue.    There  was  an  increased  level  of  HSPA  expression  following  heat  shock, 
although maximum levels of expression were seen at different time points through the 
post mortem period used in experiments. Maximum expression was observed at: 6 h 
within 0 h PMI; at 0 h within 3 h PMI; 24 h within 6 h PMI; 12 h within 12 h PMI and 3 
h within 24 PMI. Under non-heat shock conditions, HSPA transcripts were observed in 
the 0 h post-mortem interval at 0 h time course (copy number 21.34 ± 1.41), followed 
by a gradual increase up to the 6 h time course interval (copy number 83.47 ± 9.03) 
returning back to near basal levels at the 24 h time course interval (copy number 31.03 
±3.90). At the 3 post-mortem, HSPA transcripts expressed high at 0 h time course (copy 
number 57.96 ± .00) with a gradual decline up to the 24 h time course (copy number 
41.59 ± 7.51). HSPA expression gradually decreased at the 6 h post-mortem interval, 
but as with non-heat shock, HSPA transcripts substantially increased at the 12 h post- 
mortem interval by approximately: 1.25 fold at 0 h time course, 1.25 fold at 3 h time 
course, 2 fold at 6 h time course, 3 fold at 12 h time course and 0 fold at 24 h time 
course. Again, as with non-heat shock, HSPA transcripts were only present at low levels 
at the 24 h post-mortem interval, below or near to the initial basal levels observed at 0 h 
post-mortem 0 h time course interval. 
 
 
 
In the third stage of this study, the levels of HSPA transcripts in brain tissue that had 
been subjected to a mild heat shock, the first at 0 h time course followed by subsequent 
heat shocks at 3, 6 and 24 h time course intervals, where accessed to determine whether 
the application of subsequent heat shocks would increase HSPA expression in a 
thermotolerant state.  In all cases there was a marked increase in HSPA expression in 
heat shocked brain tissue compared to non-heat shock. This phenomenon, known as 
thermotolerant preconditioning, is a cellular adaptation resulting from a single severe 
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non-lethal exposure to heat that allows cells to better survive subsequent potentially 
lethal heat stress episodes, and has been reported previously (Lindquist and Craig, 1988; 
Moseley, 1997; Pardue et al, 2007; Theodorakis and Morimoto, 1987; Theodorakis et 
al, 1999; Tolson and Roberts, 2005). The characteristics for thermotolerance are 
dependent on survival of the cell(s) exposed to an otherwise lethal heat stress, synthesis 
of heat shock proteins and a short duration of the thermotolerant state (Moseley, 1997). 
The response of cells to such stress conditions is dependent on the concentration of 
HSPA in the cell prior to stress and on the severity of the stress, based upon its intensity 
and duration (Lindquist and Craig, 1988; Mosser and Morimoto, 2004; Parsell and 
Lindquist, 1994). 
 
 
 
HSPA is constitutively expressed under normal conditions and inducibly in response to 
cellular stress (Lindquist 1986).   Under normal conditions, HSPA is constitutively 
expressed at relatively low but constant levels. Under conditions of stress, such as death 
or heat shock, weak hydrogen and van der Waals forces that hold cellular proteins in 
their  conformational  shape  become  weakened,  resulting  in  protein  denaturation, 
incorrect protein aggregation and mis-folding of newly synthesized proteins (Hartl and 
Hayer-Hartl, 2002; Nollen and Morimoto, 2002). Under such conditions, HSPA genes 
are induced in order to protect proteins and enhance cell survival (Calderwood et al, 
2006; Mosser and Morimoto 2004; Powers et al, 2009). In addition to the above, HSPA 
plays a strong part in cytoprotection, allowing cells to adapt and to survive under hostile 
or otherwise lethal conditions (Calderwood et al, 2006; Mosser and Morimoto 2004; 
Parcellier et al, 2003; Powers et al, 2009). 
 
 
 
The induction of HSPA production in response to stress conditions involves an increase 
in active heat shock factor 1 (HSF1) which is released from HSPA during an initial 
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stress, and subsequently binds to the heat shock element (HSE) in the HSPA gene 
promoter region (Fernandes et al, 1994; Morimoto et al, 1994; Wu et al, 1994,). 
Inducible transcription of the HSPA gene requires the de novo binding of the HSE by a 
heat shock transcription factor 1 (HSF1) protein, which is ubiquitously synthesised and 
plays a major role in the stress induced expression of the HSPA genes (de Thonel et al, 
2011). HSPA synthesis is regulated at the transcriptional level by the heat shock factor 1 
(HSF1) which assists, not only the long term induction of the HSPA gene, but also the 
regulation of gene expression and developmental processes (Morimoto, 1998; Sreedhar 
et al, 2004). This response protects the cells against further insults, and has been 
demonstrated in a number of in vivo and in vitro studies (Krishnan et al, 2006; Pespeni 
et al, 2005; Wagstaff et al, 1999). Although the production of heat shock proteins 
results in the protection of cells from the effects of further stresses, they are deemed 
toxic if present in the cells for any prolonged period (Theodorakis et al, 1999). 
 
 
 
The brain tissue that was made thermotolerant by the application of multiple heat 
shocks contained lower levels of HSPA transcripts in the 0 and 3 post-mortem intervals 
compared to non-heat shock and to single heat shock, suggesting there is a regulation of 
HSPA synthesis that is dependent on the levels of HSPA existing within the cell (Kregel, 
2002).    Studies have demonstrated that inhibition of transcription during the 
conditioning heat stress allows the maintenance of thermotolerance (Bader et al, 1992). 
Induction of HSPA was rapid with high levels of the induced transcripts present at 6 h 
post-mortem intervals. Levels were substantially higher than those observed in non-heat 
shock and single heat shock samples, which supports work undertaken by Blake et al, 
(1990) and Theodorakis et al, (1999). 
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No significant differences were observed between the level of translation of HSPA 
mRNA in non-heat shock compared to the translation level in heat shocked tissue as 
shown in section 6.2.1. It can be concluded that heat shock is not necessary for the 
efficient translation of HSPA mRNA. Results from this study have shown that the 
transcription of the HSPA gene is rapidly and transiently activated in tissue subjected to 
a single heat shock. During heat shock, HSPA transcription levels rapidly increase and 
then decline after 6 h, section 6.2.1, Figure 6.1. The high levels of HSPA mRNA in the 
multiple heat shocked tissue is maintained through effects of message stability, due to 
the increase in heat shock factor (HSF) that is released from HSPA during the initial 
stress, which subsequently binds to the heat shock element (HSE) in the HSPA gene 
promoter region (Morimoto et al, 1994).  Heat shock has an effect on the stability of 
HSPA mRNA. In non-heat shocked tissue, the half-life of HSPA mRNA, as stated by 
Theodorakis and Morimoto (1999), is approximately 50 min, but in heat shocked tissue 
the stability increases by at least 10-fold (Theodorakis and Morimoto, 1987). Previous 
studies have shown that HSPA mRNAs rapidly degrade during recovery from heat 
shock, which support the findings in this study (Blake et al, 1990; Pardue et al, 2007; 
Theodorakis et al, 1999; Theodorakis and Morimoto, 1987). 
 
 
 
Tissue that was subjected to multiple heat shocks showed limited expression of HSPA 
compared to the single heat shock in the early post-mortem intervals 0 and 3 h.  This 
could be due to a decrease in HSPA transcription and an increase in HSPA mRNA 
degradation, thus increasing cellular levels of HSPA in the recovery period, when 
returned to non-heat shock conditions 37oC. In contrast, during the heat shock period, 
no significant differences were observed in the levels of HSPA transcription in multiple 
heat shock compared to non-heat shock in the early post-mortem period 0 and 3 h. 
HSPA mRNA was observed to be less stable in multiple heat shocked tissue, compared 
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with the control non-heat shocked tissue. As stated by Theodorakis et al, (1999), a 
possible reason for this is that, under normal conditions, levels of HSPA mRNA are 
unstable, but during heat shock the mRNA becomes more stable due to mRNA 
degradation being affected by stress.  In the tissue subjected to heat shock, mRNA 
degradation begins immediately after returning to non-heat shock conditions, and 
therefore  it  could  be  postulated  that  mRNA  degradation  is  accelerated  in  tissue 
subjected to heat shock which would result in a reduced HSPA mRNA half-life. 
 
 
 
Results have also shown that the levels of HSPALA proteins were higher in non- 
stressed and stressed (tumourous) human brain than those in non-stressed and stressed 
(heat shock) rat brain which supports the findings from Pardue et al, (2007). Consistent 
with the presence of the HSPA protein, HSPA mRNA levels were also found to be 
higher in non-stressed human brain than in non-stressed rat brain.   This supports the 
overall conclusion by Pardue et al, (2007) that HSPA/HSP70 protein levels in brain 
tissue are significantly higher in humans who die suddenly and are not subjected to 
agonal stresses pre-mortem, or from disease such as brain tumours, compared to rats 
that are either non-stressed pre-mortem or that have been subjected to heat shock post- 
mortem. 
 
 
 
Given that death and heat shock are both forms of cellular stress, it is to be expected that 
HSPA protein was observed in both the cytoplasm and the nucleus of samples subject 
ted to these conditions.  HSPA protein was detected mainly in the cytoplasm in non- 
heat-shocked brain tissue in the early post-mortem period with gradual migration into 
the nucleus over time. In the heat shocked post-mortem brain tissue, HSPA protein was 
observed in both the cytoplasm and the nucleus.  Increased synthesis of heat shock 
proteins in response to heat shock, results in HSPA relocalizing to the nucleus and 
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binding to the HSF1 transcriptional transactivation domain, thereby blocking 
transcription of heat shock genes (Santoro, 2000). 
 
 
 
 
7.2     Summary 
 
 
 
Overall, we may draw a number of conclusions from this study.   Firstly, GAPDH 
showed relatively consistent expression in human normal and tumourous cell lines and 
tissue samples under normal and hypoxic conditions, and also in rat brain tissues at 
different post-mortem intervals under normal and heat shock conditions. For Homo 
sapiens GAPDH, the average transcript copy number for normal and tumourous cell 
lines was approximately 146,500 copies per 100 ng of extracted mRNA, and for normal 
and tumourous brain tissues samples this was similar at approximately 144,000 copies 
per sample. For Rattus norvegicus GAPDH, levels were higher than for human, with an 
average of 268,300 copies per 100 ng of extracted mRNA. This study supports previous 
literature (Barber et al, 2005; Said et al, 2005, 2007, 2009) in showing that the 
expression of GAPDH is not up or down regulated by post-mortem, cancer, hypoxic or 
heat shocked conditions, and therefore GAPDH is confirmed as a suitable candidate 
control gene for the purposes of this study. 
 
 
 
Secondly, it was found that it was possible to isolate mRNA fragments from post 
mortem tissue up to 24 hours post mortem, which is in agreement with the previous 
report of Inoue et al. (2002). 
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Thirdly, HSPA is expressed at low levels in normal cell lines, at approximately 1,420 
copies, and normal brain tissue samples, at approximately 200 copies, but its expression 
is highly induced by cancer in glioma cell lines, with approximately 5,360 copies and in 
glioma brain tissue samples, with approximately 1,600 copies, as shown in Figure 7.1. 
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Figure 7.1 Histogram showing the average HSPA transcript levels from experiments 
using in control, glioma cell lines and v glioma brain tissue samples. HSPA can be seen 
to be more highly expressed in glioma cell lines and glioma brain tissue samples than in 
normal cell lines and normal brain tissue samples. 
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The results from this study also show that HSPA is expressed at low levels in pre and 
post hypoxia treated normal cells, (approximately 1,420 and 1,100 copies per 100 ng of 
extracted mRNArespectively) but is highly expressed in pre and post hypoxia treated 
glioma cells, (approximately 8,200 and 7,900 copies per 100 ng of extracted mRNA 
respectively), as shown in Figure 7.2. 
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Figure 7.2 Histogram showing the average HSPA transcript levels in control and glioma 
cell lines under pre and post hypoxia conditions. HSPA can be seen to be more highly 
expressed in glioma cell lines under pre and hypoxia conditions compared to low HSPA 
expression in the normal cell lines under pre and post hypoxia conditions. 
 
 
 
 
Hypoxia is a condition resulting from decreased cellular oxygen levels in tissues. In 
cellular hypoxia, tumours require additional blood vessels, a condition which is evident 
in many neoplasms.   Hypoxia induces transcriptional activation of many genes that 
affect cellular metabolism and also promotes neoangiogenesis (the formation of new or 
recent blood vessels) (Duffy et al, 2003).   Cells are able to sense and respond to 
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decreased oxygen levels through the conserved hypoxic response pathway involved in 
tumourigenesis.  Exposure to decreased oxygen levels initiates the hypoxic response 
pathway by the regulated expression of hypoxia inducible transcription factor-1 (HIF- 
1).     Many of the hypoxia-inducible genes are up-regulated during hypoxia, thus 
increasing oxygen transport to hypoxic tissues by promoting angiogenesis and also 
promoting cell proliferation and survival. However, failure to adapt to decreased oxygen 
levels will ultimately result in cell death via apoptosis (Bruick, 2003).  Angiogenesis is 
associated with metastasis, and as tumours grow, some cells become detached from the 
tissues nutrient supply limiting the delivery of oxygen and nutrients to those cells 
(Duffy et al, 2003).  This results in cellular hypoxia and metabolic stress inducing 
changes in transcriptional regulation, promoting growth of highly permeable blood 
vessels and facilitating the passage of tumour cells into the circulatory system.   The 
response of cancer to hypoxia not only maintains the survival and growth of tumours, 
but also promotes tissue invasion and metastasis through angiogenesis (Duffy et al, 
2003). 
 
 
 
As predicted, HSPA protein was detected in both the cytoplasm and the nucleus of the 
three glioma cell lines under pre and post hypoxic conditions. Although HSPA protein 
was detected mainly in the cytoplasm in the normal (NHA) cell line pre-hypoxia, after 
hypoxia treatment, migration of HSPA protein to the nucleus was observed. 
 
 
Although this research sheds light on the localisation and production of heat shock 
proteins in cells and supports a correlation between cancer and hypoxia environments, 
further research into glioma cells under hypoxic conditions is required to underpin the 
regulating mechanisms of HSPA in different cell types under such conditions.  If cancer 
cells are expressing HSPA at high levels, then hypoxic conditions will have little or no 
further effect on these cells.  Initially, tumours grow under non-hypoxic conditions, but 
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under hypoxic conditions, enhanced necrosis at the core of the tumour mass may be 
observed.  Given that not all glioblastomas show the same degree of angiogenesis and 
necrosis, further research to address the localisation of HSPA in relation to a 
hematoxylin and eosin histology diagnosis (H and E) referring to angiogenesis and 
necrosis needs to be carried out.  Furthermore, comparisons should be made between 
HSPA transcripts and protein levels after hypoxia with HIF to address whether cancer 
cells respond to hypoxia at HIF target gene levels.  The glioma tissues indicate a 
correlation between HSPA expression and the grade of cancer, suggesting its possible 
application as a biomarker.  This may also advocate the use of HSPA as a possible 
molecular target for therapy which may prolong glioma patient‘s survival in the future. 
However, different brain regions may show differences in HSPA levels, and thus 
additional work should be carried out to compare HSPA expression levels from various 
regions within the brain.   The present study suggests that HSPA is up-regulated in 
glioma and it may be a suitable prognostic biomarker. . 
 
 
 
HSPA was expressed at low levels in normal brain tissue, but was highly expressed in 
brain tissue subjected to mild heat shock. In the non–heat shocked brain tissue, low 
level expression of HSPA was observed in the 0 h post-mortem interval at 0 h time 
course, followed by a gradual increase up to the 6 h time course interval, and returning 
to near basal levels at the 24 h time course interval. HSPA expression gradually 
decreased at 3 and 6 h post-mortem intervals but, HSPA transcripts substantially 
increased at the 12 h post-mortem interval. At the 24 h post-mortem interval, HSPA 
transcripts were only detectable at low levels, below the initial basal levels observed at 
0 h post-mortem 0 h time course interval. A higher level of HSPA expression was 
observed in samples taken at 0 h post-mortem which had been subjected to heat shock, 
compared to non-heat shocked samples at each time course interval. HSPA transcripts 
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were observed in the 0 h post-mortem interval at 0 h time course, followed by a gradual 
increase up to the 6 h time course interval, returning back to near basal levels at the 24 h 
time course interval. At 3 h post-mortem, HSPA transcripts were present at high levels 
at 0 h time course with a gradual decline up to the 24 h time course. HSPA expression 
gradually decreased at 6 h post-mortem but, as with non-heat shock, HSPA transcripts 
substantially increased at 12 h post-mortem. Again, as with non-heat shock, HSPA 
transcripts were only present at low levels at the 24 h post-mortem interval, below or 
near to the initial basal levels observed at 0 h post-mortem 0 h time course interval. 
 
 
 
Furthermore, it is possible to induce the expression of heat shock genes in post mortem 
tissues, and this expression shows the preconditioning effect characteristic of the heat 
shock response. This phenomenon, known as thermotolerant preconditioning, is a 
cellular adaptation resulting from a single severe non-lethal exposure to heat that allows 
cells to better survive subsequent potentially lethal heat stress episodes, and has been 
reported previously (Lindquist and Craig, 1988; Moseley, 1997; Pardue et al, 2007; 
Theodorakis and Morimoto, 1987; Theodorakis et al, 1999; Tolson and Roberts, 2005). 
The levels of HSPA transcripts in brain tissue that had been subjected to a mild heat 
shock, the first at 0 h time course followed by subsequent heat shocks at 3, 6 and 24 h 
time course intervals, showed a marked increase in HSPA expression in heat shocked 
brain  tissue  compared  to  non-heat  shock  within  each  post-mortem  interval.  The 
response of cells to such stress conditions is dependent on the concentration of HSPA in 
the cell prior to stress and on the severity of the stress, based upon its intensity and 
duration  (Lindquist  and  Craig,  1988;  Mosser  and  Morimoto,  2004;  Parsell  and 
Lindquist, 1994). 
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The results from this study have shown that in the early post-mortem period, (0 h post- 
mortem), HSPA is expressed higher in tissue subjected to single and multiple heat 
shocks compared to non-heat-shock. However, in later post-mortem intervals, (3 - 24 h 
post-mortem intervals) results demonstrated some expression however results were 
inconsistent  and  somewhat  irregular,  with  no  predictive  or  reproducible  patterns. 
Possible explanation for this could be that there were multiple factors involved in the 
stress  experienced  by  cells,  such  as  the  initial  sacrifice  procedure  by  cervical 
dislocation, the excision of the brain and further damage to the tissues arising from the 
dissection of the brain. During this period, the cells are also under increased stress from 
circulatory failure which prevents the delivery of oxygen and removal of waste products 
of cellular respiration, resulting in anoxia, increased toxin levels and the functional 
activity of the cells. It is therefore possible that, during this period prior to experimental 
heat shock, HSPA will be up-regulated in response to these cellular changes. This could 
indicate that the response of the cells subjected to heat shock conditions was dependent 
on the initial concentration of HSPA in the cell prior to heat shock, based on the 
severity, intensity and duration of stress, (Lindquist and Craig, 1988; Mosser and 
Morimoto, 2001;  Parsell  and  Lindquist, 1994).  Although the  production  of  HSPA 
assists in the protection of cells from the effects of further non-lethal or lethal stresses, 
they become toxic if they are present in cells for any prolonged period, which would 
result in cellular death (Theodorakis et al, 1999). 
 
 
 
Again as expected, HSPA protein was detected in both the cytoplasm and the nucleus in 
all  tissue  samples  at  each  post-mortem interval for  both  non-heat  shock  and  heat 
shocked samples. 
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It can be concluded from the results of this part of the study that there is ―de  novo” 
synthesis in post mortem brain tissue in response to the changes in cellular conditions 
during this time.  It is possible to induce expression of HSPA following systemic death, 
using an external stimulus, such as heat shock, and that the induction of multiple heat 
shocks may be suggestive of a preconditioned protection from further stress. However, 
these initial studies would indicate that HSPA would be an unsuitable gene for its use as 
an early post-mortem marker. Therefore studies in the field of PMI using HSPA as an 
early post-mortem marker requires further investigation. The use of cell lines in 
replacement for tissue samples would eliminate initial pre stressful events, resulting in 
low or no detectable levels of HPSA1A transcripts. Also, based on the results from the 
normal and tumourous cell lines, it would be beneficial to include diseased subjects to 
address these findings. 
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www.gene-quantification.com/chemistry.html 
 
 
 
 
DOGS – Database of genome sizes 
 
www.cbs.dtu.dk/databases/DOGS/index.html 
 
 
 
 
European Bioinformatics Institute – ClustalW2, sequence alignment tool 
 
http://www.ebi.ac.uk/clustalw/ 
 
 
 
 
Gene Cards – human gene database 
 
http://www.genecards.org 
 
 
 
 
Gene expression: transcription 
 
www.users.rcm.com/.../T/Transcription.html 
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Appendix 9.1 Amino acid and gene sequence for HSPA1A Homo sapiens adapted from 
 
NCBI (http://www.ncbi.nlm.nih.gov) 
 
 
 
NCBI Reference Sequence: NM_005345.5 
 
Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA 
 
LOCUS      NM_005345  2445 bp   mRNA   linear  PRI 20-DEC-2009 
 
DEFINITION Homo sapiens heat shock 70kDa protein 1A (HSPA1A), mRNA. 
ACCESSION NM_005345 
VERSION    NM_005345.5 GI:194248071 
 
 
Amino Acid Sequence 
 
/translation="MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAF 
TDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPK 
VQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKD 
AGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFE 
VKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSS 
STQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDL 
VLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLL 
LLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMT 
KDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKG 
RLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEAD 
KKKVLDKCQEVISWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGA 
 
Gene Sequence 
 
1 ataaaagccc aggggcaagc ggtccggata acggctagcc tgaggagctg 
ctgcgacagt 
61 ccactacctt tttcgagagt gactcccgtt gtcccaaggc ttcccagagc 
gaacctgtgc 
121 ggctgcaggc accggcgcgt cgagtttccg gcgtccggaa ggaccgagct 
cttctcgcgg 
181 atccagtgtt ccgtttccag cccccaatct cagagcggag ccgacagaga 
gcagggaacc 
241 ggcatggcca aagccgcggc gatcggcatc gacctgggca ccacctactc 
ctgcgtgggg 
301 gtgttccaac acggcaaggt ggagatcatc gccaacgacc agggcaaccg 
caccaccccc 
361 agctacgtgg ccttcacgga caccgagcgg ctcatcgggg atgcggccaa 
gaaccaggtg 
421 gcgctgaacc cgcagaacac cgtgtttgac gcgaagcggc tgattggccg 
caagttcggc 
481 gacccggtgg tgcagtcgga catgaagcac tggcctttcc aggtgatcaa 
cgacggagac 
432 
 
541 aagcccaagg tgcaggtgag ctacaagggg gagaccaagg cattctaccc 
cgaggagatc 
601 tcgtccatgg tgctgaccaa gatgaaggag atcgccgagg cgtacctggg 
ctacccggtg 
661 accaacgcgg tgatcaccgt gccggcctac ttcaacgact cgcagcgcca 
ggccaccaag 
721 gatgcgggtg tgatcgcggg gctcaacgtg ctgcggatca tcaacgagcc 
cacggccgcc 
781 gccatcgcct acggcctgga cagaacgggc aagggggagc gcaacgtgct 
catctttgac 
841 ctgggcgggg gcaccttcga cgtgtccatc ctgacgatcg acgacggcat 
cttcgaggtg 
901 aaggccacgg ccggggacac ccacctgggt ggggaggact ttgacaacag 
gctggtgaac 
961 cacttcgtgg aggagttcaa gagaaaacac aagaaggaca tcagccagaa 
caagcgagcc 
1021 gtgaggcggc tgcgcaccgc ctgcgagagg gccaagagga ccctgtcgtc 
cagcacccag 
1081 gccagcctgg agatcgactc cctgtttgag ggcatcgact tctacacgtc 
catcaccagg 
1141 gcgaggttcg aggagctgtg ctccgacctg ttccgaagca ccctggagcc 
cgtggagaag 
1201 gctctgcgcg acgccaagct ggacaaggcc cagattcacg acctggtcct 
ggtcgggggc 
1261 tccacccgca tccccaaggt gcagaagctg ctgcaggact tcttcaacgg 
gcgcgacctg 
1321 aacaagagca tcaaccccga cgaggctgtg gcctacgggg cggcggtgca 
ggcggccatc 
1381 ctgatggggg acaagtccga gaacgtgcag gacctgctgc tgctggacgt 
ggctcccctg 
1441 tcgctggggc tggagacggc cggaggcgtg atgactgccc tgatcaagcg 
caactccacc 
1501 atccccacca agcagacgca gatcttcacc acctactccg acaaccaacc 
cggggtgctg 
1561 atccaggtgt acgagggcga gagggccatg acgaaagaca acaatctgtt 
ggggcgcttc 
1621 gagctgagcg gcatccctcc ggcccccagg ggcgtgcccc agatcgaggt 
gaccttcgac 
1681 atcgatgcca acggcatcct gaacgtcacg gccacggaca agagcaccgg 
caaggccaac 
1741 aagatcacca tcaccaacga caagggccgc ctgagcaagg aggagatcga 
gcgcatggtg 
1801 caggaggcgg agaagtacaa agcggaggac gaggtgcagc gcgagagggt 
gtcagccaag 
1861 aacgccctgg agtcctacgc cttcaacatg aagagcgccg tggaggatga 
ggggctcaag 
1921 ggcaagatca gcgaggcgga caagaagaag gtgctggaca agtgtcaaga 
ggtcatctcg 
1981 tggctggacg ccaacacctt ggccgagaag gacgagtttg agcacaagag 
gaaggagctg 
2041 gagcaggtgt gtaaccccat catcagcgga ctgtaccagg gtgccggtgg 
tcccgggcct 
2101 gggggcttcg gggctcaggg tcccaaggga gggtctgggt caggccccac 
cattgaggag 
2161 gtagattagg ggcctttcca agattgctgt ttttgttttg gagcttcaag 
actttgcatt 
2221 tcctagtatt tctgtttgtc agttctcaat ttcctgtgtt tgcaatgttg 
aaattttttg 
2281 gtgaagtact gaacttgctt tttttccggt ttctacatgc agagatgaat 
ttatactgcc 
2341 atcttacgac tatttcttct ttttaataca cttaactcag gccatttttt 
aagttggtta 
2401 cttcaaagta aataaacttt aaaattcaaa aaaaaaaaaa aaaaa 
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Appendix 9.2 Amino acid and gene sequence for HSPA1B Homo sapiens adapted from 
 
NCBI (http://www.ncbi.nlm.nih.gov) 
 
 
NCBI Reference Sequence: NM_005346.4 
 
Homo sapiens heat shock 70kDa protein 1B (HSPA1B), mRNA 
 
LOCUS      NM_005346  2551 bp   mRNA   linear  PRI 26-SEP-2010 
 
DEFINITION Homo sapiens heat shock 70kDa protein 1B (HSPA1B), mRNA. 
ACCESSION NM_005346 
VERSION    NM_005346.4 GI:167466172 
 
 
Amino Acid Sequence 
 
 
/translation="MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAF 
TDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPK 
VQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKD 
AGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFE 
VKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSS 
STQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDL 
VLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLL 
LLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMT 
KDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKG 
RLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEAD 
KKKVLDKCQEVISWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGA 
QGPKGGSGSGPTIEEVD" 
 
 
Gene Sequence 
 
 
1 ggaaaacggc cagcctgagg agctgctgcg agggtccgct tcgtctttcg 
agagtgactc 
61 ccgcggtccc aaggctttcc agagcgaacc tgtgcggctg caggcaccgg 
cgtgttgagt 
121 ttccggcgtt ccgaaggact gagctcttgt cgcggatccc gtccgccgtt 
tccagccccc 
181 agtctcagag cggagcccac agagcagggc accggcatgg ccaaagccgc 
ggcgatcggc 
241 atcgacctgg gcaccaccta ctcctgcgtg ggggtgttcc aacacggcaa 
ggtggagatc 
301 atcgccaacg accagggcaa ccgcaccacc cccagctacg tggccttcac 
ggacaccgag 
361 cggctcatcg gggatgcggc caagaaccag gtggcgctga acccgcagaa 
caccgtgttt 
421 gacgcgaagc ggctgatcgg ccgcaagttc ggcgacccgg tggtgcagtc 
ggacatgaag 
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481 cactggcctt tccaggtgat caacgacgga gacaagccca aggtgcaggt 
gagctacaag 
541 ggggagacca aggcattcta ccccgaggag atctcgtcca tggtgctgac 
caagatgaag 
601 gagatcgccg aggcgtacct gggctacccg gtgaccaacg cggtgatcac 
cgtgccggcc 
661 tacttcaacg actcgcagcg ccaggccacc aaggatgcgg gtgtgatcgc 
ggggctcaac 
721 gtgctgcgga tcatcaacga gcccacggcc gccgccatcg cctacggcct 
ggacagaacg 
781 ggcaaggggg agcgcaacgt gctcatcttt gacctgggcg ggggcacctt 
cgacgtgtcc 
841 atcctgacga tcgacgacgg catcttcgag gtgaaggcca cggccgggga 
cacccacctg 
901 ggtggggagg actttgacaa caggctggtg aaccacttcg tggaggagtt 
caagagaaaa 
961 cacaagaagg acatcagcca gaacaagcga gccgtgaggc ggctgcgcac 
cgcctgcgag 
1021 agggccaaga ggaccctgtc gtccagcacc caggccagcc tggagatcga 
ctccctgttt 
1081 gagggcatcg acttctacac gtccatcacc agggcgaggt tcgaggagct 
gtgctccgac 
1141 ctgttccgaa gcaccctgga gcccgtggag aaggctctgc gcgacgccaa 
gctggacaag 
1201 gcccagattc acgacctggt cctggtcggg ggctccaccc gcatccccaa 
ggtgcagaag 
1261 ctgctgcagg acttcttcaa cgggcgcgac ctgaacaaga gcatcaaccc 
cgacgaggct 
1321 gtggcctacg gggcggcggt gcaggcggcc atcctgatgg gggacaagtc 
cgagaacgtg 
1381 caggacctgc tgctgctgga cgtggctccc ctgtcgctgg ggctggagac 
ggccggaggc 
1441 gtgatgactg ccctgatcaa gcgcaactcc accatcccca ccaagcagac 
gcagatcttc 
1501 accacctact ccgacaacca acccggggtg ctgatccagg tgtacgaggg 
cgagagggcc 
1561 atgacgaaag acaacaatct gttggggcgc ttcgagctga gcggcatccc 
tccggccccc 
1621 aggggcgtgc cccagatcga ggtgaccttc gacatcgatg ccaacggcat 
cctgaacgtc 
1681 acggccacgg acaagagcac cggcaaggcc aacaagatca ccatcaccaa 
cgacaagggc 
1741 cgcctgagca aggaggagat cgagcgcatg gtgcaggagg cggagaagta 
caaagcggag 
1801 gacgaggtgc agcgcgagag ggtgtcagcc aagaacgccc tggagtccta 
cgccttcaac 
1861 atgaagagcg ccgtggagga tgaggggctc aagggcaaga tcagcgaggc 
ggacaagaag 
1921 aaggttctgg acaagtgtca agaggtcatc tcgtggctgg acgccaacac 
cttggccgag 
1981 aaggacgagt ttgagcacaa gaggaaggag ctggagcagg tgtgtaaccc 
catcatcagc 
2041 ggactgtacc agggtgccgg tggtcccggg cctggcggct tcggggctca 
gggtcccaag 
2101 ggagggtctg ggtcaggccc taccattgag gaggtggatt aggggccttt 
gttctttagt 
2161 atgtttgtct ttgaggtgga ctgttgggac tcaaggactt tgctgctgtt 
ttcctatgtc 
2221 atttctgctt cagctctttg ctgcttcact tctttgtaaa gttgtaacct 
gatggtaatt 
2281 agctggcttc attatttttg tagtacaacc gatatgttca ttagaattct 
ttgcatttaa 
435 
 
2341 tgttgatact gtaagggtgt ttcgttccct ttaaatgaat caacactgcc 
accttctgta 
2401 cgagtttgtt tgtttttttt tttttttttt ttttttgctt ggcgaaaaca 
ctacaaaggc 
2461 tgggaatgta tgtttttata atttgtttat ttaaatatga aaaataaaat 
gttaaacttt 
2521 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa a 
// 
436 
 
Appendix 9.3 Amino acid and gene sequence for HSPA1L Homo sapiens adapted from 
 
NCBI (http://www.ncbi.nlm.nih.gov) 
 
 
NCBI Reference Sequence: NM_005527.3 
Homo sapiens heat shock 70kDa protein 1-like (HSPA1L), mRNA 
 
 
LOCUS      NM_005527  2550 bp   mRNA   linear  PRI 20-SEP-2010 
DEFINITION Homo sapiens heat shock 70kDa protein 1-like (HSPA1L), 
mRNA. 
ACCESSION  NM_005527 
VERSION    NM_005527.3 GI:124256495 
 
 
Amino Acid Sequence 
 
 
/translation="MATAKGIAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYV 
AFTDTERLIGDAAKNQVAMNPQNTVFDAKRLIGRKFNDPVVQADMKLWPFQVINEGGK 
PKVLVSYKGENKAFYPEEISSMVLTKLKETAEAFLGHPVTNAVITVPAYFNDSQRQAT 
KDAGVIAGLNVLRIINEPTAAAIAYGLDKGGQGERHVLIFDLGGGTFDVSILTIDDGI 
FEVKATAGDTHLGGEDFDNRLVSHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTL 
SSSTQANLEIDSLYEGIDFYTSITRARFEELCADLFRGTLEPVEKALRDAKMDKAKIH 
DIVLVGGSTRIPKVQRLLQDYFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSEKVQD 
LLLLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERA 
MTKDNNLLGRFDLTGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKVNKITITND 
KGRLSKEEIERMVLDAEKYKAEDEVQREKIAAKNALESYAFNMKSVVSDEGLKGKISE 
SDKNKILDKCNELLSWLEVNQLAEKDEFDHKRKELEQMCNPIITKLYQGGCTGPACGT 
GYVPGRPATGPTIEEVD" 
 
 
Gene Sequence 
 
 
1 tttggaaaaa gattactgag ttggagccgt ctcaaatttg cagggaggga 
cggggtgggg 
61 ggtgggggga ccccggttgt gcagtttgat attgagggag cccccaccta 
ctcgctgggg 
121 ctgcgtaatc tggacgtttc caaactgaag cgaaggcgtc gggagactag 
gcctcagaga 
181 accatggcta ctgccaaggg aatcgccata ggcatcgacc tgggcaccac 
ctactcctgt 
241 gtgggggtgt tccagcacgg caaggtggag atcatcgcca acgaccaggg 
caaccgcacc 
301 acccccagct acgtggcctt cacagacacc gagcggctca ttggggatgc 
ggccaagaac 
361 caggtagcaa tgaatcccca gaacactgtt tttgatgcta aacgtctgat 
cggcaggaaa 
421 tttaatgatc ctgttgtaca agcagatatg aaactttggc cttttcaagt 
gattaatgaa 
437 
 
481 ggaggcaagc ccaaagtcct tgtgtcctac aaaggggaga ataaagcttt 
ctaccctgag 
541 gaaatctctt cgatggtatt gactaagttg aaggagactg ctgaggcctt 
tttgggccac 
601 cctgtcacca atgcagtgat taccgtgcca gcctatttca atgactctca 
acgtcaggct 
661 actaaggatg caggtgtgat tgctggactt aatgtgctaa gaatcatcaa 
tgagcccacg 
721 gctgctgcca ttgcctatgg tttagataaa ggaggtcaag gagaacgaca 
tgtcctgatt 
781 tttgatctgg gtggaggcac atttgatgtg tcaattctga ccatagatga 
tgggattttt 
841 gaggtaaagg ccactgctgg ggacactcac ctgggtgggg aggactttga 
caacaggctt 
901 gtgagccact tcgtggagga gttcaagagg aaacacaaaa aggacatcag 
ccagaacaag 
961 cgagccgtga ggcggctgcg caccgcctgc gagagggcca agaggaccct 
gtcgtccagc 
1021 acccaggcca acctagaaat tgattcactt tatgaaggca ttgacttcta 
tacatccatc 
1081 accagagctc gatttgaaga gttgtgtgca gacctgttta ggggtaccct 
ggagcctgta 
1141 gaaaaagcgc ttcgggatgc caagatggat aaggctaaaa tccatgacat 
tgttttagta 
1201 gggggctcca cccgcatccc caaggtgcag cggctgcttc aggactactt 
caatggacgt 
1261 gatctcaaca agagcatcaa ccctgatgag gccgtagcat atggggctgc 
ggtacaagca 
1321 gccatcctga tgggggacaa gtctgagaag gtacaggacc tgctgctgct 
ggacgtggct 
1381 cccctgtccc tggggctgga gacggctggg ggcgtgatga ctgccctgat 
aaagcgcaac 
1441 tccaccatcc ccaccaagca gacacagatt ttcaccacct actctgacaa 
ccaacccggg 
1501 gtgctgatcc aggtgtatga gggcgagagg gccatgacaa aggacaacaa 
cctgctgggg 
1561 cggtttgacc tgactggaat ccctccagca cccaggggag ttcctcagat 
cgaggtgacg 
1621 tttgacattg atgccaatgg tattctcaat gtcacagcca cggacaagag 
caccggcaag 
1681 gtgaacaaga tcaccatcac caatgacaag ggccgcctga gcaaggagga 
gattgagcgc 
1741 atggttctgg atgctgagaa atataaagct gaagatgagg tccagaggga 
gaaaattgct 
1801 gcaaagaatg ccttagaatc ctatgctttt aacatgaaga gtgttgtgag 
tgatgaaggt 
1861 ttgaagggca agattagtga gtctgataaa aataaaatat tggataaatg 
caacgagctc 
1921 ctttcgtggc tggaggtcaa tcaactggca gagaaagatg agtttgatca 
taagagaaag 
1981 gaattggagc agatgtgtaa ccctatcatc acaaaactct accaaggagg 
atgcactggg 
2041 cctgcctgcg gaacagggta tgtgcctgga aggcctgcca caggccccac 
aattgaagaa 
2101 gtagattaat tctttttaga actgaagcat cctaggatgc ctctacatgt 
atttcattcc 
2161 cctcatcttc aaacatcatt attattcttg accagacctg aatctaagtt 
accatccctt 
2221 ggaaattctg gagaaggagt ctcatgcacc acctatcaca ctccctcaca 
tcctgtttct 
2281 gactttggaa tggactcagg aaaactaggc ccctctttaa accgtgtgat 
gtatttgaat 
438 
 
2341 gtctgttatt tccagccacc ctaacattct tcttcctgtg tggatgctta 
tttgtcaatc 
2401 agtaaatttg ttcgtaaaga aaattacttc tggtatttag gctgtgaatg 
taccttgaag 
2461 gggagagttc atggagagag catgtgttct ctgattgtga ggtcactgtg 
aatgattaaa 
2521 ttggtaaggg taaagtaaaa aaaaaaaaaa 
// 
439 
 
Appendix 9.4 Amino acid and gene sequence for HSPA1A Rattus norvegicus adapted 
 
from NCBI (http://www.ncbi.nlm.nih.gov) 
 
 
 
 
NCBI Reference Sequence: NM_031971.2 
 
Rattus norvegicus heat shock 70kD protein 1A (Hspa1a), mRNA 
 
 
 
LOCUS      NM_031971 4045 bp   mRNA   linear  ROD 30-APR-2010 
 
DEFINITION Rattus norvegicus heat shock 70kD protein 1A (Hspa1a), 
mRNA. 
ACCESSION  NM_031971 
 
VERSION    NM_031971.2 GI:260064044 
 
 
Amino Acid Sequence 
 
/translation="MAKKTAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAF 
TDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVVNDGDKPK 
VQVNYKGENRSFYPEEISSMVLTKMKEIAEAYLGHPVTNAVITVPAYFNDSQRQATKD 
AGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFE 
VKATAGDTHLGGEDFDNRLVSHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSS 
STQASLEIDSLFEGIDFYTSITRARFEELCSDLFRGTLEPVEKALRDAKLDKAQIHDL 
VLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLL 
LLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMT 
RDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKG 
RLSKEEIERMVQEAERYKAEDEVQRERVAAKNALESYAFNMKSAVEDEGLKGKISEAD 
KKKVLDKCQEVISWLDSNTLAEKEEFVHKREELERVCNPIISGLYQGAGAPGAGGFGA 
Gene Sequence 
1 ccaggcatcc ttctctgagt ttctatcttt ctctcgattg taactcctct 
cttcgaccat 
61 caataccata ttcaaaaagg tcttgtctgc ctccgatttc agctcagact 
aatttcagcc 
121 actaatgtcc ctcaagagcc caaccccatt ttttcttggt tgccaacacc 
caaatccaga 
181 attaaaactg gggttcctgt gtggagagcc aagaggagac ctaaggatgg 
tggcttccac 
241 tagaccacgt ctgtaaatca atcaaaccta agaaaattct tggcccatta 
aataagaacc 
301 aactggaatt ccaggctcac ctggaatctc tacgccttcg atccagtttg 
gaaaatttga 
361 agtcgctgag cccctacgag tggggagctc caggaacatc caaactgagc 
aactggggtt 
440 
 
421 ccccccaccc cccaccccgc ccctcccggc aactttgagc ctcttctggg 
acagatcctc 
481 tgattcctaa ataagtccat gaggtcagag ttagcactgc cattgtaacg 
cggctggagg 
541 ggggtcacgt caccggacac gcccccaggc acctcccttg ggtctcccaa 
ggctaggaag 
601 gggaagttat aacccttaac tcgagcccca taatcagaac tgtgcgagtc 
tgcgaacccc 
661 cacaaatcac aaccaactgt ccacaacacg gagctagcag tgacctttcc 
tgtccattcc 
721 actcaggcct cagtaatgcg tcgccatagc aacagtgtca acagcagcac 
cagcaggtcc 
781 cgccaccctc ccccacagga atccgtcctt tccagctaac cccagatctg 
tctggagagt 
841 tctgaacagg ggcggaaccc tcaactccta ttactcaaag gaggcgggga 
agctccaccc 
901 gacgcgaaac tgctggaaga ttcctggccc caaggcctcc tcccgctcgc 
tgattggccc 
961 atgggagggt gggcggggcc ggaggaggct ccttaaaggc gcagggcggc 
gcgcaggaca 
1021 ccagattcct cctcttaatc tgacagaatc agtttctggt tccactcgca 
gagaagcaga 
1081 gaagcggagc aagcggcgcg ttccagaacc tcgggcaaga ccagcctctc 
ccagagcatc 
1141 cccaccgcga agcgcaacct tctccagagc atcccccagc ggagcgcacc 
cttccccaga 
1201 gcatccccgc cgccaagcgc aaccttccag aagcagagag cggcgacatg 
gccaagaaaa 
1261 cagcgatcgg catcgacctg ggcaccacct actcgtgcgt gggcgtgttc 
cagcacggca 
1321 aggtggagat catcgccaac gaccagggca accgcacgac ccccagctac 
gtggccttca 
1381 ccgacaccga gcggctcatc ggggacgccg ccaagaacca ggtggcgctg 
aacccgcaga 
1441 acaccgtgtt cgacgcgaag cggctgatcg gccgcaagtt cggcgacccg 
gtggtgcagt 
1501 cggacatgaa gcactggccc ttccaggtgg tgaacgacgg cgacaagccc 
aaggtgcagg 
1561 tgaactacaa gggcgagaac cggtcgttct acccggagga gatctcgtcc 
atggtgctga 
1621 ccaagatgaa ggagatcgcc gaggcgtacc tgggccaccc ggtgaccaac 
gcggtgatca 
1681 ccgtgcccgc ctacttcaac gactcgcagc ggcaggccac caaggacgcg 
ggcgtgatcg 
1741 cgggtctgaa cgtgctgcgg atcatcaacg agcccacggc ggccgccatc 
gcctacgggc 
1801 tggaccggac cggcaagggc gagcgcaacg tgctcatctt cgacctgggg 
ggcggcacgt 
1861 tcgacgtgtc catcctgacg atcgacgacg gcatcttcga ggtgaaggcc 
acggcgggcg 
1921 acacgcacct gggcggggag gacttcgaca accggctggt gagccacttc 
gtggaggagt 
1981 tcaagaggaa gcacaagaag gacatcagcc agaacaagcg cgcggtgcgg 
cgactgcgca 
2041 cggcgtgcga gagggccaag aggacgctgt cgtccagcac ccaggccagc 
ctggagatcg 
2101 actctctgtt cgagggcatc gacttctaca cgtccatcac gcgggcgcgg 
ttcgaggagc 
2161 tgtgctcgga cctgttccgc ggcacgctgg agcccgtgga gaaggccctg 
cgcgacgcca 
2221 agctggacaa ggcgcagatc cacgacctgg tgctggtggg cggctcgacg 
cgcatcccca 
441 
 
2281 aggtgcagaa gctgctgcag gacttcttca acgggcgcga cctgaacaag 
agcatcaatc 
2341 cggacgaggc ggtggcctac ggggcggcgg tgcaggcggc catcctgatg 
ggggacaagt 
2401 cggagaacgt gcaggacctg ctgctgctgg acgtggcgcc gctgtcgctg 
ggtctggaga 
2461 ccgcgggcgg cgtgatgacg gcgctcatca agcgcaactc caccatcccc 
accaagcaga 
2521 cgcagacctt caccacctac tcggacaacc agcccggggt gctgatccag 
gtgtacgagg 
2581 gcgagagggc catgacgcgc gacaacaacc tgctggggcg cttcgagttg 
agcggcatcc 
2641 cgccggctcc caggggcgtg ccccagatcg aggtgacctt cgacatcgac 
gccaacggca 
2701 tcctgaacgt cacggccact gacaagagca ccggcaaggc caacaagatc 
accatcacca 
2761 acgacaaggg ccgcctgagc aaggaggaga tcgagcgcat ggtgcaggag 
gccgagcgct 
2821 acaaggcgga ggacgaggtg cagcgcgaga gggtggctgc caagaatgcg 
ctcgagtcct 
2881 atgccttcaa catgaagagc gccgtggagg acgagggtct caagggcaag 
atcagcgagg 
2941 ctgacaagaa gaaggtgctg gacaagtgcc aggaggtcat ctcctggctg 
gactctaaca 
3001 cgctggctga gaaagaggag ttcgtgcaca agcgggagga gctggagcgg 
gtgtgcaacc 
3061 cgatcatcag cgggctgtat cagggtgcgg gtgctcccgg ggctgggggc 
ttcggggccc 
3121 aggcgcccaa gggaggctct gggtcggggc ccaccatcga ggaggtggat 
tagaggctct 
3181 ttctggcgct ccaggtgtga tctaggagac agatgggtgg ccttgaggac 
tttgggttat 
3241 tgtcgtttag gacattaact ccttcgttcg gtctgcaatc aagtcctagg 
tttaagcaaa 
3301 ctgccttcca tttactctgt ggaatttcac gtgtgctttg cattcccagt 
aaattagtac 
3361 tgggagtgtg tctttgcaat agatataatt tcctgccttc aagtcagcac 
tgcccccccc 
3421 cccgaagtta tttcttttgc aggacagtca gagctatatt gatatagcaa 
gaggtgtgtt 
3481 acaaaaacac caggacactg ttgagttcct ttgtgtttgg actctcccct 
gggcgacagt 
3541 gttgaggcac tgttaagtca ggagctcagg ggccaccggt ggatcactga 
aagctgagac 
3601 tctgttgctt ctcccgtttg acactctgtt gctttccttg catggtggct 
cacctaaggc 
3661 tgagactctt gttctccttc cctgtataat cttgcctggc cgttgcactt 
gttccccagt 
3721 gtgtgaactc ggagatgagt ttacaccacc actgttagtt cacgtttttt 
gtttttacat 
3781 aaccatcctg aactcaggtc aatttttact ggctatttga aaataaactt 
caaaagaact 
3841 tgccaggtct tgtgtctgtt gtcttttgag gtcaggaatt gctgtgtatg 
tcttacagat 
3901 tggactacgc ttgactgaca ttttatggta agatggggtg gggagcaccc 
agggactttg 
3961 cattgggatc tgcttgtgtg agaaaaatga aagcagtcag agcaaataac 
aaccagtccg 
4021 gggctgaggt ctagtacagt gcaga 
// 
442 
 
Appendix 9.5 Amino acid and gene sequence for HSPA1B Rattus norvegicus adapted 
 
from NCBI (http://www.ncbi.nlm.nih.gov) 
 
 
NCBI Reference Sequence: NM_212504.1 
 
 
 
Rattus norvegicus heat shock 70kD protein 1B (mapped) (Hspa1b), 
mRNA 
 
LOCUS NM_212504 5918 bp mRNA linear ROD 20-JUN-2010 
DEFINITION Rattus norvegicus heat shock 70kD protein 1B (mapped) 
(Hspa1b), 
 
mRNA. 
 
ACCESSION  NM_212504 XM_215309 
 
VERSION    NM_212504.1 GI:47059178 
 
 
Amino Acid Sequence 
 
 
/translation="MAKKTAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAF 
TDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVVNDGDKPK 
VQVNYKGENRSFYPEEISSMVLTKMKEIAEAYLGHPVTNAVITVPAYFNDSQRQATKD 
AGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFE 
VKATAGDTHLGGEDFDNRLVSHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSS 
STQASLEIDSLFEGIDFYTSITRARFEELCSDLFRGTLEPVEKALRDAKLDKAQIHDL 
VLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENVQDLL 
LLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQTFTTYSDNQPGVLIQVYEGERAMT 
RDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKG 
RLSKEEIERMVQEAERYKAEDEVQRERVAAKNALESYAFNMKSAVEDEGLKGKISEAD 
KKKVLDKCQEVISWLDSNTLAEKEEFVHKREELERVCNPIISGLYQGAGAPGAGGFGA 
QAPKGGSGSGPTIEEVD" 
 
 
Gene Sequence 
 
 
1 gaattccagc acttgggtgt caaggctgga ggagcaagag tttaaggcta 
gcctgggcta 
61 catgagcccc tattttgaaa aagaaaacaa gaaataaaaa agttagaaaa 
aagaaaaaat 
121 gaaaacaaaa gatgtgtgcg tgtgtatgtg tgtgagagag agagacagtc 
tctctctctc 
181 tctctctctc tctctctctc tctctctctc tctctctctc tgtgtatgtg 
tgtgtgtgag 
241 acaattactc cctgctgtgg actgttacct cagaactaag actctaatgc 
aatctattct 
443 
 
301 ttttttaaaa aacaggctcg gggctgggga tttagctcag tggtagagcg 
cttacctagg 
361 aagcgcaagg ccctgggttc ggtccccagc tccgaaaaaa agaaccaaaa 
aaaaaaaaaa 
421 accaaaaaca aaaaaaaaaa acaaaaaaaa acaaaacaaa acaggctcta 
atgtagattg 
481 ggctagcctc aaactcttca tcctcctgcc tccccctcca aagcatgagg 
actacagagg 
541 tgggccacca tacccagtaa cctcatactg tttcaagaca tctaactagg 
gggtctttaa 
601 ttcgtacacg gaaggaggag cccggaagaa gaaaaaggga catcactgac 
agctaaacat 
661 atttataatg agaggaggta ggggacagac aagggacgga aaggtgatgt 
ctaggacaaa 
721 aagctaacca cataaactag taggtgggtc ccgacacctc tgcttagggt 
ctcacccaaa 
781 agtcggagtt aacagcactg tgaggccaga tgctatcaga ggacaggaca 
caccatctct 
841 ccacctagga aaggtgaact gacaggggca gcagacacag aagaatcagc 
aaactcttaa 
901 gtcaaccctg aggttactac agcacagaat agaacagtgc ctggcaagga 
gcagctgtgt 
961 gaaggagaag ccaagcagcc atcctcagca ttcttcttct attaatcttt 
tgggacaggg 
1021 tctgcctctg taacctaggc tgaccttgac tcgctgcagt ccctctgccc 
caccctctac 
1081 cgaaagtttt tttttttctc ctttctaatg ccaggctgcc gcctgaggca 
aagggagcgg 
1141 cttgcagcct ggcacggtcg gtcgattaaa ccttgctctc cccgtcctgg 
gacactttcc 
1201 ttttttgggt cacaggtcct cctaacatga gaaccgagtg tttacacaat 
gatgttcttt 
1261 tgaaaaccgt gaaaactcca caggcgatgt acttgtacgt taagcgtgac 
ataaagacag 
1321 caaagcgaat aaactatact gcaagatctc ttctctttcc ctatttaaac 
ctaaaatgga 
1381 gggagtgggg ggcagacaca gacaggcgag cattccacag gcgccccccc 
cacgctgtca 
1441 cttccaggca ggacccaatc acagacttct tagccaagcg ttatccctcc 
cgttttgaga 
1501 aactttctgc gtccgccatc ctgtaggaag aatttgtaca ccttaaactc 
cctccctggt 
1561 ctgattccca aatgtctctc accgcccagc actttcagga gctgaccctt 
ctcagcttca 
1621 catacagaga ccgctacctt gcgtcgccat ggcaacactg tcacaaccgg 
aacaagcact 
1681 tcctaccacc ccccgcctca ggaatccaat ctgtccagcg aagcccagat 
ccgtctggag 
1741 agttctggac aagggcggta ccctcaacat ggattactca tgggaggcgg 
agaagctcta 
1801 acagacccga aactgctgga agattcctgg ccccaaggcc tcctcccgct 
cgctgattgg 
1861 cccatgggag ggtgggcggg gccggaggag gctccttaaa ggcgcagggc 
ggcgcgcagg 
1921 acaccagatt cctcctccta atctgacaga accagtttct ggttccactc 
gcagagaagc 
1981 agagaagcgg agcaagcggc gcgttccaga acctcgggca agaccagcct 
ctcccagagc 
2041 atccccaccg cgaagcgcaa ccttctccag agcatccccc agcggagcgc 
acccttcccc 
2101 agagcatccc cgccgccaag cgcaaccttc cagaagcaga gagcggcgac 
atggccaaga 
444 
 
2161 aaacagcgat cggcatcgac ctgggcacca cctactcgtg cgtgggcgtg 
ttccagcacg 
2221 gcaaggtgga gatcatcgcc aacgaccagg gcaaccgcac gacccccagc 
tacgtggcct 
2281 tcaccgacac cgagcggctc atcggggacg ccgccaagaa ccaggtggcg 
ctgaacccgc 
2341 agaacaccgt gttcgacgcg aagcggctga tcggccgcaa gttcggcgac 
ccggtggtgc 
2401 agtcggacat gaagcactgg cccttccagg tggtgaacga cggcgacaag 
cccaaggtgc 
2461 aggtgaacta caagggcgag aaccggtcgt tctacccgga ggagatctcg 
tccatggtgc 
2521 tgaccaagat gaaggagatc gccgaggcgt acctgggcca cccggtgacc 
aacgcggtga 
2581 tcaccgtgcc cgcctacttc aacgactcgc agcggcaggc caccaaggac 
gcgggcgtga 
2641 tcgcgggtct gaacgtgctg cggatcatca acgagcccac ggcggccgcc 
atcgcctacg 
2701 ggctggaccg gaccggcaag ggcgagcgca acgtgctcat cttcgacctg 
gggggcggca 
2761 cgttcgacgt gtccatcctg acgatcgacg acggcatctt cgaggtgaag 
gccacggcgg 
2821 gcgacacgca cctgggcggg gaggacttcg acaaccggct ggtgagccac 
ttcgtggagg 
2881 agttcaagag gaagcacaag aaggacatca gccagaacaa gcgcgcggtg 
cggcgactgc 
2941 gcacggcgtg cgagagggcc aagaggacgc tgtcgtccag cacccaggcc 
agcctggaga 
3001 tcgactctct gttcgagggc atcgacttct acacgtccat cacgcgggcg 
cggttcgagg 
3061 agctgtgctc ggacctgttc cgcggcacgc tggagcccgt ggagaaggcc 
ctgcgcgacg 
3121 ccaagctgga caaggcgcag atccacgacc tggtgctggt gggcggctcg 
acgcgcatcc 
3181 ccaaggtgca gaagctgctg caggacttct tcaacgggcg cgacctgaac 
aagagcatca 
3241 atccggacga ggcggtggcc tacggggcgg cggtgcaggc ggccatcctg 
atgggggaca 
3301 agtcggagaa cgtgcaggac ctgctgctgc tggacgtggc gccgctgtcg 
ctgggtctgg 
3361 agaccgcggg cggcgtgatg acggcgctca tcaagcgcaa ctccaccatc 
cccaccaagc 
3421 agacgcagac cttcaccacc tactcggaca accagcccgg ggtgctgatc 
caggtgtacg 
3481 agggcgagag ggccatgacg cgcgacaaca acctgctggg gcgcttcgag 
ttgagcggca 
3541 tcccgccggc tcccaggggc gtgccccaga tcgaggtgac cttcgacatc 
gacgccaacg 
3601 gcatcctgaa cgtcacggcc actgacaaga gcaccggcaa ggccaacaag 
atcaccatca 
3661 ccaacgacaa gggccgcctg agcaaggagg agatcgagcg catggtgcag 
gaggccgagc 
3721 gctacaaggc ggaggacgag gtgcagcgcg agagggtggc tgccaagaat 
gcgctcgagt 
3781 cctatgcctt caacatgaag agcgccgtgg aggacgaggg tctcaagggc 
aagatcagcg 
3841 aggctgacaa gaagaaggtg ctggacaagt gccaggaggt catctcctgg 
ctggactcta 
3901 acacgctggc tgagaaagag gagttcgtgc acaagcggga ggagctggag 
cgggtgtgca 
3961 acccgatcat cagcgggctg tatcagggtg cgggtgctcc cggggctggg 
ggcttcgggg 
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4021 cccaggcgcc caagggaggc tctgggtcgg ggcccaccat cgaggaggtg 
gattagaggc 
4081 ttttctggct ctcagggtgt tggctagaga cagactcttg atggctgctg 
gtgcacgatt 
4141 cttatcaagt tactccttct ctccggagtt cagtttaaag ttacagcctt 
ttatacggta 
4201 attgatttga gtttgttaca ttttgtatgc tcgtgggttt tttatatatt 
caaattaagg 
4261 ttgcatgttc tttgcgttta atctaagtag ctgtgtaaaa atggtgtttc 
cttcctgcga 
4321 acacctcagc actgccaccc tgtgtacagt tttttccttg catccctaca 
aactgagaaa 
4381 aaaagttatc ttttgtaact taaacattca aaataaaatg ttacaagtat 
gttttgtccg 
4441 tgtgtatgtt gggagggcta atggattctg ggttcatgtg gatttcttag 
ctttgcgatg 
4501 acggggaaat ggggtttggg tactttggtt agaagtgtgg gttttggggt 
tggggattga 
4561 gctcagtggt agagcgcttg cctaggaagc gcaaggccct gggttcggtc 
cccagctccg 
4621 aaaaaagaac caaaaaaaaa aaaagtgtgg gttttcagcg cagttatgca 
gaaaatgcag 
4681 gtattcggtt tgagggtagg actcattggg gggaacagta gggtggtgct 
gtagttgggg 
4741 gtcagtggaa gagggactct tagggctatg atgactcagt tctcttagcc 
ctccagggct 
4801 gaaccagaac tgtttcccaa cttatgggtc gagacctctg ttggagtcag 
acgacctttc 
4861 cacagtggta gcctcggaca ttgaaaattg caggggttgt tggttgtcgg 
ttgggttttt 
4921 gttttgtctt gttttgtttt tcaagacagg gtctctctgt gtagccctgg 
ctggcctcga 
4981 tttcggatcc acatgccttt cccaaacctg gcttccttat tacttttttt 
ttttttttta 
5041 agatttattt acttattata tataagtaca atgtagctgt cttcagagac 
accagaagag 
5101 ggcatcagat cccattacag atggctgtga gccaccatgt ggttgctggg 
atttgaactc 
5161 aggacctctt caagagcagt cagtgctctt aacttctgag ccctctctcc 
agccctttat 
5221 tacttttaga gatttcttac caggttgccc tggctgtact tacactttct 
ctttagctct 
5281 gctgagcttt caattcacca gttccagacc acacccctga acccaccagc 
tgaagacaac 
5341 atgtcttgct atctttttct ttcctttttg gggcagggat ggtctgtgtg 
ttgtgtgtgt 
5401 gagagacaga ggcagagaca tccttcccat gtagccctaa ctgagtcgga 
agtcattatt 
5461 tagaccaggc tgccctgact cctgtatctg cctctccaat ggattatggg 
cacctgccac 
5521 ctcacccact cactttatcc ccaggatccc cctccctctt cccaggcagt 
aggtctggtg 
5581 atggagaaga ccacttacca tgtccatggc tcaaagaagc aggcagaacg 
taggggaaag 
5641 agttgctttc acctcaagcc tttggatcca tgggtgttca ttctagtggg 
gtaatgccat 
5701 cctttgagag ctggggggtg tgggtcaaca gagatcggtt gctatgtgtg 
catgaggccc 
5761 gcaattcagt ccctggctcc atggagaacg aaccaatcag ttgggtgagg 
tgtaaaccac 
5821 atgtaatttt agcatgtcca aacagacacg ttaaggacat cctagggtaa 
agaagtcttc 
5881 agcaatagtt taattgaggc aattatgctc atgaattc 
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Appendix 9.6 Amino acid and gene sequence for HSPA1L Rattus norvegicus adapted 
 
from NCBI (http://www.ncbi.nlm.nih.gov) 
 
 
 
NCBI Reference Sequence: NM_212546.4 
 
Rattus norvegicus heat shock protein 1-like (Hspa1l), mRNA 
 
LOCUS      NM_212546    2632 bp   mRNA   linear  ROD 27-NOV-2011 
 
DEFINITION Rattus norvegicus heat shock protein 1-like (Hspa1l), 
mRNA. 
ACCESSION  NM_212546 
 
VERSION    NM_212546.4 GI:261824059 
 
 
Amino Acid Sequence 
 
/translation="MAANKGMAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYV 
AFTDTERLIGDAAKNQVAMNPQNTVFDAKRLIGRKFNDPVVQSDMKLWPFQVINEAGK 
PKVLVSYKGEKKAFYPEEISSMVLTKMKETAEAFLGHSVTNAVITVPAYFNDSQRQAT 
KDAGVIAGLNVLRIINEPTAAAIAYGLDKGSHGERHVLIFDLGGGTFDVSILTIDDGI 
FEVKATAGDTHLGGEDFDNRLVSHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTL 
SSSTQANLEIDSLYEGIDFYTSITRARFEELCADLFRGTLEPVEKSLRDAKMDKAKIH 
DIVLVGGSTRIPKVQKLLQDYFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSEKVQD 
LLLLDVAPLSLGLETAGGVMTVLIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERA 
MTRDNNLLGRFDLTGIPPAPRGVPQIEVTFDIDANGILNVTAMDKSTGKANKITITND 
KGRLSKEEIERMVQEAERYKAEDEGQREKIAAKNALESYAFNMKSAVGDEGLKDKISE 
SDKKKILDKCSEVLSWLEANQLAEKEEFDHKRKELENMCNPIITKLYQSGCTGPTCAP 
GYTPGRAATGPTIEEVD" 
 
 
Gene Sequence 
 
1 cagaagaggc tcaaagttgc cgggaggggc ggggtggggg gtggggggaa 
ccccagttgc 
61 tcagtttgga tgttcctgga gctccccact cgtaggggct cagcgacttc 
aaattttcca 
121 aactggatcg aaggcgtaga gattccaggc ctcggaaaac catggctgct 
aataaaggaa 
181 tggccatagg catcgacctg ggcaccacct actcgtgcgt gggcgtgttc 
cagcacggca 
241 aggtggagat catcgccaac gaccagggca accgcacgac cccaagctac 
gtggccttca 
301 ccgacaccga gcggctcatc ggggacgccg ccaagaacca ggtggccatg 
aatccccaga 
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361 acactgtttt tgacgccaaa cgtctaattg gcaggaagtt taatgatccc 
gtcgtgcagt 
421 cggatatgaa gctgtggcca tttcaagtga tcaatgaagc gggcaagcct 
aaggtgctgg 
481 tgtcctacaa aggagagaag aaagccttct acccggagga gatctcgtcc 
atggtgctga 
541 ccaagatgaa ggagactgca gaggcttttt tgggccacag tgtcaccaac 
gctgtgatca 
601 ccgtgccagc ctatttcaat gactcccaga gacaggccac taaagatgca 
ggggtcatcg 
661 caggactcaa cgtgctgcga atcatcaatg agcccacagc ggcggccatc 
gcctacggct 
721 tggataaagg aagtcacgga gagcggcacg tgctcatctt cgacctgggg 
ggcggcacgt 
781 tcgacgtgtc catcctgacg atcgacgacg gcatcttcga ggtgaaggcc 
acggcgggcg 
841 acacgcacct gggcggggag gacttcgaca accggctggt gagccacttc 
gtggaggagt 
901 tcaagaggaa gcacaagaag gacatcagcc agaacaagcg cgcggtgcgg 
cgtctgcgca 
961 cggcgtgcga gagggccaag aggacgctgt cgtccagcac ccaggccaac 
ctggagatcg 
1021 actctctgta cgagggcatc gacttctaca cgtccatcac gcgggcgcgg 
ttcgaggagc 
1081 tgtgtgcaga cctatttaga ggcacgcttg agcccgtgga gaagtctctc 
cgggacgcca 
1141 agatggacaa ggctaaaatc catgacattg ttctagtagg gggctctacc 
cgcatcccaa 
1201 aggtgcaaaa gctgcttcaa gactacttta atggacggga tctcaacaag 
agtatcaatc 
1261 ccgatgaggc ggtggcgtac ggagctgcag tccaggcagc tattttaatg 
ggcgacaaat 
1321 ctgaaaaagt acaggatttg cttttgttgg acgtagctcc cctgtctcta 
ggattggaga 
1381 cagccggggg tgtgatgact gttctgatca agcgcaactc caccatcccc 
accaagcaga 
1441 cgcagatctt caccacctac tcggacaacc agcccggggt gctgatccag 
gtgtacgagg 
1501 gcgagagggc catgacgcgc gacaacaacc tcctggggcg ctttgacctg 
actggaatac 
1561 cccctgcacc taggggtgtg ccccagatcg aggtgacctt cgacatcgac 
gccaacggga 
1621 ttctcaacgt cacagccatg gacaagagca ccggcaaggc caacaagatc 
accatcacca 
1681 acgacaaggg ccgcttgagc aaggaggaga tcgagcgcat ggtgcaagag 
gccgagcggt 
1741 acaaggccga ggacgagggc cagagggaga agatcgctgc caaaaatgcc 
ttagaatcgt 
1801 atgcctttaa catgaagagc gctgtaggcg atgagggtct gaaggacaag 
atcagcgagt 
1861 ctgataaaaa gaaaatactg gataaatgca gtgaggtcct ttcctggctg 
gaggccaacc 
1921 agctggcgga gaaagaagag ttcgatcata aaagaaaaga gctggaaaac 
atgtgcaacc 
1981 ctatcatcac aaagctgtac cagagcggct gcacagggcc cacctgcgcg 
ccagggtata 
2041 cacccggcag ggctgccaca ggccccacca ttgaggaagt agattagcct 
ttcccagaaa 
2101 ggcagggtgc tagggtgcct ctaggcgaca tttattcacc tcccaacatc 
actgtgattc 
2161 ttgaactgac tggacttgag cctaagtcac catcctttgg gatctgatgc 
agaacccacg 
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2221 gactccgcct ttccacgccc ccaccctctg atctatgatc ctgaactgga 
tctttagcac 
2281 aaccaggccc ctctttgagc ctcgtgaaga atttggatgt ctgttattta 
tcatccacac 
2341 cccgcctttc acctccctgt gtggatggtt atttgtctct cagtaaattt 
gttcccaaag 
2401 gaaacgtctg tcacttttcg atttgtttag tcgagggcct tactgtatat 
gtctagctga 
2461 cctgacgctt accgcattgg ccaatttggt ccttaacttg cagcaatcct 
cctgtctctg 
2521 ccacctgaat ttcgagatta cggacctgca ccatcatgcc caacttgtga 
tttttttttt 
2581 ttgggaggca gggtttcttg aagcctaggt tagcctagaa cattctatac ac 
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Appendix 9.7 Amino acid and gene sequence for GAPDH Homo sapiens adapted from 
 
NCBI (http://www.ncbi.nlm.nih.gov) 
 
 
 
NCBI Reference Sequence: NM_002046.3 
 
Homo sapiens glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
mRNA 
 
LOCUS NM_002046 1310 bp mRNA linear PRI 16-MAY-2010 
 
DEFINITION Homo sapiens glyceraldehyde-3-phosphate dehydrogenase 
 
(GAPDH), 
 
mRNA. 
ACCESSION NM_002046 
VERSION    NM_002046.3 GI:83641890 
 
 
Amino Acid Sequence 
 
/translation="MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMV 
YMFQYDSTHGKFHGTVKAENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVF 
TTMEKAGAHLQGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPL 
AKVIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVG 
KVIPELNGKLTGMAFRVPTANVSVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGY 
TEHQVVSSDFNSDTHSSTFDAGAGIALNDHFVKLISWYDNEFGYSNRVVDLMAHMASK 
Gene Sequence 
1 aaattgagcc cgcagcctcc cgcttcgctc tctgctcctc ctgttcgaca 
gtcagccgca 
61 tcttcttttg cgtcgccagc cgagccacat cgctcagaca ccatggggaa 
ggtgaaggtc 
121 ggagtcaacg gatttggtcg tattgggcgc ctggtcacca gggctgcttt 
taactctggt 
181 aaagtggata ttgttgccat caatgacccc ttcattgacc tcaactacat 
ggtttacatg 
241 ttccaatatg attccaccca tggcaaattc catggcaccg tcaaggctga 
gaacgggaag 
301 cttgtcatca atggaaatcc catcaccatc ttccaggagc gagatccctc 
caaaatcaag 
361 tggggcgatg ctggcgctga gtacgtcgtg gagtccactg gcgtcttcac 
caccatggag 
421 aaggctgggg ctcatttgca ggggggagcc aaaagggtca tcatctctgc 
cccctctgct 
481 gatgccccca tgttcgtcat gggtgtgaac catgagaagt atgacaacag 
cctcaagatc 
541 atcagcaatg cctcctgcac caccaactgc ttagcacccc tggccaaggt 
catccatgac 
601 aactttggta tcgtggaagg actcatgacc acagtccatg ccatcactgc 
cacccagaag 
661 actgtggatg gcccctccgg gaaactgtgg cgtgatggcc gcggggctct 
ccagaacatc 
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721 atccctgcct ctactggcgc tgccaaggct gtgggcaagg tcatccctga 
gctgaacggg 
781 aagctcactg gcatggcctt ccgtgtcccc actgccaacg tgtcagtggt 
ggacctgacc 
841 tgccgtctag aaaaacctgc caaatatgat gacatcaaga aggtggtgaa 
gcaggcgtcg 
901 gagggccccc tcaagggcat cctgggctac actgagcacc aggtggtctc 
ctctgacttc 
961 aacagcgaca cccactcctc cacctttgac gctggggctg gcattgccct 
caacgaccac 
1021 tttgtcaagc tcatttcctg gtatgacaac gaatttggct acagcaacag 
ggtggtggac 
1081 ctcatggccc acatggcctc caaggagtaa gacccctgga ccaccagccc 
cagcaagagc 
1141 acaagaggaa gagagagacc ctcactgctg gggagtccct gccacactca 
gtcccccacc 
1201 acactgaatc tcccctcctc acagttgcca tgtagacccc ttgaagaggg 
gaggggccta 
1261 gggagccgca ccttgtcatg taccatcaat aaagtaccct gtgctcaacc 
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Appendix 9.8 Amino acid and gene sequence for GAPDH Rattus norvegicus adapted 
 
from NCBI (http://www.ncbi.nlm.nih.gov) 
 
 
 
NCBI Reference Sequence: NM_017008.3 
 
Rattus norvegicus glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh), mRNA 
 
LOCUS NM_017008 1307 bp mRNA linear ROD 16-MAY-2010 
 
DEFINITION Rattus norvegicus glyceraldehyde-3-phosphate dehydrogenase 
 
(Gapdh), 
 
mRNA. 
 
ACCESSION  NM_017008 XM_216453 
 
VERSION    NM_017008.3 GI:110347607 
 
 
Amino Acid Sequence 
 
/translation="MVKVGVNGFGRIGRLVTRAAFSCDKVDIVAINDPFIDLNYMVYM 
FQYDSTHGKFNGTVKAENGKLVINGKPITIFQERDPANIKWGDAGAEYVVESTGVFTT 
MEKAGAHLKGGAKRVIISAPSADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAK 
VIHDNFGIVEGLMTTVHAITATQKTVDGPSGKLWRDGRGAAQNIIPASTGAAKAVGKV 
IPELNGKLTGMAFRVPTPNVSVVDLTCRLEKPAKYDDIKKVVKQAAEGPLKGILGYTE 
DQVVSCDFNSNSHSSTFDAGAGIALNDNFVKLISWYDNEYGYSNRVVDLMAYMASKE" 
Gene Sequence 
1 gggggctctc tgctcctccc tgttctagag acagccgcat cttcttgtgc 
agtgccagcc 
61 tcgtctcata gacaagatgg tgaaggtcgg tgtgaacgga tttggccgta 
tcggacgcct 
121 ggttaccagg gctgccttct cttgtgacaa agtggacatt gttgccatca 
acgacccctt 
181 cattgacctc aactacatgg tctacatgtt ccagtatgac tctacccacg 
gcaagttcaa 
241 cggcacagtc aaggctgaga atgggaagct ggtcatcaac gggaaaccca 
tcaccatctt 
301 ccaggagcga gatcccgcta acatcaaatg gggtgatgct ggtgctgagt 
atgtcgtgga 
361 gtctactggc gtcttcacca ccatggagaa ggctggggct cacctgaagg 
gtggggccaa 
421 aagggtcatc atctccgccc cttccgctga tgcccccatg tttgtgatgg 
gtgtgaacca 
481 cgagaaatat gacaactccc tcaagattgt cagcaatgca tcctgcacca 
ccaactgctt 
541 agcccccctg gccaaggtca tccatgacaa ctttggcatc gtggaagggc 
tcatgaccac 
601 agtccatgcc atcactgcca ctcagaagac tgtggatggc ccctctggaa 
agctgtggcg 
661 tgatggccgt ggggcagccc agaacatcat ccctgcatcc actggtgctg 
ccaaggctgt 
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721 gggcaaggtc atcccagagc tgaacgggaa gctcactggc atggccttcc 
gtgttcctac 
781 ccccaatgta tccgttgtgg atctgacatg ccgcctggag aaacctgcca 
agtatgatga 
841 catcaagaag gtggtgaagc aggcggccga gggcccacta aagggcatcc 
tgggctacac 
901 tgaggaccag gttgtctcct gtgacttcaa cagcaactcc cattcttcca 
cctttgatgc 
961 tggggctggc attgctctca atgacaactt tgtgaagctc atttcctggt 
atgacaatga 
1021 atatggctac agcaacaggg tggtggacct catggcctac atggcctcca 
aggagtaaga 
1081 aaccctggac cacccagccc agcaaggata ctgagagcaa gagagaggcc 
ctcagttgct 
1141 gaggagtccc catcccaact cagcccccaa cactgagcat ctccctcaca 
attccatccc 
1201 agaccccata acaacaggag gggcctgggg agccctccct tctctcgaat 
accatcaata 
1261 aagttcgctg caccctcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 
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Appendix  9.9  Output  page  generated  from  Primer3  for  HSPA1A  Homo  sapiens 
 
(adapted from Primer3). 
 
 
HSPA1A Primer3 Output Homo sapiens 
 
 
 
. 
 
Using 1-based sequence positions 
OLIGO        start  len  tm    gc%  any  3' seq 
LEFT PRIMER  1314 20 59.98 50.00 3.00 1.00 cgacctgaacaagagcatca 
RIGHT PRIMER 1526 20 60.02 50.00 6.00 0.00 aagatctgcgtctgcttggt 
SEQUENCE SIZE: 2445 
INCLUDED REGION SIZE: 2445 
 
PRODUCT SIZE: 213, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 3.00 
<+1313 nucleotides 
tccacccgcatccccaaggtgcagaagctgctgcaggacttcttcaacgggcgcgacctg 
>>>>>>> 
 
aacaagagcatcaaccccgacgaggctgtggcctacggggcggcggtgcaggcggccatc 
>>>>>>>>>>>>> 
 
ctgatgggggacaagtccgagaacgtgcaggacctgctgctgctggacgtggctcccctg 
tcgctggggctggagacggccggaggcgtgatgactgccctgatcaagcgcaactccacc 
atccccaccaagcagacgcagatctt 
<<<<<<<<<<<<<<<<<<<< 
 
+919 nucleotides> 
Key: 
>>>>>> left (sense)forward primer binding site 
<<<<<< right(antisense)reverse primer binding site 
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Appendix  9.10  Output  page  generated  from  Primer3  for  HSPA1B  Homo  sapiens 
 
(adapted from Primer3). 
 
 
HSPA1B Primer3 Output Homo sapiens 
 
 
 
Using 1-based sequence positions 
OLIGO start  len   tm   gc%  any   3' seq 
LEFT PRIMER 1287 20 59.98 50.00 3.00 1.00 
cgacctgaacaagagcatca 
RIGHT PRIMER 1499 20 60.02 50.00 6.00 0.00 
aagatctgcgtctgcttggt 
SEQUENCE SIZE: 2551 
INCLUDED REGION SIZE: 2551 
 
PRODUCT SIZE: 213, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 3.00 
<+1260 nucleotides 
ctgctgcaggacttcttcaacgggcgcgacctgaacaagagcatcaaccccgacgaggct 
>>>>>>>>>>>>>>>>>>>> 
 
gtggcctacggggcggcggtgcaggcggccatcctgatgggggacaagtccgagaacgtg 
caggacctgctgctgctggacgtggctcccctgtcgctggggctggagacggccggaggc 
gtgatgactgccctgatcaagcgcaactccaccatccccaccaagcagacgcagatcttc 
<<<<<<<<<<<<<<<<<<<< 
 
+ 1051 nucleotides 
 
 
KEYS 
 
>>>>>> left (sense) forward primer binding site 
<<<<<< right (antisense) reverse primer binding site 
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Appendix 9.11 Output page generated from Primer3 for HSPA1A Rattus norvegicus 
 
(adapted from Primer3). 
 
 
HSPA1A Primer3 Output Rattus norvegicus 
 
Using 1-based sequence positions 
OLIGO start  len   tm   gc%  any   3' seq 
LEFT PRIMER 199 20 59.99 60.00 3.00 0.00 
gtgtggagagccaagaggag 
RIGHT PRIMER 354 20 60.04 45.00 5.00 0.00 
tttccaaactggatcgaagg 
SEQUENCE SIZE: 4045 
INCLUDED REGION SIZE: 4045 
 
PRODUCT SIZE: 156, PAIR ANY COMPL: 5.00, PAIR 3' COMPL: 0.00 
 
< + 180 nucleotides 
 
181 attaaaactggggttcctgtgtggagagccaagaggagacctaaggatggtggcttccac 
>>>>>>>>>>>>>>>>>>>> 
 
241 tagaccacgtctgtaaatcaatcaaacctaagaaaattcttggcccattaaataagaacc 
 
 
301 aactggaattccaggctcacctggaatctctacgccttcgatccagtttggaaaatttga 
<<<<<<<<<<<<<<<<<<<< 
 
+ 3685 nucleotides 
 
Key: 
 
>>>>>> left (sense)forward primer binding site 
<<<<<< right(antisense)reverse primer binding site 
456 
 
Appendix  9.12  Output  page  generated  from  Primer3  for  GAPDH  Homo  sapiens 
 
(adapted from Primer3). 
 
 
 
 
GAPDH Primer3 Output Homo sapiens 
 
 
Using 1-based sequence positions 
OLIGO start  len   tm   gc%  any    3' seq 
LEFT PRIMER  122 20 59.97 50.00 3.00 0.00 
gagtcaacggatttggtcgt 
RIGHT PRIMER 359 20 60.01 45.00 4.00 2.00 
ttgattttggagggatctcg 
SEQUENCE SIZE: 1310 
INCLUDED REGION SIZE: 1310 
 
PRODUCT SIZE: 238, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 1.00 
 
<+120 nucleotides 
 
121 ggagtcaacggatttggtcgtattgggcgcctggtcaccagggctgcttttaactctggt 
>>>>>>>>>>>>>>>>>>>> 
 
181 aaagtggatattgttgccatcaatgaccccttcattgacctcaactacatggtttacatg 
 
 
241 ttccaatatgattccacccatggcaaattccatggcaccgtcaaggctgagaacgggaag 
 
 
301 cttgtcatcaatggaaatcccatcaccatcttccaggagcgagatccctccaaaatcaag 
<<<<<<<<<<<<<<<<<<<< 
 
+950 nucleotides 
 
 
 
Key: 
 
>>>>>> left (sense)forward primer binding site 
<<<<<< right(antisense)reverse primer binding site 
457 
 
Appendix 9.13 Output page generated from Primer3 for GAPDH Rattus norvegicus 
 
(adapted from Primer3) 
 
 
GAPDH Primer3 Output Rattus norvegicus 
 
 
 
Using 1-based sequence positions 
OLIGO start  len   tm   gc%  any   3' seq 
LEFT PRIMER 29 20 60.02 50.00 4.00 0.00 
agacagccgcatcttcttgt 
RIGHT PRIMER 235 20 60.13 55.00 3.00 2.00 
cttgccgtgggtagagtcat 
SEQUENCE SIZE: 1307 
INCLUDED REGION SIZE: 1307 
 
PRODUCT SIZE: 207, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 0.00 
 
1 gggggctctctgctcctccctgttctagagacagccgcatcttcttgtgcagtgccagcc 
>>>>>>>>>>>>>>>>>>>> 
 
61 tcgtctcatagacaagatggtgaaggtcggtgtgaacggatttggccgtatcggacgcct 
 
 
121 ggttaccagggctgccttctcttgtgacaaagtggacattgttgccatcaacgacccctt 
 
 
181 cattgacctcaactacatggtctacatgttccagtatgactctacccacggcaagttcaa 
<<<<<<<<<<<<<<<<<<<< 
 
+ 1067 nucleotides 
 
Key: 
 
>>>>>> left (sense)forward primer binding site 
<<<<<< right(antisense)reverse primer binding site 
458 
 
Appendix 9.14 Gene Sequence Alignment for HSPA1A (1), HSPA1B (2) and HSPA1L 
 
(3) Homo sapiens 
 
 
 
SeqA NameLen(nt) SeqB NameLen(nt) Score 
========================================= 
1 1 2445 2 2 2551 90 
1 1 2445 3 3 2550 64 
2 2 2551 3 3 2550 61 
========================================= 
 
 
1 ATAAAAGCCCAGGGGCAAGCGGTCCGGATAACGGCTAGCCTGAGGAGCTGCTGCGACAGT 
60 
2 -------------------------GGAAAACGGCCAGCCTGAGGAGCTGCTGCGAGGGT 
35 
3 -----------------------------------------------------------T 1 
* 
 
1 CCACTACCTTTTTCGAGAGTGACTCCCGTTGTCCCAAGGCTTCCCAGAGCGAACCTGTGC 
120 
2 CCGCTTCGTCTTTCGAGAGTGACTCCCGCGGTCCCAAGGCTTTCCAGAGCGAACCTGTGC 
95 
3 TTGGAAAAAGATTACTGAGT---TGGAGCCGTCTCAAATTTGCAGGGAGGGACGGGGTGG 
58 
** **** * * *** *** * *** ** *** 
 
1 GGC-TGCAGGCACCGGCGCGTCGAGTTTCCGGCGTCCGGAAGGACCGAGCTCTTCTCGCG 
179 
2 GGC-TGCAGGCACCGGCGTGTTGAGTTTCCGGCGTTCCGAAGGACTGAGCTCTTGTCGCG 
154 
3 GGGGTGGGGGGACCCCGGTTGTGCAGTTTGATATTGAGGGAGCCCCCACCTACTCGCTGG 
118 
** ** ** *** * * ** * * ** * * ** * * * 
 
1 GATCCAGTGTTC----CGTTTCCAGCCCCCAATCTCAGAGCGGAGCCGACAGAGAGCAGG 
235 
2 GATCCCGTCCGC----CGTTTCCAGCCCCCAGTCTCAGAGCGGAGCCCACAGA--GCAGG 
208 
3 GGCTGCGTAATCTGGACGTTTCCAAACTGAAGCGAAGGCGTCGGGAGACTAGGCCTCAGA 
178 
* ** * ******** * * * * * * ** *** 
 
1 GAACC---GGCATGGCCAAAGCCGCGGCGATCGGCATCGACCTGGGCACCACCTACTCCT 
292 
2 GCACC---GGCATGGCCAAAGCCGCGGCGATCGGCATCGACCTGGGCACCACCTACTCCT 
265 
3 GAACCATGGCTACTGCCAAGGGAATCGCCATAGGCATCGACCTGGGCACCACCTACTCCT 
238 
* *** * * ***** * ** ** **************************** 
 
1 GCGTGGGGGTGTTCCAACACGGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCA 
352 
2 GCGTGGGGGTGTTCCAACACGGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCA 
325 
3 GTGTGGGGGTGTTCCAGCACGGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCA 
298 
* ************** ******************************************* 
 
1 CCACCCCCAGCTACGTGGCCTTCACGGACACCGAGCGGCTCATCGGGGATGCGGCCAAGA 
412 
2 CCACCCCCAGCTACGTGGCCTTCACGGACACCGAGCGGCTCATCGGGGATGCGGCCAAGA 
385 
3 CCACCCCCAGCTACGTGGCCTTCACAGACACCGAGCGGCTCATTGGGGATGCGGCCAAGA 
358 
************************* ***************** **************** 
898 
459 
 
1 ACCAGGTGGCGCTGAACCCGCAGAACACCGTGTTTGACGCGAAGCGGCTGATTGGCCGCA 
472 
2 ACCAGGTGGCGCTGAACCCGCAGAACACCGTGTTTGACGCGAAGCGGCTGATCGGCCGCA 
445 
3 ACCAGGTAGCAATGAATCCCCAGAACACTGTTTTTGATGCTAAACGTCTGATCGGCAGGA 
418 
******* ** **** ** ******** ** ***** ** ** ** ***** *** * * 
 
1 AGTTCGGCGACCCGGTGGTGCAGTCGGACATGAAGCACTGGCCTTTCCAGGTGATCAACG 
532 
2 AGTTCGGCGACCCGGTGGTGCAGTCGGACATGAAGCACTGGCCTTTCCAGGTGATCAACG 
505 
3 AATTTAATGATCCTGTTGTACAAGCAGATATGAAACTTTGGCCTTTTCAAGTGATTAATG 
478 
* ** ** ** ** ** ** * ** ***** * ******** ** ***** ** * 
 
1 ACGGAGACAAGCCCAAGGTGCAGGTGAGCTACAAGGGGGAGACCAAGGCATTCTACCCCG 
592 
2 ACGGAGACAAGCCCAAGGTGCAGGTGAGCTACAAGGGGGAGACCAAGGCATTCTACCCCG 
565 
3 AAGGAGGCAAGCCCAAAGTCCTTGTGTCCTACAAAGGGGAGAATAAAGCTTTCTACCCTG 
538 
* **** ********* ** * *** ****** ******* ** ** ******** * 
 
1 AGGAGATCTCGTCCATGGTGCTGACCAAGATGAAGGAGATCGCCGAGGCGTACCTGGGCT 
652 
2 AGGAGATCTCGTCCATGGTGCTGACCAAGATGAAGGAGATCGCCGAGGCGTACCTGGGCT 
625 
3 AGGAAATCTCTTCGATGGTATTGACTAAGTTGAAGGAGACTGCTGAGGCCTTTTTGGGCC 
598 
**** ***** ** ***** **** *** ********* ** ***** * ***** 
 
1 ACCCGGTGACCAACGCGGTGATCACCGTGCCGGCCTACTTCAACGACTCGCAGCGCCAGG 
712 
2 ACCCGGTGACCAACGCGGTGATCACCGTGCCGGCCTACTTCAACGACTCGCAGCGCCAGG 
685 
3 ACCCTGTCACCAATGCAGTGATTACCGTGCCAGCCTATTTCAATGACTCTCAACGTCAGG 
658 
**** ** ***** ** ***** ******** ***** ***** ***** ** ** **** 
 
1 CCACCAAGGATGCGGGTGTGATCGCGGGGCTCAACGTGCTGCGGATCATCAACGAGCCCA 
772 
2 CCACCAAGGATGCGGGTGTGATCGCGGGGCTCAACGTGCTGCGGATCATCAACGAGCCCA 
745 
3 CTACTAAGGATGCAGGTGTGATTGCTGGACTTAATGTGCTAAGAATCATCAATGAGCCCA 
718 
* ** ******** ******** ** ** ** ** ***** * ******** ******* 
 
1 CGGCCGCCGCCATCGCCTACGGCCTGGACAGAACGGGCAAGGGGGAGCGCAACGTGCTCA 
832 
2 CGGCCGCCGCCATCGCCTACGGCCTGGACAGAACGGGCAAGGGGGAGCGCAACGTGCTCA 
805 
3 CGGCTGCTGCCATTGCCTATGGTTTAGATAAAGGAGGTCAAGGAGAACGACATGTCCTGA 
778 
**** ** ***** ***** ** * ** * * ** * ** ** ** * ** ** * 
 
1 TCTTTGACCTGGGCGGGGGCACCTTCGACGTGTCCATCCTGACGATCGACGACGGCATCT 
892 
2 TCTTTGACCTGGGCGGGGGCACCTTCGACGTGTCCATCCTGACGATCGACGACGGCATCT 
865 
3 TTTTTGATCTGGGTGGAGGCACATTTGATGTGTCAATTCTGACCATAGATGATGGGATTT 
838 
* ***** ***** ** ***** ** ** ***** ** ***** ** ** ** ** ** * 
 
1 TCGAGGTGAAGGCCACGGCCGGGGACACCCACCTGGGTGGGGAGGACTTTGACAACAGGC 
952 
2 TCGAGGTGAAGGCCACGGCCGGGGACACCCACCTGGGTGGGGAGGACTTTGACAACAGGC 
925 
3 TTGAGGTAAAGGCCACTGCTGGGGACACTCACCTGGGTGGGGAGGACTTTGACAACAGGC 
1465 
460 
 
* ***** ******** ** ******** ******************************* 
 
1 TGGTGAACCACTTCGTGGAGGAGTTCAAGAGAAAACACAAGAAGGACATCAGCCAGAACA 
1012 
2 TGGTGAACCACTTCGTGGAGGAGTTCAAGAGAAAACACAAGAAGGACATCAGCCAGAACA 
985 
3 TTGTGAGCCACTTCGTGGAGGAGTTCAAGAGGAAACACAAAAAGGACATCAGCCAGAACA 
958 
* **** ************************ ******** ******************* 
 
1 AGCGAGCCGTGAGGCGGCTGCGCACCGCCTGCGAGAGGGCCAAGAGGACCCTGTCGTCCA 
1072 
2 AGCGAGCCGTGAGGCGGCTGCGCACCGCCTGCGAGAGGGCCAAGAGGACCCTGTCGTCCA 
1045 
3 AGCGAGCCGTGAGGCGGCTGCGCACCGCCTGCGAGAGGGCCAAGAGGACCCTGTCGTCCA 
1018 
************************************************************ 
 
1 GCACCCAGGCCAGCCTGGAGATCGACTCCCTGTTTGAGGGCATCGACTTCTACACGTCCA 
1132 
2 GCACCCAGGCCAGCCTGGAGATCGACTCCCTGTTTGAGGGCATCGACTTCTACACGTCCA 
1105 
3 GCACCCAGGCCAACCTAGAAATTGATTCACTTTATGAAGGCATTGACTTCTATACATCCA 
1078 
************ *** ** ** ** ** ** * *** ***** ******** ** **** 
 
1 TCACCAGGGCGAGGTTCGAGGAGCTGTGCTCCGACCTGTTCCGAAGCACCCTGGAGCCCG 
1192 
2 TCACCAGGGCGAGGTTCGAGGAGCTGTGCTCCGACCTGTTCCGAAGCACCCTGGAGCCCG 
1165 
3 TCACCAGAGCTCGATTTGAAGAGTTGTGTGCAGACCTGTTTAGGGGTACCCTGGAGCCTG 
1138 
******* ** * ** ** *** **** * ******** * * *********** * 
 
1 TGGAGAAGGCTCTGCGCGACGCCAAGCTGGACAAGGCCCAGATTCACGACCTGGTCCTGG 
1252 
2 TGGAGAAGGCTCTGCGCGACGCCAAGCTGGACAAGGCCCAGATTCACGACCTGGTCCTGG 
1225 
3 TAGAAAAAGCGCTTCGGGATGCCAAGATGGATAAGGCTAAAATCCATGACATTGTTTTAG 
1198 
* ** ** ** ** ** ** ****** **** ***** * ** ** *** * ** * * 
 
1 TCGGGGGCTCCACCCGCATCCCCAAGGTGCAGAAGCTGCTGCAGGACTTCTTCAACGGGC 
1312 
2 TCGGGGGCTCCACCCGCATCCCCAAGGTGCAGAAGCTGCTGCAGGACTTCTTCAACGGGC 
1285 
3 TAGGGGGCTCCACCCGCATCCCCAAGGTGCAGCGGCTGCTTCAGGACTACTTCAATGGAC 
1258 
* ****************************** ****** ******* ****** ** * 
 
1 GCGACCTGAACAAGAGCATCAACCCCGACGAGGCTGTGGCCTACGGGGCGGCGGTGCAGG 
1372 
2 GCGACCTGAACAAGAGCATCAACCCCGACGAGGCTGTGGCCTACGGGGCGGCGGTGCAGG 
1345 
3 GTGATCTCAACAAGAGCATCAACCCTGATGAGGCCGTAGCATATGGGGCTGCGGTACAAG 
1318 
* ** ** ***************** ** ***** ** ** ** ***** ***** ** * 
 
1 CGGCCATCCTGATGGGGGACAAGTCCGAGAACGTGCAGGACCTGCTGCTGCTGGACGTGG 
1432 
2 CGGCCATCCTGATGGGGGACAAGTCCGAGAACGTGCAGGACCTGCTGCTGCTGGACGTGG 
1405 
3 CAGCCATCCTGATGGGGGACAAGTCTGAGAAGGTACAGGACCTGCTGCTGCTGGACGTGG 
1378 
* *********************** ***** ** ************************* 
 
1 CTCCCCTGTCGCTGGGGCTGGAGACGGCCGGAGGCGTGATGACTGCCCTGATCAAGCGCA 
1492 
2 CTCCCCTGTCGCTGGGGCTGGAGACGGCCGGAGGCGTGATGACTGCCCTGATCAAGCGCA 
2032 
461 
 
3 CTCCCCTGTCCCTGGGGCTGGAGACGGCTGGGGGCGTGATGACTGCCCTGATAAAGCGCA 
1438 
********** ***************** ** ******************** ******* 
 
1 ACTCCACCATCCCCACCAAGCAGACGCAGATCTTCACCACCTACTCCGACAACCAACCCG 
1552 
2 ACTCCACCATCCCCACCAAGCAGACGCAGATCTTCACCACCTACTCCGACAACCAACCCG 
1525 
3 ACTCCACCATCCCCACCAAGCAGACACAGATTTTCACCACCTACTCTGACAACCAACCCG 
1498 
************************* ***** ************** ************* 
 
1 GGGTGCTGATCCAGGTGTACGAGGGCGAGAGGGCCATGACGAAAGACAACAATCTGTTGG 
1612 
2 GGGTGCTGATCCAGGTGTACGAGGGCGAGAGGGCCATGACGAAAGACAACAATCTGTTGG 
1585 
3 GGGTGCTGATCCAGGTGTATGAGGGCGAGAGGGCCATGACAAAGGACAACAACCTGCTGG 
1558 
******************* ******************** ** ******** *** *** 
 
1 GGCGCTTCGAGCTGAGCGGCATCCCTCCGGCCCCCAGGGGCGTGCCCCAGATCGAGGTGA 
1672 
2 GGCGCTTCGAGCTGAGCGGCATCCCTCCGGCCCCCAGGGGCGTGCCCCAGATCGAGGTGA 
1645 
3 GGCGGTTTGACCTGACTGGAATCCCTCCAGCACCCAGGGGAGTTCCTCAGATCGAGGTGA 
1618 
**** ** ** **** ** ******** ** ******** ** ** ************* 
 
1 CCTTCGACATCGATGCCAACGGCATCCTGAACGTCACGGCCACGGACAAGAGCACCGGCA 
1732 
2 CCTTCGACATCGATGCCAACGGCATCCTGAACGTCACGGCCACGGACAAGAGCACCGGCA 
1705 
3 CGTTTGACATTGATGCCAATGGTATTCTCAATGTCACAGCCACGGACAAGAGCACCGGCA 
1678 
* ** ***** ******** ** ** ** ** ***** ********************** 
 
1 AGGCCAACAAGATCACCATCACCAACGACAAGGGCCGCCTGAGCAAGGAGGAGATCGAGC 
1792 
2 AGGCCAACAAGATCACCATCACCAACGACAAGGGCCGCCTGAGCAAGGAGGAGATCGAGC 
1765 
3 AGGTGAACAAGATCACCATCACCAATGACAAGGGCCGCCTGAGCAAGGAGGAGATTGAGC 
1738 
*** ******************** ***************************** **** 
 
1 GCATGGTGCAGGAGGCGGAGAAGTACAAAGCGGAGGACGAGGTGCAGCGCGAGAGGGTGT 
1852 
2 GCATGGTGCAGGAGGCGGAGAAGTACAAAGCGGAGGACGAGGTGCAGCGCGAGAGGGTGT 
1825 
3 GCATGGTTCTGGATGCTGAGAAATATAAAGCTGAAGATGAGGTCCAGAGGGAGAAAATTG 
1798 
******* * *** ** ***** ** ***** ** ** ***** *** * **** * 
 
1 CAGCCAAGAACGCCCTGGAGTCCTACGCCTTCAACATGAAGAGCGCCGTGGAGGATGAGG 
1912 
2 CAGCCAAGAACGCCCTGGAGTCCTACGCCTTCAACATGAAGAGCGCCGTGGAGGATGAGG 
1885 
3 CTGCAAAGAATGCCTTAGAATCCTATGCTTTTAACATGAAGAGTGTTGTGAGTGATGAAG 
1858 
* ** ***** *** * ** ***** ** ** *********** * *** ***** * 
 
1 GGCTCAAGGGCAAGATCAGCGAGGCGGACAAGAAGAAGGTGCTGGACAAGTGTCAAGAGG 
1972 
2 GGCTCAAGGGCAAGATCAGCGAGGCGGACAAGAAGAAGGTTCTGGACAAGTGTCAAGAGG 
1945 
3 GTTTGAAGGGCAAGATTAGTGAGTCTGATAAAAATAAAATATTGGATAAATGCAACGAGC 
1918 
* * *********** ** *** * ** ** ** ** * **** ** ** * *** 
 
1 TCATCTCGTGGCTGGACGCCAACACCTTGGCCGAGAAGGACGAGTTTGAGCACAAGAGGA 
462  
2 TCATCTCGTGGCTGGACGCCAACACCTTGGCCGAGAAGGACGAGTTTGAGCACAAGAGGA 
2005 
3 TCCTTTCGTGGCTGGAGGTCAATCAACTGGCAGAGAAAGATGAGTTTGATCATAAGAGAA 
1978 
** * *********** * *** **** ***** ** ******** ** ***** * 
 
1 AGGAGCTGGAGCAGGTGTGTAACCCCATCATCAGCGGACTGTACCAGGGTGCCGGTGGTC 
2092 
2 AGGAGCTGGAGCAGGTGTGTAACCCCATCATCAGCGGACTGTACCAGGGTGCCGGTGGTC 
2065 
3 AGGAATTGGAGCAGATGTGTAACCCTATCATCACAAAACTCTACCAAGGAG---GATGCA 
2035 
**** ******** ********** ******* *** ***** ** * * * 
 
1 CCGGGCCTGGGGGCTTCGGGGCTCAGGGTCCCAAGGGAGGGTCTGGGTCAGGCCCCACCA 
2152 
2 CCGGGCCTGGCGGCTTCGGGGCTCAGGGTCCCAAGGGAGGGTCTGGGTCAGGCCCTACCA 
2125 
3 CTGGGCCTG---CCTGCGGAACAGGGTATGTGCCTGGAAGGCCTGCCACAGGCCCCACAA 
2092 
* ******* ** *** * * * *** ** *** ******* ** * 
 
1 TTGAGGAGGTAGATTAGGGGCCTTT--------------CCAAGATTGCTGTTTTTG--- 
2195 
2 TTGAGGAGGTGGATTAGGGGCCTTTG---------TTCTTTAGTATGTTTGTCTTTGAGG 
2176 
3 TTGAAGAAGTAGATTAATTCTTTTTAGAACTGAAGCATCCTAGGATGCCTCTACATGTAT 
2152 
**** ** ** ***** *** * ** * * ** 
 
1 -----TTTTGGAGCTTCAAGACTTTGCA-----TTTCCTAG--TATTTCTGTTT-GTCAG 
2242 
2 TGGACTGTTGGGACTCAAGGACTTTGCTGCTGTTTTCCTATGTCATTTCTGCTTCAGCTC 
2236 
3 TTCATTCCCCTCATCTTCAAACATCATT---ATTATTCTTGACCAGACCTGAAT-CTAAG 
2208 
* ** * * * ** * *** * 
 
1 TTCTCAATTTCCTGTGTTTGCAATGTTGAAATTTTTTG-GTGAAGTACTGAACTTGCTTT 
2301 
2 TTTGCTGCTTCACTTCTTTGTAAAGTTGTAACCTGATG-GTAATTAGCTGGCTTCATTAT 
2295 
3 TTACCATCCCTTGGAAATTCTGGAGAAGGAGTCTCATGCACCACCTATCACACTCCCTCA 
2268 
** * ** * * * * ** * * * 
 
1 TTTTCCGGTTT---CT-----ACATGCAGAGATGAATT---T----------ATACTGCC 
2340 
2 TTTTGTAGTACAACCG-----ATATGTTCATTAGAATT---CTTTGCATTTAATGTTGAT 
2347 
3 CATCCTGTTTCTGACTTTGGAATGGACTCAGGAAAACTAGGCCCCTCTTTAAACCGTGTG 
2328 
* * * * * ** * * ** 
 
1 AT-CTTACGACTATTTC-TTCTTTTTAATACACTTAACTCA-----------------GG 
2381 
2 AC-TGTAAGGGTGTTTCGTTCCCTTTAAATGAATCAACACT-----------------GC 
2389 
3 ATGTATTTGAATGTCTG-TTATTTCCAGCCACCCTAACATTCTTCTTCCTGTGTGGATGC 
2387 
* * * * * * ** * * *** * 
 
1 CCATTTTT---TAAGTTGGTTA--CTTCAAAGTAAATAAACTTTAAAATTC-AAAAAAAA 
2435 
2 CACCTTCTGTACGAGTTTGTTTGTTTTTTTTTTTTTTTTTTTTTTTTGCTT-GGCGAAAA 
2448 
3 TTATTTGTCAATCAGTAAATTTGTTCGTAAAGAAAATTACTTCTGGTATTTAGGCTGTGA 
2447 
** * *** ** * * * * * 
463  
1 AAAAAAAAAA-------------------------------------------------- 
2445 
2 CACTACAAAGGCTGGGAATGTATGTTTTTATAATTTGTTTATTTAAATATGAAAAATAAA 
2508 
3 ATGTACCTTGAAGGGGAGAGTTCATGGAGAGAGCATGTGTTCTCTGATTGTGAGGTCACT 
2507 
* 
 
1 ------------------------------------------- 
2 ATGTTAAACTTTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 25513 
GTGAATGATTAAATTGGTAAGGGTAAAGTAAAAAAAAAAAAAA 2550 
 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
464  
Appendix 9.15 Amino Acid Sequence Alignment for HSPA1A (1), HSPA1B (2) and 
 
HSPA1L (3) Homo sapiens 
 
 
 
 
SeqA NameLen(aa) SeqB NameLen(aa) Score 
========================================= 
1 1 624 2 2 641 100 
1 1 624 3 3 641 90 
2 2 641 3 3 641 89 
========================================= 
 
1 --MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQ 
58 
2 --MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQ 
58 
3 MATAKGIAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQ 
60 
**. ***************************************************** 
 
1 VALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEE 
118 
2 VALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEE 
118 
3 VAMNPQNTVFDAKRLIGRKFNDPVVQADMKLWPFQVINEGGKPKVLVSYKGENKAFYPEE 
120 
**:*****************.*****:*** *******:*.**** ******.******* 
 
1 ISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTA 
178 
2 ISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTA 
178 
3 ISSMVLTKLKETAEAFLGHPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTA 
180 
********:** ***:**:***************************************** 
 
1 AAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLV 
238 
2 AAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLV 
238 
3 AAIAYGLDKGGQGERHVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLV 
240 
********: *:***:******************************************** 
 
1 NHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSIT 
298 
2 NHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSIT 
298 
3 SHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQANLEIDSLYEGIDFYTSIT 
300 
.*****************************************.******:********** 
 
1 RARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRD 
358 
2 RARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRD 
358 
3 RARFEELCADLFRGTLEPVEKALRDAKMDKAKIHDIVLVGGSTRIPKVQRLLQDYFNGRD 
360 
********:****.*************:***:***:*************:****:***** 
 
1 LNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNS 
418 
2 LNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNS 
418 
3 LNKSINPDEAVAYGAAVQAAILMGDKSEKVQDLLLLDVAPLSLGLETAGGVMTALIKRNS 
420 
****************************:******************************* 
465  
1 TIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTF 
478 
2 TIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTF 
478 
3 TIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFDLTGIPPAPRGVPQIEVTF 
480 
*****************************************:*:**************** 
 
1 DIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSA 
538 
2 DIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSA 
538 
3 DIDANGILNVTATDKSTGKVNKITITNDKGRLSKEEIERMVLDAEKYKAEDEVQREKIAA 
540 
*******************.********************* :*************:::* 
 
1 KNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKE 
598 
2 KNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKE 
598 
3 KNALESYAFNMKSVVSDEGLKGKISESDKNKILDKCNELLSWLEVNQLAEKDEFDHKRKE 
600 
*************.*.**********:**:*:****:*::***:.* *******:***** 
 
1 LEQVCNPIISGLYQGAGGPGPGGFGA----------------- 624 
2 LEQVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD 641 
3 LEQMCNPIITKLYQG-GCTGP-ACGTGYVPGRPATGPTIEEVD 641 
***:*****: **** * .** . *: 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
 
 
 
MVFILAPW Non polar R-groups 
 
GNTSYQHC Polar R-groups 
 
KR Positively charged R-groups 
 
DE Negatively charged R-groups 
466  
Appendix 9.16 Gene Sequence for HSPA1A (1), HSPA1B (2) and HSPA1L (3) Rattus 
norvegicus 
 
 
SeqA NameLen(nt) SeqB NameLen(nt) Score 
========================================= 
1 1 4045 2 2 5918 78 
1 1 4045 3 3 2632 73 
2 2 5918 3 3 2632 74 
========================================= 
 
1 ---------------------------------------------------CCAGG---- 5 
2 GAATTCCAGCACTTGGGTGTCAAGGCTGGAGGAGCAAGAGTTTAAGGCTAGCCTGGGCTA 60 
3 ------------------------------------------------------------ 
 
 
1 ------------------------------------------------------------ 
2 CATGAGCCCCTATTTTGAAAAAGAAAACAAGAAATAAAAAAGTTAGAAAAAAGAAAAAAT 120 
3 ------------------------------------------------------------ 
 
 
1 ------------------------------------------------------------ 
2 GAAAACAAAAGATGTGTGCGTGTGTATGTGTGTGAGAGAGAGAGACAGTCTCTCTCTCTC 180 
3 ------------------------------------------------------------ 
 
 
1 ----------CATCCTTCTCTGAGTTTCTATCTTTCTCTCG------------------- 36 
2 TCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTGTGTATGTGTGTGTGTGAG 240 
3 ------------------------------------------------------------ 
 
 
1 ATTGTAACTCCT-----------------------------CTCTTCGACCATCAATACC 67 
2 ACAATTACTCCCTGCTGTGGACTGTTACCTCAGAACTAAGACTCTAATGCAATCTATTCT 300 
3 ------------------------------------------------------------ 
 
 
1 ATATTCAAAAAGGT------------------------------------CTTGTCTG-- 89 
2 TTTTTTAAAAAACAGGCTCGGGGCTGGGGATTTAGCTCAGTGGTAGAGCGCTTACCTAGG 360 
3 ------------------------------------------------------------ 
 
 
1 -----------CCT-----CCGATTTCAGCTCAGACTAATT------------------- 114 
2 AAGCGCAAGGCCCTGGGTTCGGTCCCCAGCTCCGAAAAAAAGAACCAAAAAAAAAAAAAA 420 
3 ------------------------------------------------------------ 
 
 
1 ----------------------------------------TCAGCCACTAATGTC----- 129 
2 ACCAAAAACAAAAAAAAAAAACAAAAAAAAACAAAACAAAACAGGCTCTAATGTAGATTG 480 
3 ------------------------------------------------------------ 
 
 
1 ------CCTCAAGAGC------------CCAACCCCATTTTTTCTTGG------------ 159 
2 GGCTAGCCTCAAACTCTTCATCCTCCTGCCTCCCCCTCCAAAGCATGAGGACTACAGAGG 540 
3 ------------------------------------------------------------ 
 
 
1 -----------------TTGCCAACACCCAAATCCAGAATTAAAACTGGGG--------- 193 
2 TGGGCCACCATACCCAGTAACCTCATACTGTTTCAAGACATCTAACTAGGGGGTCTTTAA 600 
3 ------------------------------------------------------------ 
 
 
1 ----TTCCTGTGTGGAG-AGCCAAGAG--------------------------------- 215 
2 TTCGTACACGGAAGGAGGAGCCCGGAAGAAGAAAAAGGGACATCACTGACAGCTAAACAT 660 
3 ------------------------------------------------------------ 
 
 
1 --------------------------------GAGACCTAAGGATGGTGGCTT------- 236 
1 -AACTGTGCGAGTCTGCGAACC--------------------------------CCCACA 664 
467 
 
2 ATTTATAATGAGAGGAGGTAGGGGACAGACAAGGGACGGAAAGGTGATGTCTAGGACAAA 720 
3 ------------------------------------------------------------ 
 
 
1 -------CCACTAGACCACGTCTGTAAATCAA-----------------TCAAACCTAAG 272 
2 AAGCTAACCACATAAACTAGTAGGTGGGTCCCGACACCTCTGCTTAGGGTCTCACCCAAA 780 
3 ------------------------------------------------------------ 
 
 
1 A----------------------------------------------------AAATTCT 280 
2 AGTCGGAGTTAACAGCACTGTGAGGCCAGATGCTATCAGAGGACAGGACACACCATCTCT 840 
3 ------------------------------------------------------------ 
 
 
1 TGGCCCATTAAATAAGAACCAACTGGAATTCCAGGCTCA------CCTGGAATCTCTACG 334 
2 CCACCTAGGAAAGGTGAACTGACAGGGGCAGCAGACACAGAAGAATCAGCAAACTCTTAA 900 
3 ------------------------------------------------------------ 
 
 
1 ---------------CCTTCGATCCAGTTTGGAAAATTTGAAGTCGCTGAGCCCCTACGA 379 
2 GTCAACCCTGAGGTTACTACAGCACAGAATAGAACAGTGCCTGGCAAGGAGCAGCTGTGT 960 
3 ------------------------------------------------------------ 
 
 
1 GTGGGGAGCTCCAGGAA--CATCCAAA--------------------------------- 404 
2 GAAGGAGAAGCCAAGCAGCCATCCTCAGCATTCTTCTTCTATTAATCTTTTGGGACAGGG 1020 
3 ------------------------------------------------------------ 
 
 
1 -----CTGAGCAACTGGGGTT-------------------CCCCCCACCCCCCACCCCGC 440 
2 TCTGCCTCTGTAACCTAGGCTGACCTTGACTCGCTGCAGTCCCTCTGCCCCACCCTCTAC 1080 
3 ------------------------------------------------------------ 
 
 
1 C-------------------------------------CCTCCCGG-----------CAA 452 
2 CGAAAGTTTTTTTTTTTCTCCTTTCTAATGCCAGGCTGCCGCCTGAGGCAAAGGGAGCGG 1140 
3 ------------------------------------------------------------ 
 
 
1 CTTTGAGCCT---------------------CTT------------CTGGGACAGATCCT 479 
2 CTTGCAGCCTGGCACGGTCGGTCGATTAAACCTTGCTCTCCCCGTCCTGGGACACTTTCC 1200 
3 ------------------------------------------------------------ 
 
 
1 CTGATTCCTAAATAAGTCC-------ATGAGGTCAGAGT--TAGCACTG----------- 519 
2 TTTTTTGGGTCACAGGTCCTCCTAACATGAGAACCGAGTGTTTACACAATGATGTTCTTT 1260 
3 ------------------------------------------------------------ 
 
 
1 ------CCATTGTAACGCGGCTGGAGGGG------------------------------- 542 
2 TGAAAACCGTGAAAACTCCACAGGCGATGTACTTGTACGTTAAGCGTGACATAAAGACAG 1320 
3 ------------------------------------------------------------ 
 
 
1 ------------------------GGTCACGTCAC------------------------- 553 
2 CAAAGCGAATAAACTATACTGCAAGATCTCTTCTCTTTCCCTATTTAAACCTAAAATGGA 1380 
3 ------------------------------------------------------------ 
 
 
1 ------------CGGACACG-------------CCCCCAGGCACCTCCCTTGGGTCTCCC 588 
2 GGGAGTGGGGGGCAGACACAGACAGGCGAGCATTCCACAGGCGCCCCCCCCACG-CTGTC 1439 
3 ------------------------------------------------------------ 
 
 
1 AAGGCTAGGAAGGGGAAGTTATAACCCTTAACT--CGAGC---------CCCATAATCAG 637 
2 ACTTCCAGGCAGGACCCAATCACAGACTTCTTAGCCAAGCGTTATCCCTCCCGTTTTGAG 1499 
3 ------------------------------------------------------------ 
468  
2 AAACTTTCTGCGTCCGCCATCCTGTAGGAAGAATTTGTACACCTTAAACTCCCTCCCTGG 1559 
3 ------------------------------------------------------------ 
 
 
1 AATCACAACCAACTGTC---CACAACACGGAGCTAGCAG----TGACCTTTCCTGTCCAT 717 
2 TCTGATTCCCAAATGTCTCTCACCGCCCAGCACTTTCAGGAGCTGACCCTTCTCAGCTTC 1619 
3 ------------------------------------------------------------ 
 
 
1 TCC-ACTCAGGCCTCAGTAATGCGTCGCCATAGCAACAGTGTCAACAGCAGCACCAGCAG 776 
2 ACATACAGAGACCGCTACCTTGCGTCGCCATGGCAACACTGTCACAACCGGAACAAGCAC 1679 
3 ------------------------------------------------------------ 
 
 
1 GTCCCGCCACCCTCCCCCACAGGAATCCGTCCTTTCCAGCTAACCCCAGATCTGTCTGGA 836 
2 TTCCTACCACCCCCCGCCTCAGGAATCCAATCTGTCCAGCGAAGCCCAGATCCGTCTGGA 1739 
3 ------------------------------------------------------------ 
 
 
1 GAGTTCTGAACAGGGGCGGAACCCTCAACTCCTATTACTCAAAGGAGGCGGGGAAGCTCC 896 
2 GAGTTCTGGACAAGGGCGGTACCCTCAACATGGATTACTCATGGGAGGCGGAGAAGCTCT 1799 
3 -----CAGAAGAGG-----------------------CTCAAAGTTGCCGG--------- 23 
*:*.* *.* ****:.* :* *** 
 
1 ACCCGACGCGAAACTGCTGGAAGATTCCTGGCCCCAAGGCCTCCTCCCGCTCGCTGATTG 956 
2 AACAGACCCGAAACTGCTGGAAGATTCCTGGCCCCAAGGCCTCCTCCCGCTCGCTGATTG 1859 
3 ------------------------------------------------------------ 
 
 
1 GCCCATGGGAGGGTGGGCGGGGCCGGAGGAGGCTCCTTAAAGGCGCAGGGCGGCGCGCAG 1016 
2 GCCCATGGGAGGGTGGGCGGGGCCGGAGGAGGCTCCTTAAAGGCGCAGGGCGGCGCGCAG 1919 
3 --------GAGG---GGCGGGGTGGGGGGTG-----------------GGGG-------G 48 
**** ******* **.**:* ** * * 
 
1 GACACCAGATTCCTCCTCTTAATCTGACAGAATCAGTTTCTGGTTCCACTCGCAGAGAAG 1076 
2 GACACCAGATTCCTCCTCCTAATCTGACAGAACCAGTTTCTGGTTCCACTCGCAGAGAAG 1979 
3 AACCCCAGTTG------CTCAGTTTGGATGTTCCTGGAGCT----CCCCACTCGTAGGGG 98 
.**.****:* * *.* **..:*:: *:* : ** **.*:* *. **..* 
 
1 CAGAGAAGCGGAGCAAGCGGCGCGTTCCAGAACCTCGGGCAAGACCAGCCTCTCCCAGAG 1136 
2 CAGAGAAGCGGAGCAAGCGGCGCGTTCCAGAACCTCGGGCAAGACCAGCCTCTCCCAGAG 2039 
3 CT---------------CAGCGACTTCAAATTTTCCAAACTGGATCG------------- 130 
*: *.***. ***.*.:: *...*:.** *. 
 
1 CATCCCCACCGCGAAGCGCAACCTTCTCCAGAGCATCCCCCAGCGGAGCGCACCCTTCCC 1196 
2 CATCCCCACCGCGAAGCGCAACCTTCTCCAGAGCATCCCCCAGCGGAGCGCACCCTTCCC 2099 
3 -------AAGGCGTAGAGATTCCAGG-------------------------------CCT 152 
*. ***:**.*.::**: ** 
 
1 CAGAGCATCCCCGCCGCCAAGCGCAACCTTCCAGAAGCAGAGAGCGGCGACATGGCCAAG 1256 
2 CAGAGCATCCCCGCCGCCAAGCGCAACCTTCCAGAAGCAGAGAGCGGCGACATGGCCAAG 2159 
3 CGGAAAACCATGGCTGCTAA------------------------------------TAAA 
*.**..* *. ** ** ** **. 
176 
1 AAAACAGCGATCGGCATCGACCTGGGCACCACCTACTCGTGCGTGGGCGTGTTCCAGCAC 1316 
2 AAAACAGCGATCGGCATCGACCTGGGCACCACCTACTCGTGCGTGGGCGTGTTCCAGCAC 2219 
3 GGAATGGCCATAGGCATCGACCTGGGCACCACCTACTCGTGCGTGGGCGTGTTCCAGCAC 
..** .** **.************************************************ 
236 
1 GGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCACGACCCCCAGCTACGTGGCC 1376 
2 GGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCACGACCCCCAGCTACGTGGCC 2279 
3 GGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCACGACCCCAAGCTACGTGGCC 
***********************************************.************ 
296 
1 TTCACCGACACCGAGCGGCTCATCGGGGACGCCGCCAAGAACCAGGTGGCGCTGAACCCG 1436 
2 TTCACCGACACCGAGCGGCTCATCGGGGACGCCGCCAAGAACCAGGTGGCGCTGAACCCG 2339 
3 TTCACCGACACCGAGCGGCTCATCGGGGACGCCGCCAAGAACCAGGTGGCCATGAATCCC 
************************************************** .**** ** 
356 
1 CAGAACACCGTGTTCGACGCGAAGCGGCTGATCGGCCGCAAGTTCGGCGACCCGGTGGTG 1496 
469  
2 CAGAACACCGTGTTCGACGCGAAGCGGCTGATCGGCCGCAAGTTCGGCGACCCGGTGGTG 2399 
3 CAGAACACTGTTTTTGACGCCAAACGTCTAATTGGCAGGAAGTTTAATGATCCCGTCGTG 416 
******** ** ** ***** **.** **.** ***.* ***** .. ** ** ** *** 
 
1 CAGTCGGACATGAAGCACTGGCCCTTCCAGGTGGTGAACGACGGCGACAAGCCCAAGGTG 1556 
2 CAGTCGGACATGAAGCACTGGCCCTTCCAGGTGGTGAACGACGGCGACAAGCCCAAGGTG 2459 
3 CAGTCGGATATGAAGCTGTGGCCATTTCAAGTGATCAATGAAGCGGGCAAGCCTAAGGTG 476 
******** *******: *****.** **.***.* ** **.* *.****** ****** 
 
1 CAGGTGAACTACAAGGGCGAGAACCGGTCGTTCTACCCGGAGGAGATCTCGTCCATGGTG 1616 
2 CAGGTGAACTACAAGGGCGAGAACCGGTCGTTCTACCCGGAGGAGATCTCGTCCATGGTG 2519 
3 CTGGTGTCCTACAAAGGAGAGAAGAAAGCCTTCTACCCGGAGGAGATCTCGTCCATGGTG 536 
*:****:.******.**.***** ... * ****************************** 
 
1 CTGACCAAGATGAAGGAGATCGCCGAGGCGTACCTGGGCCACCCGGTGACCAACGCGGTG 1676 
2 CTGACCAAGATGAAGGAGATCGCCGAGGCGTACCTGGGCCACCCGGTGACCAACGCGGTG 2579 
3 CTGACCAAGATGAAGGAGACTGCAGAGGCTTTTTTGGGCCACAGTGTCACCAACGCTGTG 596 
******************* **.***** *: ********. ** ******** *** 
 
1 ATCACCGTGCCCGCCTACTTCAACGACTCGCAGCGGCAGGCCACCAAGGACGCGGGCGTG 1736 
2 ATCACCGTGCCCGCCTACTTCAACGACTCGCAGCGGCAGGCCACCAAGGACGCGGGCGTG 2639 
3 ATCACCGTGCCAGCCTATTTCAATGACTCCCAGAGACAGGCCACTAAAGATGCAGGGGTC 656 
***********.***** ***** ***** ***.*.******** **.** **.** ** 
 
1 ATCGCGGGTCTGAACGTGCTGCGGATCATCAACGAGCCCACGGCGGCCGCCATCGCCTAC 1796 
2 ATCGCGGGTCTGAACGTGCTGCGGATCATCAACGAGCCCACGGCGGCCGCCATCGCCTAC 2699 
3 ATCGCAGGACTCAACGTGCTGCGAATCATCAATGAGCCCACAGCGGCGGCCATCGCCTAC 716 
*****.**:** ***********.******** ********.***** ************ 
 
1 GGGCTGGACCGGACCGGCAAGGGCGAGCGCAACGTGCTCATCTTCGACCTGGGGGGCGGC 1856 
2 GGGCTGGACCGGACCGGCAAGGGCGAGCGCAACGTGCTCATCTTCGACCTGGGGGGCGGC 2759 
3 GGCTTGGATAAAGGAAGTCACGGAGAGCGGCACGTGCTCATCTTCGACCTGGGGGGCGGC 776 
** **** .... ..* .* **.***** .***************************** 
 
1 ACGTTCGACGTGTCCATCCTGACGATCGACGACGGCATCTTCGAGGTGAAGGCCACGGCG 1916 
2 ACGTTCGACGTGTCCATCCTGACGATCGACGACGGCATCTTCGAGGTGAAGGCCACGGCG 2819 
3 ACGTTCGACGTGTCCATCCTGACGATCGACGACGGCATCTTCGAGGTGAAGGCCACGGCG 836 
************************************************************ 
 
1 GGCGACACGCACCTGGGCGGGGAGGACTTCGACAACCGGCTGGTGAGCCACTTCGTGGAG 1976 
2 GGCGACACGCACCTGGGCGGGGAGGACTTCGACAACCGGCTGGTGAGCCACTTCGTGGAG 2879 
3 GGCGACACGCACCTGGGCGGGGAGGACTTCGACAACCGGCTGGTGAGCCACTTCGTGGAG 896 
************************************************************ 
 
1 GAGTTCAAGAGGAAGCACAAGAAGGACATCAGCCAGAACAAGCGCGCGGTGCGGCGACTG 2036 
2 GAGTTCAAGAGGAAGCACAAGAAGGACATCAGCCAGAACAAGCGCGCGGTGCGGCGACTG 2939 
3 GAGTTCAAGAGGAAGCACAAGAAGGACATCAGCCAGAACAAGCGCGCGGTGCGGCGTCTG 956 
********************************************************:*** 
 
1 CGCACGGCGTGCGAGAGGGCCAAGAGGACGCTGTCGTCCAGCACCCAGGCCAGCCTGGAG 2096 
2 CGCACGGCGTGCGAGAGGGCCAAGAGGACGCTGTCGTCCAGCACCCAGGCCAGCCTGGAG 2999 
3 CGCACGGCGTGCGAGAGGGCCAAGAGGACGCTGTCGTCCAGCACCCAGGCCAACCTGGAG 1016 
****************************************************.******* 
 
1 ATCGACTCTCTGTTCGAGGGCATCGACTTCTACACGTCCATCACGCGGGCGCGGTTCGAG 2156 
2 ATCGACTCTCTGTTCGAGGGCATCGACTTCTACACGTCCATCACGCGGGCGCGGTTCGAG 3059 
3 ATCGACTCTCTGTACGAGGGCATCGACTTCTACACGTCCATCACGCGGGCGCGGTTCGAG 1076 
*************:********************************************** 
 
1 GAGCTGTGCTCGGACCTGTTCCGCGGCACGCTGGAGCCCGTGGAGAAGGCCCTGCGCGAC 2216 
2 GAGCTGTGCTCGGACCTGTTCCGCGGCACGCTGGAGCCCGTGGAGAAGGCCCTGCGCGAC 3119 
3 GAGCTGTGTGCAGACCTATTTAGAGGCACGCTTGAGCCCGTGGAGAAGTCTCTCCGGGAC 1136 
******** *.*****.** .*.******** *************** * ** ** *** 
 
1 GCCAAGCTGGACAAGGCGCAGATCCACGACCTGGTGCTGGTGGGCGGCTCGACGCGCATC 2276 
2 GCCAAGCTGGACAAGGCGCAGATCCACGACCTGGTGCTGGTGGGCGGCTCGACGCGCATC 3179 
3 GCCAAGATGGACAAGGCTAAAATCCATGACATTGTTCTAGTAGGGGGCTCTACCCGCATC 1196 
******.********** .*.***** ***.* ** **.**.** ***** ** ****** 
 
1 CCCAAGGTGCAGAAGCTGCTGCAGGACTTCTTCAACGGGCGCGACCTGAACAAGAGCATC 2336 
470  
2 CCCAAGGTGCAGAAGCTGCTGCAGGACTTCTTCAACGGGCGCGACCTGAACAAGAGCATC 3239 
3 CCAAAGGTGCAAAAGCTGCTTCAAGACTACTTTAATGGACGGGATCTCAACAAGAGTATC 1256 
**.********.******** **.****:*** ** **.** ** ** ******** *** 
 
1 AATCCGGACGAGGCGGTGGCCTACGGGGCGGCGGTGCAGGCGGCCATCCTGATGGGGGAC 2396 
2 AATCCGGACGAGGCGGTGGCCTACGGGGCGGCGGTGCAGGCGGCCATCCTGATGGGGGAC 3299 
3 AATCCCGATGAGGCGGTGGCGTACGGAGCTGCAGTCCAGGCAGCTATTTTAATGGGCGAC 1316 
***** ** *********** *****.** **.** *****.** ** *.***** *** 
 
1 AAGTCGGAGAACGTGCAGGACCTGCTGCTGCTGGACGTGGCGCCGCTGTCGCTGGGTCTG 2456 
2 AAGTCGGAGAACGTGCAGGACCTGCTGCTGCTGGACGTGGCGCCGCTGTCGCTGGGTCTG 3359 
3 AAATCTGAAAAAGTACAGGATTTGCTTTTGTTGGACGTAGCTCCCCTGTCTCTAGGATTG 1376 
**.** **.**.**.***** **** ** *******.** ** ***** **.**: ** 
 
1 GAGACCGCGGGCGGCGTGATGACGGCGCTCATCAAGCGCAACTCCACCATCCCCACCAAG 2516 
2 GAGACCGCGGGCGGCGTGATGACGGCGCTCATCAAGCGCAACTCCACCATCCCCACCAAG 3419 
3 GAGACAGCCGGGGGTGTGATGACTGTTCTGATCAAGCGCAACTCCACCATCCCCACCAAG 1436 
*****.** ** ** ******** * ** ****************************** 
 
1 CAGACGCAGACCTTCACCACCTACTCGGACAACCAGCCCGGGGTGCTGATCCAGGTGTAC 2576 
2 CAGACGCAGACCTTCACCACCTACTCGGACAACCAGCCCGGGGTGCTGATCCAGGTGTAC 3479 
3 CAGACGCAGATCTTCACCACCTACTCGGACAACCAGCCCGGGGTGCTGATCCAGGTGTAC 1496 
********** ************************************************* 
 
1 GAGGGCGAGAGGGCCATGACGCGCGACAACAACCTGCTGGGGCGCTTCGAGTTGAGCGGC 2636 
2 GAGGGCGAGAGGGCCATGACGCGCGACAACAACCTGCTGGGGCGCTTCGAGTTGAGCGGC 3539 
3 GAGGGCGAGAGGGCCATGACGCGCGACAACAACCTCCTGGGGCGCTTTGACCTGACTGGA 1556 
*********************************** *********** ** *** **. 
 
1 ATCCCGCCGGCTCCCAGGGGCGTGCCCCAGATCGAGGTGACCTTCGACATCGACGCCAAC 2696 
2 ATCCCGCCGGCTCCCAGGGGCGTGCCCCAGATCGAGGTGACCTTCGACATCGACGCCAAC 3599 
3 ATACCCCCTGCACCTAGGGGTGTGCCCCAGATCGAGGTGACCTTCGACATCGACGCCAAC 1616 
**.** ** **:** ***** *************************************** 
 
1 GGCATCCTGAACGTCACGGCCACTGACAAGAGCACCGGCAAGGCCAACAAGATCACCATC 2756 
2 GGCATCCTGAACGTCACGGCCACTGACAAGAGCACCGGCAAGGCCAACAAGATCACCATC 3659 
3 GGGATTCTCAACGTCACAGCCATGGACAAGAGCACCGGCAAGGCCAACAAGATCACCATC 1676 
** ** ** ********.**** ************************************ 
 
1 ACCAACGACAAGGGCCGCCTGAGCAAGGAGGAGATCGAGCGCATGGTGCAGGAGGCCGAG 2816 
2 ACCAACGACAAGGGCCGCCTGAGCAAGGAGGAGATCGAGCGCATGGTGCAGGAGGCCGAG 3719 
3 ACCAACGACAAGGGCCGCTTGAGCAAGGAGGAGATCGAGCGCATGGTGCAAGAGGCCGAG 1736 
****************** *******************************.********* 
 
1 CGCTACAAGGCGGAGGACGAGGTGCAGCGCGAGAGGGTGGCTGCCAAGAATGCGCTCGAG 2876 
2 CGCTACAAGGCGGAGGACGAGGTGCAGCGCGAGAGGGTGGCTGCCAAGAATGCGCTCGAG 3779 
3 CGGTACAAGGCCGAGGACGAGGGCCAGAGGGAGAAGATCGCTGCCAAAAATGCCTTAGAA 1796 
** ******** ********** ***.* ****.*.* ********.***** *.**. 
 
1 TCCTATGCCTTCAACATGAAGAGCGCCGTGGAGGACGAGGGTCTCAAGGGCAAGATCAGC 2936 
2 TCCTATGCCTTCAACATGAAGAGCGCCGTGGAGGACGAGGGTCTCAAGGGCAAGATCAGC 3839 
3 TCGTATGCCTTTAACATGAAGAGCGCTGTAGGCGATGAGGGTCTGAAGGACAAGATCAGC 1856 
** ******** ************** **.*. ** ******** ****.********** 
 
1 GAGGCTGACAAGAAGAAGGTGCTGGACAAGTGCCAGGAGGTCATCTCCTGGCTGGACTCT 2996 
2 GAGGCTGACAAGAAGAAGGTGCTGGACAAGTGCCAGGAGGTCATCTCCTGGCTGGACTCT 3899 
3 GAGTCTGATAAAAAGAAAATACTGGATAAATGCAGTGAGGTCCTTTCCTGGCTGGAGGCC 1916 
*** **** **.*****..*.***** **.***.. ******.* *********** * 
 
1 AACACGCTGGCTGAGAAAGAGGAGTTCGTGCACAAGCGGGAGGAGCTGGAGCGGGTGTGC 3056 
2 AACACGCTGGCTGAGAAAGAGGAGTTCGTGCACAAGCGGGAGGAGCTGGAGCGGGTGTGC 3959 
3 AACCAGCTGGCGGAGAAAGAAGAGTTCGATCATAAAAGAAAAGAGCTGGAAAACATGTGC 1976 
***..****** ********.*******: ** **..*..*.********... .***** 
 
1 AACCCGATCATCAGCGGGCTGTATCAGGGTGCGGGTGCTCCCGGGGCTGGGGGCTTCGGG 3116 
2 AACCCGATCATCAGCGGGCTGTATCAGGGTGCGGGTGCTCCCGGGGCTGGGGGCTTCGGG 4019 
3 AACCCTATCATCACAAAGCTGTACCAG--AGCGGCTGCACAGGGCCCAC----CTGCGCG 2030 
***** ******* ...****** *** :**** ***:*. ** *: ** ** * 
 
1 GCCCAGGCGCCCAAGGGAGGCTCTGGGTCGGGGCCCACCATCGAGGAGGTGGATTAGAGG 3176 
471  
 
2 GCCCAGGCGCCCAAGGGAGGCTCTGGGTCGGGGCCCACCATCGAGGAGGTGGATTAGAGG 4079 
3 CCAGGGTATACACCCGGCAGGGCTGCCACAGGCCCCACCATTGAGGAAGTAGATTA--GC 
*. .* . .*... **..* *** :*.** ******** *****.**.***** * 
2088 
1 CTCTTTCTGGCGCTCCAGGTGTGATCTAGGAGACAGATGGGTGG-CCTTGAGGACTTTGG 3235 
2 CT-TTTCTGGCTCTCAGGGTGTTGGCTAG-AGACAGACTCTTGATGGCTGCTGGTGCACG 4137 
3 CTTTCCCAGAAAGGCAGGGTG----CTAG-------------GGTGCCTCTAGGCG-ACA 
** * *:*.. *..**** **** *. * *. : . 
2130 
1 GTTATTGTCGTTTAGGACATTAACTCCTTCGTTCG-------------GTCTGCAATCAA 3282 
2 ATTCTTATCAAGTTACTCCTTCTCTCCGGAGTTCAGTTTAAAGTTACAGCCTTTTATACG 4197 
3 TTTATTCACCT----CCCAACATCACTGTGATTCT--------------TGAACTGACTG 
**.** :* : *.: .:*:* .*** : :.:. . 
2172 
1 GTCCTAGGTTTAAGCAAACTGCCTTCCATTTACTCTGTGGAATTTCACGTGTGCT----- 3337 
2 GTAATTGATTTGAGTTTGTTACATTTTGTATGCTCGTGGGTTTTTTATATATTCAAATTA 4257 
3 GACTTGAGCCTAAGTCACCATCCTTTGG---GATCTG----------------------- 
*:. * .. *.** : : *.** . ..** 
2206 
1 ---TTGCATTCCCAGTAAATTAGTACTGGGAGTGTGTCTTTGCAATAGATATAATTTCCT 3394 
2 AGGTTGCATGTTCTTTGCGTTTAATCTAAGTAGCTGTG-TAAAAATGGTGTTTCCTTCCT 4316 
3 ---ATGCAG-------------------------------------------AACCCACG 
:**** :. .* 
2220 
1 GCCTTCAAGTCAGCACTGCCCCCCCCCCCGAAGTTATTTCTTT--TGCAGGACAGTCAGA 3452 
2 GCGAACACCTCAGCACTGCCACCCTGTGTACAGTTTTTTCCTTGCATCCCTACAAACTGA 4376 
3 GACTCCGCCTTTCCACGCCCCCACCCTCTGATCTATGATCCTG-----------AACTGG 
*. : *.. * : *** **.*.* ..: *:: :** * .:*:*. 
2269 
1 GCTATATTG--------------------------------ATATAGCAAGAG------- 3473 
2 GAAAAAAAGTTATCTTTTGTAACTTAAACATTCAAAATAAAATGTTACAAGTATGTTTTG 4436 
3 -ATCTTTAG--------------------------------------------------- 
.:.::::* 
2277 
1 -------GTGTGTTACAAAAACACCAGGACACTG-------------------------- 3500 
2 TCCGTGTGTATGTTGGGAGGGCTAATGGATTCTGGGTTCATGTGGATTTCTTAGCTTTGC 4496 
3 ------------------CACAACCAGGCCCCTCT------------------------- 
. .:..:**. ** 
2294 
1 -------------------TTGAGTTCCTTTGT-------------------------GT 3516 
2 GATGACGGGGAAATGGGGTTTGGGTACTTTGGTTAGAAGTGTGGGTTTTGGGGTTGGGGA 4556 
3 -------------------TTGAG------------------------------------ 
***.* 
2299 
1 TTGGACTCT------------------------------CCCCTGGG--CG--------- 3535 
2 TTGAGCTCAGTGGTAGAGCGCTTGCCTAGGAAGCGCAAGGCCCTGGGTTCGGTCCCCAGC 4616 
3 ----------------------------------------CCTCGTG------------- 2306 
** * * 
 
1 -------------------------ACAGTGTTG-----AGGCACTGTTAAG-------- 3557 
2 TCCGAAAAAAGAACCAAAAAAAAAAAAAGTGTGGGTTTTCAGCGCAGTTATGCAGAAAAT 4676 
3 ------------------------------------------------------------ 
 
 
1 TCAGGAGCTCAG------------------------------------------------ 3569 
2 GCAGGTATTCGGTTTGAGGGTAGGACTCATTGGGGGGAACAGTAGGGTGGTGCTGTAGTT 4736 
3 --AAGAATTTGG------------------------------------------------ 2316 
*.*:. * .* 
 
1 --GGGCCACCG---GTGGATCACTGAAAGCTG---AGACTCTGTTG-CTTCTCCCGTTTG 3620 
2 GGGGGTCAGTGGAAGAGGGACTCTTAGGGCTATGATGACTCAGTTCTCTTAGCCCTCCAG 4796 
3 -------------------------ATGTCTG-------TTATTTATCATCCACACCCCG 2344 
* . **. * : ** *:*. .*. * 
 
1 ------------------------------------ACACTCTGTTG------------C 3632 
2 GGCTGAACCAGAACTGTTTCCCAACTTATGGGTCGAGACCTCTGTTGGAGTCAGACGACC 4856 
3 --------------------------------------CCTT------------------ 2348 
.** 
 
1 TTTCCTTGCATGGTGGCTCACCTAAG-------GCTGAGACTCTTG-------------- 3671 
472  
2 TTTCCACAGTGGTAGCCTCGGACATTGAAAATTGCAGGGGTTGTTGGTTGTCGGTTGGGT 4916 
3 TCACCTCCCTGTGTGGATG-------------------GTTATTTG-------------- 2375 
* :**: : :* .* * : *** 
 
1 -------TTCTCCT-----------------------TCCCTGTATAATCTTGCCTGGCC 3701 
2 TTTTGTTTTGTCTTGTTTTGTTTTTCAAGACAGGGTCTCTCTGTGTAGCCCTGGCTGGCC 4976 
3 -------------------------------------TCTCTCAGTAAATTTG------- 2391 
** ** :.**. ** 
 
1 ---------GTTGCACTTG---TTCCCCAGTGTG-------------------------- 3723 
2 TCGATTTCGGATCCACATGCCTTTCCCAAACCTGGCTTCCTTATTACTTTTTTTTTTTTT 5036 
3 ----------------------TTCCCAA------------------------------- 2398 
*****.* 
 
1 -----------------------------------------TGAACTCGGAG-------- 3734 
2 TTTAAGATTTATTTACTTATTATATATAAGTACAATGTAGCTGTCTTCAGAGACACCAGA 5096 
3 ------------------------------------------------------------ 
 
 
1 ------------------------ATGAGTTTACACCACCA--------CTG---TTAGT 3759 
2 AGAGGGCATCAGATCCCATTACAGATGGCTGTGAGCCACCATGTGGTTGCTGGGATTTGA 5156 
3 ---------------------------------------------------------AGG 2401 
:* 
 
1 TCACG-----------------TTTTTTGTTTTTACATAACCATCCTGAACTCAGGTCAA 3802 
2 ACTCAGGACCTCTTCAAGAGCAGTCAGTGCTCTTAACTTCTGAGCCCTCTCTCCAGCCCT 5216 
3 AAACG------------------TCTGTCACTTTTCGATTTGTTTAG--TCGAGGGCCTT 2441 
:.:*. * : * **:. :: : . :* . .* * : 
 
1 TTTTTACTGG-----------------------CTATTTGAAAATAAACTT--------- 3830 
2 TTATTACTTTTAGAGATTTCTTACCAGGTTGCCCTGGCTGTACTTACACTTTCTCTTTAG 5276 
3 ACTGTATATG----------------------TCTAGCTGACCTGACGCTT--------- 2470 
: : ** : **. **:..: *..*** 
 
1 -------------------------------------CAAAAGAACTTGCCAG------- 3846 
2 CTCTGCTGAGCTTTCAATTCACCAGTTCCAGACCACACCCCTGAACCCACCAGCTGAAGA 5336 
3 ---------------------------------------ACCGCATTGGCCAA------- 2484 
.. *.* .***. 
 
1 ------GTCTTG-----TGTCTGTTGTCTTTTGAGGTCAGGAAT--------TGCTGTGT 3887 
2 CAACATGTCTTGCTATCTTTTTCTTTCCTTTTTGGGGCAGGGATGGTCTGTGTGTTGTGT 5396 
3 ---------------------TTTGGTCCTTAACTTGCAGCAAT------CCTCCTGTCT 2517 
* * * **: *** .** * *** * 
 
1 ATGT------------------------------------CTTACAGA------------ 3899 
2 GTGTGAGAGACAGAGGCAGAGACATCCTTCCCATGTAGCCCTAACTGAGTCGGAAGTCAT 5456 
3 CTG---------------------------------CCACCTGAAT-------------- 2530 
** ** *.: 
 
1 ---TTGGACTACGCT-------------TGACTGACATTTTATGGTAAGATGG------- 3936 
2 TATTTAGACCAGGCTGCCCTGACTCCTGTATCTGCCTCTCCAATGGATTATGGGCACCTG 5516 
3 ---TTCGAGATTACG-------------GACCTGCACCATCATG---------------- 2558 
** ** : .* . ***.. : *: 
 
1 ------------------------------------------------------------ 
2 CCACCTCACCCACTCACTTTATCCCCAGGATCCCCCTCCCTCTTCCCAGGCAGTAGGTCT 5576 
3 ------------------------------------------------------------ 
 
 
1 ---GGTGGGGAG------------------------------------------------ 3945 
2 GGTGATGGAGAAGACCACTTACCATGTCCATGGCTCAAAGAAGCAGGCAGAACGTAGGGG 5636 
3 ------------------------------------------------------------ 
 
 
1 -------------CACCCAGGGACTTTG-------------------------------- 3960 
2 AAAGAGTTGCTTTCACCTCAAGCCTTTGGATCCATGGGTGTTCATTCTAGTGGGGTAATG 5696 
3 ---------------CCCAAC--------------------------------------- 2564 
** .. 
 
1 -----CATTGGGATCTGCTTG-TGTGAGAAAAATGAAAGCAG--------------TCAG 4000 
473  
2 CCATCCTTTGAGAGCTGGGGGGTGTGGGTCAACAGAGATCGGTTGCTATGTGTGCATGAG 5756 
3 -------TTGTGATTTTTTTTTTTTGGGAGGCAGGGTTTCTTG----------------- 2600 
*** ** * * **.*: ... *. : * 
 
1 ---AGCAAATAACAACCAG--TCCGGG--------------------GCTGAGGTCTAGT 4035 
2 GCCCGCAATTCAGTCCCTGGCTCCATGGAGAACGAACCAATCAGTTGGGTGAGGTGTAAA 5816 
3 --AAGCCTAGGTTAGCCTAG------------------------------AACATTCTAT 2628 
.**.:: : : **:. .* .* :.: 
 
1 ACAGTG--------------------CAGA------------------------------ 4045 
2 CCACATGTAATTTTAGCATGTCCAAACAGACACGTTAAGGACATCCTAGGGTAAAGAAGT 5876 
3 ACAC-------------------------------------------------------- 2632 
.** 
 
1 ------------------------------------------ 
2 CTTCAGCAATAGTTTAATTGAGGCAATTATGCTCATGAATTC 5918 
3 ------------------------------------------ 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
474  
Appendix 9.17 Amino Acid Sequence for HSPA1A (1), HSPA1B (2) and HSPA1L (3) 
 
Rattus norvegicus 
 
 
CLUSTAL 2.0.12 multiple sequence alignment 
SeqA NameLen(nt) SeqB NameLen(nt) Score 
========================================= 
1 1 641 2 2 641 100 
1 1 641 3 3 641 80 
2 2 641 3 3 641 80 
========================================= 
 
 
1 -- 
MAKKTAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQ 58 
2 -- 
MAKKTAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQ 58 
3 
MAANKGMAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQ 60 
* 
***************************************************** 
 
1 
VALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVVNDGDKPKVQVNYKGENRSFYPEE 118 
2 
VALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVVNDGDKPKVQVNYKGENRSFYPEE 118 
3 
VAMNPQNTVFDAKRLIGRKFNDPVVQSDMKLWPFQVINEAGKPKVLVSYKGEKKAFYPEE 120 
**:*****************.********* *****:*:..**** 
*.****:::***** 
 
1 
ISSMVLTKMKEIAEAYLGHPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTA 178 
2 
ISSMVLTKMKEIAEAYLGHPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTA 178 
3 
ISSMVLTKMKETAEAFLGHSVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTA 180 
*********** 
***:***.**************************************** 
 
1 
AAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLV 238 
2 
AAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLV 238 
3 
AAIAYGLDKGSHGERHVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLV 240 
********: 
.:***:******************************************** 
 
1 
SHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSIT 298 
2 
SHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSIT 298 
3 
SHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQANLEIDSLYEGIDFYTSIT 300 
 
******************************************.******:********** 
 
1 
RARFEELCSDLFRGTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRD 358 
2 
RARFEELCSDLFRGTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRD 358 
475  
3 
RARFEELCADLFRGTLEPVEKSLRDAKMDKAKIHDIVLVGGSTRIPKVQKLLQDYFNGRD 360 
 
********:************:*****:***:***:******************:***** 
 
1 
LNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNS 418 
2 
LNKSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNS 418 
3 
LNKSINPDEAVAYGAAVQAAILMGDKSEKVQDLLLLDVAPLSLGLETAGGVMTVLIKRNS 420 
 
****************************:************************.****** 
 
1 
TIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTRDNNLLGRFELSGIPPAPRGVPQIEVTF 478 
2 
TIPTKQTQTFTTYSDNQPGVLIQVYEGERAMTRDNNLLGRFELSGIPPAPRGVPQIEVTF 478 
3 
TIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTRDNNLLGRFDLTGIPPAPRGVPQIEVTF 480 
******** 
********************************:*:**************** 
 
1 
DIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAERYKAEDEVQRERVAA 538 
2 
DIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAERYKAEDEVQRERVAA 538 
3 
DIDANGILNVTAMDKSTGKANKITITNDKGRLSKEEIERMVQEAERYKAEDEGQREKIAA 540 
************ *************************************** 
***::** 
 
1 
KNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDSNTLAEKEEFVHKREE 598 
2 
KNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDSNTLAEKEEFVHKREE 598 
3 
KNALESYAFNMKSAVGDEGLKDKISESDKKKILDKCSEVLSWLEANQLAEKEEFDHKRKE 600 
*************** *****.****:****:****.**:***::* ******* 
***:* 
 
1 LERVCNPIISGLYQGAGAPGAGGFGAQAPKGGSGSGPTIEEVD 641 
2 LERVCNPIISGLYQGAGAPGAGGFGAQAPKGGSGSGPTIEEVD 641 
3 LENMCNPIITKLYQ-SGCTGPTCAPGYTP-GRAATGPTIEEVD 641 
**.:*****: *** :*..*. . :* * :.:******** 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
 
 
 
MVFILAPW Non polar R-groups 
 
GNTSYQHC Polar R-groups 
 
KR Positively charged R-groups 
 
DE Negatively charged R-groups 
476  
Appendix  9.18  Gene  Sequence  Alignment  for  HSPA1A  Homo  sapiens  v  Rattus 
norvegicus 
 
CLUSTAL 2.0.12 Multiple Sequence Alignments 
 
 
SeqA NameLen(nt) SeqB NameLen(nt) Score 
========================================= 
1 1 2445 2 2 4045 73 
========================================= 
 
 
1 ------------------------------------------------------------ 
2 CCAGGCATCCTTCTCTGAGTTTCTATCTTTCTCTCGATTGTAACTCCTCTCTTCGACCAT 
60 
 
 
1 ------------------------------------------------------------ 
2 CAATACCATATTCAAAAAGGTCTTGTCTGCCTCCGATTTCAGCTCAGACTAATTTCAGCC 
120 
 
 
1 ------------------------------------------------------------ 
2 ACTAATGTCCCTCAAGAGCCCAACCCCATTTTTTCTTGGTTGCCAACACCCAAATCCAGA 
180 
 
 
1 ------------------------------------------------------------ 
2 ATTAAAACTGGGGTTCCTGTGTGGAGAGCCAAGAGGAGACCTAAGGATGGTGGCTTCCAC 
240 
 
 
1 ------------------------------------------------------------ 
2 TAGACCACGTCTGTAAATCAATCAAACCTAAGAAAATTCTTGGCCCATTAAATAAGAACC 
300 
 
 
1 ------------------------------------------------------------ 
2 AACTGGAATTCCAGGCTCACCTGGAATCTCTACGCCTTCGATCCAGTTTGGAAAATTTGA 
360 
 
 
1 ------------------------------------------------------------ 
2 AGTCGCTGAGCCCCTACGAGTGGGGAGCTCCAGGAACATCCAAACTGAGCAACTGGGGTT 
420 
 
 
1 ------------------------------------------------------------ 
2 CCCCCCACCCCCCACCCCGCCCCTCCCGGCAACTTTGAGCCTCTTCTGGGACAGATCCTC 
480 
 
 
1 ------------------------------------------------------------ 
2 TGATTCCTAAATAAGTCCATGAGGTCAGAGTTAGCACTGCCATTGTAACGCGGCTGGAGG 
540 
 
 
1 ------------------------------------------------------------ 
2 GGGGTCACGTCACCGGACACGCCCCCAGGCACCTCCCTTGGGTCTCCCAAGGCTAGGAAG 
600 
 
 
1 ------------------------------------------------------------ 
2 GGGAAGTTATAACCCTTAACTCGAGCCCCATAATCAGAACTGTGCGAGTCTGCGAACCCC 
660 
477  
1 ------------------------------------------------------------ 
2 CACAAATCACAACCAACTGTCCACAACACGGAGCTAGCAGTGACCTTTCCTGTCCATTCC 
720 
 
 
1 ------------------------------------------------------------ 
2 ACTCAGGCCTCAGTAATGCGTCGCCATAGCAACAGTGTCAACAGCAGCACCAGCAGGTCC 
780 
 
 
1 ------------------------------------------------------------ 
2 CGCCACCCTCCCCCACAGGAATCCGTCCTTTCCAGCTAACCCCAGATCTGTCTGGAGAGT 
840 
 
 
1 ------------------------------------------------------------ 
2 TCTGAACAGGGGCGGAACCCTCAACTCCTATTACTCAAAGGAGGCGGGGAAGCTCCACCC 
900 
 
 
1 --------------------------------------------------ATAAAAGCCC 
10 
2 GACGCGAAACTGCTGGAAGATTCCTGGCCCCAAGGCCTCCTCCCGCTCGCTGATTGGCCC 
960 
* **** 
 
1 AGGGGCAAGCGGTCCGGAT----AACGGCTAGCCTGAGGAGCTG--CTGCG-ACAGTCCA 
63 
2 ATGGGAGGGTGGGCGGGGCCGGAGGAGGCTCCTTAAAGGCGCAGGGCGGCGCGCAGGACA 
1020 
* *** * ** * ** **** *** ** * * *** *** ** 
 
1 CTA----CCTTTTTCGAGAGTGACTCCCGTTGTCCCAAGGCT---TCCCAGAGC------ 
110 
2 CCAGATTCCTCCTCTTAATCTGACAGAATCAGTTTCTGGTTCCACTCGCAGAGAAGCAGA 
1080 
* * *** * * **** ** * * ** ***** 
 
1 GAACCTGTGCG-GCTGCAGGCACCGGCGCGTCGAGT------------TTCCGGCGT--- 
154 
2 GAAGCGGAGCAAGCGGCGCGTTCCAGAACCTCGGGCAAGACCAGCCTCTCCCAGAGCATC 
1140 
*** * * ** ** ** * ** * * *** * * ** * * 
 
1 ----CCGGAAGGACCGAGCTCTTCTCGCGGATCC--------AGTGTTCCGTTTCC---A 
199 
2 CCCACCGCGAAGCGCAACCTTCTCCAGAGCATCCCCCAGCGGAGCGCACCCTTCCCCAGA 
1200 
*** * * * * ** ** * * **** ** * ** ** ** * 
 
1 GC-CCCCAATCTCAGAGCGGAGCCGACAGAGAGCAGGGAAC--CGGCATGGCCAAAGCCG 
256 
2 GCATCCCCGCCGCCAAGCGCAACCTTCCAGAAGCAGAGAGCGGCGACATGGCCAAGAAAA 
1260 
** *** * * **** * ** * ***** ** * ** ********* 
 
1 CGGCGATCGGCATCGACCTGGGCACCACCTACTCCTGCGTGGGGGTGTTCCAACACGGCA 
316 
2 CAGCGATCGGCATCGACCTGGGCACCACCTACTCGTGCGTGGGCGTGTTCCAGCACGGCA 
1320 
* ******************************** ******** ******** ******* 
 
1 AGGTGGAGATCATCGCCAACGACCAGGGCAACCGCACCACCCCCAGCTACGTGGCCTTCA 
376 
2 AGGTGGAGATCATCGCCAACGACCAGGGCAACCGCACGACCCCCAGCTACGTGGCCTTCA 
1380 
************************************* ********************** 
 
1 CGGACACCGAGCGGCTCATCGGGGATGCGGCCAAGAACCAGGTGGCGCTGAACCCGCAGA 
436 
478  
2 CCGACACCGAGCGGCTCATCGGGGACGCCGCCAAGAACCAGGTGGCGCTGAACCCGCAGA 
1440 
* *********************** ** ******************************* 
 
1 ACACCGTGTTTGACGCGAAGCGGCTGATTGGCCGCAAGTTCGGCGACCCGGTGGTGCAGT 
496 
2 ACACCGTGTTCGACGCGAAGCGGCTGATCGGCCGCAAGTTCGGCGACCCGGTGGTGCAGT 
1500 
********** ***************** ******************************* 
 
1 CGGACATGAAGCACTGGCCTTTCCAGGTGATCAACGACGGAGACAAGCCCAAGGTGCAGG 
556 
2 CGGACATGAAGCACTGGCCCTTCCAGGTGGTGAACGACGGCGACAAGCCCAAGGTGCAGG 
1560 
******************* ********* * ******** ******************* 
 
1 TGAGCTACAAGGGGGAGACCAAGGCATTCTACCCCGAGGAGATCTCGTCCATGGTGCTGA 
616 
2 TGAACTACAAGGGCGAGAACCGGTCGTTCTACCCGGAGGAGATCTCGTCCATGGTGCTGA 
1620 
*** ********* **** * * * ******** ************************* 
 
1 CCAAGATGAAGGAGATCGCCGAGGCGTACCTGGGCTACCCGGTGACCAACGCGGTGATCA 
676 
2 CCAAGATGAAGGAGATCGCCGAGGCGTACCTGGGCCACCCGGTGACCAACGCGGTGATCA 
1680 
*********************************** ************************ 
 
1 CCGTGCCGGCCTACTTCAACGACTCGCAGCGCCAGGCCACCAAGGATGCGGGTGTGATCG 
736 
2 CCGTGCCCGCCTACTTCAACGACTCGCAGCGGCAGGCCACCAAGGACGCGGGCGTGATCG 
1740 
******* *********************** ************** ***** ******* 
 
1 CGGGGCTCAACGTGCTGCGGATCATCAACGAGCCCACGGCCGCCGCCATCGCCTACGGCC 
796 
2 CGGGTCTGAACGTGCTGCGGATCATCAACGAGCCCACGGCGGCCGCCATCGCCTACGGGC 
1800 
**** ** ******************************** ***************** * 
 
1 TGGACAGAACGGGCAAGGGGGAGCGCAACGTGCTCATCTTTGACCTGGGCGGGGGCACCT 
856 
2 TGGACCGGACCGGCAAGGGCGAGCGCAACGTGCTCATCTTCGACCTGGGGGGCGGCACGT 
1860 
***** * ** ******** ******************** ******** ** ***** * 
 
1 TCGACGTGTCCATCCTGACGATCGACGACGGCATCTTCGAGGTGAAGGCCACGGCCGGGG 
916 
2 TCGACGTGTCCATCCTGACGATCGACGACGGCATCTTCGAGGTGAAGGCCACGGCGGGCG 
1920 
******************************************************* ** * 
 
1 ACACCCACCTGGGTGGGGAGGACTTTGACAACAGGCTGGTGAACCACTTCGTGGAGGAGT 
976 
2 ACACGCACCTGGGCGGGGAGGACTTCGACAACCGGCTGGTGAGCCACTTCGTGGAGGAGT 
1980 
**** ******** *********** ****** ********* ***************** 
 
1 TCAAGAGAAAACACAAGAAGGACATCAGCCAGAACAAGCGAGCCGTGAGGCGGCTGCGCA 
1036 
2 TCAAGAGGAAGCACAAGAAGGACATCAGCCAGAACAAGCGCGCGGTGCGGCGACTGCGCA 
2040 
******* ** ***************************** ** *** **** ******* 
 
1 CCGCCTGCGAGAGGGCCAAGAGGACCCTGTCGTCCAGCACCCAGGCCAGCCTGGAGATCG 
1096 
2 CGGCGTGCGAGAGGGCCAAGAGGACGCTGTCGTCCAGCACCCAGGCCAGCCTGGAGATCG 
2100 
* ** ******************** ********************************** 
2820 
479 
 
1 ACTCCCTGTTTGAGGGCATCGACTTCTACACGTCCATCACCAGGGCGAGGTTCGAGGAGC 
1156 
2 ACTCTCTGTTCGAGGGCATCGACTTCTACACGTCCATCACGCGGGCGCGGTTCGAGGAGC 
2160 
**** ***** ***************************** ***** ************ 
 
1 TGTGCTCCGACCTGTTCCGAAGCACCCTGGAGCCCGTGGAGAAGGCTCTGCGCGACGCCA 
1216 
2 TGTGCTCGGACCTGTTCCGCGGCACGCTGGAGCCCGTGGAGAAGGCCCTGCGCGACGCCA 
2220 
******* *********** **** ******************** ************* 
 
1 AGCTGGACAAGGCCCAGATTCACGACCTGGTCCTGGTCGGGGGCTCCACCCGCATCCCCA 
1276 
2 AGCTGGACAAGGCGCAGATCCACGACCTGGTGCTGGTGGGCGGCTCGACGCGCATCCCCA 
2280 
************* ***** *********** ***** ** ***** ** ********** 
 
1 AGGTGCAGAAGCTGCTGCAGGACTTCTTCAACGGGCGCGACCTGAACAAGAGCATCAACC 
1336 
2 AGGTGCAGAAGCTGCTGCAGGACTTCTTCAACGGGCGCGACCTGAACAAGAGCATCAATC 
2340 
********************************************************** * 
 
1 CCGACGAGGCTGTGGCCTACGGGGCGGCGGTGCAGGCGGCCATCCTGATGGGGGACAAGT 
1396 
2 CGGACGAGGCGGTGGCCTACGGGGCGGCGGTGCAGGCGGCCATCCTGATGGGGGACAAGT 
2400 
* ******** ************************************************* 
 
1 CCGAGAACGTGCAGGACCTGCTGCTGCTGGACGTGGCTCCCCTGTCGCTGGGGCTGGAGA 
1456 
2 CGGAGAACGTGCAGGACCTGCTGCTGCTGGACGTGGCGCCGCTGTCGCTGGGTCTGGAGA 
2460 
* *********************************** ** *********** ******* 
 
1 CGGCCGGAGGCGTGATGACTGCCCTGATCAAGCGCAACTCCACCATCCCCACCAAGCAGA 
1516 
2 CCGCGGGCGGCGTGATGACGGCGCTCATCAAGCGCAACTCCACCATCCCCACCAAGCAGA 
2520 
* ** ** *********** ** ** ********************************** 
 
1 CGCAGATCTTCACCACCTACTCCGACAACCAACCCGGGGTGCTGATCCAGGTGTACGAGG 
1576 
2 CGCAGACCTTCACCACCTACTCGGACAACCAGCCCGGGGTGCTGATCCAGGTGTACGAGG 
2580 
****** *************** ******** **************************** 
 
1 GCGAGAGGGCCATGACGAAAGACAACAATCTGTTGGGGCGCTTCGAGCTGAGCGGCATCC 
1636 
2 GCGAGAGGGCCATGACGCGCGACAACAACCTGCTGGGGCGCTTCGAGTTGAGCGGCATCC 
2640 
***************** ******** *** ************** ************ 
 
1 CTCCGGCCCCCAGGGGCGTGCCCCAGATCGAGGTGACCTTCGACATCGATGCCAACGGCA 
1696 
2 CGCCGGCTCCCAGGGGCGTGCCCCAGATCGAGGTGACCTTCGACATCGACGCCAACGGCA 
2700 
* ***** ***************************************** ********** 
 
1 TCCTGAACGTCACGGCCACGGACAAGAGCACCGGCAAGGCCAACAAGATCACCATCACCA 
1756 
2 TCCTGAACGTCACGGCCACTGACAAGAGCACCGGCAAGGCCAACAAGATCACCATCACCA 
2760 
******************* **************************************** 
 
1 ACGACAAGGGCCGCCTGAGCAAGGAGGAGATCGAGCGCATGGTGCAGGAGGCGGAGAAGT 
1816 
2 ACGACAAGGGCCGCCTGAGCAAGGAGGAGATCGAGCGCATGGTGCAGGAGGCCGAGCGCT 
2445 
480 
 
**************************************************** *** * 
 
1 ACAAAGCGGAGGACGAGGTGCAGCGCGAGAGGGTGTCAGCCAAGAACGCCCTGGAGTCCT 
1876 
2 ACAAGGCGGAGGACGAGGTGCAGCGCGAGAGGGTGGCTGCCAAGAATGCGCTCGAGTCCT 
2880 
**** ****************************** * ******** ** ** ******* 
 
1 ACGCCTTCAACATGAAGAGCGCCGTGGAGGATGAGGGGCTCAAGGGCAAGATCAGCGAGG 
1936 
2 ATGCCTTCAACATGAAGAGCGCCGTGGAGGACGAGGGTCTCAAGGGCAAGATCAGCGAGG 
2940 
* ***************************** ***** ********************** 
 
1 CGGACAAGAAGAAGGTGCTGGACAAGTGTCAAGAGGTCATCTCGTGGCTGGACGCCAACA 
1996 
2 CTGACAAGAAGAAGGTGCTGGACAAGTGCCAGGAGGTCATCTCCTGGCTGGACTCTAACA 
3000 
* ************************** ** *********** ********* * **** 
 
1 CCTTGGCCGAGAAGGACGAGTTTGAGCACAAGAGGAAGGAGCTGGAGCAGGTGTGTAACC 
2056 
2 CGCTGGCTGAGAAAGAGGAGTTCGTGCACAAGCGGGAGGAGCTGGAGCGGGTGTGCAACC 
3060 
* **** ***** ** ***** * ******* ** ************ ****** **** 
 
1 CCATCATCAGCGGACTGTACCAGGGTGCCGGTGGTCCCGGGCCTGGGGGCTTCGGGGCTC 
2116 
2 CGATCATCAGCGGGCTGTATCAGGGTGCGGGTGCTCCCGGGGCTGGGGGCTTCGGGGCCC 
3120 
* *********** ***** ******** **** ******* **************** * 
 
1 AGGGTCCCAAGGGAGGGTCTGGGTCAGGCCCCACCATTGAGGAGGTAGATTAGGGGC-CT 
2175 
2 AGGCGCCCAAGGGAGGCTCTGGGTCGGGGCCCACCATCGAGGAGGTGGATTAGAGGCTCT 
3180 
*** *********** ******** ** ******** ******** ****** *** ** 
 
1 TTCCAAGATTGCTGTTTTTGTTTTGGAG-------------CTTCAAGACTTTGCATTTC 
2222 
2 TTCTGGCGCTCCAGGTGTGATCTAGGAGACAGATGGGTGGCCTTGAGGACTTTGGGTTAT 
3240 
*** * * * * * * * **** *** * ******* ** 
 
1 C-----------TAGTATTTCTGTTTGTCAGTTCTCAATT---TCCTGTGTTT--GCAA- 
2265 
2 TGTCGTTTAGGACATTAACTCCTTCGTTCGGTCTGCAATCAAGTCCTAGGTTTAAGCAAA 
3300 
* ** ** * ** ** **** **** **** **** 
 
1 ---TGTTGAAATTTTTTGGTGAAGTACTGAACTTGCTTTT--TTTCCGGTTTCTACATGC 
2320 
2 CTGCCTTCCATTTACTCTGTGGAATTTCACGTGTGCTTTGCATTCCCAGTAAATTAGTAC 
3360 
** * ** * *** * * ****** ** ** ** * * * 
 
1 AGAGA-TGAATTTATACTGCCATCTTACGACTATTTCTTCTTTTTAATACACTTAACTC- 
2378 
2 TGGGAGTGTGTCTTTGCAATAGATATAATTTCCTGCCTTCAAGTCAGCACTGCCCCCCCC 
3420 
* ** ** * * * * ** * **** * * ** * * 
 
1 ----AGGCCATTTTTTAAGTTGGTTACTTCAAAGTAAATAAACTT--TAAAATTCAAAAA 
2432 
2 CCCGAAGTTATTTCTTTTGCAGGACAGTCAGAGCTATATTGATATAGCAAGAGGTGTGTT 
3480 
* * **** ** * ** * * * ** ** * * ** * 
 
1 AAAAAAAAAAAAA----------------------------------------------- 
481  
2 ACAAAAACACCAGGACACTGTTGAGTTCCTTTGTGTTTGGACTCTCCCCTGGGCGACAGT 
3540 
* ***** * * 
 
1 ------------------------------------------------------------ 
2 GTTGAGGCACTGTTAAGTCAGGAGCTCAGGGGCCACCGGTGGATCACTGAAAGCTGAGAC 
3600 
 
 
1 ------------------------------------------------------------ 
2 TCTGTTGCTTCTCCCGTTTGACACTCTGTTGCTTTCCTTGCATGGTGGCTCACCTAAGGC 
3660 
 
 
1 ------------------------------------------------------------ 
2 TGAGACTCTTGTTCTCCTTCCCTGTATAATCTTGCCTGGCCGTTGCACTTGTTCCCCAGT 
3720 
 
 
1 ------------------------------------------------------------ 
2 GTGTGAACTCGGAGATGAGTTTACACCACCACTGTTAGTTCACGTTTTTTGTTTTTACAT 
3780 
 
 
1 ------------------------------------------------------------ 
2 AACCATCCTGAACTCAGGTCAATTTTTACTGGCTATTTGAAAATAAACTTCAAAAGAACT 
3840 
 
 
1 ------------------------------------------------------------ 
2 TGCCAGGTCTTGTGTCTGTTGTCTTTTGAGGTCAGGAATTGCTGTGTATGTCTTACAGAT 
3900 
 
 
1 ------------------------------------------------------------ 
2 TGGACTACGCTTGACTGACATTTTATGGTAAGATGGGGTGGGGAGCACCCAGGGACTTTG 
3960 
 
 
1 ------------------------------------------------------------ 
2 CATTGGGATCTGCTTGTGTGAGAAAAATGAAAGCAGTCAGAGCAAATAACAACCAGTCCG 
4020 
 
 
1 ------------------------- 
2 GGGCTGAGGTCTAGTACAGTGCAGA 4045 
 
 
 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
482  
Appendix 9.19 Amino Acid Sequence for HSPA1A Homo sapiens v Rattus norvegicus 
 
 
 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
SeqA NameLen(aa) SeqB NameLen(aa) Score 
========================================= 
1 1 641 2 2 641 96 
========================================= 
 
1 MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVA 
60 
2 MAKKTAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVA 
60 
*** :******************************************************* 
 
1 LNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEIS 
120 
2 LNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVVNDGDKPKVQVNYKGENRSFYPEEIS 
120 
**********************************:**********.****.::******* 
 
1 SMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAA 
180 
2 SMVLTKMKEIAEAYLGHPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAA 
180 
****************:******************************************* 
 
1 IAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNH 
240 
2 IAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVSH 
240 
**********************************************************.* 
 
1 FVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRA 
300 
2 FVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRA 
300 
************************************************************ 
 
1 RFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLN 
360 
2 RFEELCSDLFRGTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLN 
360 
***********.************************************************ 
 
1 KSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTI 
420 
2 KSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTI 
420 
************************************************************ 
 
1 PTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDI 
480 
2 PTKQTQTFTTYSDNQPGVLIQVYEGERAMTRDNNLLGRFELSGIPPAPRGVPQIEVTFDI 
480 
****** ***********************:***************************** 
 
1 DANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKN 
540 
2 DANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAERYKAEDEVQRERVAAKN 
540 
*******************************************:************:*** 
 
1 ALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKELE 
600 
2 ALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDSNTLAEKEEFVHKREELE 
600 
483  
******************************************:******:** ***:*** 
 
1 QVCNPIISGLYQGAGGPGPGGFGA 624 
2 RVCNPIISGLYQGAGAPGAGGFGA 624 
:**************.**.***** 
 
 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
 
 
 
MVFILAPW Non polar R-groups 
 
GNTSYQHC Polar R-groups 
 
KR Positively charged R-groups 
 
DE Negatively charged R-groups 
720 
484 
 
Appendix  9.20  Gene  Sequence  Alignment  for  HSPA1B  Homo  sapiens  v  Rattus 
norvegicus 
SeqA NameLen(nt) SeqB NameLen(nt) Score 
========================================= 
1 1 2551 2 2 5918 78 
========================================= 
 
1 ------------------------------------------------------------ 
2 GAATTCCAGCACTTGGGTGTCAAGGCTGGAGGAGCAAGAGTTTAAGGCTAGCCTGGGCTA 
60 
 
 
1 ------------------------------------------------------------ 
2 CATGAGCCCCTATTTTGAAAAAGAAAACAAGAAATAAAAAAGTTAGAAAAAAGAAAAAAT 
120 
 
 
1 ------------------------------------------------------------ 
2 GAAAACAAAAGATGTGTGCGTGTGTATGTGTGTGAGAGAGAGAGACAGTCTCTCTCTCTC 
180 
 
 
1 ------------------------------------------------------------ 
2 TCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTGTGTATGTGTGTGTGTGAG 
240 
 
 
1 ------------------------------------------------------------ 
2 ACAATTACTCCCTGCTGTGGACTGTTACCTCAGAACTAAGACTCTAATGCAATCTATTCT 
300 
 
 
1 ------------------------------------------------------------ 
2 TTTTTTAAAAAACAGGCTCGGGGCTGGGGATTTAGCTCAGTGGTAGAGCGCTTACCTAGG 
360 
 
 
1 ------------------------------------------------------------ 
2 AAGCGCAAGGCCCTGGGTTCGGTCCCCAGCTCCGAAAAAAAGAACCAAAAAAAAAAAAAA 
420 
 
 
1 ------------------------------------------------------------ 
2 ACCAAAAACAAAAAAAAAAAACAAAAAAAAACAAAACAAAACAGGCTCTAATGTAGATTG 
480 
 
 
1 ------------------------------------------------------------ 
2 GGCTAGCCTCAAACTCTTCATCCTCCTGCCTCCCCCTCCAAAGCATGAGGACTACAGAGG 
540 
 
 
1 ------------------------------------------------------------ 
2 TGGGCCACCATACCCAGTAACCTCATACTGTTTCAAGACATCTAACTAGGGGGTCTTTAA 
600 
 
 
1 ------------------------------------------------------------ 
2 TTCGTACACGGAAGGAGGAGCCCGGAAGAAGAAAAAGGGACATCACTGACAGCTAAACAT 
660 
 
 
1 ------------------------------------------------------------ 
2 ATTTATAATGAGAGGAGGTAGGGGACAGACAAGGGACGGAAAGGTGATGTCTAGGACAAA 
1560 
485 
 
1 ------------------------------------------------------------ 
2 AAGCTAACCACATAAACTAGTAGGTGGGTCCCGACACCTCTGCTTAGGGTCTCACCCAAA 
780 
 
 
1 ------------------------------------------------------------ 
2 AGTCGGAGTTAACAGCACTGTGAGGCCAGATGCTATCAGAGGACAGGACACACCATCTCT 
840 
 
 
1 ------------------------------------------------------------ 
2 CCACCTAGGAAAGGTGAACTGACAGGGGCAGCAGACACAGAAGAATCAGCAAACTCTTAA 
900 
 
 
1 ------------------------------------------------------------ 
2 GTCAACCCTGAGGTTACTACAGCACAGAATAGAACAGTGCCTGGCAAGGAGCAGCTGTGT 
960 
 
 
1 ------------------------------------------------------------ 
2 GAAGGAGAAGCCAAGCAGCCATCCTCAGCATTCTTCTTCTATTAATCTTTTGGGACAGGG 
1020 
 
 
1 ------------------------------------------------------------ 
2 TCTGCCTCTGTAACCTAGGCTGACCTTGACTCGCTGCAGTCCCTCTGCCCCACCCTCTAC 
1080 
 
 
1 ------------------------------------------------------------ 
2 CGAAAGTTTTTTTTTTTCTCCTTTCTAATGCCAGGCTGCCGCCTGAGGCAAAGGGAGCGG 
1140 
 
 
1 ------------------------------------------------------------ 
2 CTTGCAGCCTGGCACGGTCGGTCGATTAAACCTTGCTCTCCCCGTCCTGGGACACTTTCC 
1200 
 
 
1 ------------------------------------------------------------ 
2 TTTTTTGGGTCACAGGTCCTCCTAACATGAGAACCGAGTGTTTACACAATGATGTTCTTT 
1260 
 
 
1 ------------------------------------------------------------ 
2 TGAAAACCGTGAAAACTCCACAGGCGATGTACTTGTACGTTAAGCGTGACATAAAGACAG 
1320 
 
 
1 ------------------------------------------------------------ 
2 CAAAGCGAATAAACTATACTGCAAGATCTCTTCTCTTTCCCTATTTAAACCTAAAATGGA 
1380 
 
 
1 ------------------------------------------------------------ 
2 GGGAGTGGGGGGCAGACACAGACAGGCGAGCATTCCACAGGCGCCCCCCCCACGCTGTCA 
1440 
 
 
1 ------------------------------------------------------------ 
2 CTTCCAGGCAGGACCCAATCACAGACTTCTTAGCCAAGCGTTATCCCTCCCGTTTTGAGA 
1500 
 
 
1 ------------------------------------------------------------ 
2 AACTTTCTGCGTCCGCCATCCTGTAGGAAGAATTTGTACACCTTAAACTCCCTCCCTGGT 
486  
1 ------------------------------------------------------------ 
2 CTGATTCCCAAATGTCTCTCACCGCCCAGCACTTTCAGGAGCTGACCCTTCTCAGCTTCA 
1620 
 
 
1 ------------------------------------------------------------ 
2 CATACAGAGACCGCTACCTTGCGTCGCCATGGCAACACTGTCACAACCGGAACAAGCACT 
1680 
 
 
1 ------------------------------------------------------------ 
2 TCCTACCACCCCCCGCCTCAGGAATCCAATCTGTCCAGCGAAGCCCAGATCCGTCTGGAG 
1740 
 
 
1 ------------------------------------------------------------ 
2 AGTTCTGGACAAGGGCGGTACCCTCAACATGGATTACTCATGGGAGGCGGAGAAGCTCTA 
1800 
 
 
1 ------------------------------------------------------------ 
2 ACAGACCCGAAACTGCTGGAAGATTCCTGGCCCCAAGGCCTCCTCCCGCTCGCTGATTGG 
1860 
 
 
1 -----------------------GGAAAACGGCC------AGCCTGAGGAGCTGCTGCGA 
31 
2 CCCATGGGAGGGTGGGCGGGGCCGGAGGAGGCTCCTTAAAGGCGCAGGGCGGCGCGCAGG 
1920 
*** * * * ** ** * ** * 
 
1 GGGTCCGCTTCGTCTTTCGAGAGTGACTCCCGCGGTCCCAAGGCTTTCCAG-AGCGAACC 
90 
2 ACACCAGATTCCTCCTCCTAATCTGACAGAACCAGTTTCTGGTTCCACTCGCAGAGAAGC 
1980 
* * *** ** * * * **** * ** * * * * ** *** * 
 
1 TGTGCGGCTGCAGGCACCGGCGTGTT---GAGTTTCCGGCG-----------TTCCGAAG 
136 
2 AGAGAAGC-GGAGCAAGCGGCGCGTTCCAGAACCTCGGGCAAGACCAGCCTCTCCCAGAG 
2039 
* * ** * ** * ***** *** ** ** *** * ** ** 
 
1 GACT---------------GAGCTCTTGTCGCGGATCCC--------GTCCGCCGTTTCC 
173 
2 CATCCCCACCGCGAAGCGCAACCTTCTCCAGAGCATCCCCCAGCGGAGCGCACCCTTCCC 
2099 
* * ** * * * ***** * * ** ** ** 
 
1 ---AGC-CCCCAGTCTCAGAGCGGAGCCCAC----AGAGCAGGGCACCGGCATGGCCAAA 
225 
2 CAGAGCATCCCCGCCGCCAAGCGCAACCTTCCAGAAGCAGAGAGCGGCGACATGGCCAAG 
2159 
*** *** * * * **** * ** * ** ** ** ** ********* 
 
1 GCCGCGGCGATCGGCATCGACCTGGGCACCACCTACTCCTGCGTGGGGGTGTTCCAACAC 
285 
2 AAAACAGCGATCGGCATCGACCTGGGCACCACCTACTCGTGCGTGGGCGTGTTCCAGCAC 
2219 
* ******************************** ******** ******** *** 
 
1 GGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCACCACCCCCAGCTACGTGGCC 
345 
2 GGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCACGACCCCCAGCTACGTGGCC 
2279 
***************************************** ****************** 
2999 
487 
 
1 TTCACGGACACCGAGCGGCTCATCGGGGATGCGGCCAAGAACCAGGTGGCGCTGAACCCG 
405 
2 TTCACCGACACCGAGCGGCTCATCGGGGACGCCGCCAAGAACCAGGTGGCGCTGAACCCG 
2339 
***** *********************** ** *************************** 
 
1 CAGAACACCGTGTTTGACGCGAAGCGGCTGATCGGCCGCAAGTTCGGCGACCCGGTGGTG 
465 
2 CAGAACACCGTGTTCGACGCGAAGCGGCTGATCGGCCGCAAGTTCGGCGACCCGGTGGTG 
2399 
************** ********************************************* 
 
1 CAGTCGGACATGAAGCACTGGCCTTTCCAGGTGATCAACGACGGAGACAAGCCCAAGGTG 
525 
2 CAGTCGGACATGAAGCACTGGCCCTTCCAGGTGGTGAACGACGGCGACAAGCCCAAGGTG 
2459 
*********************** ********* * ******** *************** 
 
1 CAGGTGAGCTACAAGGGGGAGACCAAGGCATTCTACCCCGAGGAGATCTCGTCCATGGTG 
585 
2 CAGGTGAACTACAAGGGCGAGAACCGGTCGTTCTACCCGGAGGAGATCTCGTCCATGGTG 
2519 
******* ********* **** * * * ******** ********************* 
 
1 CTGACCAAGATGAAGGAGATCGCCGAGGCGTACCTGGGCTACCCGGTGACCAACGCGGTG 
645 
2 CTGACCAAGATGAAGGAGATCGCCGAGGCGTACCTGGGCCACCCGGTGACCAACGCGGTG 
2579 
*************************************** ******************** 
 
1 ATCACCGTGCCGGCCTACTTCAACGACTCGCAGCGCCAGGCCACCAAGGATGCGGGTGTG 
705 
2 ATCACCGTGCCCGCCTACTTCAACGACTCGCAGCGGCAGGCCACCAAGGACGCGGGCGTG 
2639 
*********** *********************** ************** ***** *** 
 
1 ATCGCGGGGCTCAACGTGCTGCGGATCATCAACGAGCCCACGGCCGCCGCCATCGCCTAC 
765 
2 ATCGCGGGTCTGAACGTGCTGCGGATCATCAACGAGCCCACGGCGGCCGCCATCGCCTAC 
2699 
******** ** ******************************** *************** 
 
1 GGCCTGGACAGAACGGGCAAGGGGGAGCGCAACGTGCTCATCTTTGACCTGGGCGGGGGC 
825 
2 GGGCTGGACCGGACCGGCAAGGGCGAGCGCAACGTGCTCATCTTCGACCTGGGGGGCGGC 
2759 
** ****** * ** ******** ******************** ******** ** *** 
 
1 ACCTTCGACGTGTCCATCCTGACGATCGACGACGGCATCTTCGAGGTGAAGGCCACGGCC 
885 
2 ACGTTCGACGTGTCCATCCTGACGATCGACGACGGCATCTTCGAGGTGAAGGCCACGGCG 
2819 
** ******************************************************** 
 
1 GGGGACACCCACCTGGGTGGGGAGGACTTTGACAACAGGCTGGTGAACCACTTCGTGGAG 
945 
2 GGCGACACGCACCTGGGCGGGGAGGACTTCGACAACCGGCTGGTGAGCCACTTCGTGGAG 
2879 
** ***** ******** *********** ****** ********* ************* 
 
1 GAGTTCAAGAGAAAACACAAGAAGGACATCAGCCAGAACAAGCGAGCCGTGAGGCGGCTG 
1005 
2 GAGTTCAAGAGGAAGCACAAGAAGGACATCAGCCAGAACAAGCGCGCGGTGCGGCGACTG 
2939 
*********** ** ***************************** ** *** **** *** 
 
1 CGCACCGCCTGCGAGAGGGCCAAGAGGACCCTGTCGTCCAGCACCCAGGCCAGCCTGGAG 
1065 
2 CGCACGGCGTGCGAGAGGGCCAAGAGGACGCTGTCGTCCAGCACCCAGGCCAGCCTGGAG 
1785 
488 
 
***** ** ******************** ****************************** 
 
1 ATCGACTCCCTGTTTGAGGGCATCGACTTCTACACGTCCATCACCAGGGCGAGGTTCGAG 
1125 
2 ATCGACTCTCTGTTCGAGGGCATCGACTTCTACACGTCCATCACGCGGGCGCGGTTCGAG 
3059 
******** ***** ***************************** ***** ******** 
 
1 GAGCTGTGCTCCGACCTGTTCCGAAGCACCCTGGAGCCCGTGGAGAAGGCTCTGCGCGAC 
1185 
2 GAGCTGTGCTCGGACCTGTTCCGCGGCACGCTGGAGCCCGTGGAGAAGGCCCTGCGCGAC 
3119 
*********** *********** **** ******************** ********* 
 
1 GCCAAGCTGGACAAGGCCCAGATTCACGACCTGGTCCTGGTCGGGGGCTCCACCCGCATC 
1245 
2 GCCAAGCTGGACAAGGCGCAGATCCACGACCTGGTGCTGGTGGGCGGCTCGACGCGCATC 
3179 
***************** ***** *********** ***** ** ***** ** ****** 
 
1 CCCAAGGTGCAGAAGCTGCTGCAGGACTTCTTCAACGGGCGCGACCTGAACAAGAGCATC 
1305 
2 CCCAAGGTGCAGAAGCTGCTGCAGGACTTCTTCAACGGGCGCGACCTGAACAAGAGCATC 
3239 
************************************************************ 
 
1 AACCCCGACGAGGCTGTGGCCTACGGGGCGGCGGTGCAGGCGGCCATCCTGATGGGGGAC 
1365 
2 AATCCGGACGAGGCGGTGGCCTACGGGGCGGCGGTGCAGGCGGCCATCCTGATGGGGGAC 
3299 
** ** ******** ********************************************* 
 
1 AAGTCCGAGAACGTGCAGGACCTGCTGCTGCTGGACGTGGCTCCCCTGTCGCTGGGGCTG 
1425 
2 AAGTCGGAGAACGTGCAGGACCTGCTGCTGCTGGACGTGGCGCCGCTGTCGCTGGGTCTG 
3359 
***** *********************************** ** *********** *** 
 
1 GAGACGGCCGGAGGCGTGATGACTGCCCTGATCAAGCGCAACTCCACCATCCCCACCAAG 
1485 
2 GAGACCGCGGGCGGCGTGATGACGGCGCTCATCAAGCGCAACTCCACCATCCCCACCAAG 
3419 
***** ** ** *********** ** ** ****************************** 
 
1 CAGACGCAGATCTTCACCACCTACTCCGACAACCAACCCGGGGTGCTGATCCAGGTGTAC 
1545 
2 CAGACGCAGACCTTCACCACCTACTCGGACAACCAGCCCGGGGTGCTGATCCAGGTGTAC 
3479 
********** *************** ******** ************************ 
 
1 GAGGGCGAGAGGGCCATGACGAAAGACAACAATCTGTTGGGGCGCTTCGAGCTGAGCGGC 
1605 
2 GAGGGCGAGAGGGCCATGACGCGCGACAACAACCTGCTGGGGCGCTTCGAGTTGAGCGGC 
3539 
********************* ******** *** ************** ******** 
 
1 ATCCCTCCGGCCCCCAGGGGCGTGCCCCAGATCGAGGTGACCTTCGACATCGATGCCAAC 
1665 
2 ATCCCGCCGGCTCCCAGGGGCGTGCCCCAGATCGAGGTGACCTTCGACATCGACGCCAAC 
3599 
***** ***** ***************************************** ****** 
 
1 GGCATCCTGAACGTCACGGCCACGGACAAGAGCACCGGCAAGGCCAACAAGATCACCATC 
1725 
2 GGCATCCTGAACGTCACGGCCACTGACAAGAGCACCGGCAAGGCCAACAAGATCACCATC 
3659 
*********************** ************************************ 
 
1 ACCAACGACAAGGGCCGCCTGAGCAAGGAGGAGATCGAGCGCATGGTGCAGGAGGCGGAG 
489 
 
2 ACCAACGACAAGGGCCGCCTGAGCAAGGAGGAGATCGAGCGCATGGTGCAGGAGGCCGAG 
3719 
******************************************************** *** 
 
1 AAGTACAAAGCGGAGGACGAGGTGCAGCGCGAGAGGGTGTCAGCCAAGAACGCCCTGGAG 
1845 
2 CGCTACAAGGCGGAGGACGAGGTGCAGCGCGAGAGGGTGGCTGCCAAGAATGCGCTCGAG 
3779 
***** ****************************** * ******** ** ** *** 
 
1 TCCTACGCCTTCAACATGAAGAGCGCCGTGGAGGATGAGGGGCTCAAGGGCAAGATCAGC 
1905 
2 TCCTATGCCTTCAACATGAAGAGCGCCGTGGAGGACGAGGGTCTCAAGGGCAAGATCAGC 
3839 
***** ***************************** ***** ****************** 
 
1 GAGGCGGACAAGAAGAAGGTTCTGGACAAGTGTCAAGAGGTCATCTCGTGGCTGGACGCC 
1965 
2 GAGGCTGACAAGAAGAAGGTGCTGGACAAGTGCCAGGAGGTCATCTCCTGGCTGGACTCT 
3899 
***** ************** *********** ** *********** ********* * 
 
1 AACACCTTGGCCGAGAAGGACGAGTTTGAGCACAAGAGGAAGGAGCTGGAGCAGGTGTGT 
2025 
2 AACACGCTGGCTGAGAAAGAGGAGTTCGTGCACAAGCGGGAGGAGCTGGAGCGGGTGTGC 
3959 
***** **** ***** ** ***** * ******* ** ************ ****** 
 
1 AACCCCATCATCAGCGGACTGTACCAGGGTGCCGGTGGTCCCGGGCCTGGCGGCTTCGGG 
2085 
2 AACCCGATCATCAGCGGGCTGTATCAGGGTGCGGGTGCTCCCGGGGCTGGGGGCTTCGGG 
4019 
***** *********** ***** ******** **** ******* **** ********* 
 
1 GCTCAGGGTCCCAAGGGAGGGTCTGGGTCAGGCCCTACCATTGAGGAGGTGGATTAGGGG 
2145 
2 GCCCAGGCGCCCAAGGGAGGCTCTGGGTCGGGGCCCACCATCGAGGAGGTGGATTAGAGG 
4079 
** **** *********** ******** ** ** ***** *************** ** 
 
1 CCTTTGT--TCTTTAGTATGTTTGTCTTTGAGGTGGACTGTTG--GGACTCAAGGACTTT 
2201 
2 CTTTTCTGGCTCTCAGGGTGTTGG--CTAGAGACAGACTCTTGATGGCTGCTGGTGCACG 
4137 
* *** * * ** **** * * *** **** *** ** * * * 
 
1 GCTGCTGTTTTCCTATGTCATTTCTGCTTCAGCTC--TTTGCTGCTTCACTTCTTTGTAA 
2259 
2 ATTCTTATCAAGTTACTCCTTCTCT-CCGGAGTTCAGTTTAAAGTTACAGCCTTTTATAC 
4196 
* * * ** * * *** * ** ** *** * * ** *** ** 
 
1 AGTTGT-AACCTGA---TGGTA-ATTAGCTGGCTTCATTATTTTTGTAGTACAACCGATA 
2314 
2 GGTAATTGATTTGAGTTTGTTACATTTTGTATGCTCGTGGGTTTTTTA-TATATTCAAAT 
4255 
** * * *** ** ** *** * ** * **** ** ** * * * 
 
1 TGTTCATTAGAATTCTTTGCATTTAATGTTGATA-CTGT-----AAGGGTGTTTCGTTCC 
2368 
2 TAAGGTTGCATGTTCTTTGCGTTTAATCTAAGTAGCTGTGTAAAAATGGTGTTTCCTTCC 
4315 
* * ******** ****** * ** **** ** ******** **** 
 
1 CTTTAAATGAATCAACACTGCCACCTTCTGTACGAGTTTGTTTGTTTTTTTTTTTTTTTT 
2428 
2 -TGCGAACACCTCAGCACTGCCACCCTGTGTAC-AGTTTTTTCCTTGCATCCCTACAAAC 
4373 
* ** *** ********** * ***** ***** ** ** * * 
490 
 
1 T-----------TTTTTTTGCTTGGCGAAAACACTACAAA--GGCTGGGA-ATGTATGTT 
2474 
2 TGAGAAAAAAAGTTATCTTTTGTAACTTAAACATTCAAAATAAAATGTTACAAGTATGTT 
4433 
* ** * ** * * ***** * *** ** * * ******* 
 
1 TTTATAATTTGTTTATTTAAAT-----ATGAAAAATAAA---ATGTTAAACTTTAAAAAA 
2526 
2 TTGTCCGTGTGTATGTTGGGAGGGCTAATGGATTCTGGGTTCATGTGGATTTCTTAGCTT 
4493 
** * *** * ** * *** * * **** * * * * 
 
1 AAAAAAAAAAAAAAAAAAAAAAAAA----------------------------------- 
2551 
2 TGCGATGACGGGGAAATGGGGTTTGGGTACTTTGGTTAGAAGTGTGGGTTTTGGGGTTGG 
4553 
* * *** 
 
1 ------------------------------------------------------------ 
2 GGATTGAGCTCAGTGGTAGAGCGCTTGCCTAGGAAGCGCAAGGCCCTGGGTTCGGTCCCC 
4613 
 
 
1 ------------------------------------------------------------ 
2 AGCTCCGAAAAAAGAACCAAAAAAAAAAAAAGTGTGGGTTTTCAGCGCAGTTATGCAGAA 
4673 
 
 
1 ------------------------------------------------------------ 
2 AATGCAGGTATTCGGTTTGAGGGTAGGACTCATTGGGGGGAACAGTAGGGTGGTGCTGTA 
4733 
 
 
1 ------------------------------------------------------------ 
2 GTTGGGGGTCAGTGGAAGAGGGACTCTTAGGGCTATGATGACTCAGTTCTCTTAGCCCTC 
4793 
 
 
1 ------------------------------------------------------------ 
2 CAGGGCTGAACCAGAACTGTTTCCCAACTTATGGGTCGAGACCTCTGTTGGAGTCAGACG 
4853 
 
 
1 ------------------------------------------------------------ 
2 ACCTTTCCACAGTGGTAGCCTCGGACATTGAAAATTGCAGGGGTTGTTGGTTGTCGGTTG 
4913 
 
 
1 ------------------------------------------------------------ 
2 GGTTTTTGTTTTGTCTTGTTTTGTTTTTCAAGACAGGGTCTCTCTGTGTAGCCCTGGCTG 
4973 
 
 
1 ------------------------------------------------------------ 
2 GCCTCGATTTCGGATCCACATGCCTTTCCCAAACCTGGCTTCCTTATTACTTTTTTTTTT 
5033 
 
 
1 ------------------------------------------------------------ 
2 TTTTTTAAGATTTATTTACTTATTATATATAAGTACAATGTAGCTGTCTTCAGAGACACC 
5093 
 
 
1 ------------------------------------------------------------ 
2 AGAAGAGGGCATCAGATCCCATTACAGATGGCTGTGAGCCACCATGTGGTTGCTGGGATT 
5153 
 
 
1 ------------------------------------------------------------ 
491 
 
2 TGAACTCAGGACCTCTTCAAGAGCAGTCAGTGCTCTTAACTTCTGAGCCCTCTCTCCAGC 
5213 
 
 
1 ------------------------------------------------------------ 
2 CCTTTATTACTTTTAGAGATTTCTTACCAGGTTGCCCTGGCTGTACTTACACTTTCTCTT 
5273 
 
 
1 ------------------------------------------------------------ 
2 TAGCTCTGCTGAGCTTTCAATTCACCAGTTCCAGACCACACCCCTGAACCCACCAGCTGA 
5333 
 
 
1 ------------------------------------------------------------ 
2 AGACAACATGTCTTGCTATCTTTTTCTTTCCTTTTTGGGGCAGGGATGGTCTGTGTGTTG 
5393 
 
 
1 ------------------------------------------------------------ 
2 TGTGTGTGAGAGACAGAGGCAGAGACATCCTTCCCATGTAGCCCTAACTGAGTCGGAAGT 
5453 
 
 
1 ------------------------------------------------------------ 
2 CATTATTTAGACCAGGCTGCCCTGACTCCTGTATCTGCCTCTCCAATGGATTATGGGCAC 
5513 
 
 
1 ------------------------------------------------------------ 
2 CTGCCACCTCACCCACTCACTTTATCCCCAGGATCCCCCTCCCTCTTCCCAGGCAGTAGG 
5573 
 
 
1 ------------------------------------------------------------ 
2 TCTGGTGATGGAGAAGACCACTTACCATGTCCATGGCTCAAAGAAGCAGGCAGAACGTAG 
5633 
 
 
1 ------------------------------------------------------------ 
2 GGGAAAGAGTTGCTTTCACCTCAAGCCTTTGGATCCATGGGTGTTCATTCTAGTGGGGTA 
5693 
 
 
1 ------------------------------------------------------------ 
2 ATGCCATCCTTTGAGAGCTGGGGGGTGTGGGTCAACAGAGATCGGTTGCTATGTGTGCAT 
5753 
 
 
1 ------------------------------------------------------------ 
2 GAGGCCCGCAATTCAGTCCCTGGCTCCATGGAGAACGAACCAATCAGTTGGGTGAGGTGT 
5813 
 
 
1 ------------------------------------------------------------ 
2 AAACCACATGTAATTTTAGCATGTCCAAACAGACACGTTAAGGACATCCTAGGGTAAAGA 
5873 
 
 
1 --------------------------------------------- 
2 AGTCTTCAGCAATAGTTTAATTGAGGCAATTATGCTCATGAATTC 5918 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
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Appendix 9.21 Amino Acid Sequence for HSPA1B Homo sapiens v Rattus norvegicus 
 
 
 
SeqA NameLen(aa) SeqB NameLen(aa) Score 
========================================= 
1 1 641 2 2 641 96 
========================================= 
 
1 MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVA 
60 
2 MAKKTAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVA 
60 
*** :******************************************************* 
 
1 LNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEIS 
120 
2 LNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVVNDGDKPKVQVNYKGENRSFYPEEIS 
120 
**********************************:**********.****.::******* 
 
1 SMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAA 
180 
2 SMVLTKMKEIAEAYLGHPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAA 
180 
****************:******************************************* 
 
1 IAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNH 
240 
2 IAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVSH 
240 
**********************************************************.* 
 
1 FVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRA 
300 
2 FVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRA 
300 
************************************************************ 
 
1 RFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLN 
360 
2 RFEELCSDLFRGTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLN 
360 
***********.************************************************ 
 
1 KSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTI 
420 
2 KSINPDEAVAYGAAVQAAILMGDKSENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTI 
420 
************************************************************ 
 
1 PTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDI 
480 
2 PTKQTQTFTTYSDNQPGVLIQVYEGERAMTRDNNLLGRFELSGIPPAPRGVPQIEVTFDI 
480 
****** ***********************:***************************** 
 
1 DANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKN 
540 
2 DANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAERYKAEDEVQRERVAAKN 
540 
*******************************************:************:*** 
 
1 ALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKELE 
600 
2 ALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDSNTLAEKEEFVHKREELE 
600 
******************************************:******:** ***:*** 
493 
 
1 QVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD 641 
2 RVCNPIISGLYQGAGAPGAGGFGAQAPKGGSGSGPTIEEVD 641 
:**************.**.******.*************** 
 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
 
 
 
 
 
MVFILAPW Non polar R-groups 
 
GNTSYQHC Polar R-groups 
 
KR Positively charged R-groups 
 
DE Negatively charged R-groups 
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Appendix  9.22  Gene  Sequence  Alignment  for  HSPA1L  Homo  sapiens  v  Rattus 
norvegicus 
 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
SeqA NameLen(nt) SeqB NameLen(nt) Score 
========================================= 
1 1 2550 2 2 2632 78 
========================================= 
 
 
 
1 TTTGGAAAAAGATTACTGAGTTGGAGCCGTCTCAAATTTGCAGGGAGGGACGGGGTGGGG 60 
2 ---------------CAGAAGAGG------CTCAAAGTTGCCGGGAGGGGCGGGGTGGGG 39 
*:**. :** ****** ****.*******.********** 
 
1 GGTGGGGGG-ACCCCGGTTGTGCAGTTTG-ATATTGAGGGAGCCCCCACCTACTCGCTGG 118 
2 GGTGGGGGGAACCCCAGTTGCTCAGTTTGGATGTTCCTGGAGCTCCCC---ACTCGTAGG 96 
********* *****.**** ******* **.** . ***** ***. ***** :** 
 
1 GGCTGCGTAATCTGGACGTTTCCAAACTGAAGCGAAGGCGTCGGGAGACTAGGCCTCAGA 178 
2 GGCTCAGCGACTTCAAATTTTCCAAACTGGATCGAAGGCGTAGAGATTCCAGGCCTCGGA 156 
**** .* .* * .*. ***********.* *********.*.** :* *******.** 
 
1 GAACCATGGCTACTGCCAAGGGAATCGCCATAGGCATCGACCTGGGCACCACCTACTCCT 238 
2 AAACCATGGCTGCTAATAAAGGAATGGCCATAGGCATCGACCTGGGCACCACCTACTCGT 216 
.**********.**.. **.***** ******************************** * 
 
1 GTGTGGGGGTGTTCCAGCACGGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCA 298 
2 GCGTGGGCGTGTTCCAGCACGGCAAGGTGGAGATCATCGCCAACGACCAGGGCAACCGCA 276 
* ***** **************************************************** 
 
1 CCACCCCCAGCTACGTGGCCTTCACAGACACCGAGCGGCTCATTGGGGATGCGGCCAAGA 358 
2 CGACCCCAAGCTACGTGGCCTTCACCGACACCGAGCGGCTCATCGGGGACGCCGCCAAGA 336 
* *****.*****************.***************** ***** ** ******* 
 
1 ACCAGGTAGCAATGAATCCCCAGAACACTGTTTTTGATGCTAAACGTCTGATCGGCAGGA 418 
2 ACCAGGTGGCCATGAATCCCCAGAACACTGTTTTTGACGCCAAACGTCTAATTGGCAGGA 396 
*******.**.************************** ** ********.** ******* 
 
1 AATTTAATGATCCTGTTGTACAAGCAGATATGAAACTTTGGCCTTTTCAAGTGATTAATG 478 
2 AGTTTAATGATCCCGTCGTGCAGTCGGATATGAAGCTGTGGCCATTTCAAGTGATCAATG 456 
*.*********** ** **.**. *.********.** *****:*********** **** 
 
1 AAGGAGGCAAGCCCAAAGTCCTTGTGTCCTACAAAGGGGAGAATAAAGCTTTCTACCCTG 538 
2 AAGCGGGCAAGCCTAAGGTGCTGGTGTCCTACAAAGGAGAGAAGAAAGCCTTCTACCCGG 516 
*** .******** **.** ** **************.***** ***** ******** * 
 
1 AGGAAATCTCTTCGATGGTATTGACTAAGTTGAAGGAGACTGCTGAGGCCTTTTTGGGCC 598 
2 AGGAGATCTCGTCCATGGTGCTGACCAAGATGAAGGAGACTGCAGAGGCTTTTTTGGGCC 576 
****.***** ** *****. **** ***:*************:***** ********** 
 
1 ACCCTGTCACCAATGCAGTGATTACCGTGCCAGCCTATTTCAATGACTCTCAACGTCAGG 658 
2 ACAGTGTCACCAACGCTGTGATCACCGTGCCAGCCTATTTCAATGACTCCCAGAGACAGG 636 
**. ********* **:***** ************************** **..*:**** 
 
1 CTACTAAGGATGCAGGTGTGATTGCTGGACTTAATGTGCTAAGAATCATCAATGAGCCCA 718 
2 CCACTAAAGATGCAGGGGTCATCGCAGGACTCAACGTGCTGCGAATCATCAATGAGCCCA 696 
* *****.******** ** ** **:***** ** *****..****************** 
 
1 CGGCTGCTGCCATTGCCTATGGTTTAGATAAAGGAGGTCAAGGAGAACGACATGTCCTGA 778 
2 CAGCGGCGGCCATCGCCTACGGCTTGGATAAAGGAAGTCACGGAGAGCGGCACGTGCTCA 756 
*.** ** ***** ***** ** **.*********.****.*****.**.** ** ** * 
 
1 TTTTTGATCTGGGTGGAGGCACATTTGATGTGTCAATTCTGACCATAGATGATGGGATTT 838 
495 
 
2 TCTTCGACCTGGGGGGCGGCACGTTCGACGTGTCCATCCTGACGATCGACGACGGCATCT 816 
* ** ** ***** **.*****.** ** *****.** ***** **.** ** ** ** * 
 
1 TTGAGGTAAAGGCCACTGCTGGGGACACTCACCTGGGTGGGGAGGACTTTGACAACAGGC 898 
2 TCGAGGTGAAGGCCACGGCGGGCGACACGCACCTGGGCGGGGAGGACTTCGACAACCGGC 876 
* *****.******** ** ** ***** ******** *********** ******.*** 
 
1 TTGTGAGCCACTTCGTGGAGGAGTTCAAGAGGAAACACAAAAAGGACATCAGCCAGAACA 958 
2 TGGTGAGCCACTTCGTGGAGGAGTTCAAGAGGAAGCACAAGAAGGACATCAGCCAGAACA 936 
* ********************************.*****.******************* 
 
1 AGCGAGCCGTGAGGCGGCTGCGCACCGCCTGCGAGAGGGCCAAGAGGACCCTGTCGTCCA 1018 
2 AGCGCGCGGTGCGGCGTCTGCGCACGGCGTGCGAGAGGGCCAAGAGGACGCTGTCGTCCA 996 
****.** ***.**** ******** ** ******************** ********** 
 
1 GCACCCAGGCCAACCTAGAAATTGATTCACTTTATGAAGGCATTGACTTCTATACATCCA 1078 
2 GCACCCAGGCCAACCTGGAGATCGACTCTCTGTACGAGGGCATCGACTTCTACACGTCCA 1056 
****************.**.** ** **:** ** **.***** ******** **.**** 
 
1 TCACCAGAGCTCGATTTGAAGAGTTGTGTGCAGACCTGTTTAGGGGTACCCTGGAGCCTG 1138 
2 TCACGCGGGCGCGGTTCGAGGAGCTGTGTGCAGACCTATTTAGAGGCACGCTTGAGCCCG 1116 
**** .*.** **.** **.*** *************.*****.** ** ** ***** * 
 
1 TAGAAAAAGCGCTTCGGGATGCCAAGATGGATAAGGCTAAAATCCATGACATTGTTTTAG 1198 
2 TGGAGAAGTCTCTCCGGGACGCCAAGATGGACAAGGCTAAAATCCATGACATTGTTCTAG 1176 
*.**.**. * ** ***** *********** ************************ *** 
 
1 TAGGGGGCTCCACCCGCATCCCCAAGGTGCAGCGGCTGCTTCAGGACTACTTCAATGGAC 1258 
2 TAGGGGGCTCTACCCGCATCCCAAAGGTGCAAAAGCTGCTTCAAGACTACTTTAATGGAC 1236 
********** ***********.********...*********.******** ******* 
 
1 GTGATCTCAACAAGAGCATCAACCCTGATGAGGCCGTAGCATATGGGGCTGCGGTACAAG 1318 
2 GGGATCTCAACAAGAGTATCAATCCCGATGAGGCGGTGGCGTACGGAGCTGCAGTCCAGG 1296 
* ************** ***** ** ******** **.**.** **.*****.**.**.* 
 
1 CAGCCATCCTGATGGGGGACAAGTCTGAGAAGGTACAGGACCTGCTGCTGCTGGACGTGG 1378 
2 CAGCTATTTTAATGGGCGACAAATCTGAAAAAGTACAGGATTTGCTTTTGTTGGACGTAG 1356 
**** ** *.***** *****.*****.**.******** **** ** *******.* 
 
1 CTCCCCTGTCCCTGGGGCTGGAGACGGCTGGGGGCGTGATGACTGCCCTGATAAAGCGCA 1438 
2 CTCCCCTGTCTCTAGGATTGGAGACAGCCGGGGGTGTGATGACTGTTCTGATCAAGCGCA 1416 
********** **.**. *******.** ***** ********** *****.******* 
 
1 ACTCCACCATCCCCACCAAGCAGACACAGATTTTCACCACCTACTCTGACAACCAACCCG 1498 
2 ACTCCACCATCCCCACCAAGCAGACGCAGATCTTCACCACCTACTCGGACAACCAGCCCG 1476 
*************************.***** ************** ********.**** 
 
1 GGGTGCTGATCCAGGTGTATGAGGGCGAGAGGGCCATGACAAAGGACAACAACCTGCTGG 1558 
2 GGGTGCTGATCCAGGTGTACGAGGGCGAGAGGGCCATGACGCGCGACAACAACCTCCTGG 1536 
******************* ********************... *********** **** 
 
1 GGCGGTTTGACCTGACTGGAATCCCTCCAGCACCCAGGGGAGTTCCTCAGATCGAGGTGA 1618 
2 GGCGCTTTGACCTGACTGGAATACCCCCTGCACCTAGGGGTGTGCCCCAGATCGAGGTGA 1596 
**** *****************.** **:***** *****:** ** ************* 
 
1 CGTTTGACATTGATGCCAATGGTATTCTCAATGTCACAGCCACGGACAAGAGCACCGGCA 1678 
2 CCTTCGACATCGACGCCAACGGGATTCTCAACGTCACAGCCATGGACAAGAGCACCGGCA 1656 
* ** ***** ** ***** ** ******** ********** ***************** 
 
1 AGGTGAACAAGATCACCATCACCAATGACAAGGGCCGCCTGAGCAAGGAGGAGATTGAGC 1738 
2 AGGCCAACAAGATCACCATCACCAACGACAAGGGCCGCTTGAGCAAGGAGGAGATCGAGC 1716 
*** ******************** ************ **************** **** 
 
1 GCATGGTTCTGGATGCTGAGAAATATAAAGCTGAAGATGAGGTCCAGAGGGAGAAAATTG 1798 
2 GCATGGTGCAAGAGGCCGAGCGGTACAAGGCCGAGGACGAGGGCCAGAGGGAGAAGATCG 1776 
******* *:.** ** ***...** **.** **.** **** ************.** * 
 
1 CTGCAAAGAATGCCTTAGAATCCTATGCTTTTAACATGAAGAGTGTTGTGAGTGATGAAG 1858 
2 CTGCCAAAAATGCCTTAGAATCGTATGCCTTTAACATGAAGAGCGCTGTAGGCGATGAGG 1836 
****.**.************** ***** ************** * ***..* *****.* 
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1 GTTTGAAGGGCAAGATTAGTGAGTCTGATAAAAATAAAATATTGGATAAATGCAACGAGC 1918 
2 GTCTGAAGGACAAGATCAGCGAGTCTGATAAAAAGAAAATACTGGATAAATGCAGTGAGG 1896 
** ******.****** ** ************** ****** ************. *** 
 
1 TCCTTTCGTGGCTGGAGGTCAATCAACTGGCAGAGAAAGATGAGTTTGATCATAAGAGAA 1978 
2 TCCTTTCCTGGCTGGAGGCCAACCAGCTGGCGGAGAAAGAAGAGTTCGATCATAAAAGAA 1956 
******* ********** *** **.*****.********:***** ********.**** 
 
1 AGGAATTGGAGCAGATGTGTAACCCTATCATCACAAAACTCTACCAAGGAGGATGCACTG 2038 
2 AAGAGCTGGAAAACATGTGCAACCCTATCATCACAAAGCTGTACCAGAGCGGCTGCACAG 2016 
*.**. ****..* ***** *****************.** *****..*.**.*****:* 
 
1 GGCCTGCCTGCGGAACAGGGTATGTGCCTGGAAGGCCTGCCACAGGCCCCACAATTGAAG 2098 
2 GGCCCACCTGCGCGCCAGGGTATACACCCGGCAGGGCTGCCACAGGCCCCACCATTGAGG 2076 
**** .****** ..********. .** **.*** ****************.*****.* 
 
1 AAGTAGATTAATTCTTTTTAGAACTGAAGCATCCTAGGATGCCTCTACATGTATTTCATT 2158 
2 AAGTAGATTAGCCTTTCCCAGAAAGGCAGGGTGCTAGGGTGCCTCTAGGCGACATTTATT 2136 
**********. ** ****. *.** .* *****.******** . *:.:** *** 
 
1 CCCCTCATCTTCAAACATCATTATTATTCTT-----GACCAGACCTGAATCTAAGTTACC 2213 
2 CACCTC-----CCAACATCACTGTGATTCTTGAACTGACTGGACTTGAGCCTAAGTCACC 2191 
*.**** *.******* *.* ****** *** .*** ***. ****** *** 
 
1 ATCCCTTGGAAATTCTGGAGAAGGAGTCTCATGCACCACCTATCACACTCCCTCACATCC 2273 
2 ATCCTTTG--GGATCTGATGCAGAACCCACGGACTCCGCCTTTCCACGCCCCCACCCTCT 2249 
**** *** ..:****.:*.**.* *:*. .*:**.***:**... *** ..*.** 
 
1 TGTTTCTGACTTTGGAATGGA--CTCAGGAAAACTAGGCCCCTCTTTAAACCGTGTGATG 2331 
2 GATCTATGATCCTGAACTGGATCTTTAGCACAACCAGGCCCCTCTTTGAGCCTCGTGAAG 2309 
.* *.*** **.*.**** * ** *.*** ************.*.** ****:* 
 
1 TATTTGAATGTCTGTTATTTCCAG---CCACCCTAACATTCTTCTTCCTGTGTGGATGCT 2388 
2 AATTTGGATGTCTGTTATTTATCATCCACACCCCGCCTTTCACCTCCCTGTGTGGATGGT 2369 
:*****.*************. .. .***** ..*:***: ** ************ * 
 
1 TATTTGTCAATCAGTAAATTTGTTCGTAAAGAAAAT------TACTTCTGGTATT----- 2437 
2 TATTTGTCTCTCAGTAAATTTGTTCCCAAAGGAAACGTCTGTCACTTTTCGATTTGTTTA 2429 
********:.*************** ****.*** **** * *::** 
 
1 ---TAGG------CTGTGAATG------------------TACCTTGAAGGGGAGAGT-- 2468 
2 GTCGAGGGCCTTACTGTATATGTCTAGCTGACCTGACGCTTACCGCATTGGCCAATTTGG 2489 
*** ****.:*** **** .::** *.: * 
 
1 ------TCATGGAGAGAGCATGTGTTCTCTG--------ATTGTGAGGTCAC-------- 2506 
2 TCCTTAACTTGCAGCAATCCTCCTGTCTCTGCCACCTGAATTTCGAGATTACGGACCTGC 2549 
:*:** **..* *.* ****** *** ***.* ** 
 
1 ----------------TGTGAATGATTAAATTGGTAAG--------------------GG 2530 
2 ACCATCATGCCCAACTTGTGATTTTTTTTTTTTGGGAGGCAGGGTTTCTTGAAGCCTAGG 2609 
*****:* :**:::** * .** ** 
 
1 TAAAGTAAAAAAAAAAAAAA--- 2550 
2 TTAGCCTAGAACATTCTATACAC 2632 
*:*. :*.**.*::.:*:* 
 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
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Appendix 9.23 Amino Acid Sequence for HSPA1L Homo sapiens v Rattus norvegicus 
 
 
 
SeqA NameLen(aa) SeqB NameLen(aa) Score 
========================================= 
1 1 641 2 2 641 94 
========================================= 
 
1 
MATAKGIAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQ 60 
2 
MAANKGMAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQ 60 
**: 
**:***************************************************** 
 
1 
VAMNPQNTVFDAKRLIGRKFNDPVVQADMKLWPFQVINEGGKPKVLVSYKGENKAFYPEE 120 
2 
VAMNPQNTVFDAKRLIGRKFNDPVVQSDMKLWPFQVINEAGKPKVLVSYKGEKKAFYPEE 120 
 
**************************:************.************:******* 
 
1 
ISSMVLTKLKETAEAFLGHPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTA 180 
2 
ISSMVLTKMKETAEAFLGHSVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTA 180 
 
********:**********.**************************************** 
 
1 
AAIAYGLDKGGQGERHVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLV 240 
2 
AAIAYGLDKGSHGERHVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLV 240 
 
**********.:************************************************ 
 
1 
SHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQANLEIDSLYEGIDFYTSIT 300 
2 
SHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQANLEIDSLYEGIDFYTSIT 300 
 
************************************************************ 
 
1 
RARFEELCADLFRGTLEPVEKALRDAKMDKAKIHDIVLVGGSTRIPKVQRLLQDYFNGRD 360 
2 
RARFEELCADLFRGTLEPVEKSLRDAKMDKAKIHDIVLVGGSTRIPKVQKLLQDYFNGRD 360 
 
*********************:***************************:********** 
 
1 
LNKSINPDEAVAYGAAVQAAILMGDKSEKVQDLLLLDVAPLSLGLETAGGVMTALIKRNS 420 
2 
LNKSINPDEAVAYGAAVQAAILMGDKSEKVQDLLLLDVAPLSLGLETAGGVMTVLIKRNS 420 
 
*****************************************************.****** 
 
1 
TIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFDLTGIPPAPRGVPQIEVTF 480 
2 
TIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTRDNNLLGRFDLTGIPPAPRGVPQIEVTF 480 
498 
 
********************************:*************************** 
 
1 
DIDANGILNVTATDKSTGKVNKITITNDKGRLSKEEIERMVLDAEKYKAEDEVQREKIAA 540 
2 
DIDANGILNVTAMDKSTGKANKITITNDKGRLSKEEIERMVQEAERYKAEDEGQREKIAA 540 
************ ******.********************* :**:****** 
******* 
 
1 
KNALESYAFNMKSVVSDEGLKGKISESDKNKILDKCNELLSWLEVNQLAEKDEFDHKRKE 600 
2 
KNALESYAFNMKSAVGDEGLKDKISESDKKKILDKCSEVLSWLEANQLAEKEEFDHKRKE 600 
 
*************.*.*****.*******:******.*:*****.******:******** 
 
1 LEQMCNPIITKLYQGGCTGPACGTGYVPGRPATGPTIEEVD 641 
2 LENMCNPIITKLYQSGCTGPTCAPGYTPGRAATGPTIEEVD 641 
**:***********.*****:*..**.***.********** 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
 
 
 
 
 
MVFILAPW Non polar R-groups 
 
GNTSYQHC Polar R-groups 
 
KR Positively charged R-groups 
 
DE Negatively charged R-groups 
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Appendix  9.24  Gene  Sequence  Alignment  for  GAPDH  Homo  sapiens  v  Rattus 
norvegicus 
 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
SeqA NameLen(nt) SeqB NameLen(nt) Score 
========================================= 
1 1 1310 2 2 1307 84 
========================================= 
 
1 AAATTGAGCCCGCAGCCTCCCGCTTCGCTCTCTGCTCCTCC-TGTTCGACAGTCAGCCGC 
59 
2 ----------------------GGGGGCTCTCTGCTCCTCCCTGTTCTAGAGACAGCCGC 
38 
*************** ***** * ** ******* 
 
1 ATCTTCTTTTGCGTCGCCAGCCGAGCCACATCGCTCAGACACCATGGGGAAGGTGAAGGT 
119 
2 ATCTTCTTGTGCAGTGCCAGCCTCGTCTCAT-----AGACA------AGATGGTGAAGGT 
87 
******** *** ******* * * *** ***** ** ********* 
 
1 CGGAGTCAACGGATTTGGTCGTATTGGGCGCCTGGTCACCAGGGCTGCTTTTAACTCTGG 
179 
2 CGGTGTGAACGGATTTGGCCGTATCGGACGCCTGGTTACCAGGGCTGCCTTCTCTTGTGA 
147 
*** ** *********** ***** ** ******** *********** ** * ** 
 
1 TAAAGTGGATATTGTTGCCATCAATGACCCCTTCATTGACCTCAACTACATGGTTTACAT 
239 
2 CAAAGTGGACATTGTTGCCATCAACGACCCCTTCATTGACCTCAACTACATGGTCTACAT 
207 
******** ************** ***************************** ***** 
 
1 GTTCCAATATGATTCCACCCATGGCAAATTCCATGGCACCGTCAAGGCTGAGAACGGGAA 
299 
2 GTTCCAGTATGACTCTACCCACGGCAAGTTCAACGGCACAGTCAAGGCTGAGAATGGGAA 
267 
****** ***** ** ***** ***** *** * ***** ************** ***** 
 
1 GCTTGTCATCAATGGAAATCCCATCACCATCTTCCAGGAGCGAGATCCCTCCAAAATCAA 
359 
2 GCTGGTCATCAACGGGAAACCCATCACCATCTTCCAGGAGCGAGATCCCGCTAACATCAA 
327 
*** ******** ** ** ****************************** * ** ***** 
 
1 GTGGGGCGATGCTGGCGCTGAGTACGTCGTGGAGTCCACTGGCGTCTTCACCACCATGGA 
419 
2 ATGGGGTGATGCTGGTGCTGAGTATGTCGTGGAGTCTACTGGCGTCTTCACCACCATGGA 
387 
***** ******** ******** *********** *********************** 
 
1 GAAGGCTGGGGCTCATTTGCAGGGGGGAGCCAAAAGGGTCATCATCTCTGCCCCCTCTGC 
479 
2 GAAGGCTGGGGCTCACCTGAAGGGTGGGGCCAAAAGGGTCATCATCTCCGCCCCTTCCGC 
447 
*************** ** **** ** ******************** ***** ** ** 
 
1 TGATGCCCCCATGTTCGTCATGGGTGTGAACCATGAGAAGTATGACAACAGCCTCAAGAT 
539 
2 TGATGCCCCCATGTTTGTGATGGGTGTGAACCACGAGAAATATGACAACTCCCTCAAGAT 
507 
*************** ** ************** ***** ********* ********* 
 
1 CATCAGCAATGCCTCCTGCACCACCAACTGCTTAGCACCCCTGGCCAAGGTCATCCATGA 
599 
500 
 
2 TGTCAGCAATGCATCCTGCACCACCAACTGCTTAGCCCCCCTGGCCAAGGTCATCCATGA 
567 
********** *********************** *********************** 
 
1 CAACTTTGGTATCGTGGAAGGACTCATGACCACAGTCCATGCCATCACTGCCACCCAGAA 
659 
2 CAACTTTGGCATCGTGGAAGGGCTCATGACCACAGTCCATGCCATCACTGCCACTCAGAA 
627 
********* *********** ******************************** ***** 
 
1 GACTGTGGATGGCCCCTCCGGGAAACTGTGGCGTGATGGCCGCGGGGCTCTCCAGAACAT 
719 
2 GACTGTGGATGGCCCCTCTGGAAAGCTGTGGCGTGATGGCCGTGGGGCAGCCCAGAACAT 
687 
****************** ** ** ***************** ***** ********* 
 
1 CATCCCTGCCTCTACTGGCGCTGCCAAGGCTGTGGGCAAGGTCATCCCTGAGCTGAACGG 
779 
2 CATCCCTGCATCCACTGGTGCTGCCAAGGCTGTGGGCAAGGTCATCCCAGAGCTGAACGG 
747 
********* ** ***** ***************************** *********** 
 
1 GAAGCTCACTGGCATGGCCTTCCGTGTCCCCACTGCCAACGTGTCAGTGGTGGACCTGAC 
839 
2 GAAGCTCACTGGCATGGCCTTCCGTGTTCCTACCCCCAATGTATCCGTTGTGGATCTGAC 
807 
*************************** ** ** **** ** ** ** ***** ***** 
 
1 CTGCCGTCTAGAAAAACCTGCCAAATATGATGACATCAAGAAGGTGGTGAAGCAGGCGTC 
899 
2 ATGCCGCCTGGAGAAACCTGCCAAGTATGATGACATCAAGAAGGTGGTGAAGCAGGCGGC 
867 
***** ** ** *********** ********************************* * 
 
1 GGAGGGCCCCCTCAAGGGCATCCTGGGCTACACTGAGCACCAGGTGGTCTCCTCTGACTT 
959 
2 CGAGGGCCCACTAAAGGGCATCCTGGGCTACACTGAGGACCAGGTTGTCTCCTGTGACTT 
927 
******** ** ************************ ******* ******* ****** 
 
1 CAACAGCGACACCCACTCCTCCACCTTTGACGCTGGGGCTGGCATTGCCCTCAACGACCA 
1019 
2 CAACAGCAACTCCCATTCTTCCACCTTTGATGCTGGGGCTGGCATTGCTCTCAATGACAA 
987 
******* ** **** ** *********** ***************** ***** *** * 
 
1 CTTTGTCAAGCTCATTTCCTGGTATGACAACGAATTTGGCTACAGCAACAGGGTGGTGGA 
1079 
2 CTTTGTGAAGCTCATTTCCTGGTATGACAATGAATATGGCTACAGCAACAGGGTGGTGGA 
1047 
****** *********************** **** ************************ 
 
1 CCTCATGGCCCACATGGCCTCCAAGGAGTAAGAC-CCCTGGACCACCAGCCCCAGCAAGA 
1138 
2 CCTCATGGCCTACATGGCCTCCAAGGAGTAAGAAACCCTGGACCACCCAGCCCAGCAAGG 
1107 
********** ********************** ************ ********* 
 
1 GCAC-AAGAGGAAGAGAGAGACCCTCA-CTGCTGGGGAGTCCCTGCCACACTCAGTCCCC 
1196 
2 ATACTGAGAGCAAGAGAGAGGCCCTCAGTTGCTGAGGAGTCCCCATCCCAACTCAGCCCC 
1167 
** **** ********* ****** ***** ******** * ** **** 
 
1 CACCACACTGAATCTCCCCTCCTCACAGTTGCCATGTAGACCCCTTGAAGAGGGGAGGGG 
1256 
2 CA--ACACTGAGCATCTCC--CTCACAATTCCATCCCAGACCCCATAACAACAGGAGGGG 
1223 
** ******* ** ** ****** ** * ******* * * * ******* 
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1 CCTAGGGAGCCGCACCTTGTCATG--TACCATCAATAAAGTACCCTGTGC--TCAACC-- 
1310 
2 CCTGGGGAGCCCTCCCTTCTCTCGAATACCATCAATAAAGTTCGCTGCACCCTCAAAAAA 
1283 
*** ******* **** ** * *************** * *** * **** 
 
1 ------------------------ 
2 AAAAAAAAAAAAAAAAAAAAAAAA 1307 
 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
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Appendix 9.25 Amino Acid Sequence for GAPDH Homo sapiens v Rattus norvegicus 
 
 
 
 
CLUSTAL 2.0.12 multiple sequence alignment 
 
SeqA NameLen(aa) SeqB NameLen(aa) Score 
========================================= 
1 1 335 2 2 333 93 
========================================= 
 
1 MGKVKVGVNGFGRIGRLVTRAAFNSGKVDIVAINDPFIDLNYMVYMFQYDSTHGKFHGTV 
60 
2 --MVKVGVNGFGRIGRLVTRAAFSCDKVDIVAINDPFIDLNYMVYMFQYDSTHGKFNGTV 
58 
********************...******************************:*** 
 
1 KAENGKLVINGNPITIFQERDPSKIKWGDAGAEYVVESTGVFTTMEKAGAHLQGGAKRVI 
120 
2 KAENGKLVINGKPITIFQERDPANIKWGDAGAEYVVESTGVFTTMEKAGAHLKGGAKRVI 
118 
***********:**********::****************************:******* 
 
1 ISAPSADAPMFVMGVNHEKYDNSLKIISNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHA 
180 
2 ISAPSADAPMFVMGVNHEKYDNSLKIVSNASCTTNCLAPLAKVIHDNFGIVEGLMTTVHA 
178 
**************************:********************************* 
 
1 ITATQKTVDGPSGKLWRDGRGALQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTANV 
240 
2 ITATQKTVDGPSGKLWRDGRGAAQNIIPASTGAAKAVGKVIPELNGKLTGMAFRVPTPNV 
238 
********************** **********************************.** 
 
1 SVVDLTCRLEKPAKYDDIKKVVKQASEGPLKGILGYTEHQVVSSDFNSDTHSSTFDAGAG 
300 
2 SVVDLTCRLEKPAKYDDIKKVVKQAAEGPLKGILGYTEDQVVSCDFNSNSHSSTFDAGAG 
298 
*************************:************.****.****::********** 
 
1 IALNDHFVKLISWYDNEFGYSNRVVDLMAHMASK- 334 
2 IALNDNFVKLISWYDNEYGYSNRVVDLMAYMASKE 333 
*****:***********:***********:**** 
 
 
 
KEY 
 
―*‖ Nucleotides are identical in all sequences in the alignment 
 
―.‖ Semi-conserved substitutions are observed 
 
―:‖ Conserved substitutions are observed 
 
 
MVFILAPW Non polar R-groups 
 
GNTSYQHC Polar R-groups 
 
KR Positively charged R-groups 
 
DE Negatively charged R-groups 
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Appendix 9.26 BLAST analysis showing sequences producing significant alignments 
for HSPA1A: 
 
 
 
 
 
Accession 
 
Description Max score 
Total 
score 
Query 
coverage 
E 
value 
Max 
ident 
 
Links 
Transcripts 
 
 
NM_005345.5 
Homo sapiens heat 
shock 70kDa protein 
1A (HSPA1A), 
mRNA 
 
 
4516 
 
 
4516 
 
 
100% 
 
 
0.0 
 
 
100% 
 
 
 
 
 
 
 
NM_005346.4 
Homo sapiens heat 
shock 70kDa protein 
1B (HSPA1B), mRNA 
 
3801 
 
3801 
 
88% 
 
0.0 
 
99% 
 
 
 
 
 
 
NM_005527.3 
Homo sapiens heat 
shock 70kDa protein 
1-like (HSPA1L), 
mRNA 
 
 
1620 
 
 
1620 
 
 
73% 
 
 
0.0 
 
 
83% 
 
 
 
 
 
 
 
 
NM_002155.3 
Homo sapiens heat 
shock 70kDa protein 6 
(HSP70B') (HSPA6), 
mRNA 
 
 
1580 
 
 
1580 
 
 
73% 
 
 
0.0 
 
 
83% 
 
 
 
 
 
 
 
NM_021979.3 
Homo sapiens heat 
shock 70kDa protein 2 
(HSPA2), mRNA 
 
1524 
 
1524 
 
74% 
 
0.0 
 
82% 
 
 
 
 
 
 
NR_024151.1 
Homo sapiens heat 
shock 70kDa protein 7 
(HSP70B) (HSPA7), 
non-coding RNA 
 
 
1474 
 
 
1474 
 
 
73% 
 
 
0.0 
 
 
82% 
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Appendix 9.27 BLAST analysis showing sequences producing significant alignments 
 
for HSPA designed primers: 
 
 
 
 
 
Accession Description  Max 
score 
Total 
score 
Query 
coverage 
E 
value 
Max 
ident 
 
Links 
 
 
Homo sapiens heat 
NM_005346.4 shock 70kDa protein 
Transcripts 
 
 
42.1 82.3 100% 0.027  100%   
1B (HSPA1B), mRNA 
Homo sapiens heat 
NM_005345.5 shock 70kDa protein 
1A (HSPA1A), mRNA 
Homo sapiens cell 
division cycle 6 
NM_001254.3 homolog (S. 
cerevisiae) (CDC6), 
mRNA 
Homo sapiens heat 
NM_021979.3 shock 70kDa protein 2 
(HSPA2), mRNA 
Homo sapiens heat 
 
 
 
42.1 82.3 100% 0.027  100%   
 
 
 
 
34.2 34.2 52% 6.5 95%  
 
 
 
 
34.2 66.4 82% 6.5 100%   
 
NR_024151.1 shock 70kDa protein 7 (HSP70B) (HSPA7), 
non-coding RNA 
Homo sapiens heat 
 
34.2 34.2 42% 6.5 100%   
NM_002155.3 shock 70kDa protein 6 (HSP70B') (HSPA6), 
mRNA 
Homo sapiens zinc 
NM_022473.1 finger protein 106 homolog (mouse) 
(ZFP106), mRNA 
Homo sapiens 
microtubule-actin 
NM_033044.3 crosslinking factor 1 
(MACF1), transcript 
variant 2, mRNA 
Homo sapiens 
microtubule-actin 
NM_012090.4 crosslinking factor 1 
(MACF1), transcript 
variant 1, mRNA 
NM_006391.2 Homo sapiens importin
 
 
34.2 34.2 42% 6.5 100%   
 
 
 
 
32.2 32.2 40% 26 100%   
 
 
 
 
 
32.2 32.2 40% 26 100%   
 
 
 
 
 
 
32.2 32.2 40% 26 100%   
7 (IPO7), mRNA 30.2 30.2 57% 101 91% 
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Accession 
 
Description Max score 
Total 
score 
Query 
coverage 
E 
value 
Max 
ident 
 
Links 
 
 
NM_018411.4 
Homo sapiens hairless 
homolog (mouse) 
(HR), transcript variant 
2, mRNA 
 
 
30.2 
 
 
30.2 
 
 
37% 
 
 
101 
 
 
100% 
 
 
 
 
 
 
 
 
NM_005144.4 
Homo sapiens hairless 
homolog (mouse) 
(HR), transcript variant 
1, mRNA 
 
 
30.2 
 
 
30.2 
 
 
37% 
 
 
101 
 
 
100% 
 
 
 
 
 
 
 
